,AID,AID Version,AID Revision,Panel Member ID,SID,CID,Bioactivity Outcome,Target GI,Target GeneID,Activity Value [uM],Activity Name,Assay Name,Bioassay Type,PubMed ID,RNAi
0,357,2,1,,11111224,3454,Inactive,,,,,AP1 Signaling Pathway,Confirmatory,,
1,357,2,1,,11111225,3454,Inactive,,,,,AP1 Signaling Pathway,Confirmatory,,
2,377,1,3,,10321977,3454,Inactive,42741659.0,5243.0,,,MDR-1,Other,,
3,410,1,5,,11111224,3454,Inactive,73915100.0,1544.0,,,p450-cyp1a2,Confirmatory,,
4,410,1,5,,11111225,3454,Inactive,73915100.0,1544.0,,,p450-cyp1a2,Confirmatory,,
5,411,2,1,,11111224,3454,Inactive,160794.0,,,Potency,qHTS Assay for Inhibitors of Firefly Luciferase,Confirmatory,,
6,411,2,1,,11111225,3454,Inactive,160794.0,,,Potency,qHTS Assay for Inhibitors of Firefly Luciferase,Confirmatory,,
7,422,1,5,,17405102,3454,Inactive,21464101.0,7532.0,,,HTS for 14-3-3 protein interaction modulators,Screening,,
8,429,1,5,,17405102,3454,Inactive,4261762.0,3326.0,,,HTS for Tumor Hsp90 Inhibitors,Screening,,
9,429,1,5,,17405102,3454,Inactive,154146191.0,3320.0,,,HTS for Tumor Hsp90 Inhibitors,Screening,,
10,436,2,1,,17405102,3454,Inactive,68565074.0,8314.0,,,HTS for BAP1 Enzyme inhibitors,Screening,,
11,444,1,1,,11111224,3454,Inactive,,,,,NFAT Signaling Pathway,Confirmatory,,
12,444,1,1,,11111225,3454,Inactive,,,,,NFAT Signaling Pathway,Confirmatory,,
13,445,3,1,,11111224,3454,Inactive,10092619.0,4792.0,,,IkB Signaling,Confirmatory,,
14,445,3,1,,11111225,3454,Inactive,10092619.0,4792.0,,,IkB Signaling,Confirmatory,,
15,446,1,1,,11111224,3454,Inactive,,,,,Stat Signaling Pathway,Confirmatory,,
16,446,1,1,,11111225,3454,Inactive,,,,,Stat Signaling Pathway,Confirmatory,,
17,447,1,1,,11111224,3454,Inconclusive,,,,,O-Glc NAc Transferase (sOGT),Confirmatory,,
18,447,1,1,,11111225,3454,Inconclusive,,,,,O-Glc NAc Transferase (sOGT),Confirmatory,,
19,448,1,2,,11111224,3454,Inactive,4325211.0,,,,Schistosoma Mansoni Peroxiredoxins (Prx2),Confirmatory,,
20,448,1,2,,11111225,3454,Inactive,4325211.0,,,,Schistosoma Mansoni Peroxiredoxins (Prx2),Confirmatory,,
21,450,1,2,,11111224,3454,Inactive,66528677.0,2908.0,,,GR-GFP Redistribution,Confirmatory,,
22,450,1,2,,11111225,3454,Inactive,66528677.0,2908.0,,,GR-GFP Redistribution,Confirmatory,,
23,451,1,2,,11111224,3454,Inactive,66528677.0,2908.0,,,GR-EFC Redistribution,Confirmatory,,
24,451,1,2,,11111225,3454,Inactive,66528677.0,2908.0,,,GR-EFC Redistribution,Confirmatory,,
25,485,1,8,,8139883,3454,Inactive,38788193.0,1903.0,,,Primary HTS Assay for S1P3 Antagonists,Screening,,
26,526,1,1,,11111224,3454,Inactive,,,,,Ubiquitin-GFP Assay,Confirmatory,,
27,526,1,1,,11111225,3454,Inactive,,,,,Ubiquitin-GFP Assay,Confirmatory,,
28,530,1,1,,11111224,3454,Inactive,2499604.0,26414.0,,,JNK3 AlphaScreen Assay,Confirmatory,,
29,530,1,1,,11111225,3454,Inactive,2499604.0,26414.0,,,JNK3 AlphaScreen Assay,Confirmatory,,
30,547,1,4,,17405102,3454,Inactive,16130533.0,947097.0,,,HTS for inhibitors of bacterial DnaK,Other,,
31,568,1,7,,8139883,3454,Inactive,5729877.0,3312.0,,IC50,High Throughput Screening Assay for Hsc70 Inhibitors,Confirmatory,,
32,568,1,7,,8139883,3454,Inactive,24234686.0,3312.0,,IC50,High Throughput Screening Assay for Hsc70 Inhibitors,Confirmatory,,
33,583,2,6,,8139883,3454,Inactive,123271505.0,,,IC50,High Throughput Screening Assay for Hsp70 Inhibitors,Confirmatory,,
34,584,1,3,,11111224,3454,Inactive,119389684.0,,,,Promiscuous and Specific Inhibitors of AmpC Beta-Lactamase (assay with detergent),Confirmatory,,
35,584,1,3,,11111225,3454,Inactive,119389684.0,,,,Promiscuous and Specific Inhibitors of AmpC Beta-Lactamase (assay with detergent),Confirmatory,,
36,585,1,4,,11111224,3454,Inactive,119389684.0,,,,Promiscuous and Specific Inhibitors of AmpC Beta-Lactamase (assay without detergent),Confirmatory,,
37,585,1,4,,11111225,3454,Inactive,119389684.0,,,,Promiscuous and Specific Inhibitors of AmpC Beta-Lactamase (assay without detergent),Confirmatory,,
38,587,1,5,,11111224,3454,Inactive,,,,,qHTS Assay for Spectroscopic Profiling in Texas Red Spectral Region,Other,,
39,587,1,5,,11111225,3454,Inactive,,,,,qHTS Assay for Spectroscopic Profiling in Texas Red Spectral Region,Other,,
40,588,1,4,,11111224,3454,Inactive,,,,,qHTS Assay for Spectroscopic Profiling in Resorufin Spectral Region,Other,,
41,588,1,4,,11111225,3454,Inactive,,,,,qHTS Assay for Spectroscopic Profiling in Resorufin Spectral Region,Other,,
42,589,1,3,,11111224,3454,Inactive,,,,,qHTS Assay for Spectroscopic Profiling in 4-MU Spectral Region,Other,,
43,589,1,3,,11111225,3454,Inactive,,,,,qHTS Assay for Spectroscopic Profiling in 4-MU Spectral Region,Other,,
44,590,1,3,,11111224,3454,Inactive,,,,,qHTS Assay for Spectroscopic Profiling in A350 Spectral Region,Other,,
45,590,1,3,,11111225,3454,Inactive,,,,,qHTS Assay for Spectroscopic Profiling in A350 Spectral Region,Other,,
46,591,1,4,,11111224,3454,Inactive,,,,,qHTS Assay for Spectroscopic Profiling in A488 Spectral Region,Other,,
47,591,1,4,,11111225,3454,Inactive,,,,,qHTS Assay for Spectroscopic Profiling in A488 Spectral Region,Other,,
48,592,1,6,,11111224,3454,Inactive,,,,,qHTS Assay for Spectroscopic Profiling in A647 Spectral Region,Other,,
49,592,1,6,,11111225,3454,Inactive,,,,,qHTS Assay for Spectroscopic Profiling in A647 Spectral Region,Other,,
50,593,1,4,,11111224,3454,Inconclusive,,,,,qHTS Assay for Spectroscopic Profiling in Fluorescein Spectral Region,Other,,
51,593,1,4,,11111225,3454,Inconclusive,,,,,qHTS Assay for Spectroscopic Profiling in Fluorescein Spectral Region,Other,,
52,594,1,4,,11111224,3454,Inactive,,,,,qHTS Assay for Spectroscopic Profiling in Rhodamine Spectral Region,Confirmatory,,
53,594,1,4,,11111225,3454,Inactive,,,,,qHTS Assay for Spectroscopic Profiling in Rhodamine Spectral Region,Confirmatory,,
54,595,1,3,,11111224,3454,Inactive,,,,,qHTS Assay for Disrupters of an Hsp90 Co-Chaperone Interaction,Confirmatory,,
55,595,1,3,,11111225,3454,Inactive,,,,,qHTS Assay for Disrupters of an Hsp90 Co-Chaperone Interaction,Confirmatory,,
56,596,1,2,,11111224,3454,Inactive,92096784.0,4137.0,,,qHTS Assay for Tau Filament Binding,Confirmatory,,
57,596,1,2,,11111225,3454,Inactive,92096784.0,4137.0,,,qHTS Assay for Tau Filament Binding,Confirmatory,,
58,597,1,3,,11111224,3454,Inactive,,,,,qHTS Assay for Epigenetic Modulators,Confirmatory,,
59,597,1,3,,11111225,3454,Inactive,,,,,qHTS Assay for Epigenetic Modulators,Confirmatory,,
60,598,1,4,,8139883,3454,Inactive,,,,,Human H69AR Lung Tumor Cell Growth Inhibition Assay - 86K Screen,Screening,,
61,602,1,4,,8139883,3454,Inactive,,,,,Identification of Molecular Probes that Reverse MRP-Mediated Drug Resistance,Screening,,
62,603,1,2,,11111224,3454,Inactive,,,,,qHTS Assay for Inhibitors of DNA Polymerase III Holoenzyme System,Confirmatory,,
63,603,1,2,,11111225,3454,Inactive,,,,,qHTS Assay for Inhibitors of DNA Polymerase III Holoenzyme System,Confirmatory,,
64,605,1,2,,11111224,3454,Inactive,84028058.0,,,,qHTS Assay for Inhibitors of YjeE,Confirmatory,,
65,605,1,2,,11111225,3454,Inactive,84028058.0,,,,qHTS Assay for Inhibitors of YjeE,Confirmatory,,
66,606,1,3,,8139883,3454,Inactive,224586929.0,26191.0,,,HTS for LYP Inhibitors-an Autoimmunity Target - Primary screen,Confirmatory,,
67,606,1,3,,8139883,3454,Inactive,301171662.0,26191.0,,,HTS for LYP Inhibitors-an Autoimmunity Target - Primary screen,Confirmatory,,
68,607,1,3,,11111224,3454,Inactive,82799486.0,5142.0,,,qHTS Assay for Inhibitors of PDE-IV,Confirmatory,,
69,607,1,3,,11111225,3454,Inactive,82799486.0,5142.0,,,qHTS Assay for Inhibitors of PDE-IV,Confirmatory,,
70,618,2,6,,8139883,3454,Inactive,6690534.0,4323.0,,EC50,Luminescent HTS for small molecule inhibitors of MT1-MMP transcription,Confirmatory,,
71,620,2,5,,8139883,3454,Inactive,,,,EC50,Fluorescent HTS Cytotoxicity/Cell viability assay (HT1080 cells),Confirmatory,,
72,629,1,3,,8139883,3454,Inactive,118764400.0,2099.0,,,HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors,Screening,,
73,630,1,1,,8139883,3454,Inactive,5174513.0,4088.0,,,HTS of Smad transcription factor inhibitors,Screening,,
74,631,1,4,,8139883,3454,Inactive,20336229.0,5468.0,,,Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma),Screening,,
75,631,1,4,,8139883,3454,Inactive,22538455.0,8648.0,,,Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma),Screening,,
76,633,1,3,,8139883,3454,Inactive,10835013.0,2100.0,,,HTS for Estrogen Receptor-beta Coactivator Binding inhibitors,Screening,,
77,639,1,2,,8139883,3454,Inactive,118764400.0,2099.0,,,HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators,Screening,,
78,648,1,3,,8139883,3454,Inactive,,,,,Human Endothelial Cell Proliferation Assay in 384-well format,Screening,,
79,662,1,1,,11111224,3454,Inactive,,,,,Cell signaling CRE-BLA (Fsk stim),Confirmatory,,
80,662,1,1,,11111225,3454,Inactive,,,,,Cell signaling CRE-BLA (Fsk stim),Confirmatory,,
81,687,1,17,,8139883,3454,Inactive,180352.0,,,,Factor XIa Single Well HTS,Screening,,
82,694,1,1,,17405102,3454,Inactive,118764400.0,2099.0,,,HTS of LOPAC library for Estrogen Receptor-alpha Coactivator Binding inhibitors,Confirmatory,,
83,701,1,17,,8139883,3454,Inactive,317373446.0,2161.0,,,Factor XIIa Single Well HTS,Screening,,
84,719,1,3,,8139883,3454,Inactive,,,,,Human Lung Fibroblast Proliferation Assay,Screening,,
85,731,1,5,,8139883,3454,Inactive,20336229.0,5468.0,,,Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma),Screening,,
86,731,1,5,,8139883,3454,Inactive,32307126.0,8202.0,,,Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma),Screening,,
87,732,1,2,,17405102,3454,Inactive,,,,,In Vivo Angiogenesis Assay for HTS,Screening,,
88,750,1,3,,8139883,3454,Inactive,,,,,Luminescent HTS for small molecule activators of MT1-MMP transcription,Screening,,
89,757,1,4,,8139883,3454,Inactive,8574038.0,5879.0,,,HTS to identify specific small molecule inhibitors of Ras and Ras-related GTPases specifically Rac wildtype,Screening,,
90,758,1,4,,8139883,3454,Inactive,164058.0,404007.0,,,HTS to identify specific small molecule inhibitors of Ras and Ras-related GTPases specifically Rab7 wildtype,Screening,,
91,759,1,4,,8139883,3454,Inactive,190938.0,3265.0,,,HTS to identify specific small molecule inhibitors of Ras and Ras-related GTPases specifically Ras wildtype,Screening,,
92,760,1,4,,8139883,3454,Inactive,46577642.0,404009.0,,,HTS to identify specific small molecule inhibitors of Ras and Ras-related GTPases specifically Rab2 wildtype,Screening,,
93,761,1,4,,8139883,3454,Inactive,56202836.0,,,,HTS to identify specific small molecule inhibitors of Ras and Ras-related GTPases specifically Cdc42 wildtype,Screening,,
94,764,1,4,,8139883,3454,Inactive,8574038.0,5879.0,,,HTS to identify specific small molecule inhibitors of Ras and Ras-related GTPases specifically Rac activated mutant,Screening,,
95,775,1,3,,8139883,3454,Inactive,,,,,Screen for Chemicals that Extend Yeast Lifespan,Screening,,
96,781,1,1,,8139883,3454,Inactive,27807367.0,287022.0,,,uHTS for 14-3-3/Bad interaction inhibitors,Screening,,
97,782,1,2,,8139883,3454,Inactive,83627717.0,13684.0,,,uHTS for Small Molecule Inhibitors of Eukaryotic Translation Initiation,Screening,,
98,782,1,2,,8139883,3454,Inactive,302699239.0,1981.0,,,uHTS for Small Molecule Inhibitors of Eukaryotic Translation Initiation,Screening,,
99,793,1,2,,8139883,3454,Inactive,4505447.0,4887.0,,,Primary cell based high-throughput screening assay for antagonists of neuropeptide Y receptor Y2 (NPY-Y2),Screening,,
100,797,1,1,,8139883,3454,Inactive,115529463.0,5587.0,,,Fluorescence polarization assay for PKD inhibitors,Screening,,
101,798,2,12,,8139883,3454,Inactive,180352.0,,,,Factor XIa 1536 HTS,Screening,,
102,799,1,5,,8139883,3454,Inactive,134142337.0,4363.0,,,Identification of Molecular Probes that Activate MRP-1,Screening,,
103,800,2,11,,8139883,3454,Inactive,317373446.0,2161.0,,,Factor XIIa 1536 HTS,Screening,,
104,803,1,4,,8139883,3454,Inactive,6016094.0,8811.0,,,Primary cell-based high-throughput screening assay to identify agonists of Galanin Receptor 2 (GALR2),Screening,,
105,804,1,3,,8139883,3454,Inactive,,,,,Screen for Chemicals that Shorten Yeast Lifespan,Screening,,
106,817,1,1,,8139883,3454,Inactive,1360328.0,,,,Identification and characterization of compounds for addressing human bone marrow failure,Other,,
107,818,1,2,,8139883,3454,Inactive,,,,,High Throughput Screen to Identify Compounds that Suppress the Growth of Human Colon Tumor Cells Lacking Oncogenic Beta Catenin Expression,Screening,,
108,827,1,2,,8139883,3454,Inactive,,,,,High Throughput Screen to Identify Compounds that Suppress the Growth of Cells with a Deletion of the PTEN Tumor Suppressor,Screening,,
109,828,1,5,,8139883,3454,Inactive,6016094.0,8811.0,,,Primary cell-based high-throughput screening assay to identify antagonists of Galanin Receptor 2 (GALR2),Screening,,
110,834,1,3,,8139883,3454,Inactive,,,,,C. albicans biofilm killing,Screening,,
111,841,1,1,,8139883,3454,Inactive,,,,,Non-Nucleoside Inhibitor of Measles Virus RNA-Dependent RNA Polymerase Complex Activity HTS Single Point (MLSMR Library),Screening,,
112,861,1,1,,8139883,3454,Inactive,55662034.0,,,,Primary cell-based high-throughput screening assay for inhibitors of TLR4-MyD88 binding,Screening,,
113,862,1,2,,8139883,3454,Inactive,13272532.0,6774.0,,,Primary cell-based high throughput screening assay to measure STAT3 inhibition,Screening,,
114,868,1,3,,8139883,3454,Inactive,,,,,Screen for Chemicals that Inhibit the RAM Network,Screening,,
115,871,1,2,,8139883,3454,Inactive,13272532.0,6774.0,,,Primary cell-based high throughput screening assay to measure STAT3 activation,Screening,,
116,873,1,13,,8139883,3454,Inactive,6912644.0,25818.0,,,Kallikrein 5 1536 HTS,Screening,,
117,875,1,2,,11111224,3454,Inactive,159162802.0,,,Potency,qHTS Assay for Inhibitors of BRCT-Phosphoprotein Interaction (Green Fluorophore),Confirmatory,,
118,875,1,2,,11111225,3454,Inactive,159162802.0,,,Potency,qHTS Assay for Inhibitors of BRCT-Phosphoprotein Interaction (Green Fluorophore),Confirmatory,,
119,878,1,2,,8139883,3454,Inactive,,,,,NIH Compound Library Profiling: Compound and DTT Dependent Redox Cycling H2O2 Generation.,Screening,,
120,879,1,2,,11111224,3454,Inactive,3290016.0,6002.0,,Potency,qHTS Assay for Inhibitors of RGS12 GoLoco Motif Activity (Green Fluorophore),Confirmatory,,
121,879,1,2,,11111224,3454,Inactive,33946324.0,2770.0,,Potency,qHTS Assay for Inhibitors of RGS12 GoLoco Motif Activity (Green Fluorophore),Confirmatory,,
122,880,2,1,,8139883,3454,Inactive,3290016.0,6002.0,,,qHTS Assay for Inhibitors of RGS12 GoLoco Motif Activity (Red Fluorophore),Confirmatory,,
123,880,2,1,,8139883,3454,Inactive,33946324.0,2770.0,,,qHTS Assay for Inhibitors of RGS12 GoLoco Motif Activity (Red Fluorophore),Confirmatory,,
124,880,2,1,,11111225,3454,Inactive,3290016.0,6002.0,,,qHTS Assay for Inhibitors of RGS12 GoLoco Motif Activity (Red Fluorophore),Confirmatory,,
125,880,2,1,,11111225,3454,Inactive,33946324.0,2770.0,,,qHTS Assay for Inhibitors of RGS12 GoLoco Motif Activity (Red Fluorophore),Confirmatory,,
126,880,2,1,,50106328,3454,Inactive,3290016.0,6002.0,,,qHTS Assay for Inhibitors of RGS12 GoLoco Motif Activity (Red Fluorophore),Confirmatory,,
127,880,2,1,,50106328,3454,Inactive,33946324.0,2770.0,,,qHTS Assay for Inhibitors of RGS12 GoLoco Motif Activity (Red Fluorophore),Confirmatory,,
128,881,2,2,,11111224,3454,Inactive,317373425.0,247.0,,Potency,qHTS Assay for Inhibitors of 15-hLO-2 (15-human lipoxygenase 2),Confirmatory,,
129,881,2,2,,11111225,3454,Inactive,317373425.0,247.0,,Potency,qHTS Assay for Inhibitors of 15-hLO-2 (15-human lipoxygenase 2),Confirmatory,,
130,883,1,3,,11111224,3454,Inactive,13699818.0,1559.0,,Potency,qHTS Assay for Inhibitors and Substrates of Cytochrome P450 2C9,Confirmatory,,
131,883,1,3,,11111225,3454,Inactive,13699818.0,1559.0,,Potency,qHTS Assay for Inhibitors and Substrates of Cytochrome P450 2C9,Confirmatory,,
132,884,1,2,,11111224,3454,Inconclusive,13435386.0,1576.0,25.1189,Potency,qHTS Assay for Inhibitors and Substrates of Cytochrome P450 3A4,Confirmatory,,
133,884,1,2,,11111225,3454,Inactive,13435386.0,1576.0,,Potency,qHTS Assay for Inhibitors and Substrates of Cytochrome P450 3A4,Confirmatory,,
134,885,1,2,,11111224,3454,Inactive,13435386.0,1576.0,25.1189,Potency,qHTS Assay for Activators of Cytochrome P450 3A4,Confirmatory,,
135,885,1,2,,11111225,3454,Inactive,13435386.0,1576.0,,Potency,qHTS Assay for Activators of Cytochrome P450 3A4,Confirmatory,,
136,886,1,2,,11111224,3454,Inactive,122921310.0,,,Potency,"qHTS Assay for Inhibitors of HADH2 (Hydroxyacyl-Coenzyme A Dehydrogenase, Type II)",Confirmatory,,
137,886,1,2,,11111224,3454,Inactive,122921311.0,,,Potency,"qHTS Assay for Inhibitors of HADH2 (Hydroxyacyl-Coenzyme A Dehydrogenase, Type II)",Confirmatory,,
138,886,1,2,,11111225,3454,Inactive,122921310.0,,,Potency,"qHTS Assay for Inhibitors of HADH2 (Hydroxyacyl-Coenzyme A Dehydrogenase, Type II)",Confirmatory,,
139,886,1,2,,11111225,3454,Inactive,122921311.0,,,Potency,"qHTS Assay for Inhibitors of HADH2 (Hydroxyacyl-Coenzyme A Dehydrogenase, Type II)",Confirmatory,,
140,887,1,2,,11111224,3454,Inactive,1832253.0,246.0,,Potency,qHTS Assay for Inhibitors of 15-hLO (15-human lipoxygenase),Confirmatory,,
141,887,1,2,,11111225,3454,Inactive,1832253.0,246.0,,Potency,qHTS Assay for Inhibitors of 15-hLO (15-human lipoxygenase),Confirmatory,,
142,889,1,3,,11111224,3454,Inactive,1730092.0,840.0,,Potency,qHTS Assay for Allosteric/Competitive Inhibitors of Caspase-7,Confirmatory,,
143,889,1,3,,11111225,3454,Inactive,1730092.0,840.0,,Potency,qHTS Assay for Allosteric/Competitive Inhibitors of Caspase-7,Confirmatory,,
144,891,1,2,,11111224,3454,Inactive,40805836.0,1565.0,,Potency,qHTS Assay for Inhibitors and Substrates of Cytochrome P450 2D6,Confirmatory,,
145,891,1,2,,11111225,3454,Inactive,40805836.0,1565.0,,Potency,qHTS Assay for Inhibitors and Substrates of Cytochrome P450 2D6,Confirmatory,,
146,892,1,2,,11111224,3454,Inactive,159162802.0,,,Potency,qHTS Assay for Inhibitors of BRCT-Phosphoprotein Interaction (Red Fluorophore),Confirmatory,,
147,892,1,2,,11111225,3454,Inactive,159162802.0,,,Potency,qHTS Assay for Inhibitors of BRCT-Phosphoprotein Interaction (Red Fluorophore),Confirmatory,,
148,893,1,2,,11111224,3454,Inactive,122921310.0,,,Potency,"qHTS Assay for Inhibitors of HSD17B4, hydroxysteroid (17-beta) dehydrogenase 4",Confirmatory,,
149,893,1,2,,11111224,3454,Inactive,122921311.0,,,Potency,"qHTS Assay for Inhibitors of HSD17B4, hydroxysteroid (17-beta) dehydrogenase 4",Confirmatory,,
150,893,1,2,,11111225,3454,Inactive,122921310.0,,,Potency,"qHTS Assay for Inhibitors of HSD17B4, hydroxysteroid (17-beta) dehydrogenase 4",Confirmatory,,
151,893,1,2,,11111225,3454,Inactive,122921311.0,,,Potency,"qHTS Assay for Inhibitors of HSD17B4, hydroxysteroid (17-beta) dehydrogenase 4",Confirmatory,,
152,894,2,1,,8139883,3454,Inactive,31542939.0,3248.0,,Potency,qHTS Assay for Inhibitors of HPGD (15-Hydroxyprostaglandin Dehydrogenase),Confirmatory,,
153,894,2,1,,11111225,3454,Inactive,31542939.0,3248.0,,Potency,qHTS Assay for Inhibitors of HPGD (15-Hydroxyprostaglandin Dehydrogenase),Confirmatory,,
154,894,2,1,,50106328,3454,Inactive,31542939.0,3248.0,,Potency,qHTS Assay for Inhibitors of HPGD (15-Hydroxyprostaglandin Dehydrogenase),Confirmatory,,
155,895,1,2,,11111224,3454,Inconclusive,21620132.0,4790.0,10.0,Potency,qHTS Assay for Identification of Small Molecule Antagonists for NFkB Signaling Pathway,Confirmatory,,
156,898,1,1,,8139883,3454,Inactive,28373018.0,1239205.0,,,YopH  HTS,Screening,,
157,899,1,2,,11111224,3454,Inactive,4503219.0,1557.0,,Potency,qHTS Assay for Inhibitors and Substrates of Cytochrome P450 2C19,Confirmatory,,
158,899,1,2,,11111225,3454,Inactive,4503219.0,1557.0,,Potency,qHTS Assay for Inhibitors and Substrates of Cytochrome P450 2C19,Confirmatory,,
159,900,1,3,,11111224,3454,Inactive,15431328.0,834.0,,Potency,qHTS Assay for Allosteric/Competitive Inhibitors of Caspase-1,Confirmatory,,
160,900,1,3,,11111225,3454,Inactive,15431328.0,834.0,,Potency,qHTS Assay for Allosteric/Competitive Inhibitors of Caspase-1,Confirmatory,,
161,901,1,2,,11111224,3454,Inactive,44888968.0,83523.0,,Potency,qHTS Assay for Identifying the Cell-Membrane Permeable IMPase Inhibitors,Confirmatory,,
162,901,1,2,,11111225,3454,Inactive,44888968.0,83523.0,,Potency,qHTS Assay for Identifying the Cell-Membrane Permeable IMPase Inhibitors,Confirmatory,,
163,902,1,2,,11111224,3454,Inactive,120407068.0,7157.0,,Potency,qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature,Confirmatory,,
164,902,1,2,,11111225,3454,Inactive,120407068.0,7157.0,,Potency,qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature,Confirmatory,,
165,912,1,2,,11111224,3454,Inactive,21392848.0,,,Potency,qHTS Assay for Anthrax Lethal Toxin Internalization,Confirmatory,,
166,912,1,2,,11111225,3454,Inactive,21392848.0,,,Potency,qHTS Assay for Anthrax Lethal Toxin Internalization,Confirmatory,,
167,914,1,3,,11111224,3454,Inconclusive,32879895.0,3091.0,3.9811,Potency,qHTS Assay for Identification of Small Molecule Agonists for Hypoxia Response Element Signaling Pathway,Confirmatory,,
168,914,1,3,,11111225,3454,Inactive,32879895.0,3091.0,,Potency,qHTS Assay for Identification of Small Molecule Agonists for Hypoxia Response Element Signaling Pathway,Confirmatory,,
169,915,1,3,,11111224,3454,Inconclusive,32879895.0,3091.0,3.9811,Potency,qHTS Assay for Identification of Small Molecule Antagonists for Hypoxia Response Element Signaling Pathway,Confirmatory,,
170,915,1,3,,11111225,3454,Inactive,32879895.0,3091.0,,Potency,qHTS Assay for Identification of Small Molecule Antagonists for Hypoxia Response Element Signaling Pathway,Confirmatory,,
171,917,1,3,,11111224,3454,Inactive,120660324.0,7066.0,,Potency,qHTS Assay for Identification of Small Molecule Agonists for Thrombopoietin (TPO) Signaling Pathway,Confirmatory,,
172,918,1,3,,11111224,3454,Inconclusive,120660324.0,7066.0,,Potency,qHTS Assay for Identification of Small Molecule Antagonists for Thrombopoietin (TPO) Signaling Pathway,Confirmatory,,
173,920,1,2,,8139883,3454,Inactive,6274552.0,6772.0,,,Primary cell-based high throughput screening assay to measure STAT1 inhibition,Screening,,
174,923,1,2,,11111224,3454,Inactive,,,,Potency,qHTS Assay for Allosteric/Competitive Inhibitors of Caspase-1: Spectroscopic Profiling in AFC Spectral Region,Confirmatory,,
175,923,1,2,,11111225,3454,Inactive,,,,Potency,qHTS Assay for Allosteric/Competitive Inhibitors of Caspase-1: Spectroscopic Profiling in AFC Spectral Region,Confirmatory,,
176,924,1,2,,11111224,3454,Inactive,120407068.0,7157.0,,Potency,qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature,Confirmatory,,
177,924,1,2,,11111225,3454,Inactive,120407068.0,7157.0,,Potency,qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature,Confirmatory,,
178,925,1,2,,11111224,3454,Inactive,4504349.0,3043.0,,Potency,qHTS Assay for Modulators of Hemoglobin Beta Chain Splicing,Confirmatory,,
179,925,1,2,,11111225,3454,Inactive,4504349.0,3043.0,,Potency,qHTS Assay for Modulators of Hemoglobin Beta Chain Splicing,Confirmatory,,
180,926,1,2,,11111224,3454,Inactive,38016895.0,7253.0,,Potency,qHTS Assay for Agonists of the Thyroid Stimulating Hormone Receptor,Confirmatory,,
181,926,1,2,,11111225,3454,Inactive,38016895.0,7253.0,,Potency,qHTS Assay for Agonists of the Thyroid Stimulating Hormone Receptor,Confirmatory,,
182,927,1,3,,11111224,3454,Inactive,188528692.0,9099.0,,Potency,qHTS Assay for Inhibitors of Ubiquitin-specific Protease USP2a,Confirmatory,,
183,927,1,3,,11111225,3454,Inactive,188528692.0,9099.0,,Potency,qHTS Assay for Inhibitors of Ubiquitin-specific Protease USP2a,Confirmatory,,
184,928,1,2,,11111224,3454,Inconclusive,21620132.0,4790.0,10.0,Potency,qHTS Assay for Identification of Small Molecule Agonists for NFkB Signaling Pathway,Confirmatory,,
185,932,1,4,,8139883,3454,Inactive,6274552.0,6772.0,,,Primary cell-based high throughput screening assay to measure STAT1 activation,Screening,,
186,938,1,2,,11111224,3454,Inactive,38016895.0,7253.0,,Potency,qHTS Assay for Agonists of the Thyroid Stimulating Hormone Receptor: Activators of Intracellular cAMP Concentrations in Parental HEK 293,Confirmatory,,
187,938,1,2,,11111225,3454,Inactive,38016895.0,7253.0,,Potency,qHTS Assay for Agonists of the Thyroid Stimulating Hormone Receptor: Activators of Intracellular cAMP Concentrations in Parental HEK 293,Confirmatory,,
188,940,1,2,,8139883,3454,Inactive,31881630.0,5732.0,,,Modulators of the EP2 prostaglandin E2 receptor - Primary Screening,Screening,,
189,940,1,2,,17405102,3454,Inactive,31881630.0,5732.0,,,Modulators of the EP2 prostaglandin E2 receptor - Primary Screening,Screening,,
190,943,1,2,,11111224,3454,Inactive,18249941.0,25229.0,,Potency,qHTS Assay for Antagonists of Acetylcholine Muscarinic M1 Receptor: Kinetic Measurement of Intracellular Calcium Response,Confirmatory,,
191,944,1,2,,11111224,3454,Inactive,18249941.0,25229.0,,Potency,qHTS Assay for Antagonists of Acetylcholine Muscarinic M1 Receptor: Measurement of IP-One Response,Confirmatory,,
192,945,1,4,,11111224,3454,Inactive,290753097.0,,,Potency,qHTS Validation Assay for Inhibitors of Leishmania Mexicana Pyruvate Kinase,Confirmatory,,
193,950,1,1,,8139883,3454,Inactive,231632.0,596.0,,,"Multiplexed high-throughput screen for small molecule regulators of Bcl-2 family protein interactions, specifically Bim-Bcl-2.",Screening,,
194,951,1,1,,8139883,3454,Inactive,23396469.0,10017.0,,,"Multiplexed high-throughput screen for small molecule regulators of Bcl-2 family protein interactions, specifically Bim-Bcl-B.",Screening,,
195,952,1,1,,8139883,3454,Inactive,1572493.0,599.0,,,"Multiplexed high-throughput screen for small molecule regulators of Bcl-2 family protein interactions, specifically Bim-Bcl-W.",Screening,,
196,954,1,2,,11111224,3454,Inactive,33286420.0,5315.0,,Potency,qHTS Assay for Activators of Human Muscle Pyruvate Kinase,Confirmatory,,
197,957,1,2,,11111224,3454,Inactive,757912.0,2717.0,,Potency,Counterscreen for Glucocerebrosidase Inhibitors: qHTS Assay for Coffee Bean alpha-Galactosidase at pH 4.5,Confirmatory,,
198,958,1,2,,11111224,3454,Inactive,33286420.0,5315.0,,Potency,qHTS Assay for Inhibitors of Human Muscle Pyruvate Kinase,Confirmatory,,
199,959,1,4,,11111224,3454,Inactive,290753097.0,,,Potency,qHTS Validation Assay for Activators of Leishmania Mexicana Pyruvate Kinase,Confirmatory,,
200,992,1,3,,11111224,3454,Inactive,757912.0,2717.0,,Potency,Counterscreen for Glucocerebrosidase Inhibitors: qHTS Assay for Human alpha-Galactosidase at pH 4.5,Confirmatory,,
201,995,1,2,,11111224,3454,Inactive,66932916.0,5594.0,,Potency,qHTS Assay for Inhibitors of the ERK Signaling Pathway using a Homogeneous Screening Assay,Confirmatory,,
202,995,1,2,,11111225,3454,Inactive,66932916.0,5594.0,,Potency,qHTS Assay for Inhibitors of the ERK Signaling Pathway using a Homogeneous Screening Assay,Confirmatory,,
203,997,1,2,,11111224,3454,Inactive,52076901.0,4341833.0,,Potency,Counterscreen for Glucocerebrosidase Inhibitors: qHTS Assay for Rice alpha-Glucosidase at pH 5.0,Confirmatory,,
204,998,1,2,,11111224,3454,Inactive,757912.0,2717.0,,Potency,Counterscreen for Glucocerebrosidase Inhibitors: qHTS Assay for Coffee Bean alpha-Galactosidase at pH 5.9,Confirmatory,,
205,1001,2,2,,8139883,3454,Inactive,116734717.0,249.0,,EC50,uHTS identification of compounds activating TNAP in the absence of phosphate acceptor performed in luminescent assay,Confirmatory,,
206,1006,1,6,,8139883,3454,Inactive,,,,,Counter Screen for Luciferase-based Primary Inhibition Assays,Screening,,
207,1007,1,1,,8139883,3454,Inactive,510901.0,598.0,,,"Multiplexed high-throughput screen for small molecule regulators of Bcl-2 family protein interactions, specifically Bim-Bcl-XL.",Screening,,
208,1008,1,2,,8139883,3454,Inactive,4757840.0,597.0,,,"Multiplexed high-throughput screen for small molecule regulators of Bcl-2 family protein interactions, specifically Bim-Bfl-1",Screening,,
209,1009,1,2,,8139883,3454,Inactive,7582271.0,4170.0,,,"Multiplexed high-throughput screen for small molecule regulators of Bcl-2 family protein interactions, specifically Bim-Mcl-1",Screening,,
210,1012,1,4,,8139883,3454,Inactive,116734717.0,249.0,,,uHTS identification of TNAP inhibitors in the absence of phosphate acceptor performed in luminescent assay,Screening,,
211,1016,1,4,,8139883,3454,Inactive,68299797.0,280993.0,,,Luminescent assay for identification of activators of bovine intestinal alkaline phosphatase,Screening,,
212,1018,2,5,,8139883,3454,Inactive,8744934.0,,,IC50,Chemical Antagonists IAP-family anti-apoptotic proteins,Confirmatory,,
213,1019,1,4,,8139883,3454,Inactive,68299797.0,280993.0,,,Luminescent assay for identification of inhibitors of bovine intestinal alkaline phosphatase,Screening,,
214,1020,1,5,,8139883,3454,Inactive,149631.0,,,,Counter Screen for Glucose-6-Phosphate Dehydrogenase-based Primary Assay,Screening,,
215,1021,1,1,,8139883,3454,Inactive,7582271.0,4170.0,,,uHTS of Mcl-1/Bid interaction inhibitors,Screening,,
216,1022,1,1,,8139883,3454,Inactive,7582271.0,4170.0,,,uHTS of Mcl-1/Noxa interaction inhibitors,Screening,,
217,1027,1,3,,8139883,3454,Inactive,,,,,Counter Screen for Luciferase-based Primary Stimulation Assays,Screening,,
218,1030,2,1,,8139883,3454,Inactive,30582681.0,216.0,,Potency,qHTS Assay for Inhibitors of Aldehyde Dehydrogenase 1 (ALDH1A1),Confirmatory,,
219,1030,2,1,,11111225,3454,Inactive,30582681.0,216.0,,Potency,qHTS Assay for Inhibitors of Aldehyde Dehydrogenase 1 (ALDH1A1),Confirmatory,,
220,1030,2,1,,50106328,3454,Inconclusive,30582681.0,216.0,39.8107,Potency,qHTS Assay for Inhibitors of Aldehyde Dehydrogenase 1 (ALDH1A1),Confirmatory,,
221,1032,1,2,,8139883,3454,Inactive,20336229.0,5468.0,,,Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma),Screening,,
222,1032,1,2,,8139883,3454,Inactive,62201602.0,,,,Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma),Screening,,
223,1040,1,2,,8139883,3454,Inactive,4505445.0,4886.0,,,Primary cell-based high-throughput screening assay for antagonists of NPY-Y1,Screening,,
224,1046,1,6,,8139883,3454,Inactive,339641.0,2147.0,,,Thrombin 1536 HTS,Screening,,
225,1048,1,1,,8139883,3454,Inactive,20336229.0,5468.0,,,Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma),Other,,
226,1048,1,1,,8139883,3454,Inactive,32307126.0,8202.0,,,Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma),Other,,
227,1049,1,1,,8139883,3454,Inactive,20336229.0,5468.0,,,Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma),Other,,
228,1049,1,1,,8139883,3454,Inactive,62201602.0,,,,Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma),Other,,
229,1051,1,1,,8139883,3454,Inactive,20336229.0,5468.0,,,Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma),Other,,
230,1051,1,1,,8139883,3454,Inactive,22538455.0,8648.0,,,Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma),Other,,
231,1063,1,1,,8139883,3454,Inactive,,,,,Leishmania major promastigote HTS,Screening,,
232,1066,1,2,,8139883,3454,Inactive,9937384.0,,,,High Throughput Screen to Identify Compounds that Inhibit Class II HMG-CoA Reductases  - Primary Screen,Screening,,
233,1085,1,1,,8139883,3454,Inactive,139424501.0,5176170.0,,,uHTS for Small Molecule Inhibitiors of Epstein-Barr Virus Inhibitors,Screening,,
234,1135,1,3,,8139883,3454,Inactive,116734717.0,249.0,,,uHTS identification of compounds inhibiting TNAP at a high concentration of phosphate acceptor detected in a luminescent assay,Screening,,
235,1136,1,3,,8139883,3454,Inactive,116734717.0,249.0,,,uHTS identification of compounds activating TNAP at a high concentration of phosphate acceptor detected in a luminescent assay,Screening,,
236,1203,1,3,,8139883,3454,Inactive,12803275.0,3303.0,,,Primary cell-based high-throughput screening assay to identify transcriptional activators of heat shock protein 70 (Hsp70),Screening,,
237,1209,2,2,,8139883,3454,Inactive,16878311.0,4351.0,,IC50,HTS identification of compounds inhibiting phosphomannose isomerase (PMI) via a fluorescence intensity assay.,Confirmatory,,
238,1214,1,4,,8139883,3454,Inactive,16878311.0,4351.0,,,HTS identification of compounds activating phosphomannose isomerase (PMI) via a fluorescence intensity assay.,Screening,,
239,1216,1,5,,8139883,3454,Inactive,16878311.0,4351.0,,,HTS identification of compounds activating phosphomannose isomerase (PMI) via a fluorescence intensity assay using a near- saturating concentration of mannose 6-phosphat,Screening,,
240,1217,1,4,,8139883,3454,Inactive,17391426.0,1738.0,,,uHTS Identification of Diaphorase Inhibitors and Chemcical Oxidizers: Counter Screen for Diaphorase-based Primary Assays,Screening,,
241,1220,2,2,,8139883,3454,Inactive,16878311.0,4351.0,,IC50,HTS identification of compounds inhibiting phosphomannose isomerase (PMI) via a fluorescence intensity assay using a high concentration of mannose 6-phosphate,Confirmatory,,
242,1222,1,6,,8139883,3454,Inactive,,,,EC50,High Throughput Screen for Inhibitors of ER Stress-induced Cell Death in a 384 well format.,Confirmatory,,
243,1229,1,3,,8139883,3454,Inactive,17391426.0,1738.0,,,uHTS Identification of Diaphorase Activators and Chemical Reducers: Counter Screen for Diaphorase-based Primary Assays,Screening,,
244,1236,1,1,,8139883,3454,Inactive,1628587.0,397393.0,,,uHTS for Calpain Inhibitors,Screening,,
245,1239,1,3,,8139883,3454,Inactive,34577122.0,4790.0,,,High Throughput Screen to Identify Compounds that increase expression of NF-kB in Human Neuronal Cells - Primary Screen,Screening,,
246,1239,1,3,,8139883,3454,Inactive,223468676.0,5970.0,,,High Throughput Screen to Identify Compounds that increase expression of NF-kB in Human Neuronal Cells - Primary Screen,Screening,,
247,1242,1,1,,8139883,3454,Inactive,11094021.0,,,,C. albicans biofilm killing---Mixture HTS,Screening,,
248,1251,1,1,,8139883,3454,Inactive,,,,,"Anti-Viral Drugs Against Arbovirus Infections, a Primary Screen",Screening,,
249,1273,1,1,,8139883,3454,Inactive,59036749.0,3630.0,,,Primary screen for compounds that inhibit Insulin promoter activity in TRM-6 cells,Screening,,
250,1274,1,2,,8139883,3454,Inactive,115298672.0,653361.0,,,"uHTS of small molecular inhibitors for p47phox, a regulatory protein of NADPH oxidases (Noxs)",Screening,,
251,1276,1,1,,8139883,3454,Inactive,257380.0,351.0,,,Primary screen for compounds that activate Alzheimer's amyloid precursor,Screening,,
252,1285,1,1,,8139883,3454,Inactive,257380.0,351.0,,,Primary screen for compounds that inhibit Alzheimer's amyloid precursor protein (APP) translation,Screening,,
253,1296,1,1,,8139883,3454,Inactive,59036749.0,3630.0,,,Primary screen for compounds that activate Insulin promoter activity in TRM-6 cells,Screening,,
254,1304,1,2,,8139883,3454,Inactive,4505445.0,4886.0,,,Primary cell-based high-throughput screening assay for potentiators or agonists of NPY-Y1,Screening,,
255,1321,1,2,,8139883,3454,Inactive,47123300.0,7465.0,,,Primary Cell-based High Throughput Screening Assay for Inhibitors of Wee1 Degradation,Screening,,
256,1325,1,2,,8139883,3454,Inactive,62526033.0,9429.0,,,"High-throughput multiplex screening for ABC transporter inhibitors: specifically ABCG2 screen, ABCB1 counter-screen",Screening,,
257,1326,1,4,,8139883,3454,Inactive,42741659.0,5243.0,,,"High-throughput multiplex screening for ABC transporter inhibitors: specifically ABCB1 screen, ABCG2 counter-screen",Screening,,
258,1332,1,1,,49698657,3454,Inactive,,,,,High Throughput Screen to Identify Inhibitors of Mycobacterium tuberculosis H37Rv,Confirmatory,,
259,1359,1,4,,8139883,3454,Inactive,4505447.0,4887.0,,,Primary cell-based high-throughput screening assay for potentiators or agonists of NPY-Y2,Screening,,
260,1362,1,2,,8139883,3454,Inactive,,,,,Chemical Genetic Screen to Identify Inhibitors of Mitochondrial Fusion - Primary Screen,Screening,,
261,1376,1,2,,8139883,3454,Inactive,15608158.0,886069.0,,IC50,Inhibitors of Mycobacterial Glucosamine-1-phosphate acetyl transferase (GlmU),Confirmatory,,
262,1377,1,1,,8139883,3454,Inactive,,,,,HTS to identify inhibitors of zVAD Induced Cell Death in L929 Cells.,Screening,,
263,1379,1,2,,8139883,3454,Inactive,1669525.0,,,Potency,Counterscreen for Luciferase (Kinase-Glo TM) Inhibition,Confirmatory,,
264,1379,1,2,,11111225,3454,Inactive,1669525.0,,,Potency,Counterscreen for Luciferase (Kinase-Glo TM) Inhibition,Confirmatory,,
265,1379,1,2,,50106328,3454,Inactive,1669525.0,,,Potency,Counterscreen for Luciferase (Kinase-Glo TM) Inhibition,Confirmatory,,
266,1381,1,1,,8139883,3454,Inactive,,,,,HCS to Identify Inhibitors of Dynein Mediated Cargo Transport on Microtubules.,Screening,,
267,1385,2,2,,8139883,3454,Inactive,49168602.0,5888.0,,,Homologous recombination - Rad 51,Screening,,
268,1415,1,2,,8139883,3454,Inactive,10567816.0,2775.0,,,"Multiplexed high-throughput screen for small molecule regulators of RGS family protein interactions, specifically RGS4-Galphao.",Screening,,
269,1415,1,2,,8139883,3454,Inactive,86301151.0,5999.0,,,"Multiplexed high-throughput screen for small molecule regulators of RGS family protein interactions, specifically RGS4-Galphao.",Screening,,
270,1416,1,2,,8139883,3454,Inactive,134304838.0,9451.0,,,Primary cell-based high-throughput screening assay to measure PERK inhibition,Screening,,
271,1422,1,1,,8139883,3454,Inactive,31881630.0,5732.0,,,Inhibitors of the EP2 Prostaglandin E2 Receptor - Primary Screen,Screening,,
272,1422,1,1,,17405102,3454,Inactive,31881630.0,5732.0,,,Inhibitors of the EP2 Prostaglandin E2 Receptor - Primary Screen,Screening,,
273,1423,1,2,,8139883,3454,Inactive,10567816.0,2775.0,,,"Multiplexed high-throughput screen for small molecule regulators of RGS family protein interactions, specifically RGS8-Galphao.",Screening,,
274,1423,1,2,,8139883,3454,Inactive,74355113.0,85397.0,,,"Multiplexed high-throughput screen for small molecule regulators of RGS family protein interactions, specifically RGS8-Galphao.",Screening,,
275,1424,1,1,,8139883,3454,Inactive,34330186.0,368273.0,,,Primary cell-based high-throughput screening assay to identify agonists of the transient receptor potential channel N1 (TRPN1),Screening,,
276,1430,1,1,,8139883,3454,Inactive,70832125.0,3663016.0,,,HTS assay for inhibitors of Trypanosoma brucei hexokinase 1,Screening,,
277,1434,2,3,,8139883,3454,Inactive,13124881.0,865.0,,IC50,uHTS identification of compounds inhibiting the binding between the RUNX1 Runt domain and CBFb-SMMHC via a fluorescence resonance energy transfer (FRET) assay.,Confirmatory,,
278,1434,2,3,,8139883,3454,Inactive,19923198.0,861.0,,IC50,uHTS identification of compounds inhibiting the binding between the RUNX1 Runt domain and CBFb-SMMHC via a fluorescence resonance energy transfer (FRET) assay.,Confirmatory,,
279,1439,1,1,,8139883,3454,Inactive,1166512.0,6000.0,,,"Multiplexed high-throughput screen for small molecule regulators of RGS family protein interactions, specifically RGS7-Galphao.",Screening,,
280,1439,1,1,,8139883,3454,Inactive,10567816.0,2775.0,,,"Multiplexed high-throughput screen for small molecule regulators of RGS family protein interactions, specifically RGS7-Galphao.",Screening,,
281,1440,1,1,,8139883,3454,Inconclusive,10567816.0,2775.0,,,"Multiplexed high-throughput screen for small molecule regulators of RGS family protein interactions, specifically RGS19-Galphao.",Screening,,
282,1440,1,1,,8139883,3454,Inconclusive,86990435.0,10287.0,,,"Multiplexed high-throughput screen for small molecule regulators of RGS family protein interactions, specifically RGS19-Galphao.",Screening,,
283,1441,1,1,,8139883,3454,Inactive,10567816.0,2775.0,,,"Multiplexed high-throughput screen for small molecule regulators of RGS family protein interactions, specifically RGS16-Galphao.",Screening,,
284,1441,1,1,,8139883,3454,Inactive,156416009.0,6004.0,,,"Multiplexed high-throughput screen for small molecule regulators of RGS family protein interactions, specifically RGS16-Galphao.",Screening,,
285,1443,1,3,,8139883,3454,Inactive,4507593.0,8743.0,,,uHTS for the identification of compounds that potentiate TRAIL-induced apoptosis of cancer cells,Screening,,
286,1445,1,1,,8139883,3454,Inactive,124512980.0,813945.0,,IC50,Inhibitors of Plasmodium falciparum M1- Family Alanyl Aminopeptidase (M1AAP),Confirmatory,,
287,1446,1,3,,8139883,3454,Inactive,119579178.0,3717.0,,,Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F,Screening,,
288,1448,1,3,,8139883,3454,Inactive,38174238.0,55283.0,,,Primary cell-based high-throughput screening assay to identify agonists of the transient receptor potential channel ML3 (TRPML3),Screening,,
289,1452,1,1,,8139883,3454,Inactive,154426292.0,239.0,,Potency,qHTS Assay for Inhibitors of 12-hLO (12-human lipoxygenase),Confirmatory,,
290,1452,1,1,,11111224,3454,Inactive,154426292.0,239.0,,Potency,qHTS Assay for Inhibitors of 12-hLO (12-human lipoxygenase),Confirmatory,,
291,1452,1,1,,11111225,3454,Inactive,154426292.0,239.0,,Potency,qHTS Assay for Inhibitors of 12-hLO (12-human lipoxygenase),Confirmatory,,
292,1454,1,1,,8139883,3454,Inactive,66932916.0,5594.0,,Potency,qHTS Assay for Inhibitors of the ERK Signaling Pathway using a Homogeneous Screening Assay; Stimulation with EGF,Confirmatory,,
293,1454,1,1,,11111225,3454,Inactive,66932916.0,5594.0,,Potency,qHTS Assay for Inhibitors of the ERK Signaling Pathway using a Homogeneous Screening Assay; Stimulation with EGF,Confirmatory,,
294,1454,1,1,,50106328,3454,Inactive,66932916.0,5594.0,,Potency,qHTS Assay for Inhibitors of the ERK Signaling Pathway using a Homogeneous Screening Assay; Stimulation with EGF,Confirmatory,,
295,1456,1,1,,8139883,3454,Inactive,12003227.0,57468.0,,,Identification of Novel Modulators of Cl- dependent Transport Process via HTS: Primary Screen,Other,,
296,1457,1,1,,8139883,3454,Inactive,44888968.0,83523.0,,Potency,qHTS Assay for Identifying the Cell-Membrane Permeable IMPase Inhibitors: Potentiation with Lithium,Confirmatory,,
297,1457,1,1,,11111225,3454,Inactive,44888968.0,83523.0,,Potency,qHTS Assay for Identifying the Cell-Membrane Permeable IMPase Inhibitors: Potentiation with Lithium,Confirmatory,,
298,1457,1,1,,50106328,3454,Inactive,44888968.0,83523.0,,Potency,qHTS Assay for Identifying the Cell-Membrane Permeable IMPase Inhibitors: Potentiation with Lithium,Confirmatory,,
299,1458,1,1,,8139883,3454,Inactive,10937869.0,6607.0,1.5849,Potency,qHTS Assay for Enhancers of SMN2 Splice Variant Expression,Confirmatory,,
300,1458,1,1,,11111225,3454,Inactive,10937869.0,6607.0,,Potency,qHTS Assay for Enhancers of SMN2 Splice Variant Expression,Confirmatory,,
301,1458,1,1,,50106328,3454,Inconclusive,10937869.0,6607.0,35.4813,Potency,qHTS Assay for Enhancers of SMN2 Splice Variant Expression,Confirmatory,,
302,1459,1,1,,50106328,3454,Inactive,27436948.0,4000.0,,Potency,Validation of Assay for Modulators of Lamin A Splicing,Confirmatory,,
303,1460,1,3,,8139883,3454,Inactive,92096784.0,4137.0,,Potency,"qHTS for Inhibitors of Tau Fibril Formation, Thioflavin T Binding",Confirmatory,,
304,1460,1,3,,50106328,3454,Inactive,92096784.0,4137.0,,Potency,"qHTS for Inhibitors of Tau Fibril Formation, Thioflavin T Binding",Confirmatory,,
305,1461,1,2,,8139883,3454,Inactive,46395496.0,387129.0,,Potency,qHTS Assay for Antagonists of the Neuropeptide S Receptor: cAMP Signal Transduction,Confirmatory,,
306,1461,1,2,,50106328,3454,Inactive,46395496.0,387129.0,,Potency,qHTS Assay for Antagonists of the Neuropeptide S Receptor: cAMP Signal Transduction,Confirmatory,,
307,1463,1,1,,8139883,3454,Inactive,,,,Potency,"Counterscreen qHTS for Inhibitors of Tau Fibril Formation, Fluorescence Polarization",Confirmatory,,
308,1463,1,1,,50106328,3454,Inactive,,,,Potency,"Counterscreen qHTS for Inhibitors of Tau Fibril Formation, Fluorescence Polarization",Confirmatory,,
309,1465,1,1,,8139883,3454,Inactive,,,,EC50,"Screen for small molecule probes relevant to Friedreich's ataxia, Single Dose and Dose Response",Confirmatory,,
310,1466,1,2,,8139883,3454,Inactive,119393891.0,2548.0,,Potency,qHTS Assay for Inhibitors of Human alpha-Glucosidase as a Potential Chaperone Treatment of Pompe Disease,Confirmatory,,
311,1467,1,3,,11111225,3454,Inactive,757912.0,2717.0,,Potency,qHTS Assay for Inhibitors of Human alpha-Galactosidase at pH 4.5.,Confirmatory,,
312,1467,1,3,,50106328,3454,Inactive,757912.0,2717.0,,Potency,qHTS Assay for Inhibitors of Human alpha-Galactosidase at pH 4.5.,Confirmatory,,
313,1468,1,1,,8139883,3454,Inactive,92096784.0,4137.0,,Potency,"qHTS for Inhibitors of Tau Fibril Formation, Fluorescence Polarization",Confirmatory,,
314,1468,1,1,,50106328,3454,Inactive,92096784.0,4137.0,,Potency,"qHTS for Inhibitors of Tau Fibril Formation, Fluorescence Polarization",Confirmatory,,
315,1469,1,1,,8139883,3454,Inactive,189491771.0,7068.0,,Potency,qHTS for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2,Confirmatory,,
316,1469,1,1,,11111225,3454,Inactive,189491771.0,7068.0,,Potency,qHTS for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2,Confirmatory,,
317,1469,1,1,,50106328,3454,Inactive,189491771.0,7068.0,,Potency,qHTS for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2,Confirmatory,,
318,1471,2,1,,11111224,3454,Inactive,90903231.0,3064.0,,,qHTS Multiplex Assay to Identify Dual Action Probes in a Cell Model of Huntington: Cytoprotection (ATP),Confirmatory,,
319,1471,2,1,,11111225,3454,Inactive,90903231.0,3064.0,,,qHTS Multiplex Assay to Identify Dual Action Probes in a Cell Model of Huntington: Cytoprotection (ATP),Confirmatory,,
320,1476,2,1,,8139883,3454,Inactive,281307097.0,,,Potency,qHTS Assay for Promiscuous and Specific Inhibitors of Cruzain (without detergent),Confirmatory,,
321,1476,2,1,,11111225,3454,Inactive,281307097.0,,,Potency,qHTS Assay for Promiscuous and Specific Inhibitors of Cruzain (without detergent),Confirmatory,,
322,1476,2,1,,50106328,3454,Inactive,281307097.0,,,Potency,qHTS Assay for Promiscuous and Specific Inhibitors of Cruzain (without detergent),Confirmatory,,
323,1477,1,1,,8139883,3454,Inactive,,,,Potency,qHTS Assay for Compounds Blocking the Interaction Between CBF-beta and RUNX1 for the Treatment of Acute Myeloid Leukemia,Confirmatory,,
324,1477,1,1,,11111225,3454,Inactive,,,,Potency,qHTS Assay for Compounds Blocking the Interaction Between CBF-beta and RUNX1 for the Treatment of Acute Myeloid Leukemia,Confirmatory,,
325,1477,1,1,,50106328,3454,Inactive,,,,Potency,qHTS Assay for Compounds Blocking the Interaction Between CBF-beta and RUNX1 for the Treatment of Acute Myeloid Leukemia,Confirmatory,,
326,1478,2,1,,8139883,3454,Inactive,281307097.0,,,Potency,qHTS Assay for Promiscuous and Specific Inhibitors of Cruzain (with detergent),Confirmatory,,
327,1478,2,1,,11111225,3454,Inactive,281307097.0,,,Potency,qHTS Assay for Promiscuous and Specific Inhibitors of Cruzain (with detergent),Confirmatory,,
328,1478,2,1,,50106328,3454,Inactive,281307097.0,,,Potency,qHTS Assay for Promiscuous and Specific Inhibitors of Cruzain (with detergent),Confirmatory,,
329,1479,1,2,,8139883,3454,Inactive,189491771.0,7068.0,,Potency,Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2,Confirmatory,,
330,1479,1,2,,11111225,3454,Inactive,189491771.0,7068.0,,Potency,Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2,Confirmatory,,
331,1479,1,2,,50106328,3454,Inactive,189491771.0,7068.0,,Potency,Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2,Confirmatory,,
332,1481,1,2,,8139883,3454,Inactive,111305821.0,7415.0,,,Primary biochemical high-throughput screening assay to measure P97 ATPase inhibition,Screening,,
333,1486,1,3,,8139883,3454,Inactive,,,,,Counterscreen for inhibitors of Janus kinase 2 mutant JAK2V617F: Cell-based high throughput assay to identify inhibitors of parental Ba/F3 cell viability.,Screening,,
334,1487,1,1,,8139883,3454,Inactive,27436948.0,4000.0,,Potency,qHTS Assay for Modulators of Lamin A Splicing,Confirmatory,,
335,1487,1,1,,11111225,3454,Inconclusive,27436948.0,4000.0,3.1623,Potency,qHTS Assay for Modulators of Lamin A Splicing,Confirmatory,,
336,1487,1,1,,50106328,3454,Inactive,27436948.0,4000.0,,Potency,qHTS Assay for Modulators of Lamin A Splicing,Confirmatory,,
337,1490,2,1,,8139883,3454,Inactive,10954339.0,,,Potency,qHTS Assay for Inhibitors of Bacillus subtilis Sfp phosphopantetheinyl transferase (PPTase),Confirmatory,,
338,1490,2,1,,11111225,3454,Inactive,10954339.0,,,Potency,qHTS Assay for Inhibitors of Bacillus subtilis Sfp phosphopantetheinyl transferase (PPTase),Confirmatory,,
339,1496,1,4,,8139883,3454,Inactive,13124881.0,865.0,,,uHTS identification of compounds inhibiting the binding between the RUNX1 Runt domain and CBFb via a fluorescence resonance energy transfer (FRET) assay.,Screening,,
340,1496,1,4,,8139883,3454,Inactive,19923198.0,861.0,,,uHTS identification of compounds inhibiting the binding between the RUNX1 Runt domain and CBFb via a fluorescence resonance energy transfer (FRET) assay.,Screening,,
341,1509,1,2,,8139883,3454,Inactive,15929025.0,8698.0,,,Primary Cell-Based Assay to Identify Agonists of the Sphingosine 1-Phosphate Receptor 4 (S1P4),Screening,,
342,1510,1,3,,8139883,3454,Inactive,15929025.0,8698.0,,,Primary Cell-Based Assay to Identify Antagonists of the Sphingosine 1-Phosphate Receptor 4 (S1P4),Screening,,
343,1511,1,3,,8139883,3454,Inactive,487738.0,3757.0,,,Primary cell-based high-throughput screening assay for identification of compounds that protect hERG from block by proarrhythmic agents,Screening,,
344,1515,1,2,,8139883,3454,Inactive,24119166.0,10741.0,,,Primary biochemical high throughput screening assay to identify inhibitors of Retinoblastoma binding protein 9 (RBBP9),Screening,,
345,1519,1,3,,11111225,3454,Inactive,,,,Potency,qHTS Assay for Lipid Storage Modulators,Confirmatory,,
346,1519,1,3,,50106328,3454,Inactive,,,,Potency,qHTS Assay for Lipid Storage Modulators,Confirmatory,,
347,1527,1,3,,8139883,3454,Inactive,7381449.0,14678525.0,,,Primary biochemical high throughput screening assay to identify inhibitors of VIM-2 metallo-beta-lactamase,Screening,,
348,1529,1,1,,8139883,3454,Inactive,42794767.0,4215.0,,,"Multiplex HTS Assay for Inhibitors of MEK Kinase PB1 Domains, specifically MEK5 MEK Kinase3 Wildtype",Screening,,
349,1530,1,1,,8139883,3454,Inactive,22035600.0,5871.0,,,"Multiplex HTS Assay for Inhibitors of MEK Kinase PB1 Domains, specifically MEK5 MEK Kinase 2 mutant",Screening,,
350,1531,1,1,,8139883,3454,Inactive,22035600.0,5871.0,,,"Multiplex HTS Assay for Inhibitors of MEK Kinase PB1 Domains, specifically MEK5 binding to MEK Kinase 2 Wildtype",Screening,,
351,1532,1,1,,8139883,3454,Inactive,,,,,Rml C and D inhibition 384-well mixture HTS,Screening,,
352,1554,1,1,,8139883,3454,Inactive,,,,,MLPCN Ras selective lethality-BJeLR viability,Screening,,
353,1556,1,4,,8139883,3454,Inactive,27368096.0,,,,Epi-absorbance primary biochemical high throughput screening assay to identify inhibitors of IMP-1 metallo-beta-lactamase,Screening,,
354,1565,2,2,,8139883,3454,Inactive,219689097.0,162466.0,,IC50,uHTS absorbance assay for the identification of compounds that inhibit PHOSPHO1,Confirmatory,,
355,1566,2,3,,8139883,3454,Inactive,11545912.0,64127.0,,EC50,uHTS luminescence assay for the identification of compounds that inhibit NOD2,Confirmatory,,
356,1578,3,2,,8139883,3454,Inactive,5174617.0,10392.0,,EC50,uHTS luminescence assay for the identification of compounds that inhibit NOD1,Confirmatory,,
357,1619,1,2,,8139883,3454,Inactive,124809582.0,812021.0,,IC50,Inhibitors of Plasmodium falciparum M17- Family Leucine Aminopeptidase (M17LAP),Confirmatory,,
358,1621,1,2,,8139883,3454,Inactive,,,,IC50,A Cell Based Assay for the Identification of Lead Compounds with Anti-Viral Activity Against West Nile Virus,Confirmatory,,
359,1626,1,2,,8139883,3454,Inactive,,,,IC50,High Throughput Screen to Identify Inhibitors of Mycobacterium tuberculosis H37Rv,Confirmatory,,
360,1631,3,1,,8139883,3454,Inactive,33286418.0,5315.0,,Potency,qHTS Assay for Activators of Human Muscle isoform 2 Pyruvate Kinase,Confirmatory,,
361,1634,3,1,,8139883,3454,Inactive,33286418.0,5315.0,,Potency,qHTS Assay for Inhibitors of Human Muscle isoform 2 Pyruvate Kinase,Confirmatory,,
362,1654,2,2,,8139883,3454,Inactive,4758208.0,1845.0,,IC50,uHTS absorbance assay for the identification of compounds that inhibit VHR1.,Confirmatory,,
363,1656,2,2,,8139883,3454,Inactive,,,,,High Throughput Imaging Assay for Hepatic Lipid Droplet Formation,Screening,,
364,1662,1,2,,8139883,3454,Inactive,15675770.0,901648.0,,,MLPCN Streptokinase Expression Inhibition,Screening,,
365,1663,1,2,,8139883,3454,Inactive,,,,,MLPCN Platelet Activation -Dense Granule Release,Screening,,
366,1672,1,3,,8139883,3454,Inactive,6680530.0,16518.0,,,Primary cell-based high-throughput screening assay for identification of compounds that inhibit/block inward-rectifying potassium ion channel Kir2.1,Screening,,
367,1688,1,1,,8139883,3454,Inactive,90903231.0,3064.0,,Potency,qHTS Multiplex Assay to Identify Dual Action Probes in a Cell Model of Huntington: Aggregate Formation (GFP),Confirmatory,,
368,1688,1,1,,11111225,3454,Inactive,90903231.0,3064.0,,Potency,qHTS Multiplex Assay to Identify Dual Action Probes in a Cell Model of Huntington: Aggregate Formation (GFP),Confirmatory,,
369,1700,1,2,,8139883,3454,Inactive,124263658.0,688.0,,,Primary cell-based high throughput screening assay to identify inhibitors of kruppel-like factor 5 (KLF5),Screening,,
370,1705,1,2,,50106328,3454,Inactive,6980812.0,,,Potency,qHTS Validation Assay for Inhibitors of the Human Apurinic/apyrimidinic  Endonuclease 1 (APE1),Confirmatory,,
371,1706,1,2,,8139883,3454,Inactive,73745819.0,,,,QFRET-based primary biochemical high throughput screening assay to identify inhibitors of the SARS coronavirus 3C-like Protease (3CLPro),Screening,,
372,1707,1,3,,50106328,3454,Inactive,,,,Potency,Counterscreen for APE1 Inhibitors: Fluorescent Dye Displacement Validation Assay,Confirmatory,,
373,1708,1,3,,50106328,3454,Inconclusive,405898.0,,12.5893,Potency,Counterscreen for APE1 Inhibitors: qHTS Validation Assay for Inhibitors of Endonuclease IV,Confirmatory,,
374,1721,1,2,,8139883,3454,Inactive,290753097.0,,,Potency,qHTS Assay for Inhibitors of Leishmania Mexicana Pyruvate Kinase (LmPK),Confirmatory,,
375,1722,1,2,,8139883,3454,Inactive,290753097.0,,,Potency,qHTS Assay for Activators of Leishmania Mexicana Pyruvate Kinase (LmPK),Confirmatory,,
376,1766,1,1,,8139883,3454,Inactive,18860839.0,4221.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Fluorescein Labeled MLL-derived Peptide,Confirmatory,,
377,1766,1,1,,8139883,3454,Inactive,56550039.0,4297.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Fluorescein Labeled MLL-derived Peptide,Confirmatory,,
378,1766,1,1,,11111225,3454,Inconclusive,18860839.0,4221.0,10.0,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Fluorescein Labeled MLL-derived Peptide,Confirmatory,,
379,1766,1,1,,11111225,3454,Inconclusive,56550039.0,4297.0,10.0,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Fluorescein Labeled MLL-derived Peptide,Confirmatory,,
380,1766,1,1,,50106328,3454,Inactive,18860839.0,4221.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Fluorescein Labeled MLL-derived Peptide,Confirmatory,,
381,1766,1,1,,50106328,3454,Inactive,56550039.0,4297.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Fluorescein Labeled MLL-derived Peptide,Confirmatory,,
382,1768,1,1,,8139883,3454,Inactive,18860839.0,4221.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Texas Red Labeled MLL-derived Mutant Peptide,Confirmatory,,
383,1768,1,1,,8139883,3454,Inactive,56550039.0,4297.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Texas Red Labeled MLL-derived Mutant Peptide,Confirmatory,,
384,1768,1,1,,11111225,3454,Inconclusive,18860839.0,4221.0,10.0,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Texas Red Labeled MLL-derived Mutant Peptide,Confirmatory,,
385,1768,1,1,,11111225,3454,Inconclusive,56550039.0,4297.0,10.0,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Texas Red Labeled MLL-derived Mutant Peptide,Confirmatory,,
386,1768,1,1,,50106328,3454,Inactive,18860839.0,4221.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Texas Red Labeled MLL-derived Mutant Peptide,Confirmatory,,
387,1768,1,1,,50106328,3454,Inactive,56550039.0,4297.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Texas Red Labeled MLL-derived Mutant Peptide,Confirmatory,,
388,1775,1,2,,8139883,3454,Inactive,,,,,Profiling compound fluorescence on Avidin Beads with 488 nm excitation and 530 nm emission,Other,,
389,1776,1,2,,8139883,3454,Inactive,,,,,Profiling compound fluorescence on GSH Beads with 488 nm excitation and 530 nm emission,Other,,
390,1777,3,2,,8139883,3454,Inactive,39725940.0,4986.0,,EC50,uHTS identification of small molecule agonists of the kappa opioid receptor via a luminescent beta-arrestin assay,Confirmatory,,
391,1778,3,3,,8139883,3454,Inactive,39725940.0,4986.0,,IC50,uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay,Confirmatory,,
392,1779,2,2,,8139883,3454,Inactive,224586929.0,26191.0,,IC50,uHTS identification of small molecule inhibitors of LYP via a fluorescence intensity assay,Confirmatory,,
393,1789,1,2,,8139883,3454,Inactive,83318444.0,3320.0,,,Luminescence-based primary biochemical high throughput screening assay to identify inhibitors of the Heat Shock Protein 90 (HSP90),Screening,,
394,1800,1,2,,8139883,3454,Inactive,125541954.0,,,,Fluorescence-based primary biochemical high throughput screening assay to identify inhibitors of the Hepatitis C Virus non-structural protein 3 helicase (NS3),Screening,,
395,1813,1,2,,8139883,3454,Inactive,,,,,MLPCN Alpha-Synuclein 5'UTR - 5'-UTR binding - inhibitors,Screening,,
396,1814,1,2,,8139883,3454,Inactive,,,,,MLPCN Alpha-Synuclein 5'UTR - 5'-UTR binding - activators,Screening,,
397,1815,1,1,,50106328,3454,Inactive,,,,Potency,qHTS for differential inhibitors of proliferation of Plasmodium falciparum line 7G8,Confirmatory,,
398,1816,1,1,,50106328,3454,Inactive,,,,Potency,qHTS for differential inhibitors of proliferation of Plasmodium falciparum line GB4,Confirmatory,,
399,1817,2,2,,8139883,3454,Inactive,40849930.0,5339.0,,IC50,uHTS identification of small molecule antagonists of the binding of Siah-1 and a peptide ligand via a fluorescence polarization assay.,Confirmatory,,
400,1822,1,3,,8139883,3454,Inactive,23505220.0,813594.0,,,QFRET-based primary biochemical high throughput screening assay to identify inhibitors of the Plasmodium falciparum M18 Aspartyl Aminopeptidase (PFM18AAP).,Screening,,
401,1825,1,1,,8139883,3454,Inactive,,,,,Luminescence-based counterscreen assay for KLF5 inhibitors: cell-based high throughput screening assay to identify cytotoxic compounds using the IEC-6 intestinal epithelial cell line.,Screening,,
402,1828,2,1,,50106328,3454,Inactive,,,,,qHTS for Inhibitors of Plasmodium falciparum proliferation: Summary,Summary,,
403,1832,2,1,,8139883,3454,Inactive,55976631.0,178296.0,,,MLPCN maternal gene expression-MEX-5 TCR-2 binding assay-Primary Screen,Screening,,
404,1845,1,2,,8139883,3454,Inactive,125541954.0,,,,Fluorescence-based counterscreen assay for HCV NS3 helicase inhibitors: biochemical high-throughput screening assay to identify compounds that cause fluorescent intercalator displacement (FID),Screening,,
405,1850,2,1,,8139883,3454,Inactive,,,,IC50,A small molecule screen for inhibitors of the PhoP regulon in Salmonella typhi,Confirmatory,,
406,1850,2,1,,56424026,3454,Inactive,,,,IC50,A small molecule screen for inhibitors of the PhoP regulon in Salmonella typhi,Confirmatory,,
407,1851,1,2,,11111224,3454,Unspecified,,,,,Cytochrome panel assay with activity outcomes,Other,,
408,1851,1,2,,11111225,3454,Unspecified,,,,,Cytochrome panel assay with activity outcomes,Other,,
409,1851,1,2,1.0,11111224,3454,Inactive,4503219.0,1557.0,,,Cytochrome panel assay with activity outcomes,Other,,
410,1851,1,2,1.0,11111225,3454,Inactive,4503219.0,1557.0,,,Cytochrome panel assay with activity outcomes,Other,,
411,1851,1,2,2.0,11111224,3454,Inactive,68509921.0,1565.0,,,Cytochrome panel assay with activity outcomes,Other,,
412,1851,1,2,2.0,11111225,3454,Inactive,68509921.0,1565.0,,,Cytochrome panel assay with activity outcomes,Other,,
413,1851,1,2,3.0,11111224,3454,Inconclusive,13435386.0,1576.0,,,Cytochrome panel assay with activity outcomes,Other,,
414,1851,1,2,3.0,11111225,3454,Inactive,13435386.0,1576.0,,,Cytochrome panel assay with activity outcomes,Other,,
415,1851,1,2,4.0,11111224,3454,Inactive,73915100.0,1544.0,,,Cytochrome panel assay with activity outcomes,Other,,
416,1851,1,2,4.0,11111225,3454,Inactive,73915100.0,1544.0,,,Cytochrome panel assay with activity outcomes,Other,,
417,1851,1,2,5.0,11111224,3454,Inactive,13699818.0,1559.0,,,Cytochrome panel assay with activity outcomes,Other,,
418,1851,1,2,5.0,11111225,3454,Inactive,13699818.0,1559.0,,,Cytochrome panel assay with activity outcomes,Other,,
419,1861,2,1,,8139883,3454,Inactive,119607128.0,2831.0,,,Fluorescence-based primary cell-based high throughput screening assay to identify antagonists of the G-protein coupled receptor 7 (GPR7).,Screening,,
420,1862,1,4,,8139883,3454,Inactive,536029.0,,,,Multiplex HTS Screen of TOR pathway GFP-fusion proteins in Saccharomyes cerevisiae_specifically_RPL19A,Screening,,
421,1863,2,1,,8139883,3454,Inactive,,,,IC50,A small molecule screen for inhibitors of the PhoP regulon in Salmonella Typhimurium,Confirmatory,,
422,1863,2,1,,56424026,3454,Inactive,,,,IC50,A small molecule screen for inhibitors of the PhoP regulon in Salmonella Typhimurium,Confirmatory,,
423,1865,1,1,,8139883,3454,Inactive,,,,Potency,Quantitative High-Throughput Screen for Regulators of Epigenetic Control,Confirmatory,,
424,1865,1,1,,11111225,3454,Inactive,,,,Potency,Quantitative High-Throughput Screen for Regulators of Epigenetic Control,Confirmatory,,
425,1865,1,1,,50106328,3454,Inactive,,,,Potency,Quantitative High-Throughput Screen for Regulators of Epigenetic Control,Confirmatory,,
426,1867,1,4,,8139883,3454,Inactive,1302091.0,,,,Multiplex HTS Screen of TOR pathway GFP-fusion proteins in Saccharomyes cerevisiae_specifically_MEP2,Screening,,
427,1868,1,4,,8139883,3454,Inactive,4503895.0,2584.0,,Potency,qHTS Assay for Inhibitors of Human Galactokinase (GALK),Confirmatory,,
428,1870,1,4,,8139883,3454,Inactive,171229.0,,,,Multiplex HTS Screen of TOR pathway GFP-fusion proteins in Saccharomyes cerevisiae_specifically_CIT2,Screening,,
429,1873,1,4,,8139883,3454,Inactive,486173.0,,,,Multiplex HTS Screen of TOR pathway GFP-fusion proteins in Saccharomyes cerevisiae_specifically_LAP4,Screening,,
430,1875,2,1,,8139883,3454,Inactive,,,,,Luminescence Cell-Based Primary HTS to Identify Inhibitors of Polyadenylation,Screening,,
431,1876,1,1,,50106328,3454,Inactive,,,,Potency,qHTS for differential inhibitors of proliferation of Plasmodium falciparum line 3D7,Confirmatory,,
432,1877,1,1,,50106328,3454,Inactive,,,,Potency,qHTS for differential inhibitors of proliferation of Plasmodium falciparum line D10,Confirmatory,,
433,1882,1,1,,50106328,3454,Inactive,,,,Potency,qHTS for differential inhibitors of proliferation of Plasmodium falciparum line Dd2,Confirmatory,,
434,1883,1,1,,50106328,3454,Inactive,,,,Potency,qHTS for differential inhibitors of proliferation of Plasmodium falciparum line W2,Confirmatory,,
435,1885,2,1,,8139883,3454,Inactive,,,,,Luminescence Cell-Based/Microorganism Primary HTS to Identify Inhibitors of T.Cruzi Replication,Screening,,
436,1886,1,1,,50106328,3454,Inactive,,,,Potency,qHTS for differential inhibitors of proliferation of Plasmodium falciparum line HB3,Confirmatory,,
437,1887,1,4,,8139883,3454,Inactive,85666113.0,850333.0,,,Multiplex HTS Screen of TOR pathway GFP-fusion proteins in Saccharomyes cerevisiae_specifically_AGP1,Screening,,
438,1899,1,3,,56424026,3454,Inactive,83779224.0,,,,TR-FRET-based primary biochemical high-throughput screening assay to identify inhibitors of Hepatitis C Virus (HCV) core protein dimerization,Screening,,
439,1903,2,3,,8139883,3454,Inactive,297591903.0,29031019.0,,IC50,Identification of SV40 T antigen inhibitors: A route to novel anti-viral reagents,Confirmatory,,
440,1903,2,3,,56424026,3454,Inactive,297591903.0,29031019.0,,IC50,Identification of SV40 T antigen inhibitors: A route to novel anti-viral reagents,Confirmatory,,
441,1906,1,3,,56424026,3454,Inactive,55958172.0,,,,QFRET-based counterscreen for PFM18AAP inhibitors: biochemical high throughput screening assay to identify inhibitors of the Cathepsin L proteinase (CTSL1).,Screening,,
442,1910,1,2,,8139883,3454,Inactive,,,,,Luminescence Cell-Based Primary HTS to Identify Transcriptional Activators of Hypoxia-Inducible Factor Pathway,Screening,,
443,1947,1,2,,56424026,3454,Inactive,21595511.0,226016.0,,,Fluorescence polarization-based counterscreen for RBBP9 inhibitors: primary biochemical high throughput screening assay to identify inhibitors of the serine hydrolase family member Fam108B.,Screening,,
444,1948,1,1,,11111225,3454,Inactive,,,,Potency,qHTS Assay for Compounds that Induce Erasure of Genomic Imprints,Confirmatory,,
445,1948,1,1,,50106328,3454,Inactive,,,,Potency,qHTS Assay for Compounds that Induce Erasure of Genomic Imprints,Confirmatory,,
446,1950,1,3,,56424026,3454,Inactive,23893623.0,3783709.0,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of the Epstein-Barr virus nuclear antigen 1 (EBNA-1).,Screening,,
447,1956,1,1,,8139883,3454,Inactive,,,,Conc @ Max Fold Increase,A high-throughput screen to identify small molecule compounds that augment HSV replication,Confirmatory,,
448,1961,2,2,,8139883,3454,Inactive,33695107.0,9290.0,,EC50,Image-based HTS for Selective Agonists of GPR55,Confirmatory,,
449,1962,1,2,,56424026,3454,Inactive,68476498.0,,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of tRNA 2'-phosphotransferase (TPT1).,Screening,,
450,1967,1,1,,85231063,3454,Inactive,4505907.0,5376.0,,Potency,qHTS Assay for Modulators of Human Peripheral Myelin Protein 22 (PMP22) Expression/Activity,Confirmatory,,
451,1974,1,2,,56424026,3454,Inactive,4758484.0,9446.0,,,Fluorescence polarization-based counterscreen for RBBP9 inhibitors: primary biochemical high throughput screening assay to identify inhibitors of the oxidoreductase glutathione S-transferase omega 1(GSTO1).,Screening,,
452,1979,1,1,,8139883,3454,Inactive,994798.0,,,,Fluorescence Cell-Based Primary HTS of C.albicans growth in the presence of Fluconazole and compound,Screening,,
453,1984,1,3,,8139883,3454,Inactive,118026946.0,17979.0,,IC50,Fluorescence for the identification of compounds that decrease p/CIP protein stability,Confirmatory,,
454,1986,1,2,,8139883,3454,Inactive,45357394.0,,,IC50,uHTS fluorescence assay for the identification of Human Immunodeficiency Virus Fusion Inhibitors.,Confirmatory,,
455,1987,1,2,,56424026,3454,Inactive,37589898.0,5536.0,,,Fluorescence-based primary biochemical high throughput screening assay to identify inhibitors of Protein Phosphatase 5 (PP5).,Screening,,
456,1996,2,2,,8139883,3454,Active,,,,,Aqueous Solubility from MLSMR Stock Solutions,Other,,
457,2006,3,2,,8139883,3454,Inactive,4507785.0,7329.0,,IC50,uHTS HTRF assay for identification of inhibitors of SUMOylation,Confirmatory,,
458,2006,3,2,,8139883,3454,Inactive,13111961.0,10054.0,,IC50,uHTS HTRF assay for identification of inhibitors of SUMOylation,Confirmatory,,
459,2006,3,2,,8139883,3454,Inactive,17390638.0,10055.0,,IC50,uHTS HTRF assay for identification of inhibitors of SUMOylation,Confirmatory,,
460,2012,3,2,,8139883,3454,Inactive,45219878.0,7458.0,,IC50,uHTS fluorescence polarization assay for the identification of translation initiation inhibitors (eIF4H),Confirmatory,,
461,2013,2,2,,8139883,3454,Inactive,33695107.0,9290.0,,IC50,Image-Based HTS for Selective Antagonists for GPR55,Confirmatory,,
462,2014,3,2,,8139883,3454,Inactive,46367787.0,26986.0,,IC50,uHTS fluorescence polarization assay for the identification of translation initiation inhibitors (PABP),Confirmatory,,
463,2016,1,3,,56424026,3454,Inactive,1302091.0,,,,Multiplex HTS Screen of TOR pathway GFP-fusion proteins in Saccharomyes cerevisiae_specifically_ MEP2_MLPCN.,Screening,,
464,2023,1,3,,56424026,3454,Inactive,486173.0,,,,Multiplex HTS Screen of TOR pathway GFP-fusion proteins in Saccharomyes cerevisiae_specifically_ LAP4_MLPCN.,Screening,,
465,2025,1,3,,56424026,3454,Inactive,536029.0,,,,Multiplex HTS Screen of TOR pathway GFP-fusion proteins in Saccharomyes cerevisiae_specifically_ RPL19A_MLPCN.,Screening,,
466,2029,1,3,,56424026,3454,Inactive,171229.0,,,,Multiplex HTS Screen of TOR pathway GFP-fusion proteins in Saccharomyes cerevisiae_specifically_ CIT2_MLPCN.,Screening,,
467,2052,2,1,,56424026,3454,Inactive,124486680.0,16408.0,,,HTS for developing T Cell Immune Modulators,Screening,,
468,2057,1,2,,56424026,3454,Inactive,78070770.0,4170.0,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of myeloid cell leukemia sequence 1 (MCL1) interactions with BIM-BH3 peptide.,Screening,,
469,2058,3,2,,8139883,3454,Inactive,33695097.0,2859.0,,IC50,Image-Based HTS for Selective Antagonists of GPR35,Confirmatory,,
470,2066,1,4,,56424026,3454,Inactive,85666113.0,850333.0,,,Multiplex HTS Screen of TOR pathway GFP-fusion proteins in Saccharomyes cerevisiae_specifically_ AGP1_MLPCN.,Screening,,
471,2071,2,2,,8139883,3454,Inactive,14719829.0,22861.0,,,Colorimetric  Assay for Inhibitors for NALP1,Screening,,
472,2073,2,3,,8139883,3454,Inactive,2625023.0,83589.0,,IC50,Homogeneous Time-Resolved Fluorescence Resonance Energy Transfer (HTRF) Assay,Confirmatory,,
473,2073,2,3,,8139883,3454,Inactive,4502523.0,774.0,,IC50,Homogeneous Time-Resolved Fluorescence Resonance Energy Transfer (HTRF) Assay,Confirmatory,,
474,2094,1,2,,8139883,3454,Inactive,67463988.0,,,,Plate Read Microorganism-Based Primary HTS to Identify Modulators of the AI-2 Quorum Sensing System,Screening,,
475,2094,1,2,,8139883,3454,Inactive,67463989.0,,,,Plate Read Microorganism-Based Primary HTS to Identify Modulators of the AI-2 Quorum Sensing System,Screening,,
476,2094,1,2,,8139883,3454,Inactive,166202459.0,,,,Plate Read Microorganism-Based Primary HTS to Identify Modulators of the AI-2 Quorum Sensing System,Screening,,
477,2097,1,2,,8139883,3454,Inactive,21361340.0,2932.0,,,Cell-Free Homogeneous Primary HTS to Identify Inhibitors of GSK3beta Activity,Screening,,
478,2098,1,1,,8139883,3454,Inactive,62740231.0,15499.0,,,Luminescence Cell-Based Primary HTS to Identify Inhibitors of Heat Shock Factor 1 (HSF1).,Screening,,
479,2099,1,1,,8139883,3454,Inactive,,,,,Fluorescence Biochemical Primary HTS to Identify Inhibitors of GASC-1 Activity,Screening,,
480,2100,1,1,,8139883,3454,Inactive,119393891.0,2548.0,,Potency,qHTS Assay for Inhibitors and Activators of Human alpha-Glucosidase Cleavage of Glycogen,Confirmatory,,
481,2101,1,1,,8139883,3454,Inactive,496369.0,2629.0,,Potency,qHTS Assay for Inhibitors and Activators of N370S glucocerebrosidase as a Potential Chaperone Treatment of Gaucher Disease,Confirmatory,,
482,2101,1,1,,11111225,3454,Inactive,496369.0,2629.0,,Potency,qHTS Assay for Inhibitors and Activators of N370S glucocerebrosidase as a Potential Chaperone Treatment of Gaucher Disease,Confirmatory,,
483,2101,1,1,,50106328,3454,Inactive,496369.0,2629.0,,Potency,qHTS Assay for Inhibitors and Activators of N370S glucocerebrosidase as a Potential Chaperone Treatment of Gaucher Disease,Confirmatory,,
484,2107,1,1,,8139883,3454,Inactive,757912.0,2717.0,,Potency,qHTS Assay for Inhibitors and Activators of Human alpha-Galactosidase From Spleen Homogenate,Confirmatory,,
485,2107,1,1,,11111225,3454,Inactive,757912.0,2717.0,,Potency,qHTS Assay for Inhibitors and Activators of Human alpha-Galactosidase From Spleen Homogenate,Confirmatory,,
486,2107,1,1,,50106328,3454,Inactive,757912.0,2717.0,,Potency,qHTS Assay for Inhibitors and Activators of Human alpha-Galactosidase From Spleen Homogenate,Confirmatory,,
487,2112,1,1,,8139883,3454,Inactive,119393891.0,2548.0,,Potency,qHTS Assay for Inhibitors and Activators of Human alpha-Glucosidase From Spleen Homogenate,Confirmatory,,
488,2112,1,1,,11111225,3454,Inactive,119393891.0,2548.0,,Potency,qHTS Assay for Inhibitors and Activators of Human alpha-Glucosidase From Spleen Homogenate,Confirmatory,,
489,2112,1,1,,50106328,3454,Inactive,119393891.0,2548.0,,Potency,qHTS Assay for Inhibitors and Activators of Human alpha-Glucosidase From Spleen Homogenate,Confirmatory,,
490,2129,1,2,,56424026,3454,Inactive,510901.0,598.0,,,"Primary biochemical high throughput screening assay to identify inhibitors of BCL2-related protein, long isoform (BCLXL).",Screening,,
491,2130,1,3,,56424026,3454,Inactive,7706645.0,51400.0,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of Protein Phosphatase Methylesterase 1 (PME-1).,Screening,,
492,2147,1,1,,8139883,3454,Inactive,221046486.0,,,Potency,qHTS Assay for Inhibitors of  Human Jumonji Domain Containing 2E (JMJD2E),Confirmatory,,
493,2147,1,1,,11111225,3454,Inactive,221046486.0,,,Potency,qHTS Assay for Inhibitors of  Human Jumonji Domain Containing 2E (JMJD2E),Confirmatory,,
494,2147,1,1,,50106328,3454,Inactive,221046486.0,,,Potency,qHTS Assay for Inhibitors of  Human Jumonji Domain Containing 2E (JMJD2E),Confirmatory,,
495,2156,2,2,,8139883,3454,Inactive,18959272.0,170848.0,,,Primary cell-based high-throughput screening assay for identification of compounds that inhibit KCNQ2 potassium channels,Screening,,
496,2174,1,3,,56424026,3454,Inactive,5453722.0,10434.0,,,Counterscreen for PME1 inhibitors: fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of lysophospholipase 1 (LYPLA1).,Screening,,
497,2177,1,3,,56424026,3454,Inactive,4581413.0,,,,Counterscreen for PME1 inhibitors: fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of lysophospholipase 2 (LYPLA2).,Screening,,
498,2205,1,1,,8139883,3454,Inactive,29788785.0,203068.0,,,HCS assay for microtubule stabilizers,Screening,,
499,2216,1,3,,8139883,3454,Inactive,,,,,Fluorescence Cell-Free Homogeneous Primary HTS to Identify Inhibitors of the RanGTP-Importin-beta complex,Screening,,
500,2221,1,2,,8139883,3454,Inactive,15609874.0,888371.0,,,Fluorescence Cell-Free Homogenous Primary HTS to Identify Inhibitors of RecA Intein Splicing Activity,Screening,,
501,2227,1,2,,8139883,3454,Inactive,2935630.0,22066.0,,,Primary cell-based high-throughput screening assay for identification of compounds that allosterically potentiate transient receptor potential cation channel C4 (TRPC4),Screening,,
502,2234,1,2,,56424026,3454,Inactive,82503229.0,3783744.0,,,"Counterscreen for inhibitors of EBNA-1: fluorescence polarization-based biochemical high throughput primary assay to identify inhibitors of the Epstein-Barr virus-encoded protein, ZTA.",Screening,,
503,2235,1,2,,56424026,3454,Inactive,56790945.0,5499.0,,,Counterscreen for inhibitors of PP5: fluorescence-based biochemical high throughput primary assay to identify inhibitors of Protein Phosphatase 1 (PP1).,Screening,,
504,2237,1,2,,8139883,3454,Inactive,2935630.0,22066.0,,,Primary cell-based screen for identification of compounds that activate transient receptor potential cation channel C4 (TRPC4).,Screening,,
505,2239,1,2,,8139883,3454,Inactive,18959272.0,170848.0,,,Primary cell-based high-throughput screening assay for identification of compounds that potentiate KCNQ2 potassium channels,Screening,,
506,2242,1,1,,8139883,3454,Inactive,119393891.0,2548.0,,Potency,qHTS Assay for Activators of Human alpha-Glucosidase as a Potential Chaperone Treatment of Pompe Disease,Confirmatory,,
507,2247,1,2,,8139883,3454,Inactive,2935630.0,22066.0,,,Primary cell-based screen for identification of compounds that inhibit transient receptor potential cation channel C4 (TRPC4).,Screening,,
508,2280,2,3,,56424026,3454,Inactive,17507875.0,172532.0,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of GLD-1 protein - TGE RNA interaction.,Screening,,
509,2288,1,1,,8139883,3454,Inactive,,,,Potency,qHTS Assay for Modulators of miRNAs and/orActivators of miR-21,Confirmatory,,
510,2289,1,1,,8139883,3454,Inactive,,,,Potency,qHTS Assay for Modulators of miRNAs and/or Inhibitors of miR-21,Confirmatory,,
511,2300,1,3,,56424026,3454,Inactive,216409728.0,10002.0,,,"TR-FRET-based primary biochemical high throughput screening assay to identify agonists of nuclear receptor subfamily 2, group E, member 3 (NR2E3).",Screening,,
512,2314,1,2,,8139883,3454,Inactive,32400299.0,,,,Cycloheximide Counterscreen for Small Molecule Inhibitors of Shiga Toxin,Screening,,
513,2314,1,2,,8139883,3454,Inactive,32400300.0,,,,Cycloheximide Counterscreen for Small Molecule Inhibitors of Shiga Toxin,Screening,,
514,2315,1,2,,8139883,3454,Inactive,32400299.0,,,,A qHTS for Small Molecule Inhibitors of Shiga Toxin,Screening,,
515,2315,1,2,,8139883,3454,Inactive,32400300.0,,,,A qHTS for Small Molecule Inhibitors of Shiga Toxin,Screening,,
516,2323,1,1,,50106328,3454,Inactive,254220970.0,,,Potency,qHTS Validation Assay for Identification of Novel General Anesthetics,Confirmatory,,
517,2326,1,1,,8139883,3454,Inactive,194352380.0,,,Potency,qHTS Assay for Inhibitors of Influenza NS1 Protein Function,Confirmatory,,
518,2326,1,1,,50106328,3454,Inactive,194352380.0,,,Potency,qHTS Assay for Inhibitors of Influenza NS1 Protein Function,Confirmatory,,
519,2353,1,3,,50106328,3454,Inactive,282403581.0,,,Potency,qHTS Validation Assay for Inhibitors of RecQ-Like Dna Helicase 1 (RECQ1),Confirmatory,,
520,2364,1,2,,50106328,3454,Inconclusive,4557365.0,641.0,0.0032,Potency,qHTS Validation Assay for Inhibitors of Bloom's syndrome helicase (BLM),Confirmatory,,
521,2380,1,2,,56424026,3454,Inactive,,,,,uHTS identification of small molecules that induce b-cell replication in the MIN-6 cell line,Screening,,
522,2391,1,1,,56424026,3454,Inactive,,,,IC50,A Cell Based HTS Approach for the Discovery of New Inhibitors of Respiratory syncytial virus (RSV),Confirmatory,,
523,2417,1,1,,8139883,3454,Inconclusive,4506243.0,5725.0,,,High Content Assay for Compounds that inhibit the Assembly of the Perinucleolar Compartment,Screening,,
524,2435,1,2,,56424026,3454,Inactive,32307152.0,5021.0,,,Fluorescence-based primary cell-based high throughput screening assay to identify agonists of the Oxytocin Receptor (OXTR).,Screening,,
525,2445,1,2,,56424026,3454,Inactive,32307152.0,5021.0,,,Fluorescence-based primary cell-based high throughput screening assay to identify potentiators of Oxytocin Receptor (OXTR),Screening,,
526,2451,1,2,,8139883,3454,Inactive,122920737.0,,,Potency,"qHTS Assay for Inhibitors of Fructose-1,6-bisphosphate Aldolase from Giardia Lamblia",Confirmatory,,
527,2451,1,2,,11111225,3454,Inactive,122920737.0,,,Potency,"qHTS Assay for Inhibitors of Fructose-1,6-bisphosphate Aldolase from Giardia Lamblia",Confirmatory,,
528,2451,1,2,,50106328,3454,Inactive,122920737.0,,,Potency,"qHTS Assay for Inhibitors of Fructose-1,6-bisphosphate Aldolase from Giardia Lamblia",Confirmatory,,
529,2462,1,1,,56424026,3454,Inactive,20336315.0,10018.0,,,Luminescence Cell-Based Primary HTS to Identify Inhibitors of A1 Apoptosis.,Screening,,
530,2462,1,1,,56424026,3454,Inactive,167013344.0,,,,Luminescence Cell-Based Primary HTS to Identify Inhibitors of A1 Apoptosis.,Screening,,
531,2472,1,2,,8139883,3454,Inactive,7669492.0,2597.0,,,"qHTS Assay for Inhibitors of Fructose-1,6-bisphosphate Aldolase from Giardia Lamblia: Coupling assay counterscreen",Screening,,
532,2472,1,2,,11111225,3454,Inactive,7669492.0,2597.0,,,"qHTS Assay for Inhibitors of Fructose-1,6-bisphosphate Aldolase from Giardia Lamblia: Coupling assay counterscreen",Screening,,
533,2517,2,1,,8139883,3454,Inactive,6980812.0,,14.1254,Potency,qHTS Assay for Inhibitors of the Human Apurinic/apyrimidinic Endonuclease 1 (APE1),Confirmatory,,
534,2517,2,1,,50106328,3454,Inactive,6980812.0,,,Potency,qHTS Assay for Inhibitors of the Human Apurinic/apyrimidinic Endonuclease 1 (APE1),Confirmatory,,
535,2517,2,1,,144203711,3454,Inactive,6980812.0,,,Potency,qHTS Assay for Inhibitors of the Human Apurinic/apyrimidinic Endonuclease 1 (APE1),Confirmatory,,
536,2520,1,4,,56424026,3454,Inactive,4885057.0,187.0,,,uHTS identification of small molecule agonists of the APJ  receptor  via a luminescent beta-arrestin assay,Screening,,
537,2521,1,3,,56424026,3454,Inactive,4885057.0,187.0,,,uHTS identification of small molecule antagonists of the APJ  receptor  via a luminescent beta-arrestin assay,Screening,,
538,2523,1,1,,8139883,3454,Inactive,124486680.0,16408.0,,,HTS of MLPCN Validation Compound Set for developing T Cell Immune Modulators,Screening,,
539,2524,1,2,,56424026,3454,Inactive,124376142.0,248.0,,,uHTS Luminescent assay for identification of activators of human intestinal alkaline phosphatase,Screening,,
540,2528,1,2,,8139883,3454,Inactive,4557365.0,641.0,,Potency,qHTS Assay for Inhibitors of Bloom's syndrome helicase (BLM),Confirmatory,,
541,2528,1,2,,11111225,3454,Inactive,4557365.0,641.0,,Potency,qHTS Assay for Inhibitors of Bloom's syndrome helicase (BLM),Confirmatory,,
542,2528,1,2,,50106328,3454,Inconclusive,4557365.0,641.0,0.0032,Potency,qHTS Assay for Inhibitors of Bloom's syndrome helicase (BLM),Confirmatory,,
543,2540,1,2,,56424026,3454,Inactive,262118306.0,123228.0,,,HTS Luminescent assay for identification of inhibitors of Sentrin-specific protease 8 (SENP8),Screening,,
544,2544,1,2,,56424026,3454,Inactive,124376142.0,248.0,,,uHTS Luminescent assay for identification of inhibitors of human intestinal alkaline phosphatase,Screening,,
545,2546,1,1,,8139883,3454,Inactive,188536040.0,19885.0,,Potency,VP16 counterscreen qHTS for inhibitors of ROR gamma transcriptional activity,Confirmatory,,
546,2546,1,1,,11111225,3454,Inactive,188536040.0,19885.0,,Potency,VP16 counterscreen qHTS for inhibitors of ROR gamma transcriptional activity,Confirmatory,,
547,2549,1,1,,8139883,3454,Inactive,282403581.0,,,Potency,qHTS Assay for Inhibitors of RecQ-Like Dna Helicase 1 (RECQ1),Confirmatory,,
548,2549,1,1,,11111225,3454,Inactive,282403581.0,,,Potency,qHTS Assay for Inhibitors of RecQ-Like Dna Helicase 1 (RECQ1),Confirmatory,,
549,2549,1,1,,50106328,3454,Inactive,282403581.0,,,Potency,qHTS Assay for Inhibitors of RecQ-Like Dna Helicase 1 (RECQ1),Confirmatory,,
550,2550,1,3,,8139883,3454,Inactive,160333370.0,22068.0,,,High throughput screening of activators of transient receptor potential cation channel C6 (TRPC6),Screening,,
551,2551,1,1,,8139883,3454,Inactive,188536040.0,19885.0,,Potency,qHTS for inhibitors of ROR gamma transcriptional activity,Confirmatory,,
552,2551,1,1,,11111225,3454,Inactive,188536040.0,19885.0,,Potency,qHTS for inhibitors of ROR gamma transcriptional activity,Confirmatory,,
553,2553,1,2,,8139883,3454,Inactive,160333370.0,22068.0,,,High throughput screening of inhibitors of transient receptor potential cation channel C6 (TRPC6),Screening,,
554,2557,1,3,,56424026,3454,Inactive,67191027.0,3676.0,,,HTS for Identification of VLA-4 Allosteric Modulators from MLPCN library,Screening,,
555,2563,1,1,,8139883,3454,Active,6323930.0,855317.0,,,Fluorescence Cell-Free Homogenous Primary HTS  to Identify Inhibitors of the Ras-converting Enzyme,Screening,,
556,2599,1,2,,56424026,3454,Inactive,6166485.0,26054.0,,,uHTS Luminescent assay for identification of inhibitors of Sentrin-specific protease 6 (SENP6),Screening,,
557,2606,1,2,,56424026,3454,Inactive,15610807.0,885176.0,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of the membrane-associated serine protease Rv3671c in M.tuberculosis,Screening,,
558,2629,1,1,,56424026,3454,Inactive,139472804.0,4961527.0,,,Fluorescence Polarization Cell-Free Homogeneous Primary HTS to Identify Inhibitors of the LANA Histone H2A/H2B Interaction,Screening,,
559,2642,1,2,,8139883,3454,Inactive,32479527.0,3784.0,,,Primary cell-based high-throughput screening assay for identification of compounds that inhibit KCNQ1 potassium channels,Screening,,
560,2648,1,2,,8139883,3454,Inactive,32479527.0,3784.0,,,Primary cell-based high-throughput screening assay for identification of compounds that potentiate/activate KCNQ1 potassium channels,Screening,,
561,2650,2,1,,56424026,3454,Inactive,49574532.0,2931.0,,,Luminescence Cell-Free  Homogenous Primary HTS to Identify Inhibitors of GSK-3 alpha,Screening,,
562,2660,1,1,,90341439,3454,Inactive,4826730.0,2475.0,,Potency,"Cytometric Cell-Based qHTS for Inhibitors of the mTORC1 Signaling Pathway in MEF (Tsc2-/-, p53-/-) Cells",Confirmatory,,
563,2661,1,1,,56424026,3454,Inactive,23943882.0,65975.0,,,Luminescence Cell-Free  Homogenous Primary HTS to Identify Inhibitors of Serine/Threonine  Kinase 33  Activity,Screening,,
564,2662,2,1,,8139883,3454,Inactive,56550039.0,4297.0,,Potency,qHTS Fluorescence Polarization Assay for Inhibitors of MLL CXXC domain - DNA interaction,Confirmatory,,
565,2662,2,1,,11111225,3454,Inactive,56550039.0,4297.0,,Potency,qHTS Fluorescence Polarization Assay for Inhibitors of MLL CXXC domain - DNA interaction,Confirmatory,,
566,2662,2,1,,85231063,3454,Inactive,56550039.0,4297.0,,Potency,qHTS Fluorescence Polarization Assay for Inhibitors of MLL CXXC domain - DNA interaction,Confirmatory,,
567,2666,1,1,,90341439,3454,Inactive,4826730.0,2475.0,,Potency,"High Content Imaging Cell-Based qHTS for Inhibitors of the mTORC1 Signaling Pathway in MEF (Tsc2-/-, p53-/-) Cells",Confirmatory,,
568,2667,1,1,,90341439,3454,Inactive,4826730.0,2475.0,,Potency,High Content Imaging Cell-Based qHTS for Inhibitors of the mTORC1 Signaling Pathway in MEF Cells,Confirmatory,,
569,2668,1,1,,90341439,3454,Inactive,4826730.0,2475.0,,Potency,Cytometry Cell-Based qHTS for Inhibitors of the mTORC1 Signaling Pathway in MEF cells,Confirmatory,,
570,2674,1,1,,8139883,3454,Inactive,34810098.0,,,,HTS for Identification of VLA-4 Allosteric Modulators from Validation Compound Set.,Screening,,
571,2675,1,1,,8139883,3454,Inactive,41281591.0,4154.0,,Potency,qHTS Assay for Inhibitors of MBNL1-poly(CUG) RNA binding,Confirmatory,,
572,2675,1,1,,50106328,3454,Unspecified,41281591.0,4154.0,,Potency,qHTS Assay for Inhibitors of MBNL1-poly(CUG) RNA binding,Confirmatory,,
573,2676,1,2,,8139883,3454,Inactive,85986601.0,59350.0,,Potency,qHTS Assay for Agonists of the Relaxin Receptor RXFP1,Confirmatory,,
574,2685,1,1,,8139883,3454,Inactive,,,,Potency,qHTS Assay for Lipid Storage Modulators in Drosophila S3 Cells,Confirmatory,,
575,2690,1,2,,56424026,3454,Inactive,,,,,A yeast HTS for caloric restriction mimetics that inhibit age-related superoxide,Screening,,
576,2706,1,1,,8139883,3454,Inactive,,,,,A yeast HTS for caloric restriction mimetics that inhibit age-related superoxide for Validation Compound Set,Screening,,
577,2708,1,1,,50113251,3454,Inactive,282403581.0,,,Potency,Confirmation qHTS Assay for Inhibitors of RecQ-Like Dna Helicase 1 (RECQ1),Confirmatory,,
578,2716,1,1,,56424026,3454,Inactive,,,,,Luminescence  Microorganism Primary HTS to Identify Inhibitors of the SUMOylation Pathway Using a Temperature Sensitive Growth Reversal Mutant Mot1-301,Screening,,
579,2717,1,2,,56424026,3454,Inactive,,,,,Luminescence Cell-Based Primary HTS to Identify Inhibitors of Cancer Stem Cells,Screening,,
580,2718,1,1,,56424026,3454,Inactive,13128862.0,8841.0,,,Fluorescence Cell-Free Homogeneous Primary HTS to Identify Inhibitors of Histone Deacetylase 3,Screening,,
581,2732,1,1,,8139883,3454,Inactive,160707929.0,13198.0,,,HTS for small molecule inhibitors of CHOP to regulate the unfolded protein response to ER stress,Screening,,
582,2732,1,1,,17405102,3454,Inactive,160707929.0,13198.0,,,HTS for small molecule inhibitors of CHOP to regulate the unfolded protein response to ER stress,Screening,,
583,2751,2,2,,56424026,3454,Inactive,153217451.0,9581.0,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of the prolyl oligopeptidase-like enzyme (PREPL),Screening,,
584,2774,1,3,,92303850,3454,Inactive,,,,,LOPAC Circadian Assay,Screening,,
585,2796,1,4,,56424026,3454,Inactive,4502003.0,196.0,,,Luminescence-based primary cell-based high throughput screening assay to identify activators of the Aryl Hydrocarbon Receptor (AHR),Screening,,
586,2797,1,2,,56424026,3454,Inactive,4502331.0,552.0,,,Counterscreen for Oxytocin Receptor (OXTR) agonists: Fluorescence-based primary cell-based high throughput assay to identify agonists of the vasopressin 1 receptor (V1R),Screening,,
587,2805,2,2,,56424026,3454,Inactive,124487323.0,76768.0,,,uHTS Luminescent assay for identification of activators of mouse intestinal alkaline phosphatase,Screening,,
588,2806,2,2,,56424026,3454,Inactive,124487323.0,76768.0,,,uHTS Luminescent assay for identification of inhibitors of mouse intestinal alkaline phosphatase,Screening,,
589,2825,1,2,,56424026,3454,Inactive,219518789.0,114548.0,,,uHTS Luminescent assay for identification of inhibitors of NALP3 in yeast,Screening,,
590,8611,3,4,,103504490,3454,Unspecified,,,,,Anti proliferation activity determined; Weak effect,Other,,
591,8614,6,3,,103504490,3454,Unspecified,,,,,Inhibition of cell growth by compound at a concentration of 10 uM in 9Ltk+ cells; Completely stopped the process,Other,,
592,11507,3,4,,103504490,3454,Unspecified,,,,,Oral bioavailability in rat,Other,,
593,12145,3,1,,103504490,3454,Unspecified,,,,,Area under curve (Pharmacokinetic property) was determined,Other,,
594,16012,6,1,,103504490,3454,Unspecified,,,,,Efficacy was evaluated against Systemic HSV-1 infection in mice at a daily dose of 0.8 mg/kg administered subcutaneously.,Other,2989523.0,
595,16017,6,1,,103504490,3454,Unspecified,,,,,Efficacy was evaluated against Systemic HSV-1 infection in mice at a daily dose of 3.1 mg/kg administered subcutaneously.,Other,2989523.0,
596,16021,6,1,,103504490,3454,Unspecified,,,,,Efficacy was evaluated against Systemic HSV-1 infection in mice at a daily dose of 12.5 mg/kg administered subcutaneously.,Other,2989523.0,
597,21089,6,2,,103504490,3454,Unspecified,,,,,Compound was tested for solubility in water at 25 degree C,Other,9925738.0,
598,21263,3,3,,103504490,3454,Unspecified,,,,,Permeability coefficient reported (Expressed as Permeability coefficient x 10 e 4 cm/s),Other,8941388.0,
599,22156,3,4,,103504490,3454,Unspecified,,,,,Efficacy was evaluated against Systemic HSV-1 infection in mice at a daily dose of 0.8 mg/kg administered subcutaneously; Tested mice 10,Other,2989523.0,
600,22160,3,4,,103504490,3454,Unspecified,,,,,Efficacy was evaluated against Systemic HSV-1 infection in mice at a daily dose of 12.5 mg/kg administered subcutaneously; Tested mice 10,Other,2989523.0,
601,22164,3,4,,103504490,3454,Unspecified,,,,,Efficacy was evaluated against Systemic HSV-1 infection in mice at a daily dose of 3.1 mg/kg administered subcutaneously; Tested mice 10,Other,2989523.0,
602,28956,3,3,,103504490,3454,Unspecified,,,,,Partition coefficient (logP) (dodecane),Other,11754587.0,
603,28957,3,3,,103504490,3454,Unspecified,,,,,Partition coefficient (logP),Other,11754587.0,
604,28958,4,1,,103504490,3454,Unspecified,,,,,Partition coefficient across water-dodecane interface by statistical simulation,Other,11754587.0,
605,35823,8,4,,103504490,3454,Inconclusive,,,,,Compound was evaluated for the inhibitory activity against Human alpha polymerase; No data,Other,10999475.0,
606,35826,4,6,,103504490,3454,Unspecified,,,,,Compound was tested for the inhibition of HeLa DNA polymerase,Other,3009816.0,
607,42114,6,3,,103504490,3454,Unspecified,,,100.0,IC50,Compound was evaluated for cytotoxic activity against BSC cells,Confirmatory,2163454.0,
608,42121,6,2,,103504490,3454,Active,,,3.0,IC50,Antiviral activity of the compound was evaluated against the Herpes simplex virus type-1 in BSC-1 cells,Confirmatory,2913300.0,
609,42123,6,2,,103504490,3454,Active,,,3.5,IC50,"Antiviral activity against HSV-1 (herpes simplex virus), determined by ELISA in quadruplicate wells using BSC-1 cells",Confirmatory,10882370.0,
610,42126,6,3,,103504490,3454,Unspecified,,,100.0,IC50,Cytotoxicity was evaluated against the Monkey kidney cells (BSC),Confirmatory,2913300.0,
611,42127,6,2,,103504490,3454,Active,,,3.5,IC50,ELISA assay was performed using BSC-1 cells to determine activity against HSV-1,Confirmatory,10882372.0,
612,42128,6,3,,103504490,3454,Unspecified,,,100.0,IC50,Tested for cytotoxic activity against monkey kidney cells(BSC-1) cells.,Confirmatory,2163453.0,
613,42129,6,3,,103504490,3454,Unspecified,,,100.0,IC50,Tested in vitro for cytotoxicity against the monkey kidney cells (BSC-1 cells).,Confirmatory,2175356.0,
614,42131,6,3,,103504490,3454,Unspecified,,,100.0,IC50,Cytotoxicity against uninfected monkey kidney cells (BSC-1),Confirmatory,2846837.0,
615,42132,6,3,,103504490,3454,Unspecified,,,100.0,IC50,Cytotoxicity against Monkey kidney cells(BSC-1 cells),Confirmatory,2500527.0,
616,42134,6,2,,103504490,3454,Unspecified,,,100.0,IC50,The compound was tested for cytotoxicity against BSC1 cell,Confirmatory,2840500.0,
617,43939,6,2,,103504490,3454,Active,,,29.0,IC50,In vitro toxicity against burst forming unit erythroid (BFU-E),Confirmatory,8176714.0,
618,44363,6,2,,103504490,3454,Unspecified,,,,,Antiproliferative effects on CCRF-HSB-2 (human leukemia) cells.,Other,9216836.0,
619,45841,6,2,,103504490,3454,Unspecified,,,200.0,CC50,Compound concentration required to reduce viability of CEM cells,Confirmatory,14643328.0,
620,45919,6,2,,103504490,3454,Unspecified,,,,,Minimum inhibitory concentration was determined against CMV(AD169) in E6SM cell culture,Other,10691698.0,
621,45921,6,2,,103504490,3454,Unspecified,,,,,Minimum inhibitory concentration was determined against CMV(Davis) in E6SM cell culture,Other,10691698.0,
622,45931,6,2,,103504490,3454,Unspecified,,,,,Inhibitory concentration against CMV strain AD169 in human embryonic lung (HEL) cell culture,Other,8393114.0,
623,45932,6,2,,103504490,3454,Unspecified,,,,,Inhibitory concentration against CMV strain Davis in human embryonic lung (HEL) cell culture,Other,8393114.0,
624,46023,6,2,,103504490,3454,Unspecified,,,200.0,EC50,Compound was tested for anti-viral activity against HIV-1 in CEM cells,Confirmatory,14643328.0,
625,46024,6,2,,103504490,3454,Unspecified,,,200.0,EC50,Compound was tested for anti-viral activity against HIV-2 in CEM cells,Confirmatory,14643328.0,
626,46567,6,2,,103504490,3454,Unspecified,,,390.0,IC50,"In vitro anti-HIV screen using HIV-1 infected CD4 lymphocytes (CEM cell line), determines cytotoxicity",Confirmatory,11814776.0,
627,46576,8,2,,103504490,3454,Inconclusive,,,,,Inhibitory concentration for spectrum antiviral activity against herpes viruses; ND= Not determined,Other,11814776.0,
628,47335,6,2,,103504490,3454,Active,,,19.0,IC50,In vitro toxicity against colony forming unit granulocyte macrophage (CFU-GM),Confirmatory,8176714.0,
629,53466,3,7,,103504490,3454,Unspecified,,,,,Inhibition of DNA polymerase,Other,2848125.0,
630,53487,3,5,,103504490,3454,Unspecified,,,,,Inhibition of DNA polymerase,Other,2848125.0,
631,53755,6,2,,103504490,3454,Unspecified,,,,,Concentration required to reduce the viral DNA in infected cells to 50% of untreated infected controls of Hepatitis B virus in primary duck hepatocyte (DHBV) cultures,Other,11985471.0,
632,53759,6,2,,103504490,3454,Active,,,4.0,EC50,In vitro antiviral activity against duck hepatitis B virus (DHBV),Confirmatory,11708924.0,
633,54953,7,3,,103504490,3454,Unspecified,,,,,Effective concentration required against HCMV AD169 for antiviral activity,Other,11412988.0,
634,54954,7,3,,103504490,3454,Unspecified,,,,,Effective concentration required against HCMV strain for antiviral activity,Other,11412988.0,
635,54956,7,3,,103504490,3454,Unspecified,,,,,Tested for antiviral activity against HCMV (AD169),Other,11412988.0,
636,55084,6,2,,103504490,3454,Active,,,8.8,IC50,Inhibitory activity against human cytomegalovirus determined by plaque reduction assay,Confirmatory,2840500.0,
637,55087,6,2,,103504490,3454,Unspecified,,,,,Minimum Inhibitory Concentration (MIC) tested for activity against Cytomegalovirus (CMV) using AD169 strain,Other,8709116.0,
638,55088,6,2,,103504490,3454,Unspecified,,,,,Minimum Inhibitory Concentration (MIC) tested for activity against Cytomegalovirus (CMV) using Davis strain,Other,8709116.0,
639,55107,5,3,,103504490,3454,Unspecified,,,,,Compound was tested for antiherpes activity against Cytomegalovirus virus(AD 169) in HEL cells,Other,,
640,55109,6,2,,103504490,3454,Unspecified,,,98.0,CC50,Cytotoxicity against Human cytomegalovirus (AD169) strain(HCMV),Confirmatory,10560739.0,
641,55110,6,2,,103504490,3454,Active,,,5.9,IC50,Antiviral activity against Human cytomegalovirus (AD169) strain(HCMV),Confirmatory,10560739.0,
642,55111,6,2,,103504490,3454,Active,,,5.9,IC50,Antiviral activity against clinical isolates of human origin CMV-strainA,Confirmatory,10560739.0,
643,55112,6,2,,103504490,3454,Active,,,3.9,IC50,Antiviral activity against clinical isolates of human origin CMV-strain B,Confirmatory,10560739.0,
644,55113,6,2,,103504490,3454,Active,,,3.9,IC50,Antiviral activity against clinical isolates of human origin CMV-strainC,Confirmatory,10560739.0,
645,55114,6,3,,103504490,3454,Active,,,7.9,IC50,Compound was tested for antiviral activity against human cytomegalovirus (HCMV) plaque reduction assay,Confirmatory,,
646,55115,5,3,,103504490,3454,Active,,,,,Compound was tested for antiviral activity against human cytomegalovirus (HCMV) yield reduction assay,Other,,
647,63604,6,3,,103504490,3454,Unspecified,,,,,Tested for antiviral activity against VSV-virus in human embryonic skin muscle fibroblasts,Other,11858989.0,
648,63605,10,1,,103504490,3454,Unspecified,,,,,Tested for antiviral activity against herpes simplex virus type 1(KOS) in E6SM cell line(human embryonic skin-muscle fibroblasts),Other,11858989.0,
649,63607,6,2,,103504490,3454,Unspecified,,,,,Tested for antiviral activity against thymidine kinase-deficient (TK-HSV-2G) virus in E6SM cell line(human embryonic skin-muscle fibroblasts),Other,11858989.0,
650,63609,6,3,,103504490,3454,Unspecified,,,,,Tested for antiviral activity against vaccinia virus in human embryonic skin muscle fibroblast,Other,11858989.0,
651,63718,6,2,,103504490,3454,Inconclusive,,,,,Percent inhibition of viral DNA in the presence of 10 mg/mL compound compared to untreated infected controls in duck hepatocytes; ND means Not determined,Other,11677126.0,
652,63719,6,2,,103504490,3454,Unspecified,,,,,Concentration required to reduce the viral DNA in infected cells to 50% of untreated infected controls.,Other,11677126.0,
653,63757,6,2,,103504490,3454,Unspecified,,,,,The compound was tested for antiviral activity against thymidine kinase-deficient (TK-HSV-1)virus in E6SM cell line(human embryonic skin-muscle fibroblasts),Other,11858989.0,
654,63758,6,2,,103504490,3454,Unspecified,,,,,The minimum inhibitory concentration was measured against Herpes simplex virus type 1 (KOS strain) on E6SM cells,Other,7932543.0,
655,63759,6,2,,103504490,3454,Unspecified,,,,,The minimum inhibitory concentration was measured on E6SM cells against Herpes simplex virus type 1 (F strain),Other,7932543.0,
656,63760,6,2,,103504490,3454,Unspecified,,,,,The minimum inhibitory concentration was measured on E6SM cells against Herpes simplex virus type 1 (McIntyre strain),Other,7932543.0,
657,63761,6,2,,103504490,3454,Unspecified,,,,,The minimum inhibitory concentration was measured on E6SM cells against Herpes simplex virus type 2 (196 strain),Other,7932543.0,
658,63762,6,2,,103504490,3454,Unspecified,,,,,The minimum inhibitory concentration was measured on E6SM cells against Herpes simplex virus type 2 (G strain),Other,7932543.0,
659,63763,6,2,,103504490,3454,Unspecified,,,,,The minimum inhibitory concentration was measured on E6SM cells against Herpes simplex virus type 2 (Lyons strain),Other,7932543.0,
660,63764,6,2,,103504490,3454,Unspecified,,,,,The minimum inhibitory concentration was measured on E6SM cells against TK+/TK-Herpes simplex virus type 1 (VMW1837 strain),Other,7932543.0,
661,63765,6,2,,103504490,3454,Unspecified,,,,,The minimum inhibitory concentration was measured on E6SM cells against TK-Herpes simplex virus type 1 (B2006 strain),Other,7932543.0,
662,63766,6,2,,103504490,3454,Unspecified,,,,,The minimum inhibitory concentration was measured on E6SM cells against Vaccinia virus,Other,7932543.0,
663,63767,6,2,,103504490,3454,Unspecified,,,,,The minimum inhibitory concentration was measured on E6SM cells against Vesicular stomatitis virus,Other,7932543.0,
664,63768,6,2,,103504490,3454,Unspecified,,,,,The minimum inhibitory concentration was measured on E6SM cells for morphological alteration,Other,7932543.0,
665,63914,6,2,,103504490,3454,Active,,,0.0012,EC50,Effective concentration required to inhibit Herpes simplex virus-1 (HSV-1) induced cytopathicity by 50% in E6SM cell lines,Confirmatory,11495586.0,
666,63916,6,2,,103504490,3454,Active,,,0.0012,EC50,Effective concentration required to inhibit Herpes simplex virus-2 (HSV-2) induced cytopathicity by 50% in E6SM cell lines,Confirmatory,11495586.0,
667,63917,6,2,,103504490,3454,Unspecified,,,100.0,EC50,Effective concentration required to inhibit Vaccinia virus-induced cytopathicity by 50% in E6SM cell lines,Confirmatory,11495586.0,
668,63919,8,1,,103504490,3454,Unspecified,,,,,Minimum inhibitory concentration required to elicit microscopically visible cell morphology in E6SM cell lines,Other,11495586.0,
669,63945,6,2,,103504490,3454,Unspecified,,,,,Inhibition of virus-induced cytopathicity in E6SM cell cultures of human embryonic skin-muscle,Other,12459010.0,
670,63947,6,3,,103504490,3454,Unspecified,,,,,Tested for cytotoxic activity in human embryonic skin muscle fibroblast (E6SM),Other,11858989.0,
671,65705,6,2,,103504490,3454,Unspecified,,,,,Minimum cytotoxic concentration required to cause a microscopically detectable alteration of normal cell morphology,Other,11472207.0,
672,65707,6,2,,103504490,3454,Unspecified,,,,,Antiviral activity against Vaccinia virus in E6SM cell cultures,Other,11472207.0,
673,65708,6,2,,103504490,3454,Unspecified,,,,,Antiviral activity against herpes simplex virus-1 KOS (HSV-1) in E6SM cell cultures,Other,11472207.0,
674,65709,6,2,,103504490,3454,Unspecified,,,,,Antiviral activity against herpes simplex virus-1 TK-KOS ACV (HSV-1) in E6SM cell cultures,Other,11472207.0,
675,65710,6,2,,103504490,3454,Unspecified,,,,,Antiviral activity against herpes simplex virus-1 TK-VMW 1837 (HSV-1) in E6SM cell cultures,Other,11472207.0,
676,65711,6,2,,103504490,3454,Unspecified,,,,,Antiviral activity against herpes simplex virus-2 G (HSV-2) in E6SM cell cultures,Other,11472207.0,
677,65712,6,2,,103504490,3454,Unspecified,,,,,Antiviral activity against vesicular simplex virus-1 in E6SM cell cultures,Other,11472207.0,
678,65844,6,2,,103504490,3454,Unspecified,,,,,Cytotoxic concentration required to cause microscopically detectable alteration of normal cell morphology of E6SM cells,Other,8709116.0,
679,66001,6,2,,103504490,3454,Unspecified,,,,,50% Minimum inhibitory concentration which is required to reduce cytopathogenicity induced by (196) strain of HSV-2 virus on human E6SM cells.,Other,9046339.0,
680,66002,6,2,,103504490,3454,Unspecified,,,,,50% Minimum inhibitory concentration which is required to reduce cytopathogenicity induced by (F) strain of HSV-1 virus on human E6SM cells.,Other,9046339.0,
681,66003,6,2,,103504490,3454,Unspecified,,,,,50% Minimum inhibitory concentration which is required to reduce cytopathogenicity induced by (G) strain of HSV-2 virus on human E6SM cells.,Other,9046339.0,
682,66004,6,2,,103504490,3454,Unspecified,,,,,50% Minimum inhibitory concentration which is required to reduce cytopathogenicity induced by (KOS) strain of HSV-1 virus on human E6SM cells.,Other,9046339.0,
683,66005,6,2,,103504490,3454,Unspecified,,,,,50% Minimum inhibitory concentration which is required to reduce cytopathogenicity induced by (Lyons) strain of HSV-2 virus on human E6SM cells.,Other,9046339.0,
684,66006,6,2,,103504490,3454,Unspecified,,,,,50% Minimum inhibitory concentration which is required to reduce cytopathogenicity induced by (Mc Intyre) strain of HSV-1 virus on human E6SM cells.,Other,9046339.0,
685,66007,6,2,,103504490,3454,Unspecified,,,,,50% Minimum inhibitory concentration which is required to reduce cytopathogenicity induced by TK-(B2006) strain of HSV-1 virus on human E6SM cells.,Other,9046339.0,
686,66938,4,4,,103504490,3454,Unspecified,,,,,Cytotoxicity concentration required to microscopically detectable alteration of cell morphology in E6SM,Other,10691698.0,
687,66950,7,2,,103504490,3454,Unspecified,,,,,Minimum cytotoxic concentration in E6SM fibroblast cells,Other,12408716.0,
688,66966,5,2,,103504490,3454,Unspecified,,,,,Inhibition of epstein barr virus(EBV) by nucleic acid hybridization assay in human lung fibroblast cell line; 30/380,Other,2826784.0,
689,67099,6,2,,103504490,3454,Active,,,0.05,IC50,Inhibition of growth of Epstein Barr virus(EBV) in human lung fibroblast cell line,Confirmatory,2826784.0,
690,68266,6,2,,103504490,3454,Unspecified,,,,,Concentration required to cause 50% reduction in cellular DNA synthesis in ESM cells,Other,1652016.0,
691,68267,6,2,,103504490,3454,Unspecified,,,,,Concentration required to cause a microscopically detectable alteration of normal cell morphology in ESM cells,Other,1652016.0,
692,68268,6,2,,103504490,3454,Unspecified,,,,,Concentration required to inhibit HSV-1 (F) induced cytopathogenicity in ESM cells by 50%,Other,1652016.0,
693,68269,6,2,,103504490,3454,Unspecified,,,,,Concentration required to inhibit HSV-1 (KOS) induced cytopathogenicity in ESM cells by 50%,Other,1652016.0,
694,68270,6,2,,103504490,3454,Unspecified,,,,,Concentration required to inhibit HSV-1 (McIntyre) induced cytopathogenicity in ESM cells by 50%,Other,1652016.0,
695,68271,6,2,,103504490,3454,Unspecified,,,,,Concentration required to inhibit HSV-2(196) induced cytopathogenicity in ESM cells by 50%,Other,1652016.0,
696,68272,6,2,,103504490,3454,Unspecified,,,,,Concentration required to inhibit HSV-2(G) induced cytopathogenicity in ESM cells by 50%,Other,1652016.0,
697,68273,6,2,,103504490,3454,Unspecified,,,,,Concentration required to inhibit HSV-2(lyons) induced cytopathogenicity in ESM cells by 50%,Other,1652016.0,
698,68274,6,2,,103504490,3454,Unspecified,,,,,Concentration required to inhibit TK-HSV-1 (B2006) induced cytopathogenicity in ESM cells by 50%,Other,1652016.0,
699,68275,6,2,,103504490,3454,Unspecified,,,,,Concentration required to inhibit TK-HSV-1 (VMW2837) induced cytopathogenicity in ESM cells by 50%,Other,1652016.0,
700,68277,6,2,,103504490,3454,Unspecified,,,,,Concentration required to inhibit VV induced cytopathogenicity in ESM cells by 50%.,Other,1652016.0,
701,68766,6,1,,103504490,3454,Unspecified,,,,,Anti-HCMV activity against F2002 cell line,Other,9934470.0,
702,68768,6,2,,103504490,3454,Unspecified,,,,,Compound was tested for Anti-HCMV activity against F2002 cell line(exp 1),Other,9934470.0,
703,68769,6,2,,103504490,3454,Unspecified,,,,,Compound was tested for Anti-HCMV activity against F2002 cell line(exp 2),Other,9934470.0,
704,70218,6,2,,103504490,3454,Unspecified,,,50.0,EC50,Effective concentration of compound against Epstein Barr virus was determined,Confirmatory,10377226.0,
705,70228,8,2,,103504490,3454,Inconclusive,,,,,In vitro antiviral activity against Epstein Barr virus (EBV) was determined; ND= Not determined,Other,11814776.0,
706,73621,6,3,,103504490,3454,Unspecified,,,,,Inhibitory activity against human cytomegalo virus (WFI strain) in a plaque reduction assay in flow 2002 human fibroblast cells,Other,,
707,73625,5,1,,103504490,3454,Unspecified,,,,,The compound was tested for inhibitory activity against human cytomegalovirus (HCMV) in flow 2002 cells,Other,,
708,73627,5,1,,103504490,3454,Unspecified,,,,,The compound was tested for inhibitory activity against human cytomegalovirus (HCMV) (WFl strain) in plaque reduction assay in flow 2002 cells,Other,,
709,79723,8,1,,103504490,3454,Unspecified,,,75.0,ID50,Cytotoxicity on human P3HR1 derived H1 cells,Confirmatory,10377226.0,
710,79936,6,2,,103504490,3454,Active,,,3.4,IC50,Inhibition of growth of human cytomegalovirus (HCMV) was determined by plaque reduction assay in human lung fibroblast cell line,Confirmatory,2826784.0,
711,79938,6,3,,103504490,3454,Active,,,8.8,IC50,Antiviral activity of the compound was evaluated against the Human cytomegalo virus (HCMV),Confirmatory,2913300.0,
712,79940,5,1,,103504490,3454,Unspecified,,,,,Antiviral activity against herpesvirus HCMV in AD-169 strain in tissue culture.,Other,2160539.0,
713,79944,5,1,,103504490,3454,Unspecified,,,,,"In vitro antiviral activity tested against HCMV, AD169 strain by plaque reduction assay in human foreskin fibroblasts.",Other,2329551.0,
714,79945,5,1,,103504490,3454,Unspecified,,,,,"In vitro antiviral activity tested against HCMV, CH strain by plaque reduction assay in human foreskin fibroblasts.",Other,2329551.0,
715,79946,5,1,,103504490,3454,Unspecified,,,,,"In vitro antiviral activity tested against HCMV, Davis strain by plaque reduction assay in human foreskin fibroblasts.",Other,2329551.0,
716,79947,5,1,,103504490,3454,Unspecified,,,,,"In vitro antiviral activity tested against HCMV, EC strain by plaque reduction assay in human foreskin fibroblasts.",Other,2329551.0,
717,79948,5,1,,103504490,3454,Unspecified,,,,,"In vitro antiviral activity tested against HCMV, LA strain by plaque reduction assay in human foreskin fibroblasts.",Other,2329551.0,
718,79949,5,1,,103504490,3454,Unspecified,,,,,In vitro antiviral activity tested against MCMV Smith strain by plaque reduction assay in mouse embryo fibroblasts.,Other,2329551.0,
719,79952,6,3,,103504490,3454,Active,,,0.88,IC50,Compound was tested for antiviral activity against HCMV in DNA hybridization assay,Confirmatory,10882374.0,
720,79954,6,3,,103504490,3454,Active,,,2.0,IC50,Compound was tested for antiviral activity against HCMV in viral cytopathic effect(CPE) assay,Confirmatory,10882374.0,
721,79955,6,3,,103504490,3454,Active,,,7.4,IC50,Concentration required for 50% inhibition of HCMV replication was measured using a Plaque reduction assay,Confirmatory,9057867.0,
722,79957,6,3,,103504490,3454,Active,,,8.7,IC50,Tested for antiviral activity against human cytomegalovirus (HCMV) by means of plaque reduction assay.,Confirmatory,2163453.0,
723,79958,6,3,,103504490,3454,Active,,,6.2,IC50,concentration required to reduce virus HCMV (A)plaque formation by 50%,Confirmatory,10966745.0,
724,79959,6,3,,103504490,3454,Active,,,6.2,IC50,concentration required to reduce virus HCMV (B)plaque formation by 50%,Confirmatory,10966745.0,
725,79960,6,3,,103504490,3454,Active,,,6.2,IC50,concentration required to reduce virus HCMV (C)plaque formation by 50%,Confirmatory,10966745.0,
726,79961,6,3,,103504490,3454,Active,,,4.1,IC50,concentration required to reduce virus HCMV (D)plaque formation by 50%,Confirmatory,10966745.0,
727,79962,6,3,,103504490,3454,Active,,,4.1,IC50,concentration required to reduce virus HCMV (E)plaque formation by 50%,Confirmatory,10966745.0,
728,79963,6,3,,103504490,3454,Active,,,6.2,IC50,concentration required to reduce virus HCMV (F)plaque formation by 50%,Confirmatory,10966745.0,
729,79964,6,3,,103504490,3454,Active,,,8.2,IC50,concentration required to reduce virus HCMV (G)plaque formation by 50%,Confirmatory,10966745.0,
730,79965,5,3,,103504490,3454,Active,,,,,Concentration required for 90% inhibition of HCMV replication was measured using a yield reduction assay,Other,9057867.0,
731,79969,5,1,,103504490,3454,Unspecified,,,,,"In vitro antiviral activity tested against HCMV, AD169 strain by plaque reduction assay in human foreskin fibroblasts.",Other,2329551.0,
732,79970,5,1,,103504490,3454,Unspecified,,,,,"In vitro antiviral activity tested against HCMV, CH strain by plaque reduction assay in human foreskin fibroblasts.",Other,2329551.0,
733,79971,5,1,,103504490,3454,Unspecified,,,,,"In vitro antiviral activity tested against HCMV, Davis strain by plaque reduction assay in human foreskin fibroblasts.",Other,2329551.0,
734,79972,5,1,,103504490,3454,Unspecified,,,,,"In vitro antiviral activity tested against HCMV, EC strain by plaque reduction assay in human foreskin fibroblasts.",Other,2329551.0,
735,79973,5,1,,103504490,3454,Unspecified,,,,,"In vitro antiviral activity tested against HCMV, LA strain by plaque reduction assay in human foreskin fibroblasts.",Other,2329551.0,
736,80084,6,2,,103504490,3454,Active,,,0.23,EC50,Antiviral activity against human cytomegalovirus,Confirmatory,11708924.0,
737,80085,6,2,,103504490,3454,Unspecified,,,,,Compound was evaluated for the antiviral activity against HCMV,Other,9871553.0,
738,80087,6,2,,103504490,3454,Unspecified,,,,,Tested for antiviral activity against HCMV in AD169 cell line,Other,11229780.0,
739,80088,6,2,,103504490,3454,Unspecified,,,,,Tested for antiviral activity against HCMV in Davis cell line,Other,11229780.0,
740,80095,6,2,,103504490,3454,Active,,,7.4,IC50,In vitro antiviral activity against HCMV (Towne strain) in HFF (human fibroblast) cells.,Confirmatory,9057865.0,
741,80096,6,2,,103504490,3454,Active,,,7.7,IC50,Compound was evaluated for antiviral activity by their capacity to inhibit replication of HCMV virus,Confirmatory,9548814.0,
742,80099,6,2,,103504490,3454,Active,,,7.4,IC50,Antiviral activity assayed by ability to inhibit Towne strain of HCMV virus,Confirmatory,9575044.0,
743,80103,6,2,,103504490,3454,Active,,,7.4,IC50,Concentration required for 50% inhibition of HCMV replication was measured using a Plaque reduction assay,Confirmatory,9057868.0,
744,80106,6,2,,103504490,3454,Active,,,7.7,IC50,Tested for antiviral activity against human cytomegalovirus by plaque assay,Confirmatory,8254613.0,
745,80107,5,2,,103504490,3454,Active,,,,,In vitro reduction in yield of Towne strain of HCMV in HFF (human fibroblast) cells.,Other,9057865.0,
746,80111,5,2,,103504490,3454,Active,,,,,"Compound was evaluated for the Yield reduction assays on HCMV virus,",Other,9575044.0,
747,80112,5,2,,103504490,3454,Active,,,,,Concentration required for 90% inhibition of HCMV replication was measured using a yield reduction assay,Other,9057868.0,
748,80113,5,2,,103504490,3454,Active,,,,,Tested for antiviral activity against human cytomegalovirus by yield reduction assay,Other,8254613.0,
749,80121,6,3,,103504490,3454,Active,,,5.9,IC50,Concentration required to reduce viral plaque formation by Human Cytomegalovirus (HCMV) (strain AD-169) in MRC-5 cells,Confirmatory,10966740.0,
750,80124,6,3,,103504490,3454,Unspecified,,,,,Antiviral activity was determined against Human cytomegalovirus (HCMV) strain AD-169 using CPE inhibition assay,Other,11262090.0,
751,80125,6,3,,103504490,3454,Unspecified,,,,,Antiviral activity was determined against Human cytomegalovirus (HCMV) strain Davis using CPE inhibition assay,Other,11262090.0,
752,80127,8,1,,103504490,3454,Active,,,2.0,ID50,compound was tested for antiherpes activity against HCMV(AD 169) in tissue culture by plaque reduction assay,Confirmatory,1849998.0,
753,81027,8,3,,103504490,3454,Inconclusive,,,,,The compound was tested for antiviral activity by measuring the concentration required to reduce plaque formation against Varicella zoster TK+OKA strain; Not determined,Other,10411487.0,
754,81029,8,3,,103504490,3454,Inconclusive,,,,,The compound was tested for antiviral activity by measuring the concentration required to reduce plaque formation against Varicella zoster TK+YS strain; Not determined,Other,10411487.0,
755,81031,8,3,,103504490,3454,Inconclusive,,,,,The compound was tested for antiviral activity by measuring the concentration required to reduce plaque formation against Varicella zoster TK-(deficient) 07/1 strain; Not determined,Other,10411487.0,
756,81033,8,3,,103504490,3454,Inconclusive,,,,,The compound was tested for antiviral activity by measuring the concentration required to reduce plaque formation against Varicella zoster TK-(deficient) YS/R strain; Not determined,Other,10411487.0,
757,81034,6,3,,103504490,3454,Active,,,1.0,IC50,The compound was tested for antiviral activity by measuring the concentration required to reduce plaque formation against cytomegalo virus AD-169 strain,Confirmatory,10411487.0,
758,81036,6,3,,103504490,3454,Active,,,5.0,IC50,The compound was tested for antiviral activity by measuring the concentration required to reduce plaque formation against cytomegalo virus Davis strain,Confirmatory,10411487.0,
759,81038,6,3,,103504490,3454,Unspecified,,,50.0,IC50,The compound was tested for cytotoxic concentration required to reduce human embryonic lung cell growth by 50%,Confirmatory,10411487.0,
760,81040,7,3,,103504490,3454,Unspecified,,,,,Minimum cytotoxic concentration against HEL cell morphology.,Other,12217359.0,
761,81041,5,3,,103504490,3454,Inconclusive,,,,,Minimum cytotoxic concentration against HEL cell morphology; ND denotes no data,Other,12217359.0,
762,81043,7,3,,103504490,3454,Unspecified,,,,,In vitro alteration in cell morphology in HEL cells.,Other,10966745.0,
763,81048,6,3,,103504490,3454,Unspecified,,,,,Concentration required to cause 50% reduction in HEL cell growth.,Other,1652016.0,
764,81050,6,3,,103504490,3454,Unspecified,,,,,Concentration required to inhibit CMV (AD-169) induced cytopathogenicity in HEL cells by 50%,Other,1652016.0,
765,81052,6,3,,103504490,3454,Unspecified,,,,,Concentration required to inhibit CMV (Davis) induced cytopathogenicity in HEL cells by 50%,Other,1652016.0,
766,81055,6,3,,103504490,3454,Inconclusive,,,,,Concentration required to inhibit TK-VZV (07-1) induced cytopathogenicity in HEL cells by 50%,Other,1652016.0,
767,81057,6,3,,103504490,3454,Inconclusive,,,,,Concentration required to inhibit TK-VZV (YSR) induced cytopathogenicity in HEL cells by 50%,Other,1652016.0,
768,81188,6,3,,103504490,3454,Inconclusive,,,,,Concentration required to inhibit VZV (YS) induced cytopathogenicity in HEL cells by 50%,Other,1652016.0,
769,81190,6,3,,103504490,3454,Inconclusive,,,,,Concentration required to inhibit VZV (oka) induced cytopathogenicity in HEL cells by 50%,Other,1652016.0,
770,81193,6,3,,103504490,3454,Unspecified,,,,,Inhibitory concentration required to inhibit cell growth by 50% in human embryonic lung (HEL) cell culture,Other,8393114.0,
771,81218,4,5,,103504490,3454,Unspecified,,,,,Cytotoxicity concentration required to microscopically detectable alteration of cell morphology HEL,Other,10691698.0,
772,81223,6,2,,103504490,3454,Active,,,3.7,IC50,In vitro inhibition of HCMV (AD-169) plaque formation.,Confirmatory,10966745.0,
773,81224,6,3,,103504490,3454,Active,,,5.9,IC50,In vitro inhibition of HCMV (Davis) plaque formation.,Confirmatory,10966745.0,
774,81228,3,5,,103504490,3454,Inconclusive,,,,,Concentration required to reduce Thymidine Kinase deficient Varicella Zoster Virus (07/1) plaque formation by 50%; ND=No Data,Other,10966745.0,
775,81230,3,5,,103504490,3454,Inconclusive,,,,,Concentration required to reduce Thymidine Kinase deficient Varicella Zoster Virus (YS/R) plaque formation by 50%; ND=No Data,Other,10966745.0,
776,81234,5,2,,103504490,3454,Inconclusive,,,,,Compound was evaluated for the antiviral activity against HIV-1; Not determined,Other,9871553.0,
777,81361,3,5,,103504490,3454,Inconclusive,,,,,concentration required to reduce virus Thymidine Kinase-Varicella Zoster Virus(YS)plaque formation by 50%; ND=No Data,Other,10966745.0,
778,81362,3,5,,103504490,3454,Inconclusive,,,,,concentration required to reduce virus Thymidine Kinase-Varicella-Zoster Virus(OKA)plaque formation by 50%; ND=No Data,Other,10966745.0,
779,81363,6,2,,103504490,3454,Unspecified,,,100.0,CC50,In vitro cytotoxicity of the compound (Concentration required to reduce OD value by 50%) in human embryonic lung fibroblast(HEL 299) cells determined by MTT assay.,Confirmatory,9925738.0,
780,81364,6,2,,103504490,3454,Active,,,0.63,EC50,In vitro antiviral (HCMV-AD169) activity of the compound (Concentration required to reduce 50% of the plaques) determined by plaque reduction assay.,Confirmatory,9925738.0,
781,81384,7,1,,103504490,3454,Unspecified,,,,,Cytotoxic concentration against HEP-2 cells,Other,2842505.0,
782,81905,6,2,,103504490,3454,Unspecified,,,156.0,IC50,Inhibitory activity against human foreskin fibroblast cell proliferation,Confirmatory,11708924.0,
783,81918,6,2,,103504490,3454,Unspecified,,,392.0,CC50,In vitro cytotoxic concentration required to inhibit AD169 strain of human cytomegalovirus (HCMV) replication in HFF cell line,Confirmatory,14736238.0,
784,81919,6,3,,103504490,3454,Unspecified,,,100.0,CC50,In vitro cytotoxic concentration required to inhibit towne strain of human cytomegalovirus (HCMV) replication in HFF cell line,Confirmatory,14736238.0,
785,81921,6,3,,103504490,3454,Active,,,2.3,EC50,In vitro effective concentration required to inhibit AD169 strain of human cytomegalovirus (HCMV) replication in HFF cell line,Confirmatory,14736238.0,
786,81922,6,3,,103504490,3454,Active,,,4.1,EC50,In vitro effective concentration required to inhibit towne strain of human cytomegalovirus (HCMV) replication in HFF cell line,Confirmatory,14736238.0,
787,81926,6,2,,103504490,3454,Unspecified,,,,,Anti HCMV(human cytomegalovirus) activity in HFF cell line Hs 68 infected with AD619 strain of HCMV(plaque reduction assay).,Other,7562929.0,
788,81927,6,2,,103504490,3454,Unspecified,,,,,Anti HCMV(human cytomegalovirus) activity in MRC-5 cells infected with DHPG-resistant D16 strain of HCMV(plaque reduction assay).,Other,7562929.0,
789,81928,6,2,,103504490,3454,Active,,,7.7,IC50,Antiviral activity was determined by the HCMV plaque assay using HFF cells,Confirmatory,9057866.0,
790,81929,6,2,,103504490,3454,Unspecified,,,100.0,IC50,Compound was evaluated for the visual cytotoxicity scored on HFF cells at time of HCMV plaque enumeration,Confirmatory,7562945.0,
791,81930,6,2,,103504490,3454,Unspecified,,,100.0,IC50,Visual cytotoxicity scored on HFF cells at the time of HCMV plaque enumeration.,Confirmatory,7562947.0,
792,81933,6,3,,103504490,3454,Unspecified,,,100.0,IC50,Cytotoxicity against human foreskin fibroblasts (HFF) cells,Confirmatory,,
793,81934,6,2,,103504490,3454,Unspecified,,,100.0,IC50,Cytotoxicity in HFF cells was estimated by the visual scoring of cells affected by virus infection in the plaque reduction assay (data of single experiment),Confirmatory,9057866.0,
794,82034,6,2,,103504490,3454,Unspecified,,,,,Antiviral activity against HSV-1 virus infected HEF cell lines.,Other,8765514.0,
795,82035,6,2,,103504490,3454,Unspecified,,,,,Antiviral activity against HSV-2 virus infected HEF cell lines.,Other,8765514.0,
796,82037,6,2,,103504490,3454,Unspecified,,,,,Antiviral activity against TK-HSV-1 virus infected HEF cell lines.,Other,8765514.0,
797,82039,6,2,,103504490,3454,Unspecified,,,,,Effects on cell morphology of HEF cell lines.,Other,8765514.0,
798,82041,6,2,,103504490,3454,Unspecified,,,,,Antiviral activity against vaccinia virus infected HEF cell lines.,Other,8765514.0,
799,82043,6,2,,103504490,3454,Unspecified,,,,,Antiviral activity against vesicular stomatitis virus infected HEF cell lines.,Other,8765514.0,
800,82055,6,2,,103504490,3454,Unspecified,,,100.0,IC50,Cytotoxicity produced in human foreskin fibroblasts (HFF) cells estimated by visual scoring of cells unaffected by virus infection.,Confirmatory,8784444.0,
801,82056,6,2,,103504490,3454,Unspecified,,,100.0,IC50,Cytotoxicity produced in human foreskin fibroblasts (HFF) cells was estimated by visual scoring of cells unaffected by virus infection in the plaque-reduction assay.,Confirmatory,8784445.0,
802,82062,6,2,,103504490,3454,Unspecified,,,100.0,IC50,Tested for the visual cytotoxicity on HFF cells at the time of human cytomegalovirus (HCMV) plaque enumeration,Confirmatory,8071942.0,
803,82063,6,2,,103504490,3454,Unspecified,,,100.0,IC50,Visual cytotoxicity of compound on HFF cells at time of HCMV plaque enumeration,Confirmatory,8632412.0,
804,82064,6,2,,103504490,3454,Unspecified,,,100.0,IC50,Visual cytotoxicity scored on HFF cells at time of HCMV plaque enumeration,Confirmatory,7562946.0,
805,82065,6,2,,103504490,3454,Unspecified,,,100.0,IC50,Visual cytotoxicity was scored on HFF cells at time of HCMV plaque enumeration,Confirmatory,9057867.0,
806,82066,6,2,,103504490,3454,Unspecified,,,100.0,IC50,Visual cytotoxicity was scored on HFF cells at time of HCMV plaque enumeration,Confirmatory,9057868.0,
807,82067,6,2,,103504490,3454,Unspecified,,,100.0,IC50,Visual cytotoxicity was scored on Human foreskin fibroblasts (HFF cells) at the time of plaque enumeration.,Confirmatory,9057865.0,
808,82068,5,2,,103504490,3454,Active,,,,,Antiviral activity was estimated by the HCMV yield reduction experiments,Other,9057866.0,
809,82116,5,1,,103504490,3454,Inactive,,,,,Antiviral activity against HIV-1 was determined; No inhibition,Other,2391689.0,
810,82226,5,1,,103504490,3454,Unspecified,,,,,"Visual cytotoxicity of stationary HFF Cell line Hs68, median toxic concentration is evaluated by anti HCMV plaque reduction assay performed in HFF Cell line Hs 68",Other,7562929.0,
811,82227,5,1,,103504490,3454,Unspecified,,,,,"Visual cytotoxicity of stationary MRC-5 cells, median toxic concentration is evaluated by anti HCMV plaque reduction assay performed in HFF Cell line Hs 68",Other,7562929.0,
812,82257,6,2,,103504490,3454,Active,,,7.4,IC50,Antiviral activity against towne strain HCMV was determined by plaque reduction assay in duplicate wells using HFF cells,Confirmatory,10882370.0,
813,82258,6,2,,103504490,3454,Active,,,7.4,IC50,Antiviral activity against HCMV was determined by plaque reduction assay using HFF cells,Confirmatory,10882372.0,
814,82260,6,2,,103504490,3454,Unspecified,,,100.0,IC50,Compound was evaluated for the cytotoxicity scored on HFF cells at time of HCMV plaque enumeration.,Confirmatory,9575044.0,
815,82267,6,2,,103504490,3454,Active,,,4.1,IC50,Compound was tested for antiviral activity against C-4 Towne strain of HCMV in yield reduction assay using HFF cells,Confirmatory,10882374.0,
816,82270,6,2,,103504490,3454,Active,,,7.4,IC50,Compound was tested for antiviral activity against Towne strain of HCMV in a plaque reduction assay using HFF cells,Confirmatory,10882374.0,
817,82395,6,2,,103504490,3454,Active,,,7.4,IC50,Compound was tested for antiviral activity against human cytomegalovirus (HCMV) by plaque reduction assay using HFF cells,Confirmatory,10882375.0,
818,82398,6,2,,103504490,3454,Active,,,4.5,IC50,Compound was tested for antiviral activity against wild-type Towne strain of HCMV in yield reduction assay using HFF cells,Confirmatory,10882374.0,
819,82401,6,2,,103504490,3454,Unspecified,,,100.0,IC50,Compound was tested for visual cytotoxicity on HFF cells unaffected by HCMV at the time of plaque enumeration,Confirmatory,10882374.0,
820,82402,6,2,,103504490,3454,Unspecified,,,100.0,IC50,Compound was tested for visual cytotoxicity on human foreskin fibroblasts (HFF) cells,Confirmatory,10882375.0,
821,82404,6,3,,103504490,3454,Unspecified,,,100.0,IC50,Cytotoxicity was evaluated against the Human diploid cells (HFF),Confirmatory,2913300.0,
822,82406,8,2,,103504490,3454,Inconclusive,,,,,Cytotoxicity on stationary HFF cells at time of HCMV plaque enumeration in cells not effected by the virus; Not tested,Other,9438017.0,
823,82415,6,2,,103504490,3454,Active,,,2.6,IC50,Inhibitory concentration against human cytomegalovirus replication in HFF cells was determined by cytopathic effect inhibition assay,Confirmatory,9438017.0,
824,82416,6,2,,103504490,3454,Active,,,7.4,IC50,Inhibitory concentration against human cytomegalovirus replication in HFF cells was determined by plaque reduction assay,Confirmatory,9438017.0,
825,82418,6,3,,103504490,3454,Active,,,8.4,IC50,In vitro inhibition of human cytomegalovirus in HFF cells by plaque reduction assay.,Confirmatory,,
826,82419,6,2,,103504490,3454,Unspecified,,,100.0,IC50,Tested for cytotoxic activity against human foreskin fibroblasts (HFF) cells.,Confirmatory,2163453.0,
827,82420,6,2,,103504490,3454,Unspecified,,,100.0,IC50,Tested for cytotoxicity in human foreskin fibroblasts at time of HCMV plaque enumeration,Confirmatory,8254613.0,
828,82422,6,2,,103504490,3454,Unspecified,,,100.0,IC50,Tested in vitro for cytotoxicity against the normal human diploid cells (HFF cells).,Confirmatory,2175356.0,
829,82423,6,2,,103504490,3454,Unspecified,,,100.0,IC50,The compound was tested for cytotoxicity against human foreskin fibroblast cell,Confirmatory,2840500.0,
830,82424,6,2,,103504490,3454,Unspecified,,,100.0,IC50,Visual cytotoxicity against stationary human foreskin fibroblasts (HFF) cells at the time of HCMV plaque enumeration,Confirmatory,10882370.0,
831,82426,6,2,,103504490,3454,Unspecified,,,100.0,IC50,Visual cytotoxicity was scored on HFF cells at time of HCMV plaque enumeration,Confirmatory,10882372.0,
832,82427,5,2,,103504490,3454,Active,,,,,Antiviral activity against towne strain HCMV was determined by yield reduction assay in duplicate wells using HFF cells,Other,10882370.0,
833,82428,5,2,,103504490,3454,Active,,,,,Antiviral activity against HCMV was determined by yield reduction assay using HFF cells,Other,10882372.0,
834,82429,5,2,,103504490,3454,Active,,,,,Compound was tested for antiviral activity against 2916 AD169 strain of HCMV in yield reduction assay using HFF cells,Other,10882374.0,
835,82431,5,2,,103504490,3454,Active,,,,,Compound was tested for antiviral activity against Towne strain of HCMV in a yield reduction assay using HFF cells,Other,10882374.0,
836,82432,5,2,,103504490,3454,Active,,,,,Compound was tested for antiviral activity against human cytomegalovirus (HCMV) by yield reduction assay using HFF cells,Other,10882375.0,
837,82433,5,2,,103504490,3454,Active,,,,,Compound was tested for antiviral activity against wild-type AD169 strain of HCMV in yield reduction assay using HFF cells,Other,10882374.0,
838,82435,5,2,,103504490,3454,Active,,,,,Inhibitory concentration against human cytomegalovirus replication in HFF cells was determined by yield reduction assay,Other,9438017.0,
839,82524,6,3,,103504490,3454,Unspecified,,,,,Compound was tested for its cytotoxicity against human embryonic lung fibroblast cells (HEL 299) by MTT dye reduction assay,Other,,
840,82525,6,2,,103504490,3454,Unspecified,,,,,Cytotoxic concentration of compound was tested against HEL299(human embryonic lung fibroblast) cells using cytotoxic assay,Other,11262090.0,
841,82535,6,3,,103504490,3454,Unspecified,,,400.0,CC50,Compound concentration required to reduce viability of HEL cells,Confirmatory,14643328.0,
842,82536,6,3,,103504490,3454,Unspecified,,,150.0,CC50,Concentration required against HEL cell proliferation,Confirmatory,14643358.0,
843,82537,6,3,,103504490,3454,Unspecified,,,150.0,CC50,Cytostatic concentration required to inhibit HEL cell proliferation measured at day 4,Confirmatory,15027877.0,
844,82546,6,3,,103504490,3454,Unspecified,,,150.0,CC50,Cytotoxic concentration required to reduce HEL cell growth by 50%,Confirmatory,15081019.0,
845,82548,5,3,,103504490,3454,Unspecified,,,,,Cytotoxicity (to reduce cell growth) against Cytomegalovirus in human embryonic lung (HEL) cells,Other,,
846,82551,6,3,,103504490,3454,Unspecified,,,,,"Tested for the cytotoxic concentration, required to reduce cell growth by 50% in human embryonic lung (HEL) cells.",Other,7877148.0,
847,82553,6,3,,103504490,3454,Unspecified,,,,,The concentration required to reduce cell growth by 50% was measured on Human Embryonic Lung (HEL) cells,Other,10197958.0,
848,82559,6,2,,103504490,3454,Active,,,0.6,IC50,"Antiviral activity in a cell-based plaque reduction assay, using an HFF cell line and the Davis strain of HCMV",Confirmatory,10999475.0,
849,82684,6,3,,103504490,3454,Active,,,0.06,EC50,Compound was tested for anti-viral activity against HSV-1(G) in HEL cells,Confirmatory,14643328.0,
850,82687,8,3,,103504490,3454,Inconclusive,,,,,Compound was tested for anti-viral activity against HSV-1(KOS) in HEL cells; ND=Not determined,Other,14643328.0,
851,82689,8,3,,103504490,3454,Inconclusive,,,,,Compound was tested for anti-viral activity against HSV-1TK neg in HEL cells; ND=Not determined,Other,14643328.0,
852,82690,6,3,,103504490,3454,Active,,,0.9,EC50,Effective concentration against human cytomegalovirus AD-169 strain in HEL cell cultures,Confirmatory,15081019.0,
853,82691,6,3,,103504490,3454,Active,,,0.8,EC50,Effective concentration against human cytomegalovirus Davies strain in HEL cell cultures,Confirmatory,15081019.0,
854,82692,6,3,,103504490,3454,Active,,,2.7,EC50,Effective concentration required to inhibit HCMV AD169 strain-induced cytopathicity in human embryonic lung (HEL) fibroblast cell cultures at day 7 of postinfection,Confirmatory,15027877.0,
855,82693,6,3,,103504490,3454,Active,,,3.9,EC50,Effective concentration required to inhibit HCMV Davis strain-induced cytopathicity in human embryonic lung (HEL) fibroblast cell cultures at day 7 of postinfection,Confirmatory,15027877.0,
856,82698,5,1,,103504490,3454,Unspecified,,,,,Antiviral activity against herpes simplex virus-1 VR-3 strain in HEL (human erythroleukemia) cells.,Other,9216836.0,
857,82699,5,1,,103504490,3454,Unspecified,,,,,Antiviral activity against herpes simplex virus-2 (HSV-2) Ms strain in HEL (human erythroleukemia) cells.,Other,9216836.0,
858,82700,5,1,,103504490,3454,Unspecified,,,,,Antiviral activity against human cytomegalovirus (HCMV) AD 169 strain HEL (human erythroleukemia) cells.,Other,9216836.0,
859,82701,5,1,,103504490,3454,Unspecified,,,,,Antiviral activity against varicella zoster virus (VZV) Oka strain in HEL (human erythroleukemia) cells.,Other,9216836.0,
860,82706,5,3,,103504490,3454,Unspecified,,,,,Antiviral activity against Cytomegalovirus (AD-169 strain) to reduce plaque formation in human embryonic lung (HEL) cells,Other,,
861,82707,5,3,,103504490,3454,Unspecified,,,,,Antiviral activity against Cytomegalovirus (Davis strain) to reduce plaque formation in human embryonic lung (HEL) cells,Other,,
862,82895,6,3,,103504490,3454,Unspecified,,,,,Tested for the inhibitory concentration required to reduce TK+ Varicella-Zoster virus (TK+ VZV) strain OKA plaque formation by 50%.,Other,7877148.0,
863,82896,6,3,,103504490,3454,Unspecified,,,,,Tested for the inhibitory concentration required to reduce TK+ Varicella-Zoster virus (TK+ VZV) strain YS plaque formation by 50%,Other,7877148.0,
864,83020,6,3,,103504490,3454,Unspecified,,,,,Tested for the inhibitory concentration required to reduce cytomegalovirus (CMV) strain AD-169 plaque formation by 50%.,Other,7877148.0,
865,83022,6,3,,103504490,3454,Unspecified,,,,,Tested for the inhibitory concentration required to reduce cytomegalovirus (CMV) strain Davis plaque formation by 50%.,Other,7877148.0,
866,83023,6,3,,103504490,3454,Unspecified,,,,,Tested for the inhibitory concentration required to reduce thymidine kinase deficient Varicella-Zoster virus (TK- VZV) strain 07/1 plaque formation by 50%.,Other,7877148.0,
867,83024,6,3,,103504490,3454,Unspecified,,,,,Tested for the inhibitory concentration required to reduce thymidine kinase deficient Varicella-Zoster virus (TK- VZV) strain YS/R plaque formation by 50%.,Other,7877148.0,
868,83030,6,3,,103504490,3454,Active,,,7.0,IC50,Inhibition against DNA of uninfected HEL cells by incorporation of [3H]TdR.,Confirmatory,7752205.0,
869,83031,6,3,,103504490,3454,Active,,,0.5,IC50,Inhibition of human CMV DNA synthesis in CMV-infected HEL cells.,Confirmatory,7752205.0,
870,83032,5,3,,103504490,3454,Active,,,,,Concentration that inhibits HCMV yield by 90% relative to control cultures without drugs,Other,7752205.0,
871,83036,6,3,,103504490,3454,Unspecified,,,,,Concentration required to reduce human embryonic lung (HEL) cell growth by 50%.,Other,1319491.0,
872,83037,5,3,,103504490,3454,Unspecified,,,,,Cytotoxicity (to alter cell morphology) against Cytomegalovirus in human embryonic lung (HEL) cells,Other,,
873,83039,7,3,,103504490,3454,Unspecified,,,,,Minimal cytotoxic concentration required to cause a microscopically visible alteration of HEL cell morphology as measured at day 7 postinfection,Other,15027877.0,
874,83041,7,3,,103504490,3454,Unspecified,,,,,Minimal cytotoxic concentration required to cause a morphological alteration of human embryonic lung fibroblast(HEL) cell cultures,Other,14643358.0,
875,83044,6,3,,103504490,3454,Unspecified,,,,,Tested for cytotoxic activity in human embryonic lung fibroblast (HEL),Other,11858989.0,
876,83045,6,3,,103504490,3454,Unspecified,,,,,The minimum cytotoxic concentration was measured on Human Embryonic Lung (HEL) cells,Other,10197958.0,
877,83179,6,3,,103504490,3454,Unspecified,,,,,Concentration required to reduce CMV(Davis) plaque formation by 50% at 20 plaque forming units(PFU) in human embryonic lung (HEL) cell cultures.,Other,1319491.0,
878,83180,6,3,,103504490,3454,Unspecified,,,,,Concentration required to reduce CMV (Davis) plaque formation by 50% at 100 plaque forming units(PFU) in human embryonic lung (HEL) cell cultures.,Other,1319491.0,
879,83183,6,3,,103504490,3454,Unspecified,,,,,Concentration required to reduce varicella zoster virus(VZV)OKA plaque formation by 50% at 20 plaque forming units(PFU) in human embryonic lung (HEL) cell cultures.,Other,1319491.0,
880,83189,6,3,,103504490,3454,Unspecified,,,,,Minimum inhibitory conc. for 50% inhibition of CMV (AD-169) virus plaque formation in HEL cells,Other,9135038.0,
881,83190,6,3,,103504490,3454,Unspecified,,,,,Minimum inhibitory conc. for 50% inhibition of CMV (Davis) virus plaque formation in HEL cells,Other,9135038.0,
882,83203,6,3,,103504490,3454,Unspecified,,,,,Tested for antiviral activity against human cytomegalovirus (AD-169) in human embryonic lung fibroblasts,Other,11858989.0,
883,83207,6,3,,103504490,3454,Unspecified,,,,,The minimum inhibitory concentration was measured on HEL cells against Cytomegalovirus virus (AD-169 strain),Other,7932543.0,
884,83325,6,2,,103504490,3454,Unspecified,,,,,The minimum inhibitory concentration was measured on HEL cells against Cytomegalovirus virus (Davis strain),Other,7932543.0,
885,83328,6,2,,103504490,3454,Unspecified,,,,,The minimum inhibitory concentration was measured on HEL cells against TK-Varicella zoster virus (07/1 strain),Other,7932543.0,
886,83329,6,2,,103504490,3454,Unspecified,,,,,The minimum inhibitory concentration was measured on HEL cells against TK-Varicella zoster virus (YS-R strain),Other,7932543.0,
887,83331,6,2,,103504490,3454,Unspecified,,,,,The minimum inhibitory concentration was measured on HEL cells against Varicella zoster virus (OKA strain),Other,7932543.0,
888,83332,6,2,,103504490,3454,Unspecified,,,,,The minimum inhibitory concentration was measured on HEL cells against Varicella zoster virus (YS strain),Other,7932543.0,
889,83333,6,3,,103504490,3454,Unspecified,,,,,The minimum inhibitory concentration was measured on HEL cells in cell growth,Other,7932543.0,
890,83363,6,3,,103504490,3454,Active,,,7.8,EC50,Effective concentration required to inhibit cytomegalo virus-induced cytopathicity by 50% in AD-169 strain HEL cell lines,Confirmatory,11495586.0,
891,83364,6,3,,103504490,3454,Active,,,11.8,EC50,Effective concentration required to inhibit cytomegalo virus-induced cytopathicity by 50% in Davis-169 strain HEL cell lines,Confirmatory,11495586.0,
892,83488,8,2,,103504490,3454,Unspecified,,,,,Minimum inhibitory concentration required to elicit microscopically visible cell morphology in HEL cell lines,Other,11495586.0,
893,83489,6,3,,103504490,3454,Unspecified,,,,,Antiviral activity against HCMV virus infected HEL cell lines.,Other,8765514.0,
894,83497,5,1,,103504490,3454,Unspecified,,,,,Inhibition of cell proliferation expressed as CC50,Other,9836626.0,
895,83499,7,3,,103504490,3454,Unspecified,,,,,Cytotoxic concentration reducing HEL cell growth by 50%.,Other,12217359.0,
896,83500,5,3,,103504490,3454,Inconclusive,,,,,Cytotoxic concentration to reduce HEL cell growth by 50%; ND denotes no data,Other,12217359.0,
897,83503,6,3,,103504490,3454,Unspecified,,,394.0,CC50,Inhibition of cell growth in HEL cells.,Confirmatory,10966745.0,
898,83518,5,3,,103504490,3454,Unspecified,,,,,Antiviral activity was measured against cytomegalovirus (CMV) AD-169 strain in human embryonic lung (HEL) cells,Other,,
899,83519,5,3,,103504490,3454,Unspecified,,,,,Antiviral activity was measured against cytomegalovirus (CMV) Davis strain in human embryonic lung (HEL) cells,Other,,
900,83523,6,3,,103504490,3454,Inconclusive,,,,,Compound was tested for Anti-VZV activity against 07/1 TK- in HEL cells;d ='not determined',Other,9836626.0,
901,83525,6,3,,103504490,3454,Inconclusive,,,,,Compound was tested for Anti-VZV activity against OKA strain TK+ in HEL cells;d ='not determined',Other,9836626.0,
902,83527,6,3,,103504490,3454,Inconclusive,,,,,Compound was tested for Anti-VZV activity against YS TK+ in HEL cells;d ='not determined',Other,9836626.0,
903,83529,6,3,,103504490,3454,Inconclusive,,,,,Compound was tested for Anti-VZV activity against YS/R TK- in HEL cells;d ='not determined',Other,9836626.0,
904,83530,6,3,,103504490,3454,Unspecified,,,,,Anti CMV (Cytomegalovirus- virus) activity against AD-169 strain in HEL cells,Other,9836626.0,
905,83531,6,2,,103504490,3454,Unspecified,,,,,Anti CMV (Cytomegalovirus- virus) activity against Davis strain in HEL cells,Other,9836626.0,
906,83535,6,3,,103504490,3454,Unspecified,,,50.0,IC50,Minimum cytotoxic concentration that causes a microscopically detectable alteration of cell morphology in human embryonic lung cells,Confirmatory,10411487.0,
907,83710,7,2,,103504490,3454,Unspecified,,,,,Tested for antiviral activity against HSV-1 (KOS),Other,11412988.0,
908,83711,7,2,,103504490,3454,Unspecified,,,,,Tested for antiviral activity against HSV-1 (TK-KOS),Other,11412988.0,
909,83712,6,2,,103504490,3454,Active,,,3.5,IC50,Tested for anti-viral activity against Herpes simplex virus type-1 using ELISA.,Confirmatory,8071942.0,
910,84056,4,4,,103504490,3454,Unspecified,,,,,Antiviral activity against herpes simplex virus type 1 HSV-1 (F) expressed as viral rating (VR),Other,2842505.0,
911,84084,6,2,,103504490,3454,Unspecified,,,,,Inhibitory activity against HSV-1 (F) replication in E6SM cell cultures of human embryonic skin-muscle,Other,12459010.0,
912,84085,7,2,,103504490,3454,Unspecified,,,,,Minimum inhibitory concentration was determined against HSV-1 (F) in E6SM cell culture,Other,10691698.0,
913,84217,6,2,,103504490,3454,Unspecified,,,,,Inhibitory activity against HSV-1 (KOS) replication in E6SM cell cultures of human embryonic skin-muscle,Other,12459010.0,
914,84218,6,2,,103504490,3454,Unspecified,,,,,Inhibitory activity against TK-deficient HSV-1 (KOS) replication in E6SM cell cultures of human embryonic skin-muscle,Other,12459010.0,
915,84225,7,2,,103504490,3454,Unspecified,,,,,Minimum inhibitory concentration was determined against HSV-1 (KOS) in E6SM cell culture,Other,10691698.0,
916,84226,6,2,,103504490,3454,Unspecified,,,,,Minimum inhibitory concentration was determined against HSV-1 (McIntyre) in E6SM cell culture,Other,10691698.0,
917,84228,6,2,,103504490,3454,Unspecified,,,,,Inhibitory activity against HSV-1 (McIntyre) replication in E6SM cell cultures of human embryonic skin-muscle,Other,12459010.0,
918,84229,6,2,,103504490,3454,Unspecified,,,,,Minimum inhibitory concentration was determined against HSV-1 (G) in E6SM cell culture,Other,10691698.0,
919,84243,7,2,,103504490,3454,Unspecified,,,,,Minimum inhibitory concentration was determined against HSV-1 (TK-KOS ACV) in E6SM cell culture,Other,10691698.0,
920,84405,8,1,,103504490,3454,Active,,,0.04,ID50,compound was tested for antiherpes activity against HSV-1(Schooler) in tissue culture by plaque reduction assay,Confirmatory,1849998.0,
921,84407,6,2,,103504490,3454,Unspecified,,,,,Minimal inhibitory concentration to reduce virus-induced cytopathicity against Thymidine kinase deficient(TK-) HSV-1 of Acyclovir,Other,11708929.0,
922,84409,6,2,,103504490,3454,Unspecified,,,,,Minimal inhibitory concentration to reduce virus-induced cytopathicity against TK-/TK+ HSV-1 of VMW 837,Other,11708929.0,
923,84588,10,1,,103504490,3454,Unspecified,,,,,Minimal inhibitory concentration to reduce virus-induced cytopathicity against F strain of human Herpes Simplex Virus-1 (HSV-1),Other,11708929.0,
924,84590,6,2,,103504490,3454,Unspecified,,,,,Minimal inhibitory concentration to reduce virus-induced cytopathicity against KOS strain of human Herpes Simplex Virus -1,Other,11708929.0,
925,84591,6,2,,103504490,3454,Unspecified,,,,,Minimal inhibitory concentration to reduce virus-induced cytopathicity against McIntyre strain of human Herpes Simplex Virus-1,Other,11708929.0,
926,84592,6,2,,103504490,3454,Active,,,0.1,IC50,Inhibition of growth of herpes simplex virus (HSV-2) by plaque reduction assay in vero cell line,Confirmatory,2826784.0,
927,84602,5,1,,103504490,3454,Unspecified,,,,,Antiviral activity against herpesvirus HSV-2 in G strain in tissue culture.,Other,2160539.0,
928,84930,5,2,,103504490,3454,Inconclusive,,,,,Compound was evaluated for the antiviral activity against HSV-2; Not determined,Other,9871553.0,
929,84933,6,2,,103504490,3454,Active,,,0.23,EC50,Inhibition of viral cytopathic effect in infected human foreskin fibroblast cell in monolayers of HSV-2 AD Vero cells by 50%,Confirmatory,11585457.0,
930,84940,8,1,,103504490,3454,Active,,,1.0,ED50,Concentration at which 50% of the herpes simplex virus type 2 HSV-1 (F) induced cytopathic effect are inhibited is determined,Confirmatory,2842505.0,
931,84947,7,2,,103504490,3454,Unspecified,,,,,Tested for antiviral activity against HSV-2 (G),Other,11412988.0,
932,85088,4,4,,103504490,3454,Unspecified,,,,,Antiviral activity against herpes simplex virus type 2 HSV-2 (F) expressed as viral rating (VR),Other,2842505.0,
933,85112,6,2,,103504490,3454,Unspecified,,,,,Inhibitory activity against HSV-2 (196) replication in E6SM cell cultures of human embryonic skin-muscle,Other,12459010.0,
934,85120,6,2,,103504490,3454,Unspecified,,,,,Inhibitory activity against HSV-2 (G) replication in E6SM cell cultures of human embryonic skin-muscle,Other,12459010.0,
935,85125,6,2,,103504490,3454,Unspecified,,,,,Minimum inhibitory concentration was determined against HSV-2 (196) in E6SM cell culture,Other,10691698.0,
936,85127,6,2,,103504490,3454,Unspecified,,,,,Inhibitory activity against HSV-2 (Lyons) replication in E6SM cell cultures of human embryonic skin-muscle,Other,12459010.0,
937,85129,7,2,,103504490,3454,Unspecified,,,,,Minimum inhibitory concentration was determined against HSV-2 (Lyons) in E6SM cell culture,Other,10691698.0,
938,85277,8,1,,103504490,3454,Active,,,0.04,ID50,compound was tested for antiherpes activity against HSV-2(186) in tissue culture by plaque reduction assay,Confirmatory,1849998.0,
939,85372,6,2,,103504490,3454,Unspecified,,,,,Inhibitory concentration against HSV type 1 strain F in human embryonic skin muscle (ESM) fibroblast cell culture,Other,8393114.0,
940,85373,6,2,,103504490,3454,Unspecified,,,,,Inhibitory concentration against HSV type 1 strain KOS in human embryonic skin muscle (ESM) fibroblast cell culture,Other,8393114.0,
941,85374,6,2,,103504490,3454,Unspecified,,,,,Inhibitory concentration against HSV type 1 strain Mc Intyre in human embryonic skin muscle (ESM) fibroblast cell culture,Other,8393114.0,
942,85378,6,2,,103504490,3454,Unspecified,,,,,Inhibitory concentration against HSV type 2 strain 196 in human embryonic skin muscle (ESM) fibroblast cell culture,Other,8393114.0,
943,85379,6,2,,103504490,3454,Unspecified,,,,,Inhibitory concentration against HSV type 2 strain G in human embryonic skin muscle (ESM) fibroblast cell culture,Other,8393114.0,
944,85380,6,2,,103504490,3454,Unspecified,,,,,Inhibitory concentration against HSV type 2 strain Lyons in human embryonic skin muscle (ESM) fibroblast cell culture,Other,8393114.0,
945,85391,6,2,,103504490,3454,Active,,,0.1,IC50,Inhibition of growth of herpes simplex virus (HSV-1) by plaque reduction assay in vero cell line,Confirmatory,2826784.0,
946,85421,6,2,,103504490,3454,Unspecified,,,,,Minimal inhibitory concentration to reduce virus-induced cytopathicity against 196 strain of human Herpes Simplex Virus-2,Other,11708929.0,
947,85422,10,1,,103504490,3454,Unspecified,,,,,Minimal inhibitory concentration to reduce virus-induced cytopathicity against G strain of human Herpes Simplex Virus-2,Other,11708929.0,
948,85423,6,2,,103504490,3454,Unspecified,,,,,Minimal inhibitory concentration to reduce virus-induced cytopathicity against Lyons strain of human Herpes Simplex Virus-2,Other,11708929.0,
949,85433,4,3,,103504490,3454,Unspecified,,,,,Compound was tested for the inhibition of HSV-1 polymerase,Other,3009816.0,
950,85555,5,1,,103504490,3454,Unspecified,,,,,Antiviral activity against herpesvirus HSV-1 in BWS strain in tissue culture.,Other,2160539.0,
951,85728,6,2,,103504490,3454,Active,,,2.3,IC50,Tested for antiviral activity against herpes simplex virus-1(HSV-1) by means of plaque reduction assay.,Confirmatory,2163453.0,
952,85864,6,2,,103504490,3454,Active,,,3.5,IC50,Antiviral activity was measured by plaque assay against HSV-1 virus by ELISA method,Confirmatory,9057867.0,
953,85868,6,2,,103504490,3454,Active,,,3.5,IC50,Tested for antiviral activity against Herpes simplex virus type-1 using plaque assay,Confirmatory,8254613.0,
954,85889,5,2,,103504490,3454,Inconclusive,,,,,Compound was evaluated for the antiviral activity against HSV-1; Not determined,Other,9871553.0,
955,86030,8,1,,103504490,3454,Active,,,1.0,ED50,Concentration at which 50% of the herpes simplex virus type 1 HSV-1 (F) induced cytopathic effect are inhibited is determined,Confirmatory,2842505.0,
956,86043,6,2,,103504490,3454,Active,,,3.5,IC50,Antiviral activity against herpes simplex virus type 1 (HSV-1) was performed by HSV-1 ELISA assays.,Confirmatory,8784445.0,
957,86044,6,2,,103504490,3454,Active,,,3.0,IC50,Antiviral activity against herpes simplex virus using ELISA,Confirmatory,8784444.0,
958,86047,6,2,,103504490,3454,Active,,,3.5,IC50,Antiviral activity evaluated by their ability to inhibit the KOS strain of herpes simplex virus type-1 (HSV-1).plaque assay was used,Confirmatory,9575044.0,
959,86048,6,2,,103504490,3454,Active,,,3.5,IC50,Antiviral activity in Herpes simplex virus-1 assayed by ELISA in quadruplicate wells,Confirmatory,7562946.0,
960,86049,6,2,,103504490,3454,Active,,,3.5,IC50,Antiviral activity against herpes simplex virus type 1 (HSV-1) in an ELISA assay,Confirmatory,8632412.0,
961,86054,6,2,,103504490,3454,Active,,,3.5,IC50,Antiviral activity was measured by plaque assay against HSV-1 virus by ELISA method,Confirmatory,9057868.0,
962,86055,6,2,,103504490,3454,Active,,,3.5,IC50,In vitro antiviral activity against HSV-1 virus in BSC-1 (monkey kidney) cells.,Confirmatory,9057865.0,
963,86057,6,2,,103504490,3454,Active,,,3.5,IC50,Antiviral activity against herpes simplex virus type 1(HSV-1) ELISA method,Confirmatory,7562947.0,
964,86058,6,2,,103504490,3454,Active,,,3.5,IC50,Compound was evaluated for the antiviral activity against HSV-1 determined by using ELISA method,Confirmatory,7562945.0,
965,86059,6,2,,103504490,3454,Active,,,1.8,IC50,Compound was evaluated for the antiviral activity by their capacity to inhibit the replication of HSV-1 virus,Confirmatory,9548814.0,
966,86060,6,3,,103504490,3454,Active,,,3.5,IC50,Compound was tested for antiviral activity against HSV-1,Confirmatory,,
967,86061,6,2,,103504490,3454,Active,,,3.5,IC50,Compound was tested for antiviral activity against HSV-1 assayed by ELISA in quadruplicate wells,Confirmatory,10882374.0,
968,86063,6,2,,103504490,3454,Active,,,3.5,IC50,Compound was tested for antiviral activity against herpes simplex virus type 1 (HSV-1),Confirmatory,10882375.0,
969,86684,6,2,,103504490,3454,Unspecified,,,100.0,EC50,Effective concentration required to inhibit vesicular stomatitis virus (VSV)-induced cytopathicity by 50% in HeLa cell lines,Confirmatory,11495586.0,
970,86820,5,3,,103504490,3454,Unspecified,,,,,Cytotoxic activity was measured in human embryonic lung cells (HeLa),Other,,
971,86827,3,6,,103504490,3454,Unspecified,,,,,Percentage of diphosphates (DP) in the second step of staggered assay mixture from step 1 was incubated with GMP kinase and crude extract of HSV-1 infected HeLa cells over night,Other,2848125.0,
972,87025,8,1,,103504490,3454,Active,,,,,Minimum inhibitory concentration against Herpes simplex Virus-1(F),Other,12408716.0,
973,87026,8,1,,103504490,3454,Active,,,,,Minimum inhibitory concentration against Herpes simplex Virus-1(KOS),Other,12408716.0,
974,87027,8,1,,103504490,3454,Active,,,,,Minimum inhibitory concentration against Herpes simplex Virus-1 (KOS) (ACV),Other,12408716.0,
975,87028,8,1,,103504490,3454,Active,,,,,Minimum inhibitory concentration against Herpes simplex Virus-1 (McIntyre),Other,12408716.0,
976,87029,8,1,,103504490,3454,Active,,,,,Minimum inhibitory concentration against Herpes simplex Virus-2(196),Other,12408716.0,
977,87031,8,1,,103504490,3454,Active,,,,,Minimum inhibitory concentration against Herpes simplex Virus-2(G),Other,12408716.0,
978,87032,8,1,,103504490,3454,Active,,,,,Minimum inhibitory concentration against Herpes simplex Virus-2(Lyons),Other,12408716.0,
979,87169,6,2,,103504490,3454,Active,,,32.0,IC50,Inhibitory activity against herpes simplex virus,Confirmatory,2165163.0,
980,87181,8,2,,103504490,3454,Inconclusive,,,,,In vitro antiviral activity against Herpes simplex virus (HSV-2) was determined; ND= Not determined,Other,11814776.0,
981,87186,6,2,,103504490,3454,Active,,,4.5,IC50,Inhibition of herpes simplex virus (HSV-1) in plaque reduction assay,Confirmatory,2163454.0,
982,87187,6,2,,103504490,3454,Active,,,1.2,IC50,Inhibition of herpes simplex virus (HSV-1) in yield reduction assay,Confirmatory,2163454.0,
983,87189,8,2,,103504490,3454,Inconclusive,,,,,In vitro antiviral activity against Herpes simplex virus (HSV-1) was determined; ND= Not determined,Other,11814776.0,
984,87203,6,2,,103504490,3454,Active,,,4.5,IC50,Tested in vitro for antiviral activity against HSV-1 in plaque reduction assay.,Confirmatory,2175356.0,
985,87204,5,2,,103504490,3454,Active,,,,,Tested in vitro for antiviral activity against HSV-1 in yield reduction assay.,Other,2175356.0,
986,87302,3,6,,103504490,3454,Unspecified,,,,,Percentage of monophosphates (MP) formed in the first step of staggered assay compound was incubated with HSV-1 thymidine kinase for 4 hr,Other,2848125.0,
987,87303,3,6,,103504490,3454,Unspecified,,,,,Percentage of monophosphates (MP) in the second step of staggered assay mixture from step 1 was incubated with GMP kinase and crude extract of HSV-1 infected HeLa cells over night,Other,2848125.0,
988,87340,6,2,,103504490,3454,Active,,,3.0,IC50,Antiviral activity against Herpes simplex virus type 1 determined by plaque reduction assay,Confirmatory,2840500.0,
989,87341,6,2,,103504490,3454,Active,,,2.3,IC50,Antiviral activity was determined against Herpes simplex virus type 1 by Plaque-reduction assay,Confirmatory,2500527.0,
990,87343,6,2,,103504490,3454,Active,,,4.5,IC50,Concentration required to decrease the growth rate to 50% of control was evaluated against HSV-1 by using plaque reduction assay.,Confirmatory,1310744.0,
991,87344,6,2,,103504490,3454,Active,,,3.0,IC50,Inhibitory concentration against HCMV in plaque reduction assay,Confirmatory,2846837.0,
992,87345,5,1,,103504490,3454,Unspecified,,,,,"Antiviral activity of the compound, determined by plaque-reduction assay against Herpes simplex virus (HSV) type 1, BW5 strain in Vero cells",Other,2544723.0,
993,87346,5,1,,103504490,3454,Unspecified,,,,,"Antiviral activity of the compound, determined by plaque-reduction assay against thymidine kinase deficient Herpes simplex virus type 1, Z826 strain in Vero cells",Other,2544723.0,
994,87443,3,6,,103504490,3454,Unspecified,,,,,Percentage of triphosphates (TP) in the second step of staggered assay mixture from step 1 was incubated with GMP kinase and crude extract of HSV-1 infected HeLa cells over night,Other,2848125.0,
995,87493,8,1,,103504490,3454,Active,,,0.3,ID50,In vitro antiviral and anticellular activity was evaluated against herpes simplex virus HSV-1 (F strain) in vero cells tissue culture,Confirmatory,2993615.0,
996,87640,5,1,,103504490,3454,Unspecified,,,,,Antiviral activity against HSV-1 cell line (concentration required to prevent viral cytopathic effect in half of primary rabbit kidney cell cultures),Other,2848125.0,
997,87653,5,1,,103504490,3454,Unspecified,,,,,"Antiviral activity determined by plaque-reduction assay against Herpes simplex virus type 2, G strain in Vero cells",Other,2544723.0,
998,87819,8,1,,103504490,3454,Active,,,1.3,ID50,In vitro antiviral and anticellular activity was evaluated against herpes simplex virus HSV-2 (G strain) in vero cells.,Confirmatory,2993615.0,
999,87834,5,1,,103504490,3454,Unspecified,,,,,Antiviral activity against HSV-2 cell line (concentration required to prevent viral cytopathic effect in half of primary rabbit kidney cell cultures),Other,2848125.0,
1000,88283,5,1,,103504490,3454,Unspecified,,,,,In vitro anti viral activity tested against HSV-1(Schooler) virus on Rabbit kidney cell cultures; 1-3,Other,2989523.0,
1001,88284,3,3,,103504490,3454,Unspecified,,,,,Evaluated for DNA polymerase inhibition activity against herpes simplex virus-1 (HSV-1),Other,2989523.0,
1002,88285,5,3,,103504490,3454,Unspecified,,,,,Compound was tested for antiherpes activity against Herpes simplex virus-1(KOS) in E6SM cell cultures,Other,,
1003,88301,5,1,,103504490,3454,Unspecified,,,,,In vitro anti viral activity tested against HSV-2(Curtis) virus on Rabbit kidney cell cultures; 3-6,Other,2989523.0,
1004,88302,3,4,,103504490,3454,Unspecified,,,,,Evaluated for DNA polymerase inhibition activity against HeLa cells.,Other,2989523.0,
1005,88303,6,3,,103504490,3454,Unspecified,,,,,Compound was tested for antiherpes activity against Herpes simplex virus-2(G) in E6SM cell cultures,Other,,
1006,89264,6,2,,103504490,3454,Unspecified,,,100.0,IC50,Cytotoxicity against Normal human diploid cells (human foreskin fibroblasts cells),Confirmatory,2500527.0,
1007,90591,6,3,,103504490,3454,Active,,,0.72,IC50,Concentration required to inhibit human cytomegalovirus HCMV-AD169 in antiviralplaque reduction assay,Confirmatory,14521407.0,
1008,90596,5,1,,103504490,3454,Unspecified,,,,,In vitro anti viral activity tested against HCMV(AD169) virus on MRC-5 cell monolayers; 0.4-1.6,Other,2989523.0,
1009,90608,6,2,,103504490,3454,Active,,,3.0,IC50,Inhibitory activity against human cytomegalo virus (HCMV) using standard plaque reduction assay,Confirmatory,11454465.0,
1010,90612,6,3,,103504490,3454,Active,,,8.7,IC50,Inhibition of human cytomegalovirus (HCMV) in plaque reduction assay,Confirmatory,2163454.0,
1011,90615,6,2,,103504490,3454,Active,,,7.9,IC50,Antiviral activity against Human cytomegalovirus in a plaque-reduction assay,Confirmatory,2500527.0,
1012,90616,6,2,,103504490,3454,Active,,,8.4,IC50,Concentration required to decrease the growth rate to 50% of control was evaluated against HCMV by using plaque reduction assay.,Confirmatory,1310744.0,
1013,90617,6,2,,103504490,3454,Active,,,8.8,IC50,Inhibitory concentration against human cytomegalovirus (HCMV) in plaque reduction assay,Confirmatory,2846837.0,
1014,90618,5,2,,103504490,3454,Active,,,,,Concentration required to decrease the growth rate to 50% of control was evaluated against HCMV by using yield reduction assay.,Other,1310744.0,
1015,90620,5,1,,103504490,3454,Unspecified,,,,,"Antiviral activity determined by plaque-reduction assay against Human cytomegalovirus, AD-169 strain in MRC-5 cells",Other,2544723.0,
1016,90759,5,3,,103504490,3454,Unspecified,,,,,Compound was tested in vitro for cytotoxic activity against HCMV (Human cytomegalovirus),Other,,
1017,90762,6,2,,103504490,3454,Active,,,4.0,EC50,Antiviral activity evaluated against human cytomegalovirus (HCMV) AD169,Confirmatory,14643358.0,
1018,90763,6,2,,103504490,3454,Active,,,5.7,EC50,Antiviral activity evaluated against human cytomegalovirus (HCMV) Davis,Confirmatory,14643358.0,
1019,90764,5,3,,103504490,3454,Unspecified,,,,,Concentration of compound required to inhibit 50% of HCMV strain AD-169 induced cytopathic effect,Other,,
1020,90765,5,3,,103504490,3454,Unspecified,,,,,Concentration of compound required to inhibit 50% of HCMV strain Davis induced cytopathic effect,Other,,
1021,90766,6,2,,103504490,3454,Active,,,8.7,IC50,Antiviral activity against human cytomegalovirus by plaque reduction assay,Confirmatory,8784444.0,
1022,90767,6,2,,103504490,3454,Active,,,2.2,IC50,Antiviral activity against human cytomegalo virus using ELISA,Confirmatory,8784444.0,
1023,90769,6,2,,103504490,3454,Active,,,7.4,IC50,Antiviral activity against human cytomegalovirus (HCMV) in plaque reduction assay,Confirmatory,8784445.0,
1024,90770,6,2,,103504490,3454,Active,,,7.4,IC50,Antiviral activity against human cytomegalovirus (HCM virus) in plaque assay,Confirmatory,8632412.0,
1025,90774,7,2,,103504490,3454,Unspecified,,,,,Antiviral activity was tested against human cytomegalovirus AD-169 which reduces virus plaque formation by 50%,Other,12217359.0,
1026,90776,7,2,,103504490,3454,Unspecified,,,,,Antiviral activity was tested against human cytomegalovirus Davis which reduces virus plaque formation by 50%,Other,12217359.0,
1027,90778,6,2,,103504490,3454,Active,,,7.7,IC50,In vitro antiviral activity against human cytomegalovirus by plaque method.,Confirmatory,7562947.0,
1028,90779,6,2,,103504490,3454,Active,,,7.4,IC50,Compound was evaluated for the antiviral activity against HCMV determined by using Plaque assay,Confirmatory,7562945.0,
1029,90782,5,3,,103504490,3454,Unspecified,,,,,Compound was tested in vitro for inhibitory activity against HCMV (Human cytomegalovirus),Other,,
1030,90788,6,2,,103504490,3454,Active,,,7.4,IC50,Activity against human cytomegalovirus (HCMV) using plaque reduction assay,Confirmatory,8071942.0,
1031,90794,6,2,,103504490,3454,Active,,,9.2,IC50,Tested in vitro for antiviral activity against human cytomegalovirus (HCMV) in plaque reduction assay.,Confirmatory,2175356.0,
1032,90926,6,2,,103504490,3454,Unspecified,,,,,The concentration required to reduce virus plaque formation by 50% was measured on AD-169 strains of human cytomegalovirus,Other,10197958.0,
1033,90927,6,2,,103504490,3454,Unspecified,,,,,The concentration required to reduce virus plaque formation by 50% was measured on Davis strains of human cytomegalovirus,Other,10197958.0,
1034,90928,6,2,,103504490,3454,Active,,,7.4,IC50,antiviral activity in Human cytomegalovirus by plaque assay (HCMV),Confirmatory,7562946.0,
1035,90930,5,2,,103504490,3454,Active,,,,,Antiviral activity against human cytomegalo virus (HCMV) in yield reduction assay,Other,8784445.0,
1036,90931,5,2,,103504490,3454,Active,,,,,Antiviral activity of compound against HCM virus in yield reduction experiments,Other,8632412.0,
1037,90934,6,2,,103504490,3454,Active,,,,,In vitro antiviral activity against human cytomegalovirus by yield reduction assay.,Other,7562947.0,
1038,90935,5,2,,103504490,3454,Active,,,,,Compound was evaluated for the antiviral activity against HCMV determined by using Yield reduction assay,Other,7562945.0,
1039,90936,5,2,,103504490,3454,Active,,,,,Tested for the activity against human cytomegalovirus (HCMV) using yield reduction assay,Other,8071942.0,
1040,90937,9,1,,103504490,3454,Unspecified,,,,,Tested in vitro for antiviral activity against human cytomegalovirus (HCMV) in yield reduction assay.,Other,2175356.0,
1041,90938,6,2,,103504490,3454,Active,,,,,antiviral activity in Human cytomegalovirus by plaque assay given as yield,Other,7562946.0,
1042,90939,8,1,,103504490,3454,Active,,,6.0,ID50,In vitro antiviral and anticellular activity was evaluated against human cytomegalovirus (HCMV AD 169) in (HCMV AD 169) cells.,Confirmatory,2993615.0,
1043,90940,5,1,,103504490,3454,Inactive,,,,,Antiviral activity against HCMV was determined; No inhibition,Other,2391689.0,
1044,90945,6,3,,103504490,3454,Unspecified,,,,,The compound was tested for the cytomegalovirus; Effective concentration required to inhibit 50% virus proliferation,Other,,
1045,90952,6,2,,103504490,3454,Unspecified,,,100.0,IC50,Cytotoxicity of compound was determined visually in human diploid fibroblasts (HFF).,Confirmatory,1310744.0,
1046,90979,6,2,,103504490,3454,Unspecified,,,100.0,IC50,Cytotoxicity of compound was determined by assaying cell growth in human neoplastic cell line(KB).,Confirmatory,1310744.0,
1047,90980,6,2,,103504490,3454,Unspecified,,,100.0,IC50,Compound was evaluated for cytotoxic activity against KB cells,Confirmatory,2163454.0,
1048,91025,6,2,,103504490,3454,Unspecified,,,,,Cytotoxic activity in Hs 68 cell line by inhibition of cell proliferation,Other,10888336.0,
1049,91028,6,2,,103504490,3454,Unspecified,,,,,Cytotoxicity in the Hs 68 cell line,Other,10447945.0,
1050,91030,6,3,,103504490,3454,Unspecified,,,,,Antiviral activity determined against human cytomegalovirus (HCMV) in Hs 68 cell line by plaque reduction assay,Other,10888336.0,
1051,91031,6,3,,103504490,3454,Unspecified,,,,,Anti-HCMV activity in the human fibroblast Hs 68 cell line,Other,10447945.0,
1052,91272,3,3,,103504490,3454,Unspecified,,,,,Cytotoxicity was determined at 100 uM,Other,2822928.0,
1053,91275,3,3,,103504490,3454,Unspecified,,,,,Cytotoxicity was determined at 32 uM,Other,2822928.0,
1054,91276,3,3,,103504490,3454,Unspecified,,,,,Cytotoxicity was determined at 320 uM,Other,2822928.0,
1055,91280,3,3,,103504490,3454,Unspecified,,,,,Antiviral activity against Varicella-Zoster virus (VV) in human foreskin cell cultures in virus plaque reduction assay at 10 uM,Other,2822928.0,
1056,91282,3,3,,103504490,3454,Unspecified,,,,,Antiviral activity against Varicella-Zoster virus (VV) in human foreskin cell cultures in virus plaque reduction assay at 100 uM,Other,2822928.0,
1057,91284,3,3,,103504490,3454,Unspecified,,,,,Antiviral activity against Varicella-Zoster virus (VV) in human foreskin cell cultures in virus plaque reduction assay at 1000 uM,Other,2822928.0,
1058,91286,3,3,,103504490,3454,Unspecified,,,,,Antiviral activity against Varicella-Zoster virus (VV) in human foreskin cell cultures in virus plaque reduction assay at 3.2 uM,Other,2822928.0,
1059,91288,3,3,,103504490,3454,Unspecified,,,,,Antiviral activity against Varicella-Zoster virus (VV) in human foreskin cell cultures in virus plaque reduction assay at 32 uM,Other,2822928.0,
1060,91290,3,3,,103504490,3454,Unspecified,,,,,Antiviral activity against Varicella-Zoster virus (VV) in human foreskin cell cultures in virus plaque reduction assay at 320 uM,Other,2822928.0,
1061,91292,3,3,,103504490,3454,Unspecified,,,,,Cytotoxicity was determined at 1000 uM,Other,2822928.0,
1062,91294,6,2,,103504490,3454,Unspecified,,,100.0,IC50,Cytotoxicity against uninfected human foreskin fibroblast(HFF cells),Confirmatory,2846837.0,
1063,91295,6,2,,103504490,3454,Active,,,0.5,EC50,Inhibitory concentration of the drug against the cytopathic effect for AD169 strain of epstein barr virus-2 (HCMV) in human HFF cells,Confirmatory,8394933.0,
1064,91298,8,2,,103504490,3454,Inconclusive,,,,,Inhibitory concentration of the drug against the cytopathic effect for E-377 strain of herpes simplex virus-1 (HSV-1) in human HFF cells; ND is Not Determined,Other,8394933.0,
1065,91300,8,2,,103504490,3454,Inconclusive,,,,,Inhibitory concentration of the drug against the cytopathic effect for MS strain of herpes simplex virus-2 (HSV-2) in human HFF cells; ND is Not Determined,Other,8394933.0,
1066,91302,8,2,,103504490,3454,Inconclusive,,,,,Inhibitory concentration of the drug against the cytopathic effect for ellen strain of varicella zoster virus-2 (VZV-2) in human HFF cells; ND is Not Determined,Other,8394933.0,
1067,91306,6,2,,103504490,3454,Unspecified,,,168.0,IC50,Concentration of the drug required to reduce the proliferation of human foreskin fibroblast cells,Confirmatory,8394933.0,
1068,91307,6,2,,103504490,3454,Unspecified,,,390.0,IC50,Concentration of the drug required to reduce the uptake of neural red stain by uninfected cell monolayers (HFF),Confirmatory,8394933.0,
1069,91309,6,2,,103504490,3454,Unspecified,,,100.0,IC50,Compound was evaluated for cytotoxic activity against HFF cells,Confirmatory,2163454.0,
1070,95487,6,2,,103504490,3454,Unspecified,,,100.0,IC50,Compound was tested for inhibition of KB cell growth in quadruplicate assay,Confirmatory,10882374.0,
1071,95677,6,2,,103504490,3454,Active,,,3.5,IC50,Antiviral activity was estimated by HSV-1 ELISA method (data of single experiment),Confirmatory,9057866.0,
1072,95681,6,2,,103504490,3454,Unspecified,,,100.0,IC50,Compound was evaluated for the cytotoxicity by the inhibition of KB cell growth.,Confirmatory,9575044.0,
1073,95682,6,2,,103504490,3454,Unspecified,,,100.0,IC50,Compound was evaluated for the inhibition of KB cell growth determined in quadruplicate assay,Confirmatory,7562945.0,
1074,95683,6,2,,103504490,3454,Unspecified,,,100.0,IC50,In vitro inhibition of KB cell proliferation.,Confirmatory,7562947.0,
1075,95686,6,3,,103504490,3454,Unspecified,,,320.0,IC50,Cytotoxicity (growth inhibition) against human epidermoid oral carcinoma KB cell line.,Confirmatory,8784444.0,
1076,95831,6,2,,103504490,3454,Unspecified,,,100.0,IC50,Cytotoxicity for the compound was determined by the inhibition of the growing KB cells.,Confirmatory,9548814.0,
1077,95834,6,2,,103504490,3454,Unspecified,,,100.0,IC50,Cytotoxicity in KB cells.,Confirmatory,9057866.0,
1078,95837,8,2,,103504490,3454,Inconclusive,,,,,Cytotoxicity was evaluated by measuring the inhibition of KB cell growth; Not tested,Other,9438017.0,
1079,95856,6,2,,103504490,3454,Unspecified,,,100.0,IC50,Inhibition of KB cell growth was determined,Confirmatory,9057867.0,
1080,95857,6,2,,103504490,3454,Unspecified,,,100.0,IC50,Inhibition of KB cell growth was determined,Confirmatory,9057868.0,
1081,95860,6,2,,103504490,3454,Unspecified,,,100.0,IC50,In vitro inhibition of KB (human carcinoma) cell growth.,Confirmatory,9057865.0,
1082,95861,6,2,,103504490,3454,Unspecified,,,100.0,IC50,Inhibitory activity against growth of KB cell.,Confirmatory,8784445.0,
1083,95864,6,2,,103504490,3454,Unspecified,,,100.0,IC50,Inhibitory activity of compound against KB cell growth [>-indicates IC50/IC90 was not reached at the noted (highest) concentration tested],Confirmatory,8632412.0,
1084,96010,6,2,,103504490,3454,Unspecified,,,100.0,IC50,cell growth inhibition was determined in KB cells in quadruplicate assays,Confirmatory,7562946.0,
1085,96185,7,1,,103504490,3454,Unspecified,,,,,Cytotoxicity of compound in uninfected cells determined by examining the effect on growth of KBcells,Other,,
1086,96218,6,2,,103504490,3454,Unspecified,,,1000.0,IC50,"Average percent inhibition of DNA, RNA, and protein synthesis determined in KB cells",Confirmatory,2840500.0,
1087,96225,6,3,,103504490,3454,Unspecified,,,100.0,IC50,Compound was tested for inhibition activity of human oral carcinoma cell line (KB ) cells in quadruplicate assay.,Confirmatory,10882375.0,
1088,96348,6,2,,103504490,3454,Unspecified,,,100.0,IC50,Compound was tested for the inhibition of KB cell growth in quadruplicate wells,Confirmatory,10882370.0,
1089,96357,6,2,,103504490,3454,Unspecified,,,1000.0,IC50,Cytotoxicity against human neoplastic cell line (KB),Confirmatory,2500527.0,
1090,96359,6,2,,103504490,3454,Unspecified,,,1000.0,IC50,Cytotoxicity was evaluated in Human neoplastic cell line (KB),Confirmatory,2913300.0,
1091,96373,6,2,,103504490,3454,Unspecified,,,100.0,IC50,Inhibition of KB cell growth was determined.,Confirmatory,10882372.0,
1092,96379,6,2,,103504490,3454,Unspecified,,,1000.0,IC50,Tested for cytotoxic activity against human neoplastic cell line(KB cells).,Confirmatory,2163453.0,
1093,96381,6,2,,103504490,3454,Unspecified,,,100.0,IC50,Tested for the inhibition of KB cell growth,Confirmatory,8254613.0,
1094,96382,6,3,,103504490,3454,Unspecified,,,100.0,IC50,Tested in vitro for cytotoxicity against the human neoplastic cell line (KB cells).,Confirmatory,2175356.0,
1095,96400,4,3,,103504490,3454,Unspecified,,,,,Cytotoxicity against human neoplastic cell line(KB cells),Other,2846837.0,
1096,103948,4,2,,103504490,3454,Unspecified,,,,,Tested for the effective dose required to inhibit systemic MCMV in infected mice,Other,2329551.0,
1097,103949,5,1,,103504490,3454,Unspecified,,,,,In vitro antiviral activity tested against MCMV Smith strain by plaque reduction assay in mouse embryo fibroblasts.,Other,2329551.0,
1098,103950,3,3,,103504490,3454,Unspecified,,,,,Tested for mean day to death of nonsurvivors against systemic MCMV infection in mice at 1.9 mg/kg per day,Other,2329551.0,
1099,103951,3,4,,103504490,3454,Unspecified,,,,,Number of survivors per number of systemic MCMV infected mice treated with 11.2 mg/kg per day; 15/15,Other,2329551.0,
1100,103952,3,4,,103504490,3454,Unspecified,,,,,Number of survivors per number of systemic MCMV infected mice treated with 3.8 mg/kg per day; 10/15,Other,2329551.0,
1101,103953,3,4,,103504490,3454,Unspecified,,,,,Number of survivors per number of systemic MCMV infected mice treated with 33.4 mg/kg per day; 15/15,Other,2329551.0,
1102,104097,8,1,,103504490,3454,Active,,,4.0,ID50,compound was tested for antiherpes activity against MCMV(Smith) in tissue culture by plaque reduction assay,Confirmatory,1849998.0,
1103,105854,6,2,,103504490,3454,Unspecified,,,,,Compound was tested for cytotoxicity by measuring inhibition of MRC-5 cell proliferation.,Other,9934471.0,
1104,105856,6,1,,103504490,3454,Unspecified,,,,,Cytotoxic dose for anti-HCMV activity against AD-169 strain in MRC-5 cells,Other,9836613.0,
1105,105987,6,2,,103504490,3454,Unspecified,,,,,Anti HCMV (human cytomegalovirus) activity in MRC-5 cells infected with AD619 strain of HCMV (plaque reduction assay).,Other,7562929.0,
1106,105988,6,2,,103504490,3454,Active,,,1.7,IC50,In vitro antiviral activity against Human cytomegalovirus (HCMV)strain AD169 in MRC-5 lung fibroblasts using a DNA-hybridization assay,Confirmatory,8176714.0,
1107,105989,6,2,,103504490,3454,Unspecified,,,,,Compound was tested for cytotoxicity by measuring inhibition of MRC-5 cell proliferation.,Other,9934471.0,
1108,106005,6,2,,103504490,3454,Active,,,6.3,IC50,Inhibitory concentration for anti-HCMV activity against AD-169 strain in MRC-5 cells,Confirmatory,9836613.0,
1109,106010,5,1,,103504490,3454,Unspecified,,,,,Anti viral activity against MRC-5 cells (concentration required to reduce the log phase cell growth by 50%).,Other,7562929.0,
1110,106011,5,1,,103504490,3454,Unspecified,,,,,"Visual cytotoxicity of stationary MRC-5 cells, median toxic concentration is evaluated by anti HCMV plaque reduction assay performed in MRC-5 cells using the AD169 strain of HCMV",Other,7562929.0,
1111,106147,6,2,,103504490,3454,Unspecified,,,35.0,CC50,In vitro cytotoxic concentration required to inhibit murine cytomegalovirus (MCMV) replication in MEF cell line,Confirmatory,14736238.0,
1112,106149,6,2,,103504490,3454,Active,,,5.0,EC50,In vitro effective concentration required to inhibit murine cytomegalovirus (MCMV) replication in MEF cell line,Confirmatory,14736238.0,
1113,106153,8,2,,103504490,3454,Inconclusive,,,,,Cytotoxicity on stationary MEF cells at time of MCMV plaque enumeration in cells not effected by the virus; Not tested,Other,9438017.0,
1114,106154,6,2,,103504490,3454,Active,,,3.4,IC50,Inhibitory concentration against murine cytomegalovirus replication in MEF cells was determined by plaque reduction assay,Confirmatory,9438017.0,
1115,106175,6,2,,103504490,3454,Active,,,9.4,EC50,Inhibitory activity of compound against human cytomegalovirus (HCMV) in MRC-5 cells.,Confirmatory,12723951.0,
1116,106179,6,2,,103504490,3454,Active,,,4.0,IC50,In vitro antiherpesvirus activity against MRC-5 cells infected with HCMV (AD-169 strain),Confirmatory,1323678.0,
1117,106206,6,2,,103504490,3454,Unspecified,,,98.0,CC50,Concentration required to reduce MRC-5 cell growth by 50%,Confirmatory,10966740.0,
1118,106381,6,1,,103504490,3454,Unspecified,,,,,Effect of compound treatment on yields of human cytomegalovirus (HCMV) in MRC5 (human diploid embryonic lung cells) monolayer cultures at the concentration of 32 uM,Other,2157013.0,
1119,106522,6,1,,103504490,3454,Unspecified,,,,,Effect of compound treatment on yields of human cytomegalovirus (HCMV) in MRC5 (human diploid embryonic lung cells) monolayer cultures at the concentration of 32 uM,Other,2157013.0,
1120,106528,6,2,,103504490,3454,Active,,,1.6,IC50,Inhibitory concentration against 2599R strain of HCMV in MRC5 cells,Confirmatory,11454465.0,
1121,106530,6,2,,103504490,3454,Active,,,3.0,IC50,Inhibitory concentration against AD169 strain of HCMV in MRC5 cells,Confirmatory,11454465.0,
1122,106532,8,2,,103504490,3454,Inconclusive,,,,,Inhibitory concentration against C8805 strain of HCMV in MRC5 cells; ND means not determined,Other,11454465.0,
1123,106534,6,2,,103504490,3454,Active,,,1.4,IC50,Inhibitory concentration against Davis strain of HCMV in MRC5 cells,Confirmatory,11454465.0,
1124,106536,6,2,,103504490,3454,Active,,,1.5,IC50,Inhibitory concentration against Towne strain of HCMV in MRC5 cells,Confirmatory,11454465.0,
1125,106538,6,2,,103504490,3454,Unspecified,,,10.0,IC50,Inhibitory concentration against Xba F strain of HCMV in MRC5 cells,Confirmatory,11454465.0,
1126,106539,8,1,,103504490,3454,Active,,,5.0,ID50,In vitro antiviral activity was measured against HCMV(AD-169) in MRC5 cells,Confirmatory,3009811.0,
1127,106699,5,1,,103504490,3454,Unspecified,,,,,Antiviral activity against herpesvirus MRS-5 cells in tissue culture.,Other,2160539.0,
1128,114967,3,4,,103504490,3454,Unspecified,,,,,Effect of oral treatment with compound on HSV-2 induced mortality in mice at 10 mg/kg dose,Other,3009811.0,
1129,114969,3,4,,103504490,3454,Unspecified,,,,,Effect of oral treatment with compound on HSV-2 induced mortality in mice at 20 mg/kg dose,Other,3009811.0,
1130,114971,3,4,,103504490,3454,Unspecified,,,,,Effect of oral treatment with compound on HSV-2 induced mortality in mice at 5 mg/kg dose,Other,3009811.0,
1131,114973,3,4,,103504490,3454,Unspecified,,,,,Effect of subcutaneous treatment with compound on HSV-2 induced mortality in mice at 1.5 mg/kg dose,Other,3009811.0,
1132,114974,3,4,,103504490,3454,Unspecified,,,,,Effect of subcutaneous treatment with compound on HSV-2 induced mortality in mice at 15 mg/kg dose,Other,3009811.0,
1133,114976,3,4,,103504490,3454,Unspecified,,,,,Effect of subcutaneous treatment with compound on HSV-2 induced mortality in mice at 5 mg/kg dose,Other,3009811.0,
1134,116579,6,1,,103504490,3454,Unspecified,,,,,Effect of on mean survival time upon oral treatment on HSV-2 induced mortality in mice at 1.5 mg/kg dose,Other,3009811.0,
1135,116580,6,1,,103504490,3454,Unspecified,,,,,Effect of on mean survival time upon oral treatment on HSV-2 induced mortality in mice at 10 mg/kg dose,Other,3009811.0,
1136,116581,6,1,,103504490,3454,Unspecified,,,,,Effect of on mean survival time upon oral treatment on HSV-2 induced mortality in mice at 15 mg/kg dose,Other,3009811.0,
1137,116582,6,1,,103504490,3454,Unspecified,,,,,Effect of on mean survival time upon oral treatment on HSV-2 induced mortality in mice at 20 mg/kg dose,Other,3009811.0,
1138,116584,7,1,,103504490,3454,Unspecified,,,,,Effect of on mean survival time upon oral treatment on HSV-2 induced mortality in mice at 5 mg/kg dose,Other,3009811.0,
1139,116783,6,1,,103504490,3454,Unspecified,,,,,Mean survival time of HSV-2 encephalitis infectuous mice upon subcutaneous treatment with the compound at a dose of 20 mg/kg,Other,3016263.0,
1140,117825,4,3,,103504490,3454,Unspecified,,,,,subcutaneous efficacy of compound in a lethal MCMV infection on mouse,Other,1849998.0,
1141,117918,3,4,,103504490,3454,Unspecified,,,,,Effect of oral treatment on HSV-2 encephalitis infection in mice and survivors/total was reported at a dose 10 mg/kg; 5/20,Other,3871860.0,
1142,117920,3,4,,103504490,3454,Unspecified,,,,,Effect of oral treatment on HSV-2 encephalitis infection in mice and survivors/total was reported at a dose 20 mg/kg; 8/20,Other,3871860.0,
1143,117922,3,4,,103504490,3454,Unspecified,,,,,Effect of oral treatment on HSV-2 encephalitis infection in mice and survivors/total was reported at a dose 5 mg/kg; 8/20,Other,3871860.0,
1144,118227,3,3,,103504490,3454,Unspecified,,,,,Mean day of death for total no. of dead mouse at 12.5 mg/kg/day dose,Other,1849998.0,
1145,118228,3,3,,103504490,3454,Unspecified,,,,,Mean day of death for total no. of dead mouse at 12.5 mg/kg/day dosep<0.05,Other,1849998.0,
1146,118231,3,3,,103504490,3454,Unspecified,,,,,Mean day of death for total no. of dead mouse at 25 mg/kg/day dosep<0.05,Other,1849998.0,
1147,118232,3,3,,103504490,3454,Unspecified,,,,,Mean day of death for total no. of dead mouse at 50 mg/kg/day dose,Other,1849998.0,
1148,118396,6,1,,103504490,3454,Unspecified,,,,,Effect of subcutaneous dose at 10 mg/kg on HSV-2 induced mortality in mice,Other,2993615.0,
1149,118397,6,1,,103504490,3454,Unspecified,,,,,Effect of subcutaneous dose at 3 mg/kg on HSV-2 induced mortality in mice,Other,2993615.0,
1150,118398,6,1,,103504490,3454,Unspecified,,,,,Effect of subcutaneous dose at 30 mg/kg on HSV-2 induced mortality in mice(value in parentheses denotes probability,Other,2993615.0,
1151,118399,3,3,,103504490,3454,Unspecified,,,,,Mean survival time of HSV-2 induced mortality in mice was determined when the 10 mg/Kg of compound was administered subcutaneously,Other,2993615.0,
1152,118400,3,3,,103504490,3454,Inactive,,,,,Mean survival time of HSV-2 induced mortality in mice was determined when the 3 mg/Kg of compound was administered subcutaneously; NS means not significant,Other,2993615.0,
1153,118401,3,3,,103504490,3454,Unspecified,,,,,Mean survival time of HSV-2 induced mortality in mice was determined when the 30 mg/Kg of compound was administered subcutaneously,Other,2993615.0,
1154,119461,3,3,,103504490,3454,Unspecified,,,,,Compound was evaluated for percent mortality of mice inoculated with murine cytomegalovirus at a concentration of 0.6 mg/kg at 24 h,Other,2163454.0,
1155,119462,3,3,,103504490,3454,Unspecified,,,,,Compound was evaluated for percent mortality of mice inoculated with murine cytomegalovirus at a concentration of 0.6 mg/kg at 48 h,Other,2163454.0,
1156,119463,3,3,,103504490,3454,Unspecified,,,,,Compound was evaluated for percent mortality of mice inoculated with murine cytomegalovirus at a concentration of 0.6 mg/kg at 6 h,Other,2163454.0,
1157,119464,3,3,,103504490,3454,Unspecified,,,,,Compound was evaluated for percent mortality of mice inoculated with murine cytomegalovirus at a concentration of 1.9 mg/kg at 24 h,Other,2163454.0,
1158,119465,3,3,,103504490,3454,Unspecified,,,,,Compound was evaluated for percent mortality of mice inoculated with murine cytomegalovirus at a concentration of 1.9 mg/kg at 48 h,Other,2163454.0,
1159,119466,3,3,,103504490,3454,Unspecified,,,,,Compound was evaluated for percent mortality of mice inoculated with murine cytomegalovirus at a concentration of 1.9 mg/kg at 6 h,Other,2163454.0,
1160,119468,3,3,,103504490,3454,Unspecified,,,,,Compound was evaluated for percent mortality of mice inoculated with murine cytomegalovirus at a concentration of 16.7 mg/kg at 24 h,Other,2163454.0,
1161,119469,3,3,,103504490,3454,Unspecified,,,,,Compound was evaluated for percent mortality of mice inoculated with murine cytomegalovirus at a concentration of 16.7 mg/kg at 48 h,Other,2163454.0,
1162,119470,3,3,,103504490,3454,Unspecified,,,,,Compound was evaluated for percent mortality of mice inoculated with murine cytomegalovirus at a concentration of 16.7 mg/kg at 6 h,Other,2163454.0,
1163,119472,3,3,,103504490,3454,Unspecified,,,,,Compound was evaluated for percent mortality of mice inoculated with murine cytomegalovirus at a concentration of 5.6 mg/kg at 24 h,Other,2163454.0,
1164,119591,3,3,,103504490,3454,Unspecified,,,,,Compound was evaluated for percent mortality of mice inoculated with murine cytomegalovirus at a concentration of 5.6 mg/kg at 48 h,Other,2163454.0,
1165,119592,3,3,,103504490,3454,Unspecified,,,,,Compound was evaluated for percent mortality of mice inoculated with murine cytomegalovirus at a concentration of 5.6 mg/kg at 6 h,Other,2163454.0,
1166,121403,6,1,,103504490,3454,Unspecified,,,,,Effect of oral treatment on HSV-2 encephalitis infection in mice and mean survival time was reported at a dose 10 mg/kg,Other,3871860.0,
1167,121404,6,1,,103504490,3454,Unspecified,,,,,Effect of oral treatment on HSV-2 encephalitis infection in mice and mean survival time was reported at a dose 20 mg/kg,Other,3871860.0,
1168,121406,6,1,,103504490,3454,Unspecified,,,,,Effect of oral treatment on HSV-2 encephalitis infection in mice and mean survival time was reported at a dose 5 mg/kg,Other,3871860.0,
1169,121710,3,4,,103504490,3454,Unspecified,,,,,Effect of subcutaneous dose at 10 mg/kg on HSV-2 induced mortality in mice; 7/16,Other,2993615.0,
1170,121712,3,4,,103504490,3454,Unspecified,,,,,Effect of subcutaneous dose at 3 mg/kg on HSV-2 induced mortality in mice; 4/16,Other,2993615.0,
1171,121713,3,4,,103504490,3454,Unspecified,,,,,Effect of subcutaneous dose at 30 mg/kg on HSV-2 induced mortality in mice; 12/16,Other,2993615.0,
1172,121729,3,4,,103504490,3454,Inactive,,,,,Effect of oral treatment with compound on HSV-2 induced mortality in mice at 10 mg/kg dose; NS=Not significant,Other,3009811.0,
1173,121730,3,4,,103504490,3454,Unspecified,,,,,Effect of oral treatment with compound on HSV-2 induced mortality in mice at 20 mg/kg dose,Other,3009811.0,
1174,121732,3,4,,103504490,3454,Inactive,,,,,Effect of oral treatment with compound on HSV-2 induced mortality in mice at 5 mg/kg dose; NS=Not significant,Other,3009811.0,
1175,121733,3,4,,103504490,3454,Unspecified,,,,,Effect of subcutaneous treatment with compound on HSV-2 induced mortality in mice at 1.5 mg/kg dose,Other,3009811.0,
1176,121734,3,4,,103504490,3454,Unspecified,,,,,Effect of subcutaneous treatment with compound on HSV-2 induced mortality in mice at 15 mg/kg dose,Other,3009811.0,
1177,121737,3,4,,103504490,3454,Unspecified,,,,,Effect of subcutaneous treatment with compound on HSV-2 induced mortality in mice at 5 mg/kg dose,Other,3009811.0,
1178,122207,3,4,,103504490,3454,Unspecified,,,,,Effect of oral treatment with compound on HSV-2 induced mortality in mice at 10 mg/kg dose; 6/20,Other,3009811.0,
1179,122209,3,4,,103504490,3454,Unspecified,,,,,Effect of oral treatment with compound on HSV-2 induced mortality in mice at 20 mg/kg dose; 11/20,Other,3009811.0,
1180,122214,3,4,,103504490,3454,Unspecified,,,,,Effect of oral treatment with compound on HSV-2 induced mortality in mice at 5 mg/kg dose; 0/19,Other,3009811.0,
1181,122218,3,4,,103504490,3454,Unspecified,,,,,Effect of subcutaneous treatment with compound on HSV-2 induced mortality in mice at 1.5 mg/kg dose; 8/15,Other,3009811.0,
1182,122220,3,4,,103504490,3454,Unspecified,,,,,Effect of subcutaneous treatment with compound on HSV-2 induced mortality in mice at 15 mg/kg dose; 15/15,Other,3009811.0,
1183,122222,3,4,,103504490,3454,Unspecified,,,,,Effect of subcutaneous treatment with compound on HSV-2 induced mortality in mice at 5 mg/kg dose; 10/15,Other,3009811.0,
1184,122224,3,5,,103504490,3454,Unspecified,,,,,Effect of subcutaneous treatment with the compound on HSV-2 encephalitis infection in mice at a dose of 20 mg/kg; 10/16,Other,3016263.0,
1185,124299,3,4,,103504490,3454,Unspecified,,,,,Subcutaneous efficacy in a mouse cytomegalovirus infection at 100 mg/kg/day dose; Value expressed as survivors/total tested = 10/10,Other,1849998.0,
1186,124302,3,4,,103504490,3454,Unspecified,,,,,Subcutaneous efficacy in a mouse cytomegalovirus infection at 12.5 mg/kg/day dose; Value expressed as survivors/total tested = 7/10,Other,1849998.0,
1187,124303,3,4,,103504490,3454,Unspecified,,,,,Subcutaneous efficacy in a mouse cytomegalovirus infection at 25 mg/kg/day dose; Value expressed as survivors/total tested = 10/10,Other,1849998.0,
1188,124306,3,4,,103504490,3454,Unspecified,,,,,Subcutaneous efficacy in a mouse cytomegalovirus infection at 50 mg/kg/day dose; Value expressed as survivors/total tested = 10/10,Other,1849998.0,
1189,124309,3,4,,103504490,3454,Unspecified,,,,,oral efficacy in a mouse cytomegalovirus infection at 12.5 mg/kg/day dose; Value expressed as survivors/total tested = 1/10,Other,1849998.0,
1190,124310,3,4,,103504490,3454,Unspecified,,,,,oral efficacy in a mouse cytomegalovirus infection at 25 mg/kg/day dose; Value expressed as survivors/total tested = 1/10,Other,1849998.0,
1191,124312,3,4,,103504490,3454,Unspecified,,,,,oral efficacy in a mouse cytomegalovirus infection at 50 mg/kg/day dose; Value expressed as survivors/total tested = 5/10,Other,1849998.0,
1192,126876,3,3,,103504490,3454,Unspecified,,,,,Compound was evaluated for 15 mice treated ip twice daily for 5 days at a dose of 0.6 mg/kg at 24 h followed (MCMV) virus inoculation,Other,2163454.0,
1193,126877,3,3,,103504490,3454,Unspecified,,,,,Compound was evaluated for 15 mice treated ip twice daily for 5 days at a dose of 0.6 mg/kg at 48 h followed (MCMV) virus inoculation,Other,2163454.0,
1194,126878,3,4,,103504490,3454,Unspecified,,,,,Compound was evaluated for 15 mice treated ip twice daily for 5 days at a dose of 0.6 mg/kg at 6 hr followed (MCMV) virus inoculation,Other,2163454.0,
1195,126879,3,4,,103504490,3454,Unspecified,,,,,Compound was evaluated for 15 mice treated ip twice daily for 5 days at a dose of 1.9 mg/kg at 24 hr followed (MCMV) virus inoculation,Other,2163454.0,
1196,126880,3,4,,103504490,3454,Unspecified,,,,,Compound was evaluated for 15 mice treated ip twice daily for 5 days at a dose of 1.9 mg/kg at 48 hr followed (MCMV) virus inoculation,Other,2163454.0,
1197,126881,3,4,,103504490,3454,Unspecified,,,,,Compound was evaluated for 15 mice treated ip twice daily for 5 days at a dose of 1.9 mg/kg at 6 hr followed (MCMV) virus inoculation,Other,2163454.0,
1198,126883,3,4,,103504490,3454,Unspecified,,,,,Compound was evaluated for 15 mice treated ip twice daily for 5 days at a dose of 16.7 mg/kg at 24 hr followed (MCMV) virus inoculation,Other,2163454.0,
1199,126884,3,4,,103504490,3454,Unspecified,,,,,Compound was evaluated for 15 mice treated ip twice daily for 5 days at a dose of 16.7 mg/kg at 48 hr followed (MCMV) virus inoculation,Other,2163454.0,
1200,126885,3,4,,103504490,3454,Unspecified,,,,,Compound was evaluated for 15 mice treated ip twice daily for 5 days at a dose of 16.7 mg/kg at 6 hr followed (MCMV) virus inoculation,Other,2163454.0,
1201,126887,3,4,,103504490,3454,Unspecified,,,,,Compound was evaluated for 15 mice treated ip twice daily for 5 days at a dose of 5.6 mg/kg at 24 hr followed (MCMV) virus inoculation,Other,2163454.0,
1202,126888,3,4,,103504490,3454,Unspecified,,,,,Compound was evaluated for 15 mice treated ip twice daily for 5 days at a dose of 5.6 mg/kg at 48 hr followed (MCMV) virus inoculation,Other,2163454.0,
1203,126889,3,4,,103504490,3454,Unspecified,,,,,Compound was evaluated for 15 mice treated ip twice daily for 5 days at a dose of 5.6 mg/kg at 6 hr followed (MCMV) virus inoculation,Other,2163454.0,
1204,132928,3,3,,103504490,3454,Unspecified,,,,,Compound was evaluated for mean day of death at 0.6 mg/kg at 24 h,Other,2163454.0,
1205,132929,3,3,,103504490,3454,Unspecified,,,,,Compound was evaluated for mean day of death at 0.6 mg/kg at 48 h,Other,2163454.0,
1206,132930,3,3,,103504490,3454,Unspecified,,,,,Compound was evaluated for mean day of death at 0.6 mg/kg at 6 h,Other,2163454.0,
1207,132931,3,3,,103504490,3454,Unspecified,,,,,Compound was evaluated for mean day of death at 1.9 mg/kg at 24 h,Other,2163454.0,
1208,132932,3,3,,103504490,3454,Unspecified,,,,,Compound was evaluated for mean day of death at 1.9 mg/kg at 48 h,Other,2163454.0,
1209,132933,3,3,,103504490,3454,Unspecified,,,,,Compound was evaluated for mean day of death at 1.9 mg/kg at 6 h,Other,2163454.0,
1210,132934,3,3,,103504490,3454,Unspecified,,,,,Compound was evaluated for mean day of death at 16.7 mg/kg at 24 h,Other,2163454.0,
1211,132935,3,3,,103504490,3454,Unspecified,,,,,Compound was evaluated for mean day of death at 16.7 mg/kg at 48 h,Other,2163454.0,
1212,132936,3,3,,103504490,3454,Unspecified,,,,,Compound was evaluated for mean day of death at 16.7 mg/kg at 6 h,Other,2163454.0,
1213,132938,3,3,,103504490,3454,Unspecified,,,,,Compound was evaluated for mean day of death at 5.6 mg/kg at 24 h,Other,2163454.0,
1214,132939,3,3,,103504490,3454,Unspecified,,,,,Compound was evaluated for mean day of death at 5.6 mg/kg at 48 h,Other,2163454.0,
1215,132940,3,3,,103504490,3454,Unspecified,,,,,Compound was evaluated for mean day of death at 5.6 mg/kg at 6 h,Other,2163454.0,
1216,133911,7,1,,103504490,3454,Unspecified,,,,,Mean time survival (MTS) of the mice at the end of 28 or 49 days.,Other,2329561.0,
1217,134093,3,3,,103504490,3454,Unspecified,,,,,Topical treatment of intracutaneous HSV-1 (KOS) herpes simplex virus type 1 infection of Nu/nu mice for mean day of appearance of skin lesions and/or paralysis of the hind legs at 0.3% concentration (v/v in DMSO),Other,2329561.0,
1218,134094,3,3,,103504490,3454,Unspecified,,,,,Topical treatment of intracutaneous HSV-1 (KOS) herpes simplex virus type 1 infection of Nu/nu mice for mean day of appearance of skin lesions and/or paralysis of the hind legs at 1% concentration (v/v in DMSO),Other,2329561.0,
1219,134095,3,3,,103504490,3454,Unspecified,,,,,Topical treatment of intracutaneous HSV-1 (KOS) herpes simplex virus type 1 infection of Nu/nu mice for mean day of appearance of skin lesions and/or paralysis of the hind legs at 3% concentration (v/v in DMSO),Other,2329561.0,
1220,134099,3,3,,103504490,3454,Unspecified,,,,,Topical treatment of intracutaneous TK- herpes simplex virus type 1 of strain VMW 1837 infection of Nu/nu mice for mean day of appearance of skin lesions and/or paralysis of the hind legs at 0.3% concentration (v/v in DMSO),Other,2329561.0,
1221,134100,3,3,,103504490,3454,Unspecified,,,,,Topical treatment of intracutaneous TK- herpes simplex virus type 1 of strain VMW 1837 infection of Nu/nu mice for mean day of appearance of skin lesions and/or paralysis of the hind legs at 1% concentration (v/v in DMSO),Other,2329561.0,
1222,134101,3,3,,103504490,3454,Unspecified,,,,,Topical treatment of intracutaneous TK- herpes simplex virus type 1 of strain VMW 1837 infection of Nu/nu mice for mean day of appearance of skin lesions and/or paralysis of the hind legs at 3% concentration (v/v in DMSO),Other,2329561.0,
1223,151166,6,2,,103504490,3454,Unspecified,,,200.0,CC50,Cytotoxic concentration against HSV-1 TK- transfected osteosarcoma cells,Confirmatory,14584954.0,
1224,151167,6,2,,103504490,3454,Unspecified,,,75.0,CC50,Cytotoxic concentration against HSV-1 TK-transfected osteosarcoma cells,Confirmatory,14584954.0,
1225,151168,6,2,,103504490,3454,Unspecified,,,300.0,CC50,Cytotoxic concentration against non transfected osteosarcoma cells non transfected (MG-63-hTK1),Confirmatory,14584954.0,
1226,151171,6,2,,103504490,3454,Unspecified,,,75.0,CC50,Inhibitory activity against HSV-1-TK transfected osteosarcoma cells,Confirmatory,14584954.0,
1227,160324,8,4,,103504490,3454,Inconclusive,,,,,Compound was evaluated for the inhibitory activity against Human Cytomegalovirus (HCMV) polymerase; No data,Other,10999475.0,
1228,165291,6,4,,103504490,3454,Inconclusive,,,,,Percent inhibition of protein kinase C at 100 uM (not tested),Other,11454465.0,
1229,165905,8,2,,103504490,3454,Inconclusive,,,,,Inhibitory concentration of the drug against the antigen production against P3HR-1 strain of epstein barr virus-2 (EBV) in Raji cells; ND is Not Determined,Other,8394933.0,
1230,167889,7,2,,103504490,3454,Unspecified,,,,,Evaluated for the minimum cytotoxic concentration (MCC) upon preincubation of rabbit kidney cells in medium containing 10% fetal calf serum at 37 degree Celsius for 24 hr,Other,2329561.0,
1231,174086,3,4,,103504490,3454,Unspecified,,,,,Total amount of Ganciclovir recovered in the urine over a 48 hr period after an oral dose of 0.1 mmol/kg to male SD rat,Other,9925738.0,
1232,209373,6,2,,103504490,3454,Unspecified,,,,,Evaluated for the minimum inhibitory concentration (MIC) in primary rabbit kidney (PRK) by 50% against TK- herpes simplex virus type 1 (TK- HSV-1) with strain B2006,Other,2329561.0,
1233,209374,6,2,,103504490,3454,Unspecified,,,,,Evaluated for the minimum inhibitory concentration (MIC) in primary rabbit kidney (PRK) by 50% against TK- herpes simplex virus type 1 (TK- HSV-1) with strain VMW 1837,Other,2329561.0,
1234,209532,6,2,,103504490,3454,Unspecified,,,,,Inhibitory concentration against TK-HSV type 1 strain B2006 in human embryonic skin muscle (ESM) fibroblast cell culture,Other,8393114.0,
1235,209538,6,2,,103504490,3454,Unspecified,,,,,Inhibitory concentration against TK-VZV strain 07-1 in human embryonic lung (HEL) cell culture,Other,8393114.0,
1236,209539,6,2,,103504490,3454,Unspecified,,,,,Inhibitory concentration against TK-VZV strain YS-R in human embryonic lung (HEL) cell culture,Other,8393114.0,
1237,209950,5,2,,103504490,3454,Unspecified,,,,,Concentration required to reduce the proliferation of PHA stimulated human peripheral blood T lymphocytes; ND means Not determined,Other,11677126.0,
1238,210528,3,7,,103504490,3454,Unspecified,,,,,Phosphorylation of compound by purified HSV-1 (F strain) thymidine kinase,Other,3016263.0,
1239,210602,7,1,,103504490,3454,Unspecified,,,,,Therapeutic index for anti-HCMV activity against AD-169 strain in MRC-5 cells,Other,9836613.0,
1240,210685,3,8,,103504490,3454,Unspecified,,,,,Catalytic turnover constant of compound against HSV-1 thymidine kinase,Other,14584954.0,
1241,211494,6,3,,103504490,3454,Unspecified,,,,,Cytotoxicity in Flow 2002 cell line,Other,,
1242,216030,5,3,,103504490,3454,Inconclusive,,,,,Cytotoxicity in Vero cell line;Not determined,Other,,
1243,216035,5,3,,103504490,3454,Inconclusive,,,,,Inhibitory activity against Herpes Simplex virus type 1 (186 strain) in a Plaque reduction Assay in vero cells;Not determined,Other,,
1244,216037,5,3,,103504490,3454,Inconclusive,,,,,Inhibitory activity against Herpes Simplex virus type 1 (KOS strain) in a Plaque reduction Assay in vero cells;Not determined,Other,,
1245,216162,5,2,,103504490,3454,Inconclusive,,,,,Tested for antiviral activity against VZV (TK-KOS); Not determined,Other,11412988.0,
1246,216164,5,2,,103504490,3454,Inconclusive,,,,,Tested for antiviral activity against VZV (YS); Not determined,Other,11412988.0,
1247,216189,8,1,,103504490,3454,Active,,,0.2,ID50,Antiviral activity was determined in plaque reduction assay in vero cells against HSV-1 F strain,Confirmatory,3871860.0,
1248,216328,4,3,,103504490,3454,Inconclusive,,,,,Compound was tested for antiherpes activity against Varicella zoster virus(OKA) in HEL cells; Not determined,Other,,
1249,216460,8,2,,103504490,3454,Inconclusive,,,,,In vitro antiviral activity against Varicella zoster virus (VZV) was determined; ND= Not determined,Other,11814776.0,
1250,216470,5,1,,103504490,3454,Unspecified,,,,,In vitro anti viral activity tested against VZV(KMcC) virus on MRC-5 cell monolayers; 1-2,Other,2989523.0,
1251,216474,5,2,,103504490,3454,Inconclusive,,,,,Antiviral activity against TK+ Varicella-Zoster virus OKA which reduces virus plaque formation by 50%; ND denotes no data,Other,12217359.0,
1252,216476,5,2,,103504490,3454,Inconclusive,,,,,Antiviral activity against TK+ Varicella-Zoster virus YS which reduces virus plaque formation by 50%; ND denotes no data,Other,12217359.0,
1253,216477,5,2,,103504490,3454,Inconclusive,,,,,Antiviral activity against TK- Varicella-Zoster virus 07/1 which reduces virus plaque formation by 50%; ND denotes no data,Other,12217359.0,
1254,216480,5,2,,103504490,3454,Inconclusive,,,,,Antiviral activity against TK- Varicella-Zoster virus YS/R which reduces virus plaque formation by 50%; ND denotes no data,Other,12217359.0,
1255,216533,6,2,,103504490,3454,Unspecified,,,,,Evaluated for the minimum inhibitory concentration (MIC) in primary rabbit kidney (PRK) by 50% against vesicular stomatitis virus,Other,2329561.0,
1256,216805,5,1,,103504490,3454,Unspecified,,,,,Anti viral activity against vero cells (concentration required to reduce the log phase cell growth by 50%).,Other,7562929.0,
1257,217411,9,1,,103504490,3454,Unspecified,,,,,Growth inhibition of cytomegalovirus in Vero cells,Other,14521407.0,
1258,217483,6,2,,103504490,3454,Unspecified,,,,,Inhibitory concentration against VSV in human embryonic skin muscle (ESM) fibroblast cell culture,Other,8393114.0,
1259,217484,6,2,,103504490,3454,Unspecified,,,,,Minimal inhibitory concentration to reduce virus-induced cytopathicity against VSV,Other,11708929.0,
1260,217488,6,2,,103504490,3454,Unspecified,,,,,Inhibitory concentration against VV in human embryonic skin muscle (ESM) fibroblast cell culture,Other,8393114.0,
1261,217489,6,2,,103504490,3454,Unspecified,,,,,Minimal inhibitory concentration to reduce virus-induced cytopathicity against VV,Other,11708929.0,
1262,217498,6,2,,103504490,3454,Active,,,2.8,IC50,Inhibition of growth of varicella zoster virus(VZV) by plaque reduction assay in vero cell line,Confirmatory,2826784.0,
1263,217655,6,2,,103504490,3454,Unspecified,,,,,Minimum inhibitory concentration was determined against HSV-1 (TK-/TK+VMW1837) in E6SM cell culture,Other,10691698.0,
1264,217673,6,2,,103504490,3454,Unspecified,,,,,Inhibitory concentration against VZV strain OKA in human embryonic lung (HEL) cell culture,Other,8393114.0,
1265,217674,6,2,,103504490,3454,Unspecified,,,,,Inhibitory concentration against VZV strain YS in human embryonic lung (HEL) cell culture,Other,8393114.0,
1266,217678,8,1,,103504490,3454,Active,,,2.0,ID50,compound was tested for antiherpes activity against VZV(Ellen) in tissue culture by plaque reduction assay,Confirmatory,1849998.0,
1267,217753,8,1,,103504490,3454,Active,,,0.2,ID50,Antiviral activity determined against herpes simplex type 1 (F strain) by plaque reduction in Vero cells,Confirmatory,3016263.0,
1268,217761,8,1,,103504490,3454,Unspecified,,,450.0,ID50,In vitro anticellular activity was measured against vero cells,Confirmatory,3009811.0,
1269,217763,8,1,,103504490,3454,Active,,,10.0,ID50,In vitro antiviral activity was measured against HSV-1 (F delta 305) in Vero cells,Confirmatory,3009811.0,
1270,217764,8,1,,103504490,3454,Unspecified,,,125.0,ID50,In vitro antiviral activity was measured against HSV-1 (MP-PAA/DHPG) in Vero cells,Confirmatory,3009811.0,
1271,217765,8,1,,103504490,3454,Active,,,0.2,ID50,In vitro antiviral activity was measured against HSV-1(F) in Vero cells,Confirmatory,3009811.0,
1272,217766,8,1,,103504490,3454,Active,,,1.6,ID50,In vitro antiviral activity was measured against HSV-2(G) in Vero cells,Confirmatory,3009811.0,
1273,218000,6,2,,103504490,3454,Unspecified,,,,,Evaluated for the minimum inhibitory concentration (MIC) in primary rabbit kidney (PRK) by 50% against vaccinia virus,Other,2329561.0,
1274,218227,4,4,,103504490,3454,Unspecified,,,,,Cytotoxicity concentration required to microscopically detectable alteration of cell morphology in Vero,Other,10691698.0,
1275,218230,8,1,,103504490,3454,Unspecified,,,500.0,ID50,In vitro antiviral and anticellular activity was evaluated against vero cells in tissue culture,Confirmatory,2993615.0,
1276,218246,5,1,,103504490,3454,Unspecified,,,,,Antiviral activity against herpesvirus vero cells in tissue culture.,Other,2160539.0,
1277,218371,7,1,,103504490,3454,Unspecified,,,,,Compound was evaluated for its cytotoxicity against Vero cell line,Other,11454465.0,
1278,218501,5,2,,103504490,3454,Inconclusive,,,,,Compound was evaluated for cytotoxicity against stationary Vero cells using MTT assay; ND means Not determined,Other,11677126.0,
1279,218505,5,2,,103504490,3454,Inconclusive,,,,,Concentration required to inhibit plaque formation by HSV-1 strain KOS (TK+) in monolayers of vero cells; ND means Not determined,Other,11677126.0,
1280,218507,5,2,,103504490,3454,Inconclusive,,,,,Concentration required to inhibit plaque formation by HSV-1 strain KOSSB (TK-) in monolayers of vero cells; ND means Not determined,Other,11677126.0,
1281,221295,7,2,,103504490,3454,Unspecified,,,,,Tested for antiviral activity against HBV (Hep AD79),Other,11412988.0,
1282,221304,6,2,,103504490,3454,Unspecified,,,,,Evaluated for the minimum inhibitory concentration (MIC) in primary rabbit kidney (PRK) by 50% against herpes simplex virus type-1 (HSV-1) with strains F,Other,2329561.0,
1283,221305,6,2,,103504490,3454,Unspecified,,,,,Evaluated for the minimum inhibitory concentration (MIC) in primary rabbit kidney (PRK) by 50% against herpes simplex virus type-1 (HSV-1) with strains KOS,Other,2329561.0,
1284,221306,6,2,,103504490,3454,Unspecified,,,,,Evaluated for the minimum inhibitory concentration (MIC) in primary rabbit kidney (PRK) by 50% against herpes simplex virus type-1 (HSV-1) with strains McIntyre,Other,2329561.0,
1285,221311,6,2,,103504490,3454,Unspecified,,,,,Evaluated for the minimum inhibitory concentration (MIC) in primary rabbit kidney (PRK) by 50% against herpes simplex virus type-2 (HSV-2) with strains 196,Other,2329561.0,
1286,221312,6,2,,103504490,3454,Unspecified,,,,,Evaluated for the minimum inhibitory concentration (MIC) in primary rabbit kidney (PRK) by 50% against herpes simplex virus type-2 (HSV-2) with strains G,Other,2329561.0,
1287,221313,6,2,,103504490,3454,Unspecified,,,,,Evaluated for the minimum inhibitory concentration (MIC) in primary rabbit kidney (PRK) by 50% against herpes simplex virus type-2 (HSV-2) with strains Lyons,Other,2329561.0,
1288,221758,6,2,,103504490,3454,Unspecified,,,100.0,IC50,Cytotoxicity for the compound was determined in uninfected stationary human foreskin fibroblasts (HFF) cells.,Confirmatory,9548814.0,
1289,222144,6,3,,103504490,3454,Active,,,0.78,EC50,In vitro antiviral activity against Human cytomegalovirus (HCMV) was determined,Confirmatory,11814776.0,
1290,226670,6,2,,103504490,3454,Unspecified,,,,,Compound was evaluated for its cytotoxicity.,Other,9871553.0,
1291,228729,6,2,,103504490,3454,Unspecified,,,,,Minimal cytotoxic concentration (MCC) to cause a microscopically detectable change in normal cell morphology,Other,11708929.0,
1292,228733,6,2,,103504490,3454,Unspecified,,,,,Minimum cytotoxic concentration which causes microscopically detectable alteration of normal cell morphology after 2 days of incubation.,Other,9046339.0,
1293,229024,6,2,,103504490,3454,Unspecified,,,,,Inhibitory activity against vaccinia virus (VV) replication in E6SM cell cultures of human embryonic skin-muscle,Other,12459010.0,
1294,229235,6,2,,103504490,3454,Unspecified,,,,,Inhibitory activity against vesicular stomatitis virus (VSV) replication in E6SM cell cultures of human embryonic skin-muscle,Other,12459010.0,
1295,231620,4,4,,103504490,3454,Unspecified,,,,,"Antiviral activity on mock infected cell culture, activity and expressed as EC50/TC50; value given as 8.9/>100 uM",Other,,
1296,235552,3,3,,103504490,3454,Unspecified,,,,,Ratio of Cytotoxicity concentration to that of virus-inhibitory concentration.,Other,9836626.0,
1297,235622,3,4,,103504490,3454,Unspecified,,,,,Therapeutic index measured as ratio of EC50 for AD-169/CC50 for HEL 299,Other,,
1298,235623,3,4,,103504490,3454,Unspecified,,,,,Therapeutic index measured as ratio of EC50 for Davis/CC50 for HEL 299,Other,,
1299,236268,3,4,,103504490,3454,Unspecified,,,,,Fraction absorbed in human intestine after oral administration compound was measured,Other,15658873.0,
1300,236912,6,1,,103504490,3454,Unspecified,,,,,Permeability Coefficient in 2/4/A1 cell model,Other,15658873.0,
1301,236913,6,1,,103504490,3454,Unspecified,,,,,Permeability Coefficient in Caco-2 cell culture model,Other,15658873.0,
1302,236916,6,1,,103504490,3454,Unspecified,,,,,Percentage of mass balance in hexadecane membranes model,Other,15658873.0,
1303,244769,6,2,,103504490,3454,Unspecified,,,,,Minimum cytotoxic concentration that causes a microscopically detectable alteration of cell morphology,Other,15689173.0,
1304,244770,7,3,,103504490,3454,Unspecified,,,,,Minimum cytotoxic concentration of compound that causes alteration of cell morphology in human embryonic lung cells,Other,15658861.0,
1305,244773,7,3,,103504490,3454,Unspecified,,,,,Minimum cytotoxic concentration required to cause a microscopically visible alteration of HEL fibroblast cell morphology,Other,15801851.0,
1306,244774,6,2,,103504490,3454,Unspecified,,,,,Minimum cytotoxic concentration that caused a microscopically detectable alteration of cell morphology in E6SM Cell Culture,Other,15481985.0,
1307,245891,6,3,,103504490,3454,Unspecified,,,150.0,CC50,Cytotoxic concentration required to reduce HEL cell growth,Confirmatory,15801851.0,
1308,245928,5,2,,103504490,3454,Inconclusive,,,,,Cytotoxic concentration required to reduce cell growth by 50%; nd=not determined,Other,15689173.0,
1309,245945,6,2,,103504490,3454,Unspecified,,,392.0,CC50,Cytotoxic concentration against murine cytomegalovirus infected MEF cells,Confirmatory,15634003.0,
1310,245963,7,3,,103504490,3454,Unspecified,,,,,Cytotoxic concentration to reduce the 50% cell growth of human embryonic lung cells,Other,15658861.0,
1311,245991,6,2,,103504490,3454,Unspecified,,,100.0,CC50,Cytotoxic concentration against town strain of human cytomegalovirus infected HFF cells of human (visual cytotoxicity),Confirmatory,15634003.0,
1312,245994,6,2,,103504490,3454,Unspecified,,,392.0,CC50,Cytotoxic concentration against AD169 strain of human cytomegalovirus infected HFF cells of human (by neutral red uptake),Confirmatory,15634003.0,
1313,246223,6,2,,103504490,3454,Unspecified,,,,,Effective concentration against AD-169 strain of CMV virus expressed in HEL cells,Other,15689173.0,
1314,246259,6,2,,103504490,3454,Unspecified,,,,,Effective concentration required to reduce vaccinia virus plaque formation by 50% in E6SM Cell Culture,Other,15481985.0,
1315,246264,6,2,,103504490,3454,Unspecified,,,,,Effective concentration against Davis strain of CMV virus expressed in HEL cells,Other,15689173.0,
1316,246308,6,2,,103504490,3454,Unspecified,,,,,Effective concentration required to reduce HSV-2 strain G virus plaque formation by 50% in E6SM Cell Culture,Other,15481985.0,
1317,246311,6,3,,103504490,3454,Active,,,0.5,EC50,Effective concentration required to reduce CMV AD169 strain virus plaque formation by 50% in HEL cell culture,Confirmatory,15481985.0,
1318,246312,6,3,,103504490,3454,Active,,,1.5,EC50,Effective concentration required to reduce CMV davis strain virus plaque formation by 50% in HEL cell culture,Confirmatory,15481985.0,
1319,246316,6,2,,103504490,3454,Unspecified,,,,,Effective concentration required to reduce HSV-1 strain KOS virus plaque formation by 50% in E6SM Cell Culture,Other,15481985.0,
1320,246353,8,2,,103504490,3454,Inconclusive,,,,,Effective concentration required to inhibit Coxsackie B3 virus induced cytopathicity in vero cells; not determined,Other,15658858.0,
1321,246354,6,2,,103504490,3454,Active,,,5.0,EC50,Effective concentration required to inhibit Epstein-barr virus replication in H-1 cells in DNA hybridization assay,Confirmatory,15634003.0,
1322,246356,6,2,,103504490,3454,Unspecified,,,,,Effective concentration required to reduce HSV-1 strain KOS ACV virus plaque formation by 50% in E6SM Cell Culture,Other,15481985.0,
1323,246376,6,2,,103504490,3454,Active,,,0.06,EC50,Effective concentration required to inhibit herpes simplex virus type 1 Kos strain induced cytopathicity in Hel cells,Confirmatory,15658858.0,
1324,246381,6,2,,103504490,3454,Active,,,1.6,EC50,Effective concentration for antiviral activity against AD169 strain of human cytomegalovirus in plaque reduction assay,Confirmatory,15634003.0,
1325,246382,6,2,,103504490,3454,Active,,,2.1,EC50,Effective concentration for antiviral activity against towne strain of human cytomegalovirus in plaque reduction assay,Confirmatory,15634003.0,
1326,246389,6,2,,103504490,3454,Active,,,2.1,EC50,Effective concentration for antiviral activity against AD169 strain of murine cytomegalovirus in plaque reduction assay,Confirmatory,15634003.0,
1327,246442,6,2,,103504490,3454,Unspecified,,,,,Effective concentration required to reduce plaque formation by Davis strain of CMV virus in Human embryonic lung cells,Other,15658861.0,
1328,246454,6,2,,103504490,3454,Unspecified,,,,,Effective concentration required to reduce plaque formation by AD-169 strain of CMV virus in Human embryonic lung cells,Other,15658861.0,
1329,246475,6,2,,103504490,3454,Unspecified,,,,,Effective concentration of the compound to reduce plaque-formation of Cytomegalovirus davis strain in human embryonic lungcell cultures,Other,15658861.0,
1330,246512,6,2,,103504490,3454,Unspecified,,,,,Effective concentration to reduce plaque formation of Cytomegalovirus AD-169 strain in human embryonic lung cell cultures,Other,15658861.0,
1331,246614,6,3,,103504490,3454,Active,,,1.5,EC50,Effective concentration required to inhibit human cytomegalo virus Davis induced cytopathicity in HEL fibroblast cell line after 7 days of postinfection,Confirmatory,15801851.0,
1332,246626,6,3,,103504490,3454,Active,,,1.5,EC50,Effective concentration required to inhibit human cytomegalo virus AD-169 induced cytopathicity in HEL fibroblast cell line after 7 days of postinfection,Confirmatory,15801851.0,
1333,246710,5,2,,103504490,3454,Inconclusive,,,,,Effective concentration of compound required to reduce plaque formation by OKA strain of thymidine kinase positive VZ virus TK+ in human embryonic lung cells; ND=Not determined,Other,15658861.0,
1334,246718,5,2,,103504490,3454,Inconclusive,,,,,Effective concentration of compound required to reduce plaque formation by VZV07/1 strain of thymidine kinase(TK-) deficient VZ virus in human embryonic lung cells; ND=Not determined,Other,15658861.0,
1335,246725,5,2,,103504490,3454,Inconclusive,,,,,Effective concentration to reduce plaque formation of thymidine kinase positive Varicella zoster virus TK+ VZ OKA strain in human embryonic lung cell cultures; ND=Not determined,Other,15658861.0,
1336,246728,5,2,,103504490,3454,Inconclusive,,,,,Effective concentration to reduce plaque formation of thymidine kinase deficient Varicella zoster virus TK- VZV 07/1 strain in human embryonic lung cell cultures; ND=Not determined,Other,15658861.0,
1337,248111,6,2,,103504490,3454,Active,,,3.5,IC50,Inhibitory activity against herpes simplex virus type-1 cultures was determined by ELISA assay,Confirmatory,15509173.0,
1338,248192,6,2,,103504490,3454,Active,,,7.4,IC50,Concentration required to inhibit plaque formation in human cytomegalovirus cultures was determined,Confirmatory,15509173.0,
1339,248250,6,2,,103504490,3454,Unspecified,,,100.0,IC50,Concentration required to inhibit KB cell line growth was determined by crystal violet staining method,Confirmatory,15509173.0,
1340,248356,6,2,,103504490,3454,Unspecified,,,100.0,IC50,Cytotoxicity produced in stationary HFF cells was determined by microscopic inspection of uninfected cells,Confirmatory,15509174.0,
1341,248357,6,2,,103504490,3454,Unspecified,,,100.0,IC50,Cytotoxicity produced in stationary HFF cells was determined by microscopic inspection of uninfected cells,Confirmatory,15509175.0,
1342,248358,6,2,,103504490,3454,Unspecified,,,100.0,IC50,Cytotoxicity produced in stationary HFF cells was determined by microscopic inspection of uninfected cells,Confirmatory,15509176.0,
1343,248488,6,2,,103504490,3454,Unspecified,,,100.0,IC50,Concentration required to inhibit stationary human HFF cell line growth was determined by microscopy examination,Confirmatory,15509173.0,
1344,248696,6,2,,103504490,3454,Unspecified,,,,,Compound concentration to reduce virus cytopathic effect by 50% tested against herpes simplex virus-1(G) using Vero cell line,Other,15745823.0,
1345,248724,6,2,,103504490,3454,Unspecified,,,,,Compound concentration to reduce virus cytopathic effect by 50% tested against herpes simplex virus-1(KOS) using Vero cell line,Other,15745823.0,
1346,248791,6,3,,103504490,3454,Active,,,3.5,IC50,Inhibitory concentration required against herpes simplex virus type-1 (HSV-1) expressed in BSC-1 cells was determined by ELISA assay,Confirmatory,15509174.0,
1347,248792,6,2,,103504490,3454,Active,,,3.5,IC50,Inhibitory concentration required against herpes simplex virus type-1 (HSV-1) expressed in BSC-1 cells was determined by ELISA assay,Confirmatory,15509175.0,
1348,248793,6,2,,103504490,3454,Active,,,3.5,IC50,Inhibitory concentration required against herpes simplex virus type-1 (HSV-1) expressed in BSC-1 cells was determined by ELISA assay,Confirmatory,15509176.0,
1349,248811,6,2,,103504490,3454,Active,,,7.4,IC50,Inhibitory concentration required against human cytomegalovirus (HCMV) expressed in HFF cells was determined by plaque reduction assay,Confirmatory,15509174.0,
1350,248812,6,2,,103504490,3454,Active,,,7.4,IC50,Inhibitory concentration required against human cytomegalovirus (HCMV) expressed in HFF cells was determined by plaque reduction assay,Confirmatory,15509175.0,
1351,248813,6,2,,103504490,3454,Active,,,7.4,IC50,Inhibitory concentration required against human cytomegalovirus (HCMV) expressed in HFF cells was determined by plaque reduction assay,Confirmatory,15509176.0,
1352,248868,7,2,,103504490,3454,Unspecified,,,,,Compound concentration to reduce virus plague formation by 50% tested against human cytomegalovirus laboratory strains P8 using MRC-5 cell line,Other,15745823.0,
1353,248872,6,3,,103504490,3454,Unspecified,,,,,Compound concentration to reduce virus plague formation by 50% tested against human cytomegalovirus laboratory strains Davis using HEL cell line,Other,15745823.0,
1354,248884,6,2,,103504490,3454,Active,,,1.2,IC50,Inhibitory concentration required against human cytomegalovirus (HCMV) wild type expressed in HFF cells was determined by plaque reduction assay,Confirmatory,15509176.0,
1355,248901,7,2,,103504490,3454,Unspecified,,,,,Compound concentration to reduce virus plague formation by 50% tested against human cytomegalovirus laboratory strains Ad169 using MRC-5 cell line,Other,15745823.0,
1356,248939,6,3,,103504490,3454,Unspecified,,,100.0,IC50,Cytotoxicity against KB cells was determined by crystal violet staining and spectrophotometric quantitation of dye eluted from stained cells,Confirmatory,15509174.0,
1357,248940,6,3,,103504490,3454,Unspecified,,,100.0,IC50,Cytotoxicity against KB cells was determined by crystal violet staining and spectrophotometric quantitation of dye eluted from stained cells,Confirmatory,15509175.0,
1358,248941,6,3,,103504490,3454,Unspecified,,,100.0,IC50,Cytotoxicity against KB cells was determined by crystal violet staining and spectrophotometric quantitation of dye eluted from stained cells,Confirmatory,15509176.0,
1359,248965,6,2,,103504490,3454,Active,,,1.2,IC50,Inhibitory concentration required against human cytomegalovirus (HCMV) D10 strain (UL89 mutant gene) expressed in HFF cells was determined by plaque reduction assay,Confirmatory,15509176.0,
1360,248966,6,2,,103504490,3454,Active,,,1.2,IC50,Inhibitory concentration required against human cytomegalovirus (HCMV) r56 strain (UL56 mutant gene) expressed in HFF cells was determined by plaque reduction assay,Confirmatory,15509176.0,
1361,248968,7,2,,103504490,3454,Unspecified,,,,,Compound concentration to reduce virus plague formation by 50% tested against human cytomegalovirus laboratory mutant strains D16(UL54 mutation) using MRC-5 cell line,Other,15745823.0,
1362,248975,7,2,,103504490,3454,Unspecified,,,,,Compound concentration to reduce virus plague formation by 50% tested against human cytomegalovirus laboratory mutant strains C8704(UL97 mutation) using MRC-5 cell line,Other,15745823.0,
1363,248981,6,2,,103504490,3454,Active,,,2.5,IC50,Inhibitory concentration required against human cytomegalovirus (HCMV) C4 strain (UL56 + UL89 mutant gene) expressed in HFF cells was determined by plaque reduction assay,Confirmatory,15509176.0,
1364,249179,6,1,,103504490,3454,Unspecified,,,,,Permeability Coefficient in hexadecane membranes model,Other,15658873.0,
1365,249219,5,1,,103504490,3454,Unspecified,,,,,Cytotoxic compound concentration to reduce neutral red uptake by 50% using MRC-5 cell line,Other,15745823.0,
1366,249220,5,1,,103504490,3454,Unspecified,,,,,"Minimum cytotoxic compound concentration to induce microscopically detectable alteration of cell morphology, using Vero cell line",Other,15745823.0,
1367,253316,7,2,,103504490,3454,Unspecified,,,,,Minimum cytotoxic concentration that causes microscopically detectable alteration of cell morphology in HEL cell culture,Other,15481985.0,
1368,253323,6,2,,103504490,3454,Unspecified,,,150.0,CC50,Cytotoxic concentration required to reduce HEL cell growth by 50%,Confirmatory,15481985.0,
1369,255985,6,2,,103504490,3454,Active,,,0.8,IC50,Antiviral activity against human cytomegalovirus Ad169 (WT) plaque forming unit grown on Human foreskin fibroblast cells upon incubation for 1 hour at 37 degrees C with compound dissolved in DMSO,Confirmatory,16134946.0,
1370,255989,6,2,,103504490,3454,Active,,,0.8,IC50,Antiviral activity against human cytomegalovirus Ad169 (V823A) plaque forming unit grown on Human foreskin fibroblast cells upon incubation for 1 hour at 37 degrees C with compound dissolved in DMSO,Confirmatory,16134946.0,
1371,256000,6,2,,103504490,3454,Active,,,1.3,IC50,Antiviral activity against human cytomegalovirus (Davis strain) grown on human foreskin fibroblast cells determined by reduction in plaque formation upon incubation at 37 degrees C with the compound dissolved in DMSO,Confirmatory,16134946.0,
1372,256006,8,2,,103504490,3454,Inconclusive,,,,,Antiviral activity against Varicella-Zoster virus (Webster strain) grown on human foreskin fibroblast cells determined by vedduction in plaque formation upon incubation at 37 degrees C with the compound dissolved in DMSO until plaque were formed; [nd = not determined],Other,16134946.0,
1373,256007,8,2,,103504490,3454,Inconclusive,,,,,Antiviral activity against herpes simplex virus type 1 (KOS strain) grown on human foreskin fibroblast cells determined by vedduction in plaque formation upon incubation at 37 degrees C with the compound dissolved in DMSO until plaque were formed; [nd = not determined],Other,16134946.0,
1374,256536,6,2,,103504490,3454,Unspecified,,,100.0,CC50,Toxicity on uninfected human foreskin fibroblast cells determined in microscopic evaluation and quantitative neutral red dye uptake assay,Confirmatory,16134946.0,
1375,256537,6,2,,103504490,3454,Unspecified,,,100.0,CC50,Toxicity on uninfected African green monkey kidney cells determined in microscopic evaluation and quantitative neutral red dye uptake assay,Confirmatory,16134946.0,
1376,257886,7,3,,103504490,3454,Unspecified,,,,,Antiviral activity against HEL cells,Other,16420056.0,
1377,257887,7,2,,103504490,3454,Inconclusive,,,,,Antiviral activity against vero cells,Other,16420056.0,
1378,257888,7,2,,103504490,3454,Inconclusive,,,,,Antiviral activity against HeLa cells,Other,16420056.0,
1379,257889,7,2,,103504490,3454,Unspecified,,,,,Antiviral activity against Herpes simplex virus 1 KOS strain in HEL cells,Other,16420056.0,
1380,257890,7,2,,103504490,3454,Unspecified,,,,,Antiviral activity against Herpes simplex virus 2 G strain in HEL cells,Other,16420056.0,
1381,257891,7,2,,103504490,3454,Unspecified,,,,,Antiviral activity against Vaccinia virus in HEL cells,Other,16420056.0,
1382,257892,7,2,,103504490,3454,Unspecified,,,,,Antiviral activity against Vesicular stomatitis virus in HEL cells,Other,16420056.0,
1383,257893,7,2,,103504490,3454,Unspecified,,,,,Antiviral activity against herpes simplex virus 1 TK- KOS ACVr strain in HEL cells,Other,16420056.0,
1384,257894,7,2,,103504490,3454,Inconclusive,,,,,Antiviral activity against Parainfluenza-3 virus in vero cells,Other,16420056.0,
1385,257895,7,2,,103504490,3454,Inconclusive,,,,,Antiviral activity against Reovirus 1 in vero cells,Other,16420056.0,
1386,257896,7,2,,103504490,3454,Inconclusive,,,,,Antiviral activity against Sindbis virus in vero cells,Other,16420056.0,
1387,257897,7,2,,103504490,3454,Inconclusive,,,,,Antiviral activity against Coxsackie virus B4 in vero cells,Other,16420056.0,
1388,257898,7,2,,103504490,3454,Inconclusive,,,,,Antiviral activity against Punta Toro virus in vero cells,Other,16420056.0,
1389,257899,7,2,,103504490,3454,Inconclusive,,,,,Antiviral activity against Respiratory syncytial virus in HeLa cells,Other,16420056.0,
1390,257900,7,2,,103504490,3454,Inconclusive,,,,,Antiviral activity against Coxsackie virus B4 in HeLa cells,Other,16420056.0,
1391,257901,7,2,,103504490,3454,Inconclusive,,,,,Antiviral activity against Vesicular stomatitis virus in HeLa cells,Other,16420056.0,
1392,258989,6,2,,103504490,3454,Inconclusive,,,,EC50,Antiviral activity against Varicella-Zoster virus YS strain,Confirmatory,16392824.0,
1393,258990,6,2,,103504490,3454,Inconclusive,,,,EC50,Antiviral activity against Varicella-Zoster virus 07/1 strain,Confirmatory,16392824.0,
1394,258991,6,2,,103504490,3454,Inconclusive,,,,EC50,Antiviral activity against Varicella-Zoster virus YS/R strain,Confirmatory,16392824.0,
1395,258992,6,2,,103504490,3454,Active,,,5.1,EC50,Antiviral activity against human cytomegalovirus AD169 strain,Confirmatory,16392824.0,
1396,258993,6,2,,103504490,3454,Active,,,8.7,EC50,Antiviral activity against human cytomegalovirus Davis strain,Confirmatory,16392824.0,
1397,258994,7,3,,103504490,3454,Unspecified,,,,CC50,Cytotoxic activity against cultured human embryonic lung (HEL) cells,Confirmatory,16392824.0,
1398,259177,6,2,,103504490,3454,Active,,,0.06,EC50,Antiviral activity against HSV1 KOS in HEL cells,Confirmatory,16392791.0,
1399,259179,6,2,,103504490,3454,Active,,,0.06,EC50,Antiviral activity against HSV2 G in HEL cells,Confirmatory,16392791.0,
1400,259181,6,2,,103504490,3454,Unspecified,,,50.0,EC50,Antiviral activity against HIV1 IIIB in CEM cells,Confirmatory,16392791.0,
1401,259182,6,2,,103504490,3454,Unspecified,,,50.0,EC50,Antiviral activity against HIV2 ROD in CEM cells,Confirmatory,16392791.0,
1402,260289,6,2,,103504490,3454,Unspecified,,,,,Antiviral activity against Cytomegalovirus AD169 in human embryonic lung cells,Other,16480257.0,
1403,260290,6,2,,103504490,3454,Unspecified,,,,,Antiviral activity against Cytomegalovirus Davis in human embryonic lung cells,Other,16480257.0,
1404,260293,6,3,,103504490,3454,Unspecified,,,,,Cytotoxicity as determined by alteration in the cell morphology of HEL cells,Other,16480257.0,
1405,260294,6,3,,103504490,3454,Unspecified,,,,,Cytotoxicity against HEL cells,Other,16480257.0,
1406,266282,6,2,,103504490,3454,Inconclusive,,,,CC50,Cytotoxicity against human HepG2 cell line,Confirmatory,16759112.0,
1407,266283,6,2,,103504490,3454,Inconclusive,,,,CC50,Cytotoxicity against Vero cell line,Confirmatory,16759112.0,
1408,266286,5,3,,103504490,3454,Inconclusive,,,,,Antiviral activity against HBV L180M/M204V mutant transfected in D88 cell line at 10 ug/mL,Other,16759112.0,
1409,266288,5,3,,103504490,3454,Inconclusive,,,,,Antiviral activity against HBV M204I mutant transfected in B1 cell line at 10 ug/mL,Other,16759112.0,
1410,271110,6,2,,103504490,3454,Unspecified,,,100.0,IC50,Cytotoxicity against human Jurkat cells,Confirmatory,16814545.0,
1411,271111,6,2,,103504490,3454,Unspecified,,,100.0,IC50,Cytotoxicity against HFF cells,Confirmatory,16814545.0,
1412,271112,6,2,,103504490,3454,Active,,,30.0,IC50,Cytotoxicity against human bone marrow cells assessed as inhibition of colony forming unit of granulocyte/macrophage,Confirmatory,16814545.0,
1413,271113,7,1,,103504490,3454,Active,,,,,Inhibition of human CMV growth by viral yield assay,Other,16814545.0,
1414,271114,7,1,,103504490,3454,Active,,,,,Inhibition of human CMV growth by plaque reduction assay,Other,16814545.0,
1415,273043,6,2,,103504490,3454,Active,,,1.8,EC50,Inhibition of HCMV towne replication in HFF cells by plaque reduction assay,Confirmatory,17004726.0,
1416,273044,6,2,,103504490,3454,Active,,,0.15,EC50,Inhibition of HCMV AD169 replication in HFF cells by cytopathic effect assay,Confirmatory,17004726.0,
1417,273045,6,2,,103504490,3454,Unspecified,,,100.0,CC50,Cytotoxicity against HFF cell by neutral red uptake assay,Confirmatory,17004726.0,
1418,273049,9,1,,103504490,3454,Active,,,5.0,EC50,Inhibition of EBV replication in H1 cells by DNA hybridization assay,Confirmatory,17004726.0,
1419,274894,6,2,,103504490,3454,Active,,,0.040999999999999995,IC50,Cytotoxicity against human OST TK- cells expressing HSV1 TK in presence of 10 uM 1-[6-(triphenylmethoxy)hexyl]thymine,Confirmatory,17181158.0,
1420,274895,6,2,,103504490,3454,Active,,,0.033,IC50,Cytotoxicity against human OST TK- cells expressing HSV1 TK in presence of 5 uM 1-[6-(triphenylmethoxy)hexyl]thymine,Confirmatory,17181158.0,
1421,274896,6,2,,103504490,3454,Active,,,0.018000000000000002,IC50,Cytotoxicity against human OST TK- cells expressing HSV1 TK in presence of 2.5 uM 1-[6-(triphenylmethoxy)hexyl]thymine,Confirmatory,17181158.0,
1422,274897,6,2,,103504490,3454,Active,,,0.11,IC50,"Cytotoxicity against human OST TK- cells expressing HSV1 TK in presence of 10 uM 1-[6-[1,1-(diphenyl)-1-(4-pyridyl)methoxy]hexyl]thymine",Confirmatory,17181158.0,
1423,274898,6,2,,103504490,3454,Active,,,0.081,IC50,"Cytotoxicity against human OST TK- cells expressing HSV1 TK in presence of 5 uM 1-[6-[1,1-(diphenyl)-1-(4-pyridyl)methoxy]hexyl]thymine",Confirmatory,17181158.0,
1424,274899,6,2,,103504490,3454,Active,,,0.05,IC50,"Cytotoxicity against human OST TK- cells expressing HSV1 TK in presence of 2.5 uM 1-[6-[1,1-(diphenyl)-1-(4-pyridyl)methoxy]hexyl]thymine",Confirmatory,17181158.0,
1425,274900,6,2,,103504490,3454,Active,,,0.0019,IC50,Cytotoxicity against human OST TK- cells expressing HSV1 TK,Confirmatory,17181158.0,
1426,275067,6,4,,103504490,3454,Active,,,0.019,EC50,Antiviral activity against HSV1 KOS in HEL cells,Confirmatory,17181162.0,
1427,275068,6,2,,103504490,3454,Active,,,0.032,EC50,Antiviral activity against HSV2 in HEL cells,Confirmatory,17181162.0,
1428,275069,6,2,,103504490,3454,Unspecified,,,100.0,EC50,Antiviral activity against vaccinia virus in HEL cells,Confirmatory,17181162.0,
1429,275070,6,2,,103504490,3454,Unspecified,,,100.0,EC50,Antiviral activity against vesicular somatitis virus in HEL cells,Confirmatory,17181162.0,
1430,275086,6,4,,103504490,3454,Active,,,0.48,EC50,Antiviral activity against HSV1 KOS in HEL cells,Confirmatory,17181162.0,
1431,275087,6,3,,103504490,3454,Unspecified,,,100.0,CC50,Cytotoxicity against HEL cells,Confirmatory,17181162.0,
1432,278215,6,2,,103504490,3454,Active,,,1.4,IC50,Antiviral activity against Human CMV T2241 in HFF cells by SEAP assay,Confirmatory,17043128.0,
1433,278216,6,2,,103504490,3454,Active,,,1.3,IC50,Antiviral activity against Human CMV T2211 in HFF cells by SEAP assay,Confirmatory,17043128.0,
1434,278217,6,2,,103504490,3454,Active,,,1.4,IC50,Antiviral activity against Human CMV T2233 in HFF cells by SEAP assay,Confirmatory,17043128.0,
1435,278218,6,2,,103504490,3454,Active,,,5.6,IC50,Antiviral activity against Human CMV T2293 in HFF cells by SEAP assay,Confirmatory,17043128.0,
1436,278219,6,2,,103504490,3454,Active,,,7.1,IC50,Antiviral activity against Human CMV T2291 in HFF cells by SEAP assay,Confirmatory,17043128.0,
1437,278220,6,2,,103504490,3454,Active,,,30.2,IC50,Antiviral activity against Human CMV T2311 in HFF cells by SEAP assay,Confirmatory,17043128.0,
1438,278221,6,2,,103504490,3454,Active,,,1.9,IC50,Antiviral activity against Human CMV AD169 in HFF cells by PRA,Confirmatory,17043128.0,
1439,278222,6,2,,103504490,3454,Active,,,10.0,IC50,Antiviral activity against Human CMV T2293 in HFF cells by PRA,Confirmatory,17043128.0,
1440,278223,6,2,,103504490,3454,Active,,,4.1,IC50,Antiviral activity against Human CMV T2291 in HFF cells by PRA,Confirmatory,17043128.0,
1441,278224,6,2,,103504490,3454,Active,,,12.4,IC50,Antiviral activity against Human CMV T2311 in HFF cells by PRA,Confirmatory,17043128.0,
1442,278225,6,2,,103504490,3454,Active,,,4.9,IC50,Antiviral activity against Human CMV Towne in MRC5 cells by PRA,Confirmatory,17043128.0,
1443,278226,6,2,,103504490,3454,Active,,,5.4,IC50,Antiviral activity against Human CMV T2296 in MRC5 cells by PRA,Confirmatory,17043128.0,
1444,278227,6,2,,103504490,3454,Active,,,30.1,IC50,Antiviral activity against Human CMV T2287 in MRC5 cells by PRA,Confirmatory,17043128.0,
1445,280175,6,4,,103504490,3454,Unspecified,,,,,Antiviral activity against HSV1 KOS in HEL cells assessed as inhibition of virus-induced cytopathicity,Other,17298047.0,
1446,280176,7,4,,103504490,3454,Unspecified,,,,,Antiviral activity against ACV-resistant TK- HSV1 KOS in HEL cells assessed as inhibition of virus-induced cytopathicity,Other,17298047.0,
1447,280177,7,2,,103504490,3454,Unspecified,,,,,Antiviral activity against HSV2 Lyons in HEL cells assessed as inhibition of virus-induced cytopathicity,Other,17298047.0,
1448,280178,6,2,,103504490,3454,Unspecified,,,,,Antiviral activity against HSV2 G in HEL cells assessed as inhibition of virus-induced cytopathicity,Other,17298047.0,
1449,280181,6,2,,103504490,3454,Unspecified,,,,,Antiviral activity against HCMV AD169 in HEL cells assessed as inhibition of virus-induced cytopathicity,Other,17298047.0,
1450,280182,6,2,,103504490,3454,Unspecified,,,,,Antiviral activity against HCMV Davis in HEL cells assessed as inhibition of virus-induced cytopathicity,Other,17298047.0,
1451,280186,5,1,,103504490,3454,Unspecified,,,,,Cytotoxicity against HEL cells assessed as alteration in cell morphology after 3 days,Other,17298047.0,
1452,280188,5,1,,103504490,3454,Unspecified,,,,,Cytotoxicity against HEL cells assessed as inhibition of cell growth after 3 days,Other,17298047.0,
1453,282640,6,2,,103504490,3454,Active,,,2.1,EC50,Inhibition of HCMV Towne replication in HFF cells by plaque reduction assay,Confirmatory,15615545.0,
1454,282641,6,2,,103504490,3454,Unspecified,,,100.0,CC50,Cytotoxicity against HFF cells by visual cytotoxicity,Confirmatory,15615545.0,
1455,282642,6,2,,103504490,3454,Active,,,2.2,EC50,Inhibition of HCMV AD169 replication in HFF cells by CPE inhibition assay,Confirmatory,15615545.0,
1456,282643,6,2,,103504490,3454,Unspecified,,,392.0,CC50,Cytotoxicity against HFF cells by neutral red uptake assay,Confirmatory,15615545.0,
1457,282650,6,2,,103504490,3454,Unspecified,,,50.0,EC50,Inhibition of HSV1 in Vero cells by plaque reduction assay,Confirmatory,15615545.0,
1458,282651,6,2,,103504490,3454,Unspecified,,,50.0,EC50,Inhibition of HSV2 in Vero cells by plaque reduction assay,Confirmatory,15615545.0,
1459,282655,6,2,,103504490,3454,Active,,,5.0,EC50,Inhibition of EBV replication in H1 cells by DNA hybridization assay,Confirmatory,15615545.0,
1460,282656,6,2,,103504490,3454,Active,,,5.0,CC50,Cytotoxicity against CEM cells,Confirmatory,15615545.0,
1461,284525,8,3,,103504490,3454,Active,,,,,Antiviral activity against HSV1 KOS-induced cytopathogenicity in E6SM cells,Other,17092728.0,
1462,284527,8,1,,103504490,3454,Active,,,,,Antiviral activity against HSV2 G-induced cytopathogenicity in E6SM cells,Other,17092728.0,
1463,284529,8,1,,103504490,3454,Unspecified,,,,,Antiviral activity against Vaccinia virus-induced cytopathogenicity in E6SM cells,Other,17092728.0,
1464,284531,8,1,,103504490,3454,Unspecified,,,,,Antiviral activity against in Vesicular stomatitis virus-induced cytopathogenicity in E6SM cells,Other,17092728.0,
1465,284533,8,3,,103504490,3454,Active,,,,,Antiviral activity against HSV1 TK- KOS ACV-induced cytopathogenicity in E6SM cells,Other,17092728.0,
1466,284535,8,1,,103504490,3454,Unspecified,,,,,Cytotoxicity against E6SM cells,Other,17092728.0,
1467,286285,6,2,,103504490,3454,Unspecified,,,70.0,IC50,Cytotoxicity against Kaposi's sarcoma-associated herpesvirus infected BC3 cells after 120 hrs by MTT assay,Confirmatory,17402726.0,
1468,286286,6,2,,103504490,3454,Unspecified,,,81.0,IC50,Cytotoxicity against Kaposi's sarcoma-associated herpesvirus infected BC2 cells after 120 hrs by MTT assay,Confirmatory,17402726.0,
1469,286287,6,3,,103504490,3454,Unspecified,,,100.0,IC50,Cytotoxicity against DG75 cells after 120 hrs by MTT assay,Confirmatory,17402726.0,
1470,288915,6,2,,103504490,3454,Unspecified,,,,,Cytotoxicity against E6SM cells assessed as alteration in cell morphology,Other,17518459.0,
1471,288916,6,4,,103504490,3454,Unspecified,,,,,Antiviral activity against HSV1 KOS in E6SM cells assessed as reduction of virus-induced cytopathogenicity,Other,17518459.0,
1472,288917,6,2,,103504490,3454,Unspecified,,,,,Antiviral activity against HSV2 G in E6SM cells assessed as reduction of virus-induced cytopathogenicity,Other,17518459.0,
1473,288918,6,2,,103504490,3454,Unspecified,,,,,Antiviral activity against Vaccinia virus in E6SM cells assessed as reduction of virus-induced cytopathogenicity,Other,17518459.0,
1474,288919,6,2,,103504490,3454,Unspecified,,,,,Antiviral activity against thymidine kinase-deficient HSV1 B2006 in E6SM cells assessed as reduction of virus-induced cytopathogenicity,Other,17518459.0,
1475,288920,6,2,,103504490,3454,Unspecified,,,,,Antiviral activity against thymidine kinase deficient HSV1 VMW1837 in E6SM cells assessed as reduction of virus-induced cytopathogenicity,Other,17518459.0,
1476,288921,6,2,,103504490,3454,Active,,,6.3,EC50,Antiviral activity against HCMV AD169 in HEL cells assessed as reduction of virus plaque formation,Confirmatory,17518459.0,
1477,288922,6,2,,103504490,3454,Active,,,2.75,EC50,Antiviral activity against HCMV Davis in HEL cells assessed as reduction of virus plaque formation,Confirmatory,17518459.0,
1478,288923,7,3,,103504490,3454,Unspecified,,,,,Cytotoxicity against HEL cells assessed as alteration in cell morphology,Other,17518459.0,
1479,290119,6,2,,103504490,3454,Inconclusive,,,,EC50,Antiviral activity against HIV1 in MT4 cells,Confirmatory,17188402.0,
1480,290120,6,2,,103504490,3454,Active,,,1.5,EC50,Antiviral activity against HSV1 in CCL81 cells,Confirmatory,17188402.0,
1481,290121,6,2,,103504490,3454,Active,,,1.5,EC50,Antiviral activity against HSV2 in CCL81 cells,Confirmatory,17188402.0,
1482,290122,6,2,,103504490,3454,Active,,,1.01,EC50,Antiviral activity against HCMV AD169,Confirmatory,17188402.0,
1483,291027,6,2,,103504490,3454,Active,,,4.8,EC50,Antiviral activity against human cytomegalovirus AD169 in HEL cells assessed as reduction of plaque formation after 7 days,Confirmatory,17539622.0,
1484,291028,6,2,,103504490,3454,Active,,,1.3,EC50,Antiviral activity against human cytomegalovirus Davis in HEL cells assessed as reduction of plaque formation after 7days,Confirmatory,17539622.0,
1485,291031,7,3,,103504490,3454,Unspecified,,,,,Cytotoxicity against HEL cells assessed as cell morphology after 7 days,Other,17539622.0,
1486,291032,6,3,,103504490,3454,Unspecified,,,172.0,CC50,Cytotoxicity against HEL cells assessed as cell growth after 7 days,Confirmatory,17539622.0,
1487,293239,6,4,,103504490,3454,Active,,,3.0,IC50,Antiviral activity against HCMV Towne in HFF cells by plaque reduction assay,Confirmatory,17161946.0,
1488,293733,6,2,,103504490,3454,Unspecified,,,970.0,IC50,Cytotoxicity against MRC5 cells,Confirmatory,17239594.0,
1489,293734,6,2,,103504490,3454,Active,,,0.91,IC50,Antiviral activity against HCMV in MRC5 cells by plaque reduction assay,Confirmatory,17239594.0,
1490,293735,3,4,,103504490,3454,Unspecified,,,,,"Selectivity index, ratio of CC50 for MRC5 cells to IC50 for HCMV",Other,17239594.0,
1491,294701,6,2,,103504490,3454,Active,,,1.0,IC50,Antiviral activity against HCMV infected HFF cells after 5 days by dot blot assay,Confirmatory,17329103.0,
1492,294705,7,1,,103504490,3454,Active,,,,,Antiviral activity against HCMV infected HFF cells after 5 to 7 days by viral yield assay,Other,17329103.0,
1493,294706,6,2,,103504490,3454,Unspecified,,,100.0,CC50,Cytotoxicity against HFF cells by alamar blue assay,Confirmatory,17329103.0,
1494,294707,6,2,,103504490,3454,Unspecified,,,100.0,CC50,Cytotoxicity against human Jurkat cells by alamar blue assay,Confirmatory,17329103.0,
1495,294708,6,3,,103504490,3454,Active,,,30.0,CC50,Cytotoxicity against human bone marrow cells assessed as inhibition of CFU-GM formation after 15 days,Confirmatory,17329103.0,
1496,296672,6,2,,103504490,3454,Active,,,2.3,EC50,Antiviral activity against TK+ VZV YS in HEL cells assessed as reduction of virus plaque formation after 5 days,Confirmatory,17622128.0,
1497,296673,6,2,,103504490,3454,Inconclusive,,,,EC50,Antiviral activity against TK+ VZV OKA in HEL cells assessed as reduction of virus plaque formation after 5 days,Confirmatory,17622128.0,
1498,296674,6,2,,103504490,3454,Inconclusive,,,,EC50,Antiviral activity against thymidine kinase deficient VZV 07/1 in HEL cells assessed as reduction of virus plaque formation after 5 days,Confirmatory,17622128.0,
1499,296675,6,2,,103504490,3454,Inconclusive,,,,EC50,Antiviral activity against thymidine kinase deficient VZV YS/R in HEL cells assessed as reduction of virus plaque formation after 5 days,Confirmatory,17622128.0,
1500,296676,6,2,,103504490,3454,Active,,,5.1,EC50,Antiviral activity against HCMV AD169 in HEL cells assessed as reduction of virus plaque formation after 7 days,Confirmatory,17622128.0,
1501,296677,6,2,,103504490,3454,Active,,,8.7,EC50,Antiviral activity against HCMV Davis in HEL cells assessed as reduction of virus plaque formation after 7 days,Confirmatory,17622128.0,
1502,296678,7,3,,103504490,3454,Unspecified,,,,,Cytotoxicity against HEL cells assessed as alteration in cell morphology after 3 days,Other,17622128.0,
1503,296679,6,3,,103504490,3454,Unspecified,,,200.0,CC50,Cytotoxicity against HEL cells after 3 days,Confirmatory,17622128.0,
1504,297308,6,2,,103504490,3454,Active,,,6.5,EC50,Antiviral activity against CMV AD169 in human HEL cells after 7 days,Confirmatory,17672445.0,
1505,297309,6,2,,103504490,3454,Active,,,2.6,EC50,Antiviral activity against CMV Davis in human HEL cells after 7 days,Confirmatory,17672445.0,
1506,297310,7,3,,103504490,3454,Unspecified,,,,,Cytotoxicity against human HEL cells assessed as alteration in cell morphology,Other,17672445.0,
1507,297311,6,3,,103504490,3454,Unspecified,,,262.0,CC50,Cytotoxicity against human HEL cells assessed as reduction of cell growth,Confirmatory,17672445.0,
1508,297314,8,3,,103504490,3454,Active,,,,,Antiviral activity against HSV1 KOS in HEL cells assessed as reduction of virus-induced cytopathogenicity,Other,17672445.0,
1509,297315,8,1,,103504490,3454,Active,,,,,Antiviral activity against HSV2 G in HEL cells assessed as reduction of virus-induced cytopathogenicity,Other,17672445.0,
1510,297316,8,1,,103504490,3454,Unspecified,,,,,Antiviral activity against Vaccinia virus in HEL cells assessed as reduction of virus-induced cytopathogenicity,Other,17672445.0,
1511,299438,6,2,,103504490,3454,Active,,,1.3,IC50,Antiviral activity against HCMV in human foreskin fibroblast assessed as inhibition of virus plaque formation,Confirmatory,17513108.0,
1512,299443,6,2,,103504490,3454,Inconclusive,,,,IC50,Antiviral activity against HSV1 in human foreskin fibroblast assessed as inhibition of virus plaque formation,Confirmatory,17513108.0,
1513,299444,6,2,,103504490,3454,Inconclusive,,,,IC50,Antiviral activity against VZV in human foreskin fibroblast assessed as inhibition of virus plaque formation,Confirmatory,17513108.0,
1514,303209,6,2,,103504490,3454,Unspecified,,,,,Antiviral activity against HSV1 KOS in HEL cells assessed as reduction of virus-induced cytopathogenicity,Other,17948980.0,
1515,303210,6,2,,103504490,3454,Unspecified,,,,,Antiviral activity against acyclovir-resistant HSV1 KOS TK- in HEL cells assessed as reduction of virus-induced cytopathogenicity,Other,17948980.0,
1516,303211,6,2,,103504490,3454,Unspecified,,,,,Antiviral activity against HSV2 Lyons in HEL cells assessed as reduction of virus-induced cytopathogenicity,Other,17948980.0,
1517,303212,6,2,,103504490,3454,Unspecified,,,,,Antiviral activity against HSV2 G in HEL cells assessed as reduction of virus-induced cytopathogenicity,Other,17948980.0,
1518,303215,6,2,,103504490,3454,Unspecified,,,,,Antiviral activity against HCMV AD169 in HEL cells assessed as reduction of virus-induced cytopathogenicity,Other,17948980.0,
1519,303216,6,2,,103504490,3454,Unspecified,,,,,Antiviral activity against HCMV Davis in HEL cells assessed as reduction of virus-induced cytopathogenicity,Other,17948980.0,
1520,303221,6,3,,103504490,3454,Unspecified,,,,,Cytotoxicity against HEL cells assessed as alteration in morphology after 3 days,Other,17948980.0,
1521,303224,8,1,,103504490,3454,Unspecified,,,,,Cytotoxicity against HEL cells assessed as cell growth after 3 days,Other,17948980.0,
1522,303438,6,3,,103504490,3454,Unspecified,,,270.0,IC50,Cytotoxicity against MCA cells,Confirmatory,17960926.0,
1523,303439,8,1,,103504490,3454,Active,,,0.15,IC50,Cytotoxicity against MCA-TK cells,Confirmatory,17960926.0,
1524,307430,4,4,,103504490,3454,Active,,,1.3,IC50,Antiviral activity against HCMV Davis in HFF cells by plaque reduction assay,Confirmatory,17434304.0,
1525,307431,4,4,,103504490,3454,Inconclusive,,,,IC50,Antiviral activity against HSV1 KOS in Vero cells by plaque reduction assay,Confirmatory,17434304.0,
1526,307432,4,4,,103504490,3454,Inconclusive,,,,IC50,Antiviral activity against VZV Webster in HFF cells by plaque reduction assay,Confirmatory,17434304.0,
1527,307433,6,2,,103504490,3454,Unspecified,,,100.0,CC50,Cytotoxicity against HFF cells after 3 days,Confirmatory,17434304.0,
1528,309810,7,2,,103504490,3454,Inconclusive,,,,,Antiviral activity against TK+ VZV OKA in HEL cells assessed as reduction of virus plaque formation,Other,17869124.0,
1529,309811,7,2,,103504490,3454,Inconclusive,,,,,Antiviral activity against TK- VZV 07/1 in HEL cells assessed as reduction of virus plaque formation,Other,17869124.0,
1530,309812,7,2,,103504490,3454,Unspecified,,,,,Antiviral activity against HCMV AD169 in HEL cells assessed as reduction of virus plaque formation after 5 days,Other,17869124.0,
1531,309813,7,2,,103504490,3454,Unspecified,,,,,Antiviral activity against HCMV Davis in HEL cells assessed as reduction of virus plaque formation after 5 days,Other,17869124.0,
1532,309814,6,3,,103504490,3454,Unspecified,,,,,Cytotoxicity against HEL cells assessed as alteration in cell morphology after 3 days,Other,17869124.0,
1533,309815,7,3,,103504490,3454,Unspecified,,,,,Cytotoxicity against HEL cells assessed as reduction of cell growth after 3 days,Other,17869124.0,
1534,326127,9,2,,103504490,3454,Unspecified,,,800.0,IC50,Inhibition of Herpes B virus recombinant thymidine kinase-mediated [3H]TdR phosphorylation,Confirmatory,17438061.0,
1535,326131,4,7,,103504490,3454,Inactive,,,,,Activity of Herpes B virus recombinant thymidine kinase at 100 uM,Other,17438061.0,
1536,326132,3,7,,103504490,3454,Inactive,,,,,Activity of Herpes B virus recombinant thymidine kinase at 1 mM,Other,17438061.0,
1537,326134,6,4,,103504490,3454,Active,,,14.5,EC50,Antiviral activity against Herpes B virus 24105 infected in african green monkey Vero cells assessed as plaque reduction after 36 to 48 hrs,Confirmatory,17438061.0,
1538,326135,6,4,,103504490,3454,Active,,,23.5,EC50,Antiviral activity against Herpes B virus 32425 infected in african green monkey Vero cells assessed as plaque reduction after 36 to 48 hrs,Confirmatory,17438061.0,
1539,326136,6,4,,103504490,3454,Active,,,19.2,EC50,Antiviral activity against Herpes B virus E90-136 infected in african green monkey Vero cells assessed as plaque reduction after 36 to 48 hrs,Confirmatory,17438061.0,
1540,326137,6,2,,103504490,3454,Active,,,0.7,EC50,Antiviral activity against Herpes simplex virus 1 F infected in african green monkey Vero cells assessed as plaque reduction after 36 to 48 hrs,Confirmatory,17438061.0,
1541,326138,6,2,,103504490,3454,Unspecified,,,666.0,CC50,Cytotoxicity against african green monkey Vero cells after 2 days,Confirmatory,17438061.0,
1542,326210,6,4,,103504490,3454,Active,,,2.5,EC50,Antiviral activity against Human cytomegalovirus Towne infected in HFF cells by plaque reduction assay,Confirmatory,18082410.0,
1543,326212,6,2,,103504490,3454,Unspecified,,,100.0,CC50,Cytotoxicity against HFF cells,Confirmatory,18082410.0,
1544,340469,4,3,,103504490,3454,Inconclusive,,,,IC50,Antiviral activity against HSV1 KOS by plaque reduction assay,Confirmatory,18595689.0,
1545,340471,4,3,,103504490,3454,Active,,,1.3,IC50,Antiviral activity against HCMV Davis by plaque reduction assay,Confirmatory,18595689.0,
1546,340472,4,3,,103504490,3454,Inconclusive,,,,IC50,Antiviral activity against VZV Webster by plaque reduction assay,Confirmatory,18595689.0,
1547,340473,4,3,,103504490,3454,Inconclusive,,,,IC50,Antiviral activity against EBV lytic replication in GG68 cells after 72 hrs by Southern blot analysis,Confirmatory,18595689.0,
1548,340474,6,2,,103504490,3454,Unspecified,,,100.0,CC50,Cytotoxicity against HFF cells after 3 days by neutral red dye uptake assay,Confirmatory,18595689.0,
1549,350197,6,2,,103504490,3454,Active,,,1.2,EC50,Antiviral activity against Human cytomegalovirus Towne infected in human foreskin fibroblast cells by plaque reduction assay,Confirmatory,19397271.0,
1550,350198,6,2,,103504490,3454,Unspecified,,,100.0,CC50,Cytotoxicity against HFF cells by plaque reduction assay,Confirmatory,19397271.0,
1551,350199,6,2,,103504490,3454,Active,,,0.04,EC50,Antiviral activity against Human cytomegalovirus AD169 infected in human foreskin fibroblast cells assessed as inhibition of virus-induced cytopathic effect,Confirmatory,19397271.0,
1552,350200,6,2,,103504490,3454,Unspecified,,,100.0,CC50,Cytotoxicity against HFF cells by neutral red uptake assay,Confirmatory,19397271.0,
1553,350203,6,2,,103504490,3454,Active,,,5.5,EC50,Antiviral activity against Murine cytomegalovirus infected in mouse embryonic fibroblast cells by plaque reduction assay,Confirmatory,19397271.0,
1554,350210,3,3,,103504490,3454,Inactive,,,,,Antiviral activity against Hepatitis B virus,Other,19397271.0,
1555,350211,3,3,,103504490,3454,Inactive,,,,,Antiviral activity against Hepatitis C virus,Other,19397271.0,
1556,350212,6,2,,103504490,3454,Active,,,42.0,EC50,Antiviral activity against cyclopropavir-resistant Human cytomegalovirus isolate 2696r with phosphotransferase UL97 mutation by plaque reduction assay,Confirmatory,19397271.0,
1557,350213,6,2,,103504490,3454,Active,,,22.0,EC50,Antiviral activity against Human cytomegalovirus E8 with phosphotransferase UL97 two point mutation by plaque reduction assay,Confirmatory,19397271.0,
1558,354674,6,2,,103504490,3454,Unspecified,,,,,Antiviral activity against mouse cytomegalovirus assessed as effect on virus-induced cytopathic effect,Other,8792629.0,
1559,354675,6,2,,103504490,3454,Unspecified,,,,,Antiviral activity against mouse cytomegalovirus by plaque-neutralization assay,Other,8792629.0,
1560,354676,6,2,,103504490,3454,Unspecified,,,,,Antiviral activity against human cytomegalovirus by plaque-neutralization assay,Other,8792629.0,
1561,363782,6,2,,103504490,3454,Active,,,4.8,EC50,Antiviral activity against HCMV AD169 infected in HEL cells assessed as reduction of virus-induced cytopathogenicity after 3 days,Confirmatory,17961851.0,
1562,363783,6,2,,103504490,3454,Active,,,1.3,EC50,Antiviral activity against HCMV Davis infected in HEL cells assessed as reduction of virus-induced cytopathogenicity after 3 days,Confirmatory,17961851.0,
1563,363784,6,3,,103504490,3454,Unspecified,,,,,Cytotoxicity against HEL cells assessed as change in cell morphology,Other,17961851.0,
1564,363785,6,3,,103504490,3454,Unspecified,,,172.0,CC50,Cytotoxicity against HEL cells assessed as reduction in cell growth,Confirmatory,17961851.0,
1565,365169,6,2,,103504490,3454,Unspecified,,,,,Antiviral activity against ganciclovir-resistant HCMV with DNA polymerase mutant in HEL cells assessed as reduction of virus-induced cytopathogenicity,Other,18707089.0,
1566,365170,6,2,,103504490,3454,Unspecified,,,,,Antiviral activity against (S)-3-hydroxy-2-phosphonomethoxypropyl cytosine-resistant HCMV with DNA polymerase mutant in HEL cells assessed as reduction of virus-induced cytopathogenicity,Other,18707089.0,
1567,365171,6,2,,103504490,3454,Unspecified,,,,,Antiviral activity against (S)-3-hydroxy-2-phosphonomethoxypropyl adenine-resistant HCMV with DNA polymerase mutant in HEL cells assessed as reduction of virus-induced cytopathogenicity,Other,18707089.0,
1568,365172,6,2,,103504490,3454,Unspecified,,,,,Antiviral activity against foscarnet-resistant HCMV with DNA polymerase mutant in HEL cells assessed as reduction of virus-induced cytopathogenicity,Other,18707089.0,
1569,365173,6,2,,103504490,3454,Unspecified,,,,,Antiviral activity against acyclovir-resistant HCMV with DNA polymerase mutant in HEL cells assessed as reduction of virus-induced cytopathogenicity,Other,18707089.0,
1570,365174,6,2,,103504490,3454,Unspecified,,,,,Antiviral activity against HCMV 6 with U97 mutation in HEL cells assessed as reduction of virus-induced cytopathogenicity,Other,18707089.0,
1571,365175,6,2,,103504490,3454,Unspecified,,,,,Antiviral activity against HCMV 521 with U97 and DNA polymerase mutation in HEL cells assessed as reduction of virus-induced cytopathogenicity,Other,18707089.0,
1572,365176,6,2,,103504490,3454,Unspecified,,,,,Antiviral activity against HCMV 530 with U97 and DNA polymerase mutation in HEL cells assessed as reduction of virus-induced cytopathogenicity,Other,18707089.0,
1573,372961,6,2,,103504490,3454,Active,,,1.1,EC50,Antiviral activity against Cytomegalovirus CMV T2211 infected in HFF cells by SEAP reporter gene assay,Confirmatory,17709468.0,
1574,372962,6,2,,103504490,3454,Active,,,3.9,EC50,Antiviral activity against Cytomegalovirus CMV T2258 with UL97 C592G mutant infected in HFF cells by SEAP reporter gene assay,Confirmatory,17709468.0,
1575,372963,6,2,,103504490,3454,Active,,,2.6,EC50,Antiviral activity against Cytomegalovirus CMV T2417 with pol A809V mutant infected in HFF cells by SEAP reporter gene assay,Confirmatory,17709468.0,
1576,372964,6,2,,103504490,3454,Active,,,6.1,EC50,Antiviral activity against Cytomegalovirus CMV T2784 with pol A809V UL97 C592G double mutant infected in HFF cells by SEAP reporter gene assay,Confirmatory,17709468.0,
1577,372965,6,2,,103504490,3454,Active,,,2.7,EC50,Antiviral activity against Cytomegalovirus CMV T2542 with pol T813S mutant infected in HFF cells by SEAP reporter gene assay,Confirmatory,17709468.0,
1578,372966,6,2,,103504490,3454,Active,,,6.6,EC50,Antiviral activity against Cytomegalovirus CMV T2798 with pol T813S UL97 C592G double mutant infected in HFF cells by SEAP reporter gene assay,Confirmatory,17709468.0,
1579,372967,6,2,,103504490,3454,Active,,,3.5,EC50,Antiviral activity against Cytomegalovirus CMV T2420 with pol G841A mutant infected in HFF cells by SEAP reporter gene assay,Confirmatory,17709468.0,
1580,372968,6,2,,103504490,3454,Active,,,8.4,EC50,Antiviral activity against Cytomegalovirus CMV 2817 with pol G841A UL97 C592G double mutant infected in HFF cells by SEAP reporter gene assay,Confirmatory,17709468.0,
1581,372969,3,4,,103504490,3454,Unspecified,,,,,"Drug resistance, ratio of EC50 for Cytomegalovirus CMV pol A384P mutant to EC50 for Cytomegalovirus CMV T2211 by SEAP reporter gene assay",Other,17709468.0,
1582,372970,3,4,,103504490,3454,Unspecified,,,,,"Drug resistance, ratio of EC50 for Cytomegalovirus CMV T2784 with pol A809V UL97 C592G double mutant to EC50 for Cytomegalovirus CMV T2211 by SEAP reporter gene assay",Other,17709468.0,
1583,372971,3,4,,103504490,3454,Unspecified,,,,,"Drug resistance, ratio of EC50 for Cytomegalovirus CMV T2798 with pol T813S UL97 C592G double mutant to EC50 for Cytomegalovirus CMV T2211 by SEAP reporter gene assay",Other,17709468.0,
1584,372972,3,4,,103504490,3454,Unspecified,,,,,"Drug resistance, ratio of EC50 for Cytomegalovirus CMV T2817 with pol G841A UL97 C592G double mutant to EC50 for Cytomegalovirus CMV T2211 by SEAP reporter gene assay",Other,17709468.0,
1585,372973,3,4,,103504490,3454,Unspecified,,,,,"Drug resistance, ratio of EC50 for Cytomegalovirus CMV pol T821I mutant to EC50 for Cytomegalovirus CMV T2211 by SEAP reporter gene assay",Other,17709468.0,
1586,372974,3,4,,103504490,3454,Unspecified,,,,,"Drug resistance, ratio of EC50 for Cytomegalovirus CMV T2417 pol A809V mutant to EC50 for Cytomegalovirus CMV T2211 by plaque reduction assay",Other,17709468.0,
1587,383510,8,1,,103504490,3454,Unspecified,,,,,Cytotoxicity against human E6SM cells,Other,17583388.0,
1588,383511,6,3,,103504490,3454,Unspecified,,,,,Cytotoxicity against human HEL cells assessed as alteration of cell morphology,Other,17583388.0,
1589,383512,6,2,,103504490,3454,Unspecified,,,,,Antiviral activity against HSV1 KOS in human E6SM cells assessed as reduction of virus-induced cytopathogenicity,Other,17583388.0,
1590,383513,6,2,,103504490,3454,Unspecified,,,,,Antiviral activity against HSV1 KOS in human HEL cells assessed as reduction of virus-induced cytopathogenicity,Other,17583388.0,
1591,383514,6,2,,103504490,3454,Unspecified,,,,,Antiviral activity against HSV2 G in human E6SM cells assessed as reduction of virus-induced cytopathogenicity,Other,17583388.0,
1592,383515,6,2,,103504490,3454,Unspecified,,,,,Antiviral activity against HSV2 G in human HEL cells assessed as reduction of virus-induced cytopathogenicity,Other,17583388.0,
1593,383516,6,2,,103504490,3454,Unspecified,,,,,Antiviral activity against Vaccinia virus in human E6SM cells assessed as reduction of virus-induced cytopathogenicity,Other,17583388.0,
1594,383517,6,2,,103504490,3454,Unspecified,,,,,Antiviral activity against Vaccinia virus in human HEL cells assessed as reduction of virus-induced cytopathogenicity,Other,17583388.0,
1595,383518,6,2,,103504490,3454,Unspecified,,,,,Antiviral activity against in Vesicular stomatitis virus in human E6SM cells assessed as reduction of virus-induced cytopathogenicity,Other,17583388.0,
1596,383519,6,2,,103504490,3454,Unspecified,,,,,Antiviral activity against in Vesicular stomatitis virus in human HEL cells assessed as reduction of virus-induced cytopathogenicity,Other,17583388.0,
1597,383520,6,2,,103504490,3454,Unspecified,,,,,Antiviral activity against thymidine kinase deficient and acyclovir resistant HSV1 KOS in human E6SM cells assessed as reduction of virus-induced cytopathogenicity,Other,17583388.0,
1598,383521,6,2,,103504490,3454,Unspecified,,,,,Antiviral activity against thymidine kinase deficient and acyclovir resistant HSV1 KOS in human HEL cells assessed as reduction of virus-induced cytopathogenicity,Other,17583388.0,
1599,383525,6,2,,103504490,3454,Unspecified,,,,,Antiviral activity against human cytomegalovirus AD169 infected HEL cells assessed as reduction in virus plaque formation,Other,17583388.0,
1600,383526,6,2,,103504490,3454,Unspecified,,,,,Antiviral activity against human cytomegalovirus Davis infected HEL cells assessed as reduction in virus plaque formation,Other,17583388.0,
1601,383533,6,3,,103504490,3454,Unspecified,,,,,Cytotoxicity against human HEL cells assessed as reduction of cell growth,Other,17583388.0,
1602,386623,4,8,,103504490,3454,Unspecified,313104181.0,6580.0,,,Inhibition of 4-(4-(dimethylamino)styryl)-N-methylpyridinium uptake at human OCT1 expressed in HEK293 cells at 100 uM by confocal microscopy,Other,18788725.0,
1603,387577,6,3,,103504490,3454,Unspecified,,,100.0,CC50,Cytotoxicity against CRFK cells assessed as decrease in cell viability by MTS assay,Confirmatory,18778942.0,
1604,387854,6,3,,103504490,3454,Unspecified,,,,,Cytotoxicity against HEL cells assessed as alteration in cell morphology by MTS assay,Other,18778942.0,
1605,388918,7,2,,103504490,3454,Inconclusive,,,,,Antiviral activity against thymidine kinase expressing Varicella-Zoster virus Oka in HEL cells assessed as inhibition of viral cytopathicity,Other,18835175.0,
1606,388919,7,2,,103504490,3454,Inconclusive,,,,,Antiviral activity against thymidine kinase deficient Varicella-Zoster virus 07/1 in HEL cells assessed as inhibition of viral cytopathicity,Other,18835175.0,
1607,388920,7,2,,103504490,3454,Unspecified,,,,,Antiviral activity against human cytomegalovirus AD169 in HEL cells assessed as inhibition of viral cytopathicity,Other,18835175.0,
1608,388921,7,2,,103504490,3454,Unspecified,,,,,Antiviral activity against human cytomegalovirus Davis in HEL cells assessed as inhibition of viral cytopathicity,Other,18835175.0,
1609,388922,7,3,,103504490,3454,Unspecified,,,,,Cytotoxicity against HEL cells assessed as morphological alteration after 3 days,Other,18835175.0,
1610,388923,7,3,,103504490,3454,Unspecified,,,,,Cytotoxicity against HEL cells assessed as reduction of growth after 3 days,Other,18835175.0,
1611,390367,3,3,,103504490,3454,Unspecified,,,,,Antiviral activity against human cytomegalovirus,Other,19053744.0,
1612,391674,6,3,,103504490,3454,Active,,,5.86,CC50,Cytotoxicity against HSV1-tk gene overexpressing RG2TK+ cells after 72 hrs by MTT assay,Confirmatory,18800764.0,
1613,391675,6,2,,103504490,3454,Unspecified,,,377.0,CC50,Cytotoxicity against RG2 cells after 72 hrs by MTT assay,Confirmatory,18800764.0,
1614,392501,6,2,,103504490,3454,Active,,,35.0,IC50,Antiviral activity against Human adenovirus 2,Confirmatory,19112024.0,
1615,392536,6,2,,103504490,3454,Unspecified,,,392.0,IC50,Antiviral activity against Vaccinia virus,Confirmatory,19112024.0,
1616,393964,6,2,,103504490,3454,Active,,,4.3,EC50,Antiviral activity against ganciclovir-resistant HCMV AD169 clone 4 infected in HEL cells assessed as inhibition of virus-induced cytopathicity,Confirmatory,19226140.0,
1617,393977,6,2,,103504490,3454,Active,,,3.6,EC50,Antiviral activity against HCMV Davis infected in human HEL cells assessed inhibition of virus-induced cytopathicity after 7 days postinfection,Confirmatory,19226140.0,
1618,393978,6,2,,103504490,3454,Active,,,2.0,EC50,Antiviral activity against HCMV AD169 infected in human HEL cells assessed inhibition of virus-induced cytopathicity after 7 days postinfection,Confirmatory,19226140.0,
1619,393981,6,3,,103504490,3454,Unspecified,,,,,Cytotoxicity against human HEL cells assessed as morphological alteration after 3 days,Other,19226140.0,
1620,393982,6,3,,103504490,3454,Unspecified,,,134.0,CC50,Cytotoxicity against human HEL cells assessed as reduction of growth after 3 days,Confirmatory,19226140.0,
1621,393987,6,2,,103504490,3454,Active,,,2.6,EC50,Antiviral activity against foscarnet-resistant HCMV AD169 clone C infected in HEL cells assessed as inhibition of virus-induced cytopathicity,Confirmatory,19226140.0,
1622,393988,6,2,,103504490,3454,Active,,,4.0,EC50,Antiviral activity against cidofovir HCMV AD169 clone 5 infected in human HEL cells assessed as inhibition of virus-induced cytopathicity,Confirmatory,19226140.0,
1623,393989,6,2,,103504490,3454,Active,,,3.5,EC50,Antiviral activity against PMEDAP-resistant HCMV AD169 clone 4 infected in HEL cells assessed as inhibition of virus-induced cytopathicity,Confirmatory,19226140.0,
1624,393990,6,2,,103504490,3454,Active,,,1.2,EC50,Antiviral activity against HPMPA-resistant HCMV AD169 clone 2 mutant infected in HEL cells assessed as inhibition of virus-induced cytopathicity,Confirmatory,19226140.0,
1625,393991,6,2,,103504490,3454,Active,,,0.69,EC50,Antiviral activity against acyclovir-resistant HCMV AD169 clone 1 infected in HEL cells assessed as inhibition of virus-induced cytopathicity,Confirmatory,19226140.0,
1626,393992,6,2,,103504490,3454,Active,,,0.7,EC50,Antiviral activity against wild type HCMV AD169 infected in HEL cells assessed as inhibition of virus-induced cytopathicity,Confirmatory,19226140.0,
1627,393993,6,2,,103504490,3454,Active,,,0.66,EC50,Antiviral activity against wild type HCMV Davis infected in HEL cells assessed as inhibition of virus-induced cytopathicity,Confirmatory,19226140.0,
1628,400420,6,2,,103504490,3454,Unspecified,,,,,Antiviral activity against mCMV RM461 infected in human Hep2 cells assessed as virus-induced cytopathic effect after 3 days,Other,9599250.0,
1629,400422,6,2,,103504490,3454,Unspecified,,,,,Antiviral activity against VZV 3CV-1 infected in human Hep2 cells after 3 days by plaque neutralization assay,Other,9599250.0,
1630,400426,3,3,,103504490,3454,Unspecified,,,,,"Selectivity index, ratio of EC50 for mCMV RM461 by cytopathic effect over IC50 for human Hep2 cells",Other,9599250.0,
1631,400429,3,3,,103504490,3454,Unspecified,,,,,"Selectivity index, ratio of EC50 for VZV 3CV-1 by plaque neutralization over IC50 for human Hep2 cells",Other,9599250.0,
1632,400433,6,3,,103504490,3454,Unspecified,,,,,Cytotoxicity against mCMV RM-461 infected human Hep2 cells after 3 days,Other,9599250.0,
1633,400436,6,3,,103504490,3454,Unspecified,,,,,Cytotoxicity against VZV 3CV-1 infected human Hep2 cells after 3 days,Other,9599250.0,
1634,409958,3,9,,103504490,3454,Inactive,124028637.0,281293.0,,,Inhibition of bovine brain MAOA,Other,18834112.0,
1635,409960,3,9,,103504490,3454,Inactive,124028638.0,338445.0,,,Inhibition of bovine brain MAOB,Other,18834112.0,
1636,412416,6,2,,103504490,3454,Inconclusive,,,,IC50,Antiviral activity against acyclovir-sensitive HSV1 K161 isolate replication in african green monkey Vero cells by plaque reduction assay,Confirmatory,19010684.0,
1637,412417,6,2,,103504490,3454,Inconclusive,,,,IC50,Antiviral activity against acyclovir-resistant HSV1 K143 isolate replication in african green monkey Vero cells by plaque reduction assay,Confirmatory,19010684.0,
1638,412418,6,2,,103504490,3454,Inconclusive,,,,IC50,Antiviral activity against acyclovir-sensitive HSV1 L177 isolate replication in african green monkey Vero cells by plaque reduction assay,Confirmatory,19010684.0,
1639,412419,6,2,,103504490,3454,Inconclusive,,,,IC50,Antiviral activity against acyclovir-resistant HSV1 L182 isolate replication in african green monkey Vero cells by plaque reduction assay,Confirmatory,19010684.0,
1640,412420,6,2,,103504490,3454,Active,,,3.22,IC50,Antiviral activity against ganciclovir-sensitive HCMV1 isolate replication in HFF cells by plaque reduction assay,Confirmatory,19010684.0,
1641,412421,6,2,,103504490,3454,Active,,,16.4,IC50,Antiviral activity against ganciclovir-resistant HCMV3 isolate replication in HFF cells by plaque reduction assay,Confirmatory,19010684.0,
1642,412422,6,2,,103504490,3454,Inconclusive,,,,IC50,Antiviral activity against ganciclovir-resistant HCMV U405 isolate replication in HFF cells by plaque reduction assay,Confirmatory,19010684.0,
1643,416772,6,3,,103504490,3454,Unspecified,,,,,Cytotoxicity against human HEL cells assessed as drug level causing microscopically detectable alteration of normal cell morphology after 3 days,Other,19281225.0,
1644,416773,6,2,,103504490,3454,Active,,,0.02,EC50,Antiviral activity against HSV1 KOS in human HEL cells assessed as protection against virus-induced cytopathicity,Confirmatory,19281225.0,
1645,416774,6,2,,103504490,3454,Active,,,0.2,EC50,Antiviral activity against HSV2 G in human HEL cells assessed as protection against virus-induced cytopathicity,Confirmatory,19281225.0,
1646,416775,6,2,,103504490,3454,Unspecified,,,100.0,EC50,Antiviral activity against Vaccinia virus Lederle in human HEL cells assessed as protection against virus-induced cytopathicity,Confirmatory,19281225.0,
1647,416776,6,2,,103504490,3454,Unspecified,,,100.0,EC50,Antiviral activity against VSV in human HEL cells assessed as protection against virus-induced cytopathicity,Confirmatory,19281225.0,
1648,416777,6,2,,103504490,3454,Active,,,9.0,EC50,Antiviral activity against thymidine kinase deficient and acyclovir resistant HSV1 KOS in human HEL cells assessed as protection against virus-induced cytopathicity,Confirmatory,19281225.0,
1649,416786,6,3,,103504490,3454,Unspecified,,,100.0,CC50,Cytotoxicity against feline CRFK cells by MTS assay,Confirmatory,19281225.0,
1650,416787,6,2,,103504490,3454,Unspecified,,,100.0,EC50,Antiviral activity against Feline coronavirus in feline FRCK cells assessed as inhibition of virus-induced cytopathicity,Confirmatory,19281225.0,
1651,416788,6,2,,103504490,3454,Active,,,1.2,EC50,Antiviral activity against Feline herpesvirus in feline FRCK cells assessed as inhibition of virus-induced cytopathicity,Confirmatory,19281225.0,
1652,419591,7,3,,103504490,3454,Unspecified,,,,,Cytotoxicity against human HEL cells assessed as alteration in cell morphology,Other,18851889.0,
1653,419592,7,2,,103504490,3454,Unspecified,,,,,Antiviral activity against HSV1 KOS infected in human HEL cells assessed as reduction in virus-induced cytopathogenicity after 3 days,Other,18851889.0,
1654,419593,7,2,,103504490,3454,Unspecified,,,,,Antiviral activity against HSV2 G infected in human HEL cells assessed as reduction in virus-induced cytopathogenicity after 3 days,Other,18851889.0,
1655,419594,7,2,,103504490,3454,Unspecified,,,,,Antiviral activity against Vaccinia virus infected in human HEL cells assessed as reduction in virus-induced cytopathogenicity after 3 days,Other,18851889.0,
1656,419595,7,2,,103504490,3454,Unspecified,,,,,Antiviral activity against VSV infected in human HEL cells assessed as reduction in virus-induced cytopathogenicity after 3 days,Other,18851889.0,
1657,419596,7,2,,103504490,3454,Unspecified,,,,,Antiviral activity against thymidine kinase-deficient acyclovir-resistant HSV1 KOS infected in human HEL cells assessed as reduction in virus-induced cytopathogenicity after 3 days,Other,18851889.0,
1658,425652,7,2,,103504490,3454,Unspecified,,,,,Total body clearance in human,Other,19445515.0,
1659,425653,7,2,,103504490,3454,Unspecified,,,,,Renal clearance in human,Other,19445515.0,
1660,429196,6,2,,103504490,3454,Active,,,1.1,EC50,Antiviral activity against Varicella zoster virus YS infected in human HEL cells assessed as inhibition of virus induced cytopathicity after 5 days,Confirmatory,19339082.0,
1661,429197,6,2,,103504490,3454,Active,,,0.59,EC50,Antiviral activity against Varicella zoster virus OKA infected in human HEL cells assessed as inhibition of virus-induced cytopathicity after 5 days,Confirmatory,19339082.0,
1662,429198,6,2,,103504490,3454,Active,,,2.5,EC50,Antiviral activity against thymidine kinase deficient Varicella zoster virus 07/1 infected in human HEL cells assessed as inhibition of virus-induced cytopathicity after 5 days,Confirmatory,19339082.0,
1663,429199,6,2,,103504490,3454,Active,,,12.6,EC50,Antiviral activity against human cytomegalovirus AD169 infected in human HEL cells assessed as inhibition of virus-induced cytopathicity after 7 days post infection,Confirmatory,19339082.0,
1664,429200,6,2,,103504490,3454,Active,,,2.5,EC50,Antiviral activity against human cytomegalovirus Davis infected in human HEL cells assessed as inhibition of virus-induced cytopathicity after 7 days post infection,Confirmatory,19339082.0,
1665,429201,6,3,,103504490,3454,Unspecified,,,,,Cytotoxicity against human HEL cells assessed as microscopically detectable morphological alterations after 3 days,Other,19339082.0,
1666,429202,6,3,,103504490,3454,Unspecified,,,221.0,CC50,Cytotoxicity against human HEL cells assessed as reduction in cell growth after 3 days,Confirmatory,19339082.0,
1667,432169,7,3,,103504490,3454,Unspecified,,,,,Cytotoxicity against HEL cells assessed as minimum cytotoxic concentration required to cause microscopically detectable alteration in normal cell morphology,Other,19419804.0,
1668,432170,7,2,,103504490,3454,Unspecified,,,,,Antiviral activity against HSV2 G infected in human HEL cells assessed as inhibition of virus-induced cytopathicity after 3 days,Other,19419804.0,
1669,432171,7,2,,103504490,3454,Unspecified,,,,,Antiviral activity against Vaccinia virus infected in in human HEL cells assessed as inhibition of virus-induced cytopathicity after 3 days,Other,19419804.0,
1670,432172,7,2,,103504490,3454,Unspecified,,,,,Antiviral activity against Vesicular stomatitis virus infected in human HEL cells assessed as inhibition of virus-induced cytopathicity after 3 days,Other,19419804.0,
1671,432173,7,2,,103504490,3454,Unspecified,,,,,Antiviral activity against thymidine kinase-deficient ACV-resistant HSV1 KOS infected in human HEL cells assessed as inhibition of virus-induced cytopathicity after 3 days,Other,19419804.0,
1672,432176,7,2,,103504490,3454,Unspecified,,,,,Antiviral activity against HSV1 KOS infected in human HEL cells assessed as inhibition of virus-induced cytopathicity after 3 days,Other,19419804.0,
1673,434307,7,2,,103504490,3454,Unspecified,,,,,Antiviral activity against HSV1 KOS infected in HEL cells assessed as protection against virus-induced cytopathogenicity,Other,19324473.0,
1674,434308,7,2,,103504490,3454,Unspecified,,,,,Antiviral activity against Herpes simplex virus 2 infected in HEL cells assessed as protection against in virus-induced cytopathogenicity,Other,19324473.0,
1675,434309,7,2,,103504490,3454,Unspecified,,,,,Antiviral activity against Vaccinia virus infected in human HEL cells assessed as protection against virus-induced cytopathogenicity,Other,19324473.0,
1676,434310,7,2,,103504490,3454,Unspecified,,,,,Antiviral activity against sVesicular stomatitis virus infected in HEL cells assessed as protection against virus-induced cytopathogenicity,Other,19324473.0,
1677,434311,7,2,,103504490,3454,Unspecified,,,,,Antiviral activity against acyclovir-resistant thymidine kinase-deficient HSV1 KOS infected in human HEL cells assessed as protection against virus-induced cytopathogenicity,Other,19324473.0,
1678,434320,7,3,,103504490,3454,Unspecified,,,,,Cytotoxicity against HEL cells assessed as change in cell morphology,Other,19324473.0,
1679,434322,7,2,,103504490,3454,Unspecified,,,,,Antiviral activity against Cytomegalovirus AD169 infected in HEL cells assessed as reduction in virus plaque formation,Other,19324473.0,
1680,434323,7,2,,103504490,3454,Unspecified,,,,,Antiviral activity against Cytomegalovirus Davis infected in HEL cells assessed as reduction in virus plaque formation,Other,19324473.0,
1681,434324,7,2,,103504490,3454,Unspecified,,,,,Antiviral activity against Varicella Zoster Virus OKA infected in HEL cells assessed as reduction in virus plaque formation,Other,19324473.0,
1682,434325,7,2,,103504490,3454,Unspecified,,,,,Antiviral activity against thymidine kinase deficient Varicella Zoster Virus 07/1 infected in HEL cells assessed as reduction in virus plaque formation,Other,19324473.0,
1683,434326,7,3,,103504490,3454,Unspecified,,,,,Cytotoxicity against Cytomegalovirus infected HEL cells assessed as change in cell morphology,Other,19324473.0,
1684,434327,7,3,,103504490,3454,Unspecified,,,,,Cytotoxicity against Cytomegalovirus infected HEL cells assessed as reduction in cell growth,Other,19324473.0,
1685,434328,7,2,,103504490,3454,Unspecified,,,,,Cytotoxicity against Varicella Zoster Virus infected human HeLa cells assessed as change in cell morphology,Other,19324473.0,
1686,434329,7,2,,103504490,3454,Unspecified,,,,,Cytotoxicity against Varicella Zoster Virus infected human HeLa cells assessed as reduction in cell growth,Other,19324473.0,
1687,434955,1,2,,56424026,3454,Inactive,,,,IC90,Screen to Identify Novel Compounds That Sensitize Mycobacterium Tuberculosis to Beta-lactam Antibiotics,Confirmatory,,
1688,434962,1,2,,56424026,3454,Inactive,155969707.0,3416.0,,,Fluorescence polarization-based cell-based primary high throughput screening assay to identify inhibitors of insulin-degrading enzyme (IDE),Screening,,
1689,434973,1,3,,56424026,3454,Inactive,120538355.0,57337.0,,,uHTS Luminescent assay for identification of inhibitors of Sentrin-specific protease 7 (SENP7),Screening,,
1690,434989,1,1,,56424026,3454,Inactive,222080095.0,3061.0,,,Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the orexin 1 receptor (OX1R; HCRTR1),Screening,,
1691,435003,1,3,,56424026,3454,Inactive,,,,,uHTS luminescence assay for the identification of chemical inhibitors of T-cell specific antigen receptor-induced NF-kB activation,Screening,,
1692,435005,1,1,,56424026,3454,Inactive,,,,,Luminescence Cell-Based Primary HTS to Identify Inhibitors of Beta Cell Apoptosis.,Screening,,
1693,435022,2,2,,56424026,3454,Inactive,,,,,uHTS luminescence assay for the identification of chemical inhibitors of B-cell specific antigen receptor-induced NF-kB activation,Screening,,
1694,435030,1,2,,56424026,3454,Inactive,15645703.0,899625.0,,,Absorbance-based primary bacterial cell-based high throughput screening assay to identify inhibitors of AddAB recombination protein complex,Screening,,
1695,435030,1,2,,56424026,3454,Inactive,15646160.0,899738.0,,,Absorbance-based primary bacterial cell-based high throughput screening assay to identify inhibitors of AddAB recombination protein complex,Screening,,
1696,444050,7,1,,103504490,3454,Unspecified,,,,,Fraction unbound in human plasma,Other,20070106.0,
1697,444051,6,2,,103504490,3454,Unspecified,,,,,Total clearance in human,Other,20070106.0,
1698,444052,6,2,,103504490,3454,Unspecified,,,,,Hepatic clearance in human,Other,20070106.0,
1699,444053,6,2,,103504490,3454,Unspecified,,,,,Renal clearance in human,Other,20070106.0,
1700,444054,6,1,,103504490,3454,Unspecified,,,,,Oral bioavailability in human,Other,20070106.0,
1701,444055,3,3,,103504490,3454,Unspecified,,,,,Fraction absorbed in human,Other,20070106.0,
1702,444056,3,3,,103504490,3454,Unspecified,,,,,Fraction escaping gut-wall elimination in human,Other,20070106.0,
1703,444057,3,3,,103504490,3454,Unspecified,,,,,Fraction escaping hepatic elimination in human,Other,20070106.0,
1704,444058,6,2,,103504490,3454,Unspecified,,,,,Volume of distribution at steady state in human,Other,20070106.0,
1705,445445,7,1,,103504490,3454,Unspecified,,,,,Permeability at pH 6.5 by PAMPA method,Other,19947605.0,
1706,445446,3,4,,103504490,3454,Unspecified,,,,,Oral bioavailability in human,Other,19947605.0,
1707,449728,1,2,,56424026,3454,Inactive,,,,,Counterscreen for inhibitors of AddAB: absorbance-based bacterial cell-based high throughput screening assay to identify inhibitors of bacterial viability,Screening,,
1708,449739,1,2,,8139883,3454,Inactive,53832009.0,8912.0,,,Inhibitors of Cav3 T-type Calcium Channels: Primary Screen,Screening,,
1709,449762,1,2,,56424026,3454,Inactive,,,,IC50,High Throughput Screening Assay used to Identify Novel Compounds that Inhibit Mycobacterium Tuberculosis in 7H9 Media,Confirmatory,,
1710,449763,1,3,,56424026,3454,Inactive,,,,,uHTS identification of small molecule activators of the apoptotic arm of the Unfolded Protein response via a luminescent-based reporter assay,Screening,,
1711,449768,1,1,,8139883,3454,Inactive,7108463.0,6531.0,,,High Throughput Screening for Cocaine Antagonists: Primary Screen,Screening,,
1712,455986,3,5,,103504490,3454,Unspecified,,,,,Permeability across human Caco-2 cells,Other,19734051.0,
1713,463073,1,2,,8139883,3454,Inactive,216548487.0,23569.0,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of Protein Arginine Deiminase 4 (PAD4),Screening,,
1714,463075,1,1,,8139883,3454,Inactive,,,,,HTS to identify inhibitors of TNF-alpha Induced Cell Death in Jurkat FADD-/- Cells.,Screening,,
1715,463079,1,2,,56424026,3454,Inactive,,,,,Fluorescence-based counterscreen for orexin 1 receptor (OX1R) antagonists: cell-based assay to identify antagonists of the parental CHO cell line,Screening,,
1716,463082,1,1,,56424026,3454,Inactive,270133071.0,7941.0,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of the plasma platelet activating factor acetylhydrolase (pPAFAH),Screening,,
1717,463096,1,1,,50106328,3454,Inactive,,,,Potency,Validation screen for inhibitors of Lassa infection,Confirmatory,,
1718,463097,1,1,,50106328,3454,Inactive,7705682.0,51053.0,,Potency,Validation screen for small molecules that induce DNA re-replication in MCF 10A normal breast cells,Confirmatory,,
1719,463104,1,2,,56424026,3454,Inactive,,,,,uHTS identification of small molecule activators of the adaptive arm of the Unfolded Protein response via a luminescent-based reporter assay,Screening,,
1720,463106,1,2,,90341439,3454,Inactive,188528692.0,9099.0,,Potency,qHTS Validation Assay for Inhibitors of Ubiquitin-specific Protease USP2a Using CHOP2 as the Reporter,Confirmatory,,
1721,463111,1,1,,8139883,3454,Inactive,5032039.0,5999.0,,,Primary cell-based high-throughput screening assay for identification of compounds that potentiate/activate regulator of G-protein signaling 4 (RGS4),Screening,,
1722,463115,1,1,,8139883,3454,Inactive,119622516.0,5045.0,,,High throughput fluorescence intensity-based biochemical assay to screen for small molecule inhibitors of Furin conducted by the Pittsburgh Molecular Library Screening Center.,Screening,,
1723,463141,1,2,,56424026,3454,Inactive,14790119.0,836.0,,,Absorbance-based primary biochemical high throughput screening assay to identify activators of procaspase-3,Screening,,
1724,463165,1,1,,8139883,3454,Inactive,5032039.0,5999.0,,,Primary cell-based high-throughput screening assay for identification of compounds that inhibit regulator of   G-protein signaling 4 (RGS4),Screening,,
1725,463187,1,1,,8139883,3454,Inactive,,,,,384-well Z-Lyte format Hck-Nef inhibitor HTS run at the PMLSC,Screening,,
1726,463189,1,1,,53777645,3454,Inactive,,,,,96-well format Chlamydomonas reinhardtii Algae Gravitaxis Assay to measure the difference in the absorbance between the small compact plug of WT swimming algae versus the MUT algae lacking cilia.,Screening,,
1727,463190,1,2,,56424026,3454,Inactive,285809906.0,856395.0,,,uHTS identification of small molecule inhibitors of tim10-1 yeast via a luminescent assay,Screening,,
1728,463193,1,1,,8139883,3454,Inactive,31563518.0,84557.0,,,High-content cell-based screening for modulators of autophagy,Screening,,
1729,463195,1,2,,56424026,3454,Inactive,285809906.0,856395.0,,,uHTS identification of small molecule inhibitors of tim10 yeast via a luminescent assay,Screening,,
1730,463210,1,2,,56424026,3454,Inactive,55960760.0,,,,Counterscreen for procaspase-3 activators: absorbance-based primary biochemical high throughput screening assay to identify activators of procaspase-7,Screening,,
1731,463212,1,1,,56424026,3454,Inactive,285814664.0,855751.0,,,uHTS identification of small molecule inhibitors of tim23-1 yeast via a luminescent assay,Screening,,
1732,463254,1,1,,8139883,3454,Inactive,188528692.0,9099.0,,Potency,qHTS Assay for Inhibitors of Ubiquitin-specific Protease USP2a Using CHOP2 as the Reporter,Confirmatory,,
1733,463989,5,2,,103504490,3454,Active,,,0.03,EC50,Antiviral activity against Herpes simplex virus 1 KOS infected in HEL cells assessed as protection from virus-induced cytopathogenicity after 2 to 3 days by MTT assay,Confirmatory,20034711.0,
1734,463990,5,2,,103504490,3454,Active,,,0.03,EC50,Antiviral activity against Herpes simplex virus 2 G infected in HEL cells assessed as protection from virus-induced cytopathogenicity after 2 to 3 days by MTT assay,Confirmatory,20034711.0,
1735,463991,5,2,,103504490,3454,Unspecified,,,100.0,EC50,Antiviral activity against Vaccinia virus infected in HEL cells assessed as protection from virus-induced cytopathogenicity after 2 to 3 days by MTT assay,Confirmatory,20034711.0,
1736,463992,5,2,,103504490,3454,Unspecified,,,100.0,EC50,Antiviral activity against VSV infected in HEL cells assessed as protection from virus-induced cytopathogenicity after 1 to 2 days by MTT assay,Confirmatory,20034711.0,
1737,463993,5,2,,103504490,3454,Active,,,0.03,EC50,Antiviral activity against acyclovir-sensitive Herpes simplex virus 1 KOS infected in HEL cells assessed as protection from virus-induced cytopathogenicity after 2 to 3 days by MTT assay,Confirmatory,20034711.0,
1738,463998,5,2,,103504490,3454,Unspecified,,,100.0,EC50,Antiviral activity against Feline coronavirus infected in cat CRFK cells assessed as protection from virus-induced cytopathogenicity by MTT assay,Confirmatory,20034711.0,
1739,463999,5,2,,103504490,3454,Active,,,2.6,EC50,Antiviral activity against Feline herpesvirus infected in cat CRFK cells assessed as protection from virus-induced cytopathogenicity by MTT assay,Confirmatory,20034711.0,
1740,464097,3,4,,103504490,3454,Active,,,1.3,IC50,Antiviral activity against Human cytomegalovirus infected in HFF cells by plaque reduction assay,Confirmatory,20167488.0,
1741,464178,5,3,,103504490,3454,Unspecified,,,100.0,CC50,Cytotoxicity against Herpes simplex virus 1 KOS infected HEL cells by trypan blue exclusion method,Confirmatory,20034711.0,
1742,464179,5,3,,103504490,3454,Unspecified,,,100.0,CC50,Cytotoxicity against Herpes simplex virus 2 G infected HEL cells by trypan blue exclusion method,Confirmatory,20034711.0,
1743,464180,5,3,,103504490,3454,Unspecified,,,100.0,CC50,Cytotoxicity against Vaccinia virus infected HEL cells by trypan blue exclusion method,Confirmatory,20034711.0,
1744,464181,5,3,,103504490,3454,Unspecified,,,100.0,CC50,Cytotoxicity against VSV infected HEL cells by trypan blue exclusion method,Confirmatory,20034711.0,
1745,464182,5,3,,103504490,3454,Unspecified,,,100.0,CC50,Cytotoxicity against acyclovir-sensitive Herpes simplex virus 1 KOS infected HEL cells by trypan blue exclusion method,Confirmatory,20034711.0,
1746,464188,5,3,,103504490,3454,Unspecified,,,100.0,CC50,Cytotoxicity against Feline coronavirus infected cat CRFK cells by trypan blue exclusion method,Confirmatory,20034711.0,
1747,464189,5,3,,103504490,3454,Unspecified,,,100.0,CC50,Cytotoxicity against Feline herpesvirus infected cat CRFK cells by trypan blue exclusion method,Confirmatory,20034711.0,
1748,481581,5,2,,103504490,3454,Active,,,1.3,IC50,Inhibition of HCMV DNA polymerase infected in HFF cells,Confirmatory,20403696.0,
1749,481585,5,2,,103504490,3454,Inconclusive,,,,IC50,Antiviral activity against HSV1 KOS infected in african green monkey Vero cells assessed as reduction in plaque formation,Confirmatory,20403696.0,
1750,481587,5,2,,103504490,3454,Inconclusive,,,,IC50,Antiviral activity against VZV Webster infected in HFF cells assessed as reduction in plaque formation,Confirmatory,20403696.0,
1751,481810,5,2,,103504490,3454,Unspecified,,,100.0,CC50,Cytotoxicity against HFF cells after 3 days by neutral red dye uptake assay,Confirmatory,20403696.0,
1752,485270,1,1,,56424026,3454,Inactive,222080095.0,3061.0,,,FRET-based cell-based primary high throughput screening assay to identify antagonists of the orexin 1 receptor (OX1R; HCRTR1),Screening,,
1753,485272,1,1,,56424026,3454,Inactive,216548487.0,23569.0,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of Protein Arginine Deiminase 4 (PAD4) (1536 HTS),Screening,,
1754,485273,2,1,,56424026,3454,Inactive,4507793.0,7334.0,,,uHTS identification of UBC13 Polyubiquitin Inhibitors via a TR-FRET Assay,Screening,,
1755,485275,1,3,,56424026,3454,Inactive,,,,,Phenotypic HTS multiplex for antifungal efflux pump inhibitors,Screening,,
1756,485281,1,1,,8139883,3454,Inactive,254220970.0,,,Potency,qHTS Assay for Identification of Novel General Anesthetics,Confirmatory,,
1757,485281,1,1,,11111225,3454,Inactive,254220970.0,,,Potency,qHTS Assay for Identification of Novel General Anesthetics,Confirmatory,,
1758,485290,1,1,,8139883,3454,Inactive,20150581.0,,,Potency,qHTS Assay for Inhibitors of Tyrosyl-DNA Phosphodiesterase (TDP1),Confirmatory,,
1759,485290,1,1,,11111225,3454,Inactive,20150581.0,,,Potency,qHTS Assay for Inhibitors of Tyrosyl-DNA Phosphodiesterase (TDP1),Confirmatory,,
1760,485290,1,1,,50106328,3454,Inactive,20150581.0,,,Potency,qHTS Assay for Inhibitors of Tyrosyl-DNA Phosphodiesterase (TDP1),Confirmatory,,
1761,485290,1,1,,50113251,3454,Inactive,20150581.0,,,Potency,qHTS Assay for Inhibitors of Tyrosyl-DNA Phosphodiesterase (TDP1),Confirmatory,,
1762,485294,1,1,,8139883,3454,Inactive,119389684.0,,,Potency,qHTS Inhibitors of AmpC Beta-Lactamase (assay with detergent),Confirmatory,,
1763,485295,1,2,,90341439,3454,Inactive,30027657.0,,,Potency,qHTS Validation Assay for the Inhibitors of DNA Replication in Gram-Positive Bacteria,Confirmatory,,
1764,485297,1,1,,8139883,3454,Inactive,4759012.0,9367.0,,Potency,qHTS Assay for Rab9 Promoter Activators,Confirmatory,,
1765,485297,1,1,,90341439,3454,Inactive,4759012.0,9367.0,,Potency,qHTS Assay for Rab9 Promoter Activators,Confirmatory,,
1766,485298,1,1,,8139883,3454,Inactive,,,,Potency,qHTS Assay for Small Molecule Inhibitors of Mitochondrial Division or Activators of Mitochondrial Fusion,Confirmatory,,
1767,485298,1,1,,90341439,3454,Inactive,,,,Potency,qHTS Assay for Small Molecule Inhibitors of Mitochondrial Division or Activators of Mitochondrial Fusion,Confirmatory,,
1768,485313,1,2,,8139883,3454,Inactive,255652944.0,4864.0,,Potency,qHTS Assay for NPC1 Promoter Activators,Confirmatory,,
1769,485313,1,2,,90341439,3454,Inactive,255652944.0,4864.0,,Potency,qHTS Assay for NPC1 Promoter Activators,Confirmatory,,
1770,485314,1,1,,8139883,3454,Inactive,4505931.0,5423.0,,Potency,qHTS Assay for Inhibitors of DNA Polymerase Beta,Confirmatory,,
1771,485314,1,1,,50106328,3454,Inactive,4505931.0,5423.0,,Potency,qHTS Assay for Inhibitors of DNA Polymerase Beta,Confirmatory,,
1772,485317,1,2,,56424026,3454,Inactive,54112432.0,2671.0,,,HTS-Luminescent assay for inhibitors of ALR by detection of hydrogen peroxide production Measured in Biochemical System Using Plate Reader - 2036-02_Inhibitor_SinglePoint_HTS,Screening,,
1773,485341,1,1,,8139883,3454,Inactive,119389684.0,,,Potency,qHTS Inhibitors of AmpC Beta-Lactamase (assay without detergent),Confirmatory,,
1774,485342,1,2,,90341439,3454,Inactive,5454140.0,7251.0,,Potency,qHTS Validation Assay for Iinhibitors of HIV-1 Budding by Blocking the Interaction of PTAP/TSG101,Confirmatory,,
1775,485344,1,1,,8139883,3454,Inactive,4503385.0,1813.0,,,HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists,Screening,,
1776,485345,1,2,,90341439,3454,Inactive,,,,Potency,qHTS Validation Assay to Find Inhibitors of Chronic Active B-Cell Receptor Signaling,Confirmatory,,
1777,485346,1,1,,56424026,3454,Inactive,88702791.0,4194.0,,,uHTS for identification of Inhibitors of Mdm2/MdmX interaction in luminescent format.,Screening,,
1778,485346,1,1,,56424026,3454,Inactive,89993689.0,4193.0,,,uHTS for identification of Inhibitors of Mdm2/MdmX interaction in luminescent format.,Screening,,
1779,485347,1,2,,8139883,3454,Inactive,4503385.0,1813.0,,,HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators,Screening,,
1780,485349,1,1,,8139883,3454,Inactive,71902540.0,472.0,,Potency,qHTS Assay for Identifying a Potential Treatment of Ataxia-Telangiectasia,Confirmatory,,
1781,485350,1,2,,92125763,3454,Inactive,126642418.0,,,,A screen for compounds that inhibit the bacterial siderophore biosynthetic enzyme BasE,Screening,,
1782,485353,2,1,,8139883,3454,Inactive,30124074.0,1489680.0,,,qHTS of Yeast-based Assay for SARS-CoV PLP,Confirmatory,,
1783,485358,1,1,,8139883,3454,Inactive,4503385.0,1813.0,,,HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists,Screening,,
1784,485360,1,1,,8139883,3454,Inactive,117938328.0,26013.0,,Potency,qHTS Assay for the Inhibitors of L3MBTL1,Confirmatory,,
1785,485364,1,1,,8139883,3454,Inactive,15149312.0,8345881.0,,Potency,qHTS Assay for the Inhibitors of Schistosoma Mansoni Peroxiredoxins,Confirmatory,,
1786,485366,1,2,,90341439,3454,Inactive,4501969.0,154.0,,Potency,qHTS validation assay of beta-arrestin-biased ligands of beta2-adrenergic receptor,Confirmatory,,
1787,485367,1,2,,8139883,3454,Inactive,72386991.0,3656265.0,,Potency,qHTS Assay to Find Inhibitors of T. brucei phosphofructokinase,Confirmatory,,
1788,485368,1,2,,90341439,3454,Inactive,72386991.0,3656265.0,,Potency,qHTS Validation Assay to Find Inhibitors of T. brucei phosphofructokinase,Confirmatory,,
1789,488745,1,4,,85231063,3454,Inactive,,,,Potency,"Quantitative high throughput screen for delayed death inhibitors of the malarial parasite plastid, 96 hour incubation",Confirmatory,,
1790,488752,1,4,,85231063,3454,Inactive,,,,Potency,"Quantitative high throughput screen for delayed death inhibitors of the malarial parasite plastid, 48 hour incubation",Confirmatory,,
1791,488772,1,1,,90341439,3454,Inactive,8659577.0,58819.0,,Potency,qHTS Assay for Substrates of Mammalian Selenoprotein Thioredoxin Reductase 1 (TrxR1),Confirmatory,,
1792,488773,1,2,,90341439,3454,Inactive,8659577.0,58819.0,,Potency,qHTS Assay for Inhibitors of Mammalian Selenoprotein Thioredoxin Reductase 1 (TrxR1),Confirmatory,,
1793,488788,1,1,,8139883,3454,Inactive,6323930.0,855317.0,,AC50_uM,Ras-converting Enzyme/Cell Proliferation Pathway Measured in Biochemical System Using Plate Reader - 2034-01_Inhibitor_Dose_CherryPick,Confirmatory,,
1794,488789,1,1,,8139883,3454,Inactive,136429.0,,,AC50_uM,Trypsin Inhibition Assay Measured in Biochemical System Using Plate Reader - 2034-02_Inhibitor_Dose_CherryPick_Activity,Confirmatory,,
1795,488806,1,2,,8139883,3454,Inactive,148539876.0,156.0,,,RNA aptamer-based validation for inhibitors of GRK2,Screening,,
1796,488815,1,1,,8139883,3454,Inconclusive,1015837.0,,,AC50_uM,Ste24 Inhibition Assay Measured in Biochemical System Using Plate Reader - 2034-03_Inhibitor_Dose_CherryPick_Activity,Confirmatory,,
1797,488816,1,1,,90341439,3454,Inactive,4758356.0,2237.0,,Potency,qHTS Validation Assay for the Inhibitors of Human Flap endonuclease 1 (FEN1),Confirmatory,,
1798,488837,1,1,,8139883,3454,Inactive,26667227.0,2139.0,,Potency,qHTS Assay for Inhibitors of the Phosphatase Activity of Eya2,Confirmatory,,
1799,488837,1,1,,90341439,3454,Inactive,26667227.0,2139.0,,Potency,qHTS Assay for Inhibitors of the Phosphatase Activity of Eya2,Confirmatory,,
1800,488839,1,1,,56424026,3454,Inactive,20072248.0,8851.0,,,Development of CDK5 inhibitors   Measured in Biochemical System Using Plate Reader - 2083-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1801,488839,1,1,,56424026,3454,Inactive,48146199.0,1020.0,,,Development of CDK5 inhibitors   Measured in Biochemical System Using Plate Reader - 2083-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1802,488847,1,3,,56424026,3454,Inactive,148539876.0,156.0,,,RNA aptamer-based HTS for inhibitors of GRK2,Screening,,
1803,488862,1,1,,56424026,3454,Inactive,,,,,Inhibitors of Prion Protein 5' UTR mRNA Measured in Cell-Based System Using Plate Reader - 2078-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1804,488890,1,2,,56424026,3454,Inactive,,,,IC50,"Elucidation of physiology of non-replicating, drug-tolerant Mycobacterium tuberculosis",Confirmatory,,
1805,488895,1,2,,56424026,3454,Inactive,90111653.0,948321.0,,,High Throughput Screen for Tat Transport Inhibitors Measured in Microorganism System Using Plate Reader - 2093-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1806,488896,1,1,,56424026,3454,Inactive,14389423.0,20778.0,,,HTS using DiI-HDL to assay lipid transfer in ldlA[SR-BI] cells Measured in Cell-Based System Using Plate Reader - 2085-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1807,488899,1,1,,56424026,3454,Inactive,40807040.0,4286.0,,,MITF Measured in Cell-Based System Using Plate Reader - 2084-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1808,488922,1,2,,8139883,3454,Inactive,7706135.0,,,,Primary cell-based screen for identification of compounds that inhibit the two-pore domain potassium channel KCNK9,Screening,,
1809,488949,1,2,,85231063,3454,Inactive,41055989.0,54737.0,,Potency,qHTS Validation Assay for Inhibitors for MPP8 Chromodomain Interactions with Methylated Histone Tails,Confirmatory,,
1810,488949,1,2,,90341439,3454,Inactive,41055989.0,54737.0,,Potency,qHTS Validation Assay for Inhibitors for MPP8 Chromodomain Interactions with Methylated Histone Tails,Confirmatory,,
1811,488953,1,1,,90341439,3454,Inactive,187960037.0,10951.0,,Potency,qHTS Validation Assay for Inhibitors of HP1-beta Chromodomain Interactions with Methylated Histone Tails,Confirmatory,,
1812,488965,1,2,,56424026,3454,Inactive,218891639.0,,,,Fluorescent Biochemical Primary HTS to Identify Inhibitors of P. aeruginosa PvdQ acylase Measured in Biochemical System Using Plate Reader and Imaging Combination - 2091-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1813,488966,1,1,,56424026,3454,Inactive,,,,IC50,Primary and Confirmatory Screening for Inhibitors of Bacterial Capsule Biogenesis,Confirmatory,,
1814,488975,1,2,,56424026,3454,Inactive,11141885.0,60482.0,,,Primary cell-based screen for identification of compounds that inhibit the Choline Transporter (CHT),Screening,,
1815,488977,1,2,,56424026,3454,Inactive,11141885.0,60482.0,,,Primary cell-based screen for identification of compounds that allosterically activate the Choline Transporter (CHT),Screening,,
1816,488978,1,1,,90341439,3454,Inactive,45359078.0,,,Potency,High-Throughput Screening for Modulators of Cytosolic Chaperonin Activity: MmCpn Primary Screen,Confirmatory,,
1817,488979,1,1,,50106328,3454,Inactive,74315350.0,7442.0,,Potency,HTS Assay for Compounds that Act as Enhancers of the Vanilloid Receptor 1,Confirmatory,,
1818,488980,1,1,,85231063,3454,Inactive,38016895.0,7253.0,,Potency,qHTS Assay for Antagonists of the Thyroid Stimulating Hormone Receptor,Confirmatory,,
1819,488981,1,1,,90341439,3454,Inactive,4503383.0,1812.0,,Potency,HTS Assay for Allosteric Agonists of the Human D1 Dopamine Receptor: Primary Screen for Agonists,Confirmatory,,
1820,488982,1,1,,90341439,3454,Inactive,4503383.0,1812.0,,Potency,HTS Assay for Allosteric Agonists of the Human D1 Dopamine Receptor: Primary Screen for Potentiators,Confirmatory,,
1821,488983,1,1,,90341439,3454,Inactive,4503383.0,1812.0,,Potency,HTS Assay for Allosteric Agonists of the Human D1 Dopamine Receptor: Primary Screen for Antagonists,Confirmatory,,
1822,489030,2,1,,56424026,3454,Inactive,187952397.0,317.0,,,uHTS Fluorescent assay for identification of inhibitors of Apaf-1,Screening,,
1823,489031,2,1,,56424026,3454,Inactive,187952397.0,317.0,,,uHTS Fluorescent assay for identification of activators of Apaf-1,Screening,,
1824,491531,6,5,,103504490,3454,Active,614115254.0,887542.0,15.8489,Kd,Binding affinity to Mycobacterium tuberculosis purine nucleoside phosphorylase by spectrophotometric analysis,Confirmatory,20570524.0,
1825,492947,1,1,,8139883,3454,Inactive,4501969.0,154.0,,Potency,qHTS assay of beta-arrestin-biased ligands of beta2-adrenergic receptor,Confirmatory,,
1826,492953,1,1,,56424026,3454,Inactive,296080766.0,5049.0,,,"Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of human platelet-activating factor acetylhydrolase 1b, catalytic subunit 2 (PAFAH1B2)",Screening,,
1827,492956,1,1,,56424026,3454,Inactive,4758878.0,5051.0,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of human platelet activating factor acetylhydrolase 2 (PAFAH2),Screening,,
1828,492961,1,1,,11111225,3454,Inactive,72386991.0,3656265.0,,Potency,qHTS Assay to Find Inhibitors of T. brucei phosphofructokinase: hit validation,Confirmatory,,
1829,492967,1,2,,92125763,3454,Inactive,47566732.0,,,,A screen for compounds that inhibit the CapD enzyme of Bacillus anthracis,Other,,
1830,492972,1,1,,56424026,3454,Inactive,225543099.0,5050.0,,,"Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of human platelet-activating factor acetylhydrolase 1B, catalytic subunit 3 (PAFAH1B3)",Screening,,
1831,493005,1,1,,56424026,3454,Inactive,5454140.0,7251.0,,Potency,qHTS Assay for Iinhibitors of HIV-1 Budding by Blocking the Interaction of PTAP/TSG101,Confirmatory,,
1832,493008,1,1,,56424026,3454,Inactive,1927.0,100037999.0,,,Fluorescence-based biochemical primary high throughput screening assay to identify activators of the calcium sensitivity of cardiac Regulated Thin Filaments (RTF),Screening,,
1833,493008,1,1,,56424026,3454,Inactive,4507615.0,7134.0,,,Fluorescence-based biochemical primary high throughput screening assay to identify activators of the calcium sensitivity of cardiac Regulated Thin Filaments (RTF),Screening,,
1834,493008,1,1,,56424026,3454,Inactive,48255881.0,7139.0,,,Fluorescence-based biochemical primary high throughput screening assay to identify activators of the calcium sensitivity of cardiac Regulated Thin Filaments (RTF),Screening,,
1835,493008,1,1,,56424026,3454,Inactive,151101270.0,7137.0,,,Fluorescence-based biochemical primary high throughput screening assay to identify activators of the calcium sensitivity of cardiac Regulated Thin Filaments (RTF),Screening,,
1836,493011,1,1,,56424026,3454,Inactive,21955158.0,200315.0,,,uHTS identification of APOBEC3A DNA Deaminase Inhibitors via a fluorescence-based single-stranded DNA deaminase assay,Screening,,
1837,493012,1,1,,56424026,3454,Inactive,13399304.0,60489.0,,,uHTS identification of APOBEC3G DNA Deaminase Inhibitors via a fluorescence-based single-stranded DNA deaminase assay,Screening,,
1838,493014,1,1,,8139883,3454,Inactive,,,,Potency,qHTS Assay to Find Inhibitors of Chronic Active B-Cell Receptor Signaling,Confirmatory,,
1839,493027,1,2,,56424026,3454,Inactive,31542303.0,51099.0,,,"Luminescence-based biochemical high throughput validation assay to identify inhibitors of the interaction of the lipase co-activator protein, abhydrolase domain containing 5 (ABHD5) with perilipin-1 (PLIN1)",Screening,,
1840,493027,1,2,,56424026,3454,Inactive,223718203.0,5346.0,,,"Luminescence-based biochemical high throughput validation assay to identify inhibitors of the interaction of the lipase co-activator protein, abhydrolase domain containing 5 (ABHD5) with perilipin-1 (PLIN1)",Screening,,
1841,493033,1,2,,92125763,3454,Inactive,614089026.0,,,,A screen for compounds that inhibit the bacterial siderophore biosynthetic enzyme MbtI,Other,,
1842,493035,1,2,,56424026,3454,Inactive,31542303.0,51099.0,,,"Luminescence-based biochemical high throughput validation assay to identify inhibitors of the interaction of the lipase co-activator protein, abhydrolase domain containing 5 (ABHD5) with perilipin-5 (MLDP; PLIN5)",Screening,,
1843,493035,1,2,,56424026,3454,Inactive,116292172.0,440503.0,,,"Luminescence-based biochemical high throughput validation assay to identify inhibitors of the interaction of the lipase co-activator protein, abhydrolase domain containing 5 (ABHD5) with perilipin-5 (MLDP; PLIN5)",Screening,,
1844,493036,1,2,,56424026,3454,Inactive,110611243.0,4923.0,,,Image-Based HTS for Selective Agonists for NTR1,Screening,,
1845,493056,1,1,,8139883,3454,Inactive,4507681.0,7201.0,,,qHTS for Small Molecule Agonists and Allosteric Enhancers of Human TRH Receptor: Primary Screen for Enhancers,Screening,,
1846,493084,1,1,,8139883,3454,Inactive,4507681.0,7201.0,,,qHTS for Small Molecule Agonists and Allosteric Enhancers of Human TRH Receptor: Primary Screen for Agonists.,Screening,,
1847,493087,1,1,,56424026,3454,Inactive,155969707.0,3416.0,,,Fluorescence polarization-based cell-based primary high throughput screening assay to identify activators of insulin-degrading enzyme (IDE),Screening,,
1848,493091,1,1,,56424026,3454,Inactive,10864009.0,58190.0,,,uHTS Colorimetric assay for identification of inhibitors of Scp-1,Screening,,
1849,493098,1,1,,56424026,3454,Inactive,37187860.0,1235.0,,,uHTS identification of small molecule antagonists of the CCR6 receptor via a luminescent beta-arrestin assay,Screening,,
1850,493106,1,1,,90341439,3454,Inactive,116283940.0,79915.0,,Potency,Validation screen for small molecules that induce genotoxicity in human embryonic kidney (HEK293T) cells expressing luciferase-tagged ELG1,Confirmatory,,
1851,493107,1,1,,90341439,3454,Inactive,116283940.0,79915.0,,Potency,Validation screen for small molecules that inhibit ELG1-dependent DNA repair in human embryonic kidney (HEK293T) cells expressing luciferase-tagged ELG1,Confirmatory,,
1852,493127,1,1,,50106328,3454,Inactive,4507681.0,7201.0,,,qHTS for Small Molecule Agonists and Allosteric Enhancers of Human TRH Receptor: Validation Screen for Agonists,Screening,,
1853,493131,1,1,,56424026,3454,Inactive,6679827.0,14282.0,,,Activator for delta FosB/delta FosB homodimer Measured in Biochemical System Using Plate Reader - 2072-01_Activator_SinglePoint_HTS_Activity,Screening,,
1854,493140,1,1,,103914446,3454,Inactive,,,,,Screening small molecules to find regulators of human embryonic stem cell survival.,Screening,,
1855,493153,1,1,,90341439,3454,Inactive,,4780.0,,Potency,Nrf2 qHTS screen for inhibitors: Validation,Confirmatory,,
1856,493153,1,1,,90341439,3454,Inactive,224028257.0,4780.0,,Potency,Nrf2 qHTS screen for inhibitors: Validation,Confirmatory,,
1857,493160,1,1,,56424026,3454,Inactive,156151420.0,80201.0,,,uHTS Fluorescent assay for identification of inhibitors of hexokinase domain containing  I (HKDC1),Screening,,
1858,493164,1,2,,90341439,3454,Inactive,6679377.0,18792.0,,Potency,qHTS for Inhibitors of Cell Surface uPA Generation: Validation Assay,Confirmatory,,
1859,493164,1,2,,90341439,3454,Inactive,7242179.0,18793.0,,Potency,qHTS for Inhibitors of Cell Surface uPA Generation: Validation Assay,Confirmatory,,
1860,493164,1,2,,90341439,3454,Inactive,257471003.0,18815.0,,Potency,qHTS for Inhibitors of Cell Surface uPA Generation: Validation Assay,Confirmatory,,
1861,493187,1,2,,56424026,3454,Inactive,156151420.0,80201.0,,,uHTS Fluorescent assay for identification of activators of hexokinase domain containing  I (HKDC1),Screening,,
1862,493189,1,1,,50106328,3454,Inactive,4503895.0,2584.0,,Potency,qHTS Validation Assay for Inhibitors of Human Galactokinase (GALK),Confirmatory,,
1863,493244,1,1,,56424026,3454,Inactive,1927.0,100037999.0,,,Fluorescence-based biochemical primary high throughput screening assay to identify inhibitors of the calcium sensitivity of cardiac Regulated Thin Filaments (RTF),Screening,,
1864,493244,1,1,,56424026,3454,Inactive,4507615.0,7134.0,,,Fluorescence-based biochemical primary high throughput screening assay to identify inhibitors of the calcium sensitivity of cardiac Regulated Thin Filaments (RTF),Screening,,
1865,493244,1,1,,56424026,3454,Inactive,48255881.0,7139.0,,,Fluorescence-based biochemical primary high throughput screening assay to identify inhibitors of the calcium sensitivity of cardiac Regulated Thin Filaments (RTF),Screening,,
1866,493244,1,1,,56424026,3454,Inactive,151101270.0,7137.0,,,Fluorescence-based biochemical primary high throughput screening assay to identify inhibitors of the calcium sensitivity of cardiac Regulated Thin Filaments (RTF),Screening,,
1867,498407,4,4,,103504490,3454,Active,,,19.3,EC50,Antiviral activity against Macacine herpesvirus 1 isolate E2490 infected in african green monkey Vero cells by plaque reduction assay,Confirmatory,19858259.0,
1868,498408,4,4,,103504490,3454,Active,,,19.3,EC50,Antiviral activity against Macacine herpesvirus 1 isolate MR3 infected in african green monkey Vero cells by plaque reduction assay,Confirmatory,19858259.0,
1869,498409,4,4,,103504490,3454,Active,,,19.3,EC50,Antiviral activity against Macacine herpesvirus 1 isolate MR4 infected in african green monkey Vero cells by plaque reduction assay,Confirmatory,19858259.0,
1870,498588,4,4,,103504490,3454,Active,,,19.3,EC50,Antiviral activity against Macacine herpesvirus 1 isolate MR5 infected in african green monkey Vero cells by plaque reduction assay,Confirmatory,19858259.0,
1871,498589,4,4,,103504490,3454,Active,,,19.3,EC50,Antiviral activity against Macacine herpesvirus 1 isolate MR6 infected in african green monkey Vero cells by plaque reduction assay,Confirmatory,19858259.0,
1872,498590,4,4,,103504490,3454,Active,,,19.3,EC50,Antiviral activity against Macacine herpesvirus 1 isolate MR7 infected in african green monkey Vero cells by plaque reduction assay,Confirmatory,19858259.0,
1873,498591,4,4,,103504490,3454,Active,,,19.3,EC50,Antiviral activity against Macacine herpesvirus 1 isolate MR8 infected in african green monkey Vero cells by plaque reduction assay,Confirmatory,19858259.0,
1874,498592,4,4,,103504490,3454,Active,,,19.3,EC50,Antiviral activity against Macacine herpesvirus 1 isolate MR9 infected in african green monkey Vero cells by plaque reduction assay,Confirmatory,19858259.0,
1875,498593,4,4,,103504490,3454,Active,,,19.3,EC50,Antiviral activity against Macacine herpesvirus 1 isolate MR10 infected in african green monkey Vero cells by plaque reduction assay,Confirmatory,19858259.0,
1876,498594,4,4,,103504490,3454,Active,,,19.3,EC50,Antiviral activity against Macacine herpesvirus 1 isolate MR11 infected in african green monkey Vero cells by plaque reduction assay,Confirmatory,19858259.0,
1877,498595,4,4,,103504490,3454,Active,,,19.3,EC50,Antiviral activity against Macacine herpesvirus 1 isolate MR1 infected in african green monkey Vero cells by plaque reduction assay,Confirmatory,19858259.0,
1878,498596,4,4,,103504490,3454,Active,,,19.3,EC50,Antiviral activity against Macacine herpesvirus 1 isolate MR2 infected in african green monkey Vero cells by plaque reduction assay,Confirmatory,19858259.0,
1879,498597,4,4,,103504490,3454,Active,,,19.3,EC50,Antiviral activity against Macacine herpesvirus 1 isolate A1 infected in african green monkey Vero cells by plaque reduction assay,Confirmatory,19858259.0,
1880,498598,4,4,,103504490,3454,Active,,,19.3,EC50,Antiviral activity against Macacine herpesvirus 1 isolate A2 infected in african green monkey Vero cells by plaque reduction assay,Confirmatory,19858259.0,
1881,498599,4,4,,103504490,3454,Active,,,19.3,EC50,Antiviral activity against Macacine herpesvirus 1 isolate A3 infected in african green monkey Vero cells by plaque reduction assay,Confirmatory,19858259.0,
1882,498600,4,4,,103504490,3454,Active,,,19.3,EC50,Antiviral activity against Macacine herpesvirus 1 isolate A4 infected in african green monkey Vero cells by plaque reduction assay,Confirmatory,19858259.0,
1883,498601,4,4,,103504490,3454,Active,,,19.3,EC50,Antiviral activity against Macacine herpesvirus 1 isolate A5 infected in african green monkey Vero cells by plaque reduction assay,Confirmatory,19858259.0,
1884,498602,4,4,,103504490,3454,Active,,,19.3,EC50,Antiviral activity against Macacine herpesvirus 1 isolate A6 infected in african green monkey Vero cells by plaque reduction assay,Confirmatory,19858259.0,
1885,498603,4,4,,103504490,3454,Active,,,19.3,EC50,Antiviral activity against Macacine herpesvirus 1 isolate MC1 infected in african green monkey Vero cells by plaque reduction assay,Confirmatory,19858259.0,
1886,498604,4,4,,103504490,3454,Active,,,19.3,EC50,Antiviral activity against Macacine herpesvirus 1 isolate MC2 infected in african green monkey Vero cells by plaque reduction assay,Confirmatory,19858259.0,
1887,498605,4,4,,103504490,3454,Active,,,19.3,EC50,Antiviral activity against Macacine herpesvirus 1 isolate MJ1 infected in african green monkey Vero cells by plaque reduction assay,Confirmatory,19858259.0,
1888,498606,4,4,,103504490,3454,Active,,,19.3,EC50,Antiviral activity against Macacine herpesvirus 1 isolate MJ2 infected in african green monkey Vero cells by plaque reduction assay,Confirmatory,19858259.0,
1889,498607,4,4,,103504490,3454,Active,,,19.3,EC50,Antiviral activity against Macacine herpesvirus 1 isolate MJ3 infected in african green monkey Vero cells by plaque reduction assay,Confirmatory,19858259.0,
1890,498608,4,4,,103504490,3454,Active,,,19.3,EC50,Antiviral activity against Macacine herpesvirus 1 isolate MP1 infected in african green monkey Vero cells by plaque reduction assay,Confirmatory,19858259.0,
1891,498609,4,2,,103504490,3454,Active,,,19.3,EC50,Antiviral activity against HSV1 infected in african green monkey Vero cells by plaque reduction assay,Confirmatory,19858259.0,
1892,498610,4,2,,103504490,3454,Active,,,19.3,EC50,Antiviral activity against HSV2 infected in african green monkey Vero cells by plaque reduction assay,Confirmatory,19858259.0,
1893,498611,2,5,,103504490,3454,Unspecified,,,,,Antiviral activity against Macacine herpesvirus 1 infected in rabbits assessed as survival after 5 months,Other,19858259.0,
1894,504326,1,2,,56424026,3454,Inactive,63477962.0,4985.0,,,Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors,Screening,,
1895,504326,1,2,,56424026,3454,Inactive,117940060.0,4988.0,,,Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors,Screening,,
1896,504327,1,1,,8139883,3454,Inactive,153791535.0,2648.0,,Potency,qHTS Assay for Inhibitors of GCN5L2,Confirmatory,,
1897,504327,1,1,,11111225,3454,Inactive,153791535.0,2648.0,,Potency,qHTS Assay for Inhibitors of GCN5L2,Confirmatory,,
1898,504327,1,1,,90341439,3454,Inactive,153791535.0,2648.0,,Potency,qHTS Assay for Inhibitors of GCN5L2,Confirmatory,,
1899,504329,1,1,,56424026,3454,Inactive,227977143.0,23308111.0,,IC50,Discovery of Small Molecule Probes for H1N1 Influenza NS1A,Confirmatory,,
1900,504332,1,1,,8139883,3454,Inactive,168985070.0,,,Potency,qHTS Assay for Inhibitors of Histone Lysine Methyltransferase G9a,Confirmatory,,
1901,504332,1,1,,11111225,3454,Inactive,168985070.0,,,Potency,qHTS Assay for Inhibitors of Histone Lysine Methyltransferase G9a,Confirmatory,,
1902,504332,1,1,,50106328,3454,Inactive,168985070.0,,0.0224,Potency,qHTS Assay for Inhibitors of Histone Lysine Methyltransferase G9a,Confirmatory,,
1903,504332,1,1,,90341439,3454,Inactive,168985070.0,,,Potency,qHTS Assay for Inhibitors of Histone Lysine Methyltransferase G9a,Confirmatory,,
1904,504333,1,1,,8139883,3454,Inactive,6683500.0,29994.0,,Potency,qHTS Assay for Inhibitors of BAZ2B,Confirmatory,,
1905,504339,1,1,,50113251,3454,Inactive,162330054.0,,,Potency,qHTS Assay for Inhibitors of JMJD2A-Tudor Domain,Confirmatory,,
1906,504339,1,1,,56424026,3454,Inactive,162330054.0,,,Potency,qHTS Assay for Inhibitors of JMJD2A-Tudor Domain,Confirmatory,,
1907,504357,1,1,,56424026,3454,Inactive,63477962.0,4985.0,,,Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors,Screening,,
1908,504357,1,1,,56424026,3454,Inactive,117940060.0,4988.0,,,Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors,Screening,,
1909,504364,1,1,,85231063,3454,Inactive,7705682.0,51053.0,,Potency,Validation screen for small molecules that induce DNA re-replication in SW480 colon adenocarcinoma cells,Confirmatory,,
1910,504406,1,1,,56424026,3454,Inactive,15610945.0,886142.0,,,Inhibitors of Mycobacterium tuberculosis UDP-galactopyranose mutase (UGM) enzyme - High throughput screening using Fluorescent polarization assay Measured in Biochemical System Using Plate Reader - 2105-01_Inhibitor_SinglePoint_HTS_Activity_Set6,Screening,,
1911,504408,2,1,,8139883,3454,Inactive,,,,,Heat Shock Factor-1 (HSF-1) Measured in Cell-Based System Using Plate Reader - 2038-01_Activator_SinglePoint_HTS_Activity,Screening,,
1912,504411,1,1,,56424026,3454,Inactive,218931251.0,221955.0,,,"Fluorescence-based primary biochemical high throughput screening assay to identify inhibitors of human diacylglycerol lipase, beta (DAGLB)",Screening,,
1913,504414,1,1,,56424026,3454,Inactive,9966877.0,57120.0,,,Fluorescence Polarization with Cer CAL-PDZ Measured in Biochemical System Using Plate Reader - 2109-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1914,504414,1,1,,56424026,3454,Inactive,90421313.0,1080.0,,,Fluorescence Polarization with Cer CAL-PDZ Measured in Biochemical System Using Plate Reader - 2109-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1915,504423,1,1,,56424026,3454,Inactive,312275222.0,,,,C-LANA FP assay Measured in Biochemical System Using Plate Reader - 2117-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1916,504441,1,1,,56424026,3454,Inactive,6978787.0,25255.0,,,Dyrk1 A HTS Measured in Biochemical System Using Plate Reader - 2124-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1917,504444,1,1,,50113251,3454,Inactive,224028257.0,4780.0,,Potency,Nrf2 qHTS screen for inhibitors,Confirmatory,,
1918,504444,1,1,,56424026,3454,Inactive,224028257.0,4780.0,,Potency,Nrf2 qHTS screen for inhibitors,Confirmatory,,
1919,504454,1,3,,56424026,3454,Inactive,4501969.0,154.0,,,HTS for Beta-2AR agonists via FAP method,Screening,,
1920,504459,1,3,,8139883,3454,Inactive,4501969.0,154.0,,,HTS for Beta-2AR agonists via FAP method from Validation Set,Screening,,
1921,504462,1,1,,56424026,3454,Inactive,47132611.0,23192.0,,,uHTS fluorescent assay for identification of inhibitors of ATG4B,Screening,,
1922,504466,1,1,,8139883,3454,Inactive,116283940.0,79915.0,,Potency,qHTS screen for small molecules that induce genotoxicity in human embryonic kidney (HEK293T) cells expressing luciferase-tagged ELG1,Confirmatory,,
1923,504467,1,1,,8139883,3454,Inactive,116283940.0,79915.0,,Potency,qHTS screen for small molecules that inhibit ELG1-dependent DNA repair in human embryonic kidney (HEK293T) cells expressing luciferase-tagged ELG1,Confirmatory,,
1924,504490,1,2,,56424026,3454,Inactive,13177715.0,408.0,,,Assay for Inhibitors of the beta-Arrestin-Adaptor Protein 2 Interaction That Mediate GPCR Degradation and Recycling,Screening,,
1925,504523,1,1,,56424026,3454,Inactive,45269145.0,9817.0,,,Fluorescence polarization to screen for inhibitors that disrupt the protein-protein interaction between Keap1 and Nrf2   Measured in Biochemical System Using Plate Reader - 2119-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1926,504523,1,1,,56424026,3454,Inactive,224028257.0,4780.0,,,Fluorescence polarization to screen for inhibitors that disrupt the protein-protein interaction between Keap1 and Nrf2   Measured in Biochemical System Using Plate Reader - 2119-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1927,504536,1,1,,90341439,3454,Inactive,5453898.0,5300.0,,Potency,qHTS Validation Assay to Find Inhibitors of Pin1,Confirmatory,,
1928,504541,1,1,,8139883,3454,Inactive,13177715.0,408.0,,,Assay for Inhibitors of the beta-Arrestin-Adaptor Protein 2 Interaction for Validation Set,Screening,,
1929,504547,1,1,,90341439,3454,Inactive,115503961.0,4357161.0,,Potency,qHTS Validation Assay to Find Inhibitors of Phosphoglycerate Kinase,Confirmatory,,
1930,504548,1,2,,90341439,3454,Inactive,157877932.0,5655980.0,,Potency,qHTS Validation Assay to Find Inhibitors of Phosphoglycerate Mutase,Confirmatory,,
1931,504558,1,1,,56424026,3454,Inactive,23893668.0,3783750.0,,,Inhibitors of Epstein-Barr LMP1 inducible NF-kappaB luciferase reporter Measured in Cell-Based System Using Plate Reader - 2122-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1932,504577,2,2,,56424026,3454,Inactive,6325022.0,855842.0,,,HTS of Small Molecules that Regulate V-ATPase Proton Transport in Yeast using pHLuorin,Screening,,
1933,504582,2,1,,56424026,3454,Inactive,124809271.0,811941.0,,,In vivo-based yeast HTS to detect compounds rescuing yeast growth/survival of Plasmodium Falciparum HSP40-mediated toxicity Measured in Whole Organism System Using Plate Reader - 2120-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1934,504594,1,1,,56424026,3454,Inactive,124809506.0,811999.0,,,Anti-Malarial Hsp90 Inhibitors Measured in Microorganism System Using Plate Reader - 2121-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1935,504600,1,2,,8139883,3454,Inactive,6325022.0,855842.0,,,Validation of HTS of Small Molecules that Regulate V-ATPase Proton Transport in Yeast using pHLuorin,Screening,,
1936,504621,1,1,,56424026,3454,Inactive,124809506.0,811999.0,,,Anti-Malarial Hsp90 Inhibitors Measured in Microorganism System Using Plate Reader - 2121-01_Inhibitor_SinglePoint_HTS_Activity_Set2,Screening,,
1937,504634,1,1,,56424026,3454,Inactive,13236497.0,3361.0,,,Counterscreen for inverse agonists of OPRM1-OPRD1 heterodimerization: luminescence-based cell-based full-deck high throughput screening assay to identify inverse agonists of 5-hydroxytryptamine (serotonin) 5A receptor (HTR5A),Screening,,
1938,504648,1,1,,50113251,3454,Inactive,,,,Potency,Nrf2 qHTS screen for inhibitors: counterscreen for cytotoxicity,Confirmatory,,
1939,504648,1,1,,56424026,3454,Inactive,,,,Potency,Nrf2 qHTS screen for inhibitors: counterscreen for cytotoxicity,Confirmatory,,
1940,504651,1,1,,8139883,3454,Inactive,4503383.0,1812.0,,,Potentiators of Human D1 Dopamine Receptor: qHTS,Screening,,
1941,504652,1,1,,8139883,3454,Inactive,4503383.0,1812.0,,,Antagonist of Human D 1 Dopamine Receptor: qHTS,Screening,,
1942,504660,1,1,,8139883,3454,Inactive,4503383.0,1812.0,,,Allosteric Agonists of the Human D1 Dopamine Receptor: qHTS,Screening,,
1943,504690,1,3,,56424026,3454,Inactive,12381848.0,,,,uHTS identification of small molecule inhibitors of Plasmodium falciparum Glucose-6-phosphate dehydrogenase via a fluorescence intensity assay,Screening,,
1944,504692,2,2,,56424026,3454,Inactive,13236497.0,3361.0,,,Counterscreen for agonists of OPRM1-OPRD1 heterodimerization: luminescence-based cell-based full-deck high throughput screening assay to identify agonists of 5-hydroxytryptamine (serotonin) 5A receptor (HTR5A),Screening,,
1945,504700,1,1,,56424026,3454,Inactive,46909587.0,5567.0,,,Fluorescence polarization-based biochemical primary high throughput screening assay to identify activators of the Protein Kinase A-R2B (PKA-R2B) complex,Screening,,
1946,504700,1,1,,56424026,3454,Inactive,47132585.0,5577.0,,,Fluorescence polarization-based biochemical primary high throughput screening assay to identify activators of the Protein Kinase A-R2B (PKA-R2B) complex,Screening,,
1947,504706,1,1,,8139883,3454,Inactive,23491729.0,7157.0,,Potency,qHTS assay for re-activators of p53 using a Luc reporter,Confirmatory,,
1948,504707,1,1,,56424026,3454,Inactive,6755076.0,18749.0,,,Fluorescence polarization-based biochemical primary high throughput screening assay to identify activators of the Protein Kinase A-R1A (PKA-R1A) complex,Screening,,
1949,504707,1,1,,56424026,3454,Inactive,115496662.0,615074.0,,,Fluorescence polarization-based biochemical primary high throughput screening assay to identify activators of the Protein Kinase A-R1A (PKA-R1A) complex,Screening,,
1950,504720,1,1,,56424026,3454,Inactive,16130689.0,947252.0,,,uHTS identification of MazEF TA System activators  via a fluorescence-based single-stranded RNase assay,Screening,,
1951,504734,1,1,,56424026,3454,Inactive,194068499.0,54106.0,,,Fluorescence-based cell-based primary high throughput screening assay to identify inhibitors of TLR9-MyD88 binding.,Screening,,
1952,504749,1,3,,11111225,3454,Unspecified,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1953,504749,1,3,1.0,11111225,3454,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1954,504749,1,3,2.0,11111225,3454,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1955,504749,1,3,3.0,11111225,3454,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1956,504749,1,3,4.0,11111225,3454,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1957,504749,1,3,5.0,11111225,3454,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1958,504749,1,3,6.0,11111225,3454,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1959,504749,1,3,7.0,11111225,3454,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1960,504749,1,3,8.0,11111225,3454,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1961,504749,1,3,9.0,11111225,3454,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1962,504749,1,3,10.0,11111225,3454,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1963,504749,1,3,11.0,11111225,3454,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1964,504749,1,3,12.0,11111225,3454,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1965,504749,1,3,13.0,11111225,3454,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1966,504749,1,3,14.0,11111225,3454,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1967,504749,1,3,15.0,11111225,3454,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1968,504749,1,3,16.0,11111225,3454,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1969,504749,1,3,17.0,11111225,3454,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1970,504749,1,3,18.0,11111225,3454,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1971,504749,1,3,19.0,11111225,3454,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1972,504749,1,3,20.0,11111225,3454,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1973,504749,1,3,21.0,11111225,3454,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1974,504749,1,3,22.0,11111225,3454,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1975,504749,1,3,23.0,11111225,3454,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1976,504749,1,3,24.0,11111225,3454,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1977,504749,1,3,25.0,11111225,3454,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1978,504749,1,3,26.0,11111225,3454,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1979,504749,1,3,27.0,11111225,3454,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1980,504749,1,3,28.0,11111225,3454,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1981,504749,1,3,29.0,11111225,3454,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1982,504749,1,3,30.0,11111225,3454,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1983,504749,1,3,31.0,11111225,3454,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1984,504749,1,3,32.0,11111225,3454,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1985,504749,1,3,33.0,11111225,3454,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1986,504749,1,3,34.0,11111225,3454,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1987,504749,1,3,35.0,11111225,3454,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1988,504749,1,3,36.0,11111225,3454,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1989,504749,1,3,37.0,11111225,3454,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1990,504749,1,3,38.0,11111225,3454,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1991,504749,1,3,39.0,11111225,3454,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1992,504749,1,3,40.0,11111225,3454,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1993,504749,1,3,41.0,11111225,3454,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1994,504749,1,3,42.0,11111225,3454,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1995,504749,1,3,43.0,11111225,3454,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1996,504749,1,3,44.0,11111225,3454,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1997,504749,1,3,45.0,11111225,3454,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1998,504749,1,3,46.0,11111225,3454,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1999,504749,1,3,47.0,11111225,3454,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
2000,504749,1,3,48.0,11111225,3454,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
2001,504749,1,3,49.0,11111225,3454,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
2002,504749,1,3,50.0,11111225,3454,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
2003,504749,1,3,51.0,11111225,3454,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
2004,504749,1,3,52.0,11111225,3454,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
2005,504749,1,3,53.0,11111225,3454,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
2006,504749,1,3,54.0,11111225,3454,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
2007,504749,1,3,55.0,11111225,3454,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
2008,504749,1,3,56.0,11111225,3454,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
2009,504749,1,3,57.0,11111225,3454,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
2010,504749,1,3,58.0,11111225,3454,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
2011,504749,1,3,59.0,11111225,3454,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
2012,504749,1,3,60.0,11111225,3454,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
2013,504749,1,3,61.0,11111225,3454,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
2014,504766,2,1,,56424026,3454,Inactive,5016090.0,190.0,,,"Luminescence-based primary cell-based high throughput screening assay to identify inhibitors of the orphan nuclear receptor subfamily 0, group B, member 1 (DAX1; NR0B1)",Screening,,
2015,504775,1,1,,56424026,3454,Inactive,14389423.0,20778.0,,,HTS using DiI-HDL to assay lipid transfer in ldlA[SR-BI] cells Measured in Cell-Based System Using Plate Reader - 2085-01_Activator_SinglePoint_HTS_Activity,Screening,,
2016,504803,1,1,,56424026,3454,Inactive,121945198.0,,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of the HTRA serine peptidase 1 (HTRA1),Screening,,
2017,504810,1,2,,8139883,3454,Inactive,118341367.0,7253.0,,,Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign,Screening,20427476.0,
2018,504810,1,2,,90341439,3454,Inactive,118341367.0,7253.0,,,Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign,Screening,20427476.0,
2019,504812,1,2,,8139883,3454,Inactive,118341367.0,7253.0,,,Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign,Screening,20427476.0,
2020,504812,1,2,,90341439,3454,Inactive,118341367.0,7253.0,,,Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign,Screening,20427476.0,
2021,504821,1,1,,85231063,3454,Inactive,38016895.0,7253.0,,Potency,Antagonists of the Thyroid Stimulating Hormone Receptor: Validation,Confirmatory,,
2022,504832,1,1,,8139883,3454,Inactive,,,,Potency,"Primary qHTS for delayed death inhibitors of the malarial parasite plastid, 48 hour incubation",Confirmatory,,
2023,504832,1,1,,11111225,3454,Inactive,,,,Potency,"Primary qHTS for delayed death inhibitors of the malarial parasite plastid, 48 hour incubation",Confirmatory,,
2024,504834,1,1,,8139883,3454,Inactive,,,,Potency,"Primary qHTS for delayed death inhibitors of the malarial parasite plastid, 96 hour incubation",Confirmatory,,
2025,504834,1,1,,11111225,3454,Inactive,,,,Potency,"Primary qHTS for delayed death inhibitors of the malarial parasite plastid, 96 hour incubation",Confirmatory,,
2026,504836,1,2,,90341439,3454,Inactive,168984549.0,,,Potency,Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in human glioma: Validation,Confirmatory,11836247.0,
2027,504842,1,1,,8139883,3454,Inactive,4090929.0,10576.0,,Potency,Inhibitors of TCP-1 ring complex (TRiC) of Methanococcus maripaludis (MmCpn): qHTS,Confirmatory,,
2028,504845,1,1,,50113251,3454,Inactive,86301163.0,5999.0,,Potency,Inhibitors of Regulator of G Protein Signaling (RGS) 4: qHTS,Confirmatory,,
2029,504845,1,1,,56424026,3454,Inactive,86301163.0,5999.0,,Potency,Inhibitors of Regulator of G Protein Signaling (RGS) 4: qHTS,Confirmatory,,
2030,504845,1,1,,90341439,3454,Inactive,86301163.0,5999.0,,Potency,Inhibitors of Regulator of G Protein Signaling (RGS) 4: qHTS,Confirmatory,,
2031,504847,1,1,,11111225,3454,Inactive,63054845.0,7421.0,,Potency,Inhibitors of the vitamin D receptor (VDR): qHTS,Confirmatory,,
2032,504847,1,1,,50113251,3454,Inactive,63054845.0,7421.0,,Potency,Inhibitors of the vitamin D receptor (VDR): qHTS,Confirmatory,,
2033,504847,1,1,,56424026,3454,Inactive,63054845.0,7421.0,,Potency,Inhibitors of the vitamin D receptor (VDR): qHTS,Confirmatory,,
2034,504847,1,1,,90341439,3454,Inactive,63054845.0,7421.0,,Potency,Inhibitors of the vitamin D receptor (VDR): qHTS,Confirmatory,,
2035,504865,1,1,,11111225,3454,Inactive,118600387.0,7398.0,,Potency,Inhibitors of USP1/UAF1: Pilot qHTS,Confirmatory,,
2036,504865,1,1,,90341439,3454,Inactive,118600387.0,7398.0,,Potency,Inhibitors of USP1/UAF1: Pilot qHTS,Confirmatory,,
2037,504884,1,2,,56424026,3454,Inactive,115347926.0,1175052.0,,,Inhibitors of Y. pestis Topo-I using cleavage product accumulation Measured in Biochemical System Using Plate Reader - 2123-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
2038,504891,1,1,,50113251,3454,Inactive,5453898.0,5300.0,,Potency,qHTS Assay to Find Inhibitors of Pin1,Confirmatory,,
2039,504891,1,1,,56424026,3454,Inactive,5453898.0,5300.0,,Potency,qHTS Assay to Find Inhibitors of Pin1,Confirmatory,,
2040,504894,1,1,,56424026,3454,Inactive,553160.0,,,Potency,Activators of T cell receptors: qHTS campaign,Confirmatory,,
2041,504937,1,2,,56424026,3454,Inactive,179095.0,6609.0,,Potency,Inhibitors of Secretory Acid Sphingomyelinase (S-ASM): qHTS,Confirmatory,,
2042,510751,4,2,,103504490,3454,Active,,,1.65,EC50,Antiviral activity against human cytomegalovirus infected in human MRC5 cells after 7 days by GFP-based fluorescent reduction assay,Confirmatory,20047911.0,
2043,510752,4,2,,103504490,3454,Active,,,2.39,EC50,Antiviral activity against human cytomegalovirus infected in HEL299 cells after 7 days by GFP-based fluorescent reduction assay,Confirmatory,20047911.0,
2044,510753,4,2,,103504490,3454,Active,,,1.91,EC50,Antiviral activity against human cytomegalovirus infected in NHDF after 7 days by GFP-based fluorescent reduction assay,Confirmatory,20047911.0,
2045,510754,4,2,,103504490,3454,Active,,,0.32,EC50,Antiviral activity against human cytomegalovirus infected in human HS27 cells after 7 days by GFP-based fluorescent reduction assay,Confirmatory,20047911.0,
2046,510755,4,2,,103504490,3454,Active,,,2.33,EC50,Antiviral activity against human cytomegalovirus RV-HG infected in NHDF after 7 days by GFP-based fluorescent reduction assay,Confirmatory,20047911.0,
2047,510756,4,2,,103504490,3454,Active,,,1.73,EC50,Antiviral activity against human cytomegalovirus AD169 infected in NHDF after 7 days by GFP-based fluorescent reduction assay,Confirmatory,20047911.0,
2048,510757,4,2,,103504490,3454,Active,,,4.3,EC50,Antiviral activity against human cytomegalovirus AD169 infected in NHDF assessed as inhibition of virus-induced cytopathic effect after 6 to 7 days by giemsa staining,Confirmatory,20047911.0,
2049,510758,4,2,,103504490,3454,Active,,,2.7,EC50,Antiviral activity against human cytomegalovirus Davis infected in NHDF assessed as inhibition of virus-induced cytopathic effect after 6 to 7 days by giemsa staining,Confirmatory,20047911.0,
2050,510759,4,2,,103504490,3454,Active,,,2.07,EC50,Antiviral activity against human cytomegalovirus infected in NHLF after 7 days by GFP-based fluorescent reduction assay,Confirmatory,20047911.0,
2051,510760,4,2,,103504490,3454,Unspecified,,,333.0,CC50,Cytotoxicity against human HS27 cells infected with human cytomegalovirus after 7 days by alamar blue assay,Confirmatory,20047911.0,
2052,510761,4,2,,103504490,3454,Unspecified,,,333.0,CC50,Cytotoxicity against NHDF infected with human cytomegalovirus after 7 days by alamar blue assay,Confirmatory,20047911.0,
2053,510762,4,3,,103504490,3454,Unspecified,,,333.0,CC50,Cytotoxicity against HEL299 cells infected with human cytomegalovirus after 7 days by alamar blue assay,Confirmatory,20047911.0,
2054,510763,4,2,,103504490,3454,Unspecified,,,333.0,CC50,Cytotoxicity against human MRC5 cells infected with human cytomegalovirus after 7 days by alamar blue assay,Confirmatory,20047911.0,
2055,510764,4,2,,103504490,3454,Unspecified,,,333.0,CC50,Cytotoxicity against HLF infected with human cytomegalovirus after 7 days by alamar blue assay,Confirmatory,20047911.0,
2056,510765,1,5,,103504490,3454,Unspecified,,,,,"Selectivity index, ratio of CC50 for human HS27 cells to EC50 for human cytomegalovirus infected in human HS27 cells",Other,20047911.0,
2057,510766,1,4,,103504490,3454,Unspecified,,,,,"Selectivity index, ratio of CC50 for NHDF to EC50 for human cytomegalovirus infected in NHDF",Other,20047911.0,
2058,510767,1,4,,103504490,3454,Unspecified,,,,,"Selectivity index, ratio of CC50 for HEL299 cells to EC50 for human cytomegalovirus infected in HEL299 cells",Other,20047911.0,
2059,510768,1,4,,103504490,3454,Unspecified,,,,,"Selectivity index, ratio of CC50 for NHLF to EC50 for human cytomegalovirus infected in NHLF",Other,20047911.0,
2060,510769,1,5,,103504490,3454,Unspecified,,,,,"Selectivity index, ratio of CC50 for human MRC5 cells to EC50 for human cytomegalovirus infected in human MRC5 cells",Other,20047911.0,
2061,510770,4,2,,103504490,3454,Active,,,0.99,EC50,Antiviral activity against 0.003 MOI human cytomegalovirus AD169 infected in NHDF after 7 days by GFP-based fluorescent reduction assay,Confirmatory,20047911.0,
2062,510771,4,2,,103504490,3454,Active,,,0.68,EC50,Antiviral activity against 0.001 MOI human cytomegalovirus AD169 infected in NHDF after 7 days by GFP-based fluorescent reduction assay,Confirmatory,20047911.0,
2063,510772,4,2,,103504490,3454,Active,,,1.74,EC50,Antiviral activity against 0.03 MOI human cytomegalovirus AD169 infected in NHDF after 7 days by GFP-based fluorescent reduction assay,Confirmatory,20047911.0,
2064,510773,4,2,,103504490,3454,Active,,,2.21,EC50,Antiviral activity against 0.1 MOI human cytomegalovirus AD169 infected in NHDF after 7 days by GFP-based fluorescent reduction assay,Confirmatory,20047911.0,
2065,510774,4,2,,103504490,3454,Active,,,6.51,EC50,Antiviral activity against 0.3 MOI human cytomegalovirus AD169 infected in NHDF after 7 days by GFP-based fluorescent reduction assay,Confirmatory,20047911.0,
2066,510775,4,2,,103504490,3454,Active,,,5.26,EC50,Antiviral activity against 1 MOI human cytomegalovirus AD169 infected in NHDF after 7 days by GFP-based fluorescent reduction assay,Confirmatory,20047911.0,
2067,510776,4,2,,103504490,3454,Active,,,12.0,EC50,Antiviral activity against ganciclovir-resistant human cytomegalovirus AD169 UL97 M460I infected in NHDF assessed as inhibition of virus-induced cytopathic effect after 6 to 7 days by giemsa staining,Confirmatory,20047911.0,
2068,510780,4,2,,103504490,3454,Active,,,5.0,EC50,Antiviral activity against human cytomegalovirus isolate 472 infected in NHDF assessed as inhibition of virus-induced cytopathic effect after 6 to 7 days by giemsa staining,Confirmatory,20047911.0,
2069,510781,4,2,,103504490,3454,Active,,,1.1,EC50,Antiviral activity against human cytomegalovirus isolate E16415S infected in NHDF assessed as inhibition of virus-induced cytopathic effect after 6 to 7 days by giemsa staining,Confirmatory,20047911.0,
2070,510782,4,2,,103504490,3454,Active,,,14.0,EC50,Antiviral activity against ganciclovir-resistant human cytomegalovirus isolate E17251S infected in NHDF assessed as inhibition of virus-induced cytopathic effect after 6 to 7 days by giemsa staining,Confirmatory,20047911.0,
2071,510783,4,2,,103504490,3454,Active,,,15.0,EC50,Antiviral activity against ganciclovir-resistant human cytomegalovirus isolate 1947R infected in NHDF assessed as inhibition of virus-induced cytopathic effect after 6 to 7 days by giemsa staining,Confirmatory,20047911.0,
2072,510785,1,3,,103504490,3454,Active,,,,,Antiviral activity against human cytomegalovirus AD169 infected in NHDF assessed as inhibition of virus replication at 20 uM after 96 hrs by fluorescence assay,Other,20047911.0,
2073,510787,1,3,,103504490,3454,Active,,,,,Antiviral activity against human cytomegalovirus AD169 infected in NHDF at 10 times EC50 treated after 168 hrs postinfection measured after 7 days by GFP-based fluorescent reduction assay,Other,20047911.0,
2074,510788,1,3,,103504490,3454,Active,,,,,Antiviral activity against human cytomegalovirus AD169 infected in NHDF at 20 uM treated after 33 hrs postinfection measured after 7 days by GFP-based fluorescent reduction assay,Other,20047911.0,
2075,510793,1,3,,103504490,3454,Active,,,,,Antiviral activity against human cytomegalovirus AD169 infected in NHDF assessed as inhibition of virus replication at 50 nM measured after 24 to 72 hrs of compound wash by fluorescence assay,Other,20047911.0,
2076,516205,1,3,,103504490,3454,Unspecified,,,,,Ratio of EC50 for Human cytomegalovirus T3130 expressing UL97 kinase V665I mutant gene infected in human foreskin fibroblast to EC50 for Human cytomegalovirus T2211 expressing UL97 kinase H587Y mutant gene infected in human foreskin fibroblast,Other,20385869.0,
2077,516958,4,2,,103504490,3454,Inconclusive,,,,EC50,Antiviral activity against Vaccinia virus infected in HEL assessed as reduction in virus-induce cytopathicity,Confirmatory,20809641.0,
2078,516959,4,2,,103504490,3454,Active,,,9.4,EC50,Antiviral activity against Human cytomegalovirus AD169 infected in HEL assessed as reduction in virus-induce cytopathicity,Confirmatory,20809641.0,
2079,516960,4,2,,103504490,3454,Active,,,10.2,EC50,Antiviral activity against Human cytomegalovirus Davis infected in HEL assessed as reduction in virus-induce cytopathicity,Confirmatory,20809641.0,
2080,516961,4,2,,103504490,3454,Inconclusive,,,,EC50,Antiviral activity against Human herpesvirus 6 infected in HEL assessed as reduction in virus-induce cytopathicity,Confirmatory,20809641.0,
2081,516962,5,3,,103504490,3454,Unspecified,,,,CC50,Cytotoxicity against HEL assessed as change in cell morphology,Confirmatory,20809641.0,
2082,516963,5,3,,103504490,3454,Inconclusive,,,,,Cytotoxicity against human HSB2 cells assessed as change in cell morphology,Other,20809641.0,
2083,516964,5,3,,103504490,3454,Unspecified,,,1077.0,CC50,Cytotoxicity against HEL,Confirmatory,20809641.0,
2084,518633,4,2,,103504490,3454,Active,,,1.26,EC50,Antiviral activity against Human cytomegalovirus T3243 expressing UL97 kinase T659I mutant gene infected in human foreskin fibroblast measured 6 days post infection by SEAP reporter gene assay,Confirmatory,20385869.0,
2085,518634,4,2,,103504490,3454,Active,,,1.06,EC50,Antiviral activity against Human cytomegalovirus T3239 expressing UL97 kinase V665I mutant gene infected in human foreskin fibroblast measured 6 days post infection by SEAP reporter gene assay,Confirmatory,20385869.0,
2086,518635,4,2,,103504490,3454,Active,,,1.22,EC50,Antiviral activity against Human cytomegalovirus T3130 expressing UL97 kinase V665I mutant gene infected in human foreskin fibroblast measured 6 days post infection by SEAP reporter gene assay,Confirmatory,20385869.0,
2087,518636,1,3,,103504490,3454,Unspecified,,,,,Ratio of EC50 for Human cytomegalovirus T2789 expressing UL97 kinase L405P mutant gene infected in human foreskin fibroblast to EC50 for Human cytomegalovirus T2211 expressing UL97 kinase H587Y mutant gene infected in human foreskin fibroblast,Other,20385869.0,
2088,518637,1,3,,103504490,3454,Unspecified,,,,,Ratio of EC50 for Human cytomegalovirus T3184 expressing UL97 kinase L405P mutant gene infected in human foreskin fibroblast to EC50 for Human cytomegalovirus T2211 expressing UL97 kinase H587Y mutant gene infected in human foreskin fibroblast,Other,20385869.0,
2089,518638,1,3,,103504490,3454,Unspecified,,,,,Ratio of EC50 for Human cytomegalovirus T3346 expressing UL97 kinase M460T mutant gene infected in human foreskin fibroblast to EC50 for Human cytomegalovirus T2211 expressing UL97 kinase H587Y mutant gene infected in human foreskin fibroblast,Other,20385869.0,
2090,518639,1,3,,103504490,3454,Unspecified,,,,,Ratio of EC50 for Human cytomegalovirus T2259 expressing UL97 kinase M460V mutant gene infected in human foreskin fibroblast to EC50 for Human cytomegalovirus T2211 expressing UL97 kinase H587Y mutant gene infected in human foreskin fibroblast,Other,20385869.0,
2091,518640,1,3,,103504490,3454,Unspecified,,,,,Ratio of EC50 for Human cytomegalovirus T3257 expressing UL97 kinase V466M mutant gene infected in human foreskin fibroblast to EC50 for Human cytomegalovirus T2211 expressing UL97 kinase H587Y mutant gene infected in human foreskin fibroblast,Other,20385869.0,
2092,518641,1,3,,103504490,3454,Unspecified,,,,,Ratio of EC50 for Human cytomegalovirus T2924 expressing UL97 kinase H469Y mutant gene infected in human foreskin fibroblast to EC50 for Human cytomegalovirus T2211 expressing UL97 kinase H587Y mutant gene infected in human foreskin fibroblast,Other,20385869.0,
2093,518642,1,3,,103504490,3454,Unspecified,,,,,Ratio of EC50 for Human cytomegalovirus T3136 expressing UL97 kinase H469Y mutant gene infected in human foreskin fibroblast to EC50 for Human cytomegalovirus T2211 expressing UL97 kinase H587Y mutant gene infected in human foreskin fibroblast,Other,20385869.0,
2094,518643,1,3,,103504490,3454,Unspecified,,,,,Ratio of EC50 for Human cytomegalovirus T3242 expressing UL97 kinase A478V mutant gene infected in human foreskin fibroblast to EC50 for Human cytomegalovirus T2211 expressing UL97 kinase H587Y mutant gene infected in human foreskin fibroblast,Other,20385869.0,
2095,518644,1,3,,103504490,3454,Unspecified,,,,,Ratio of EC50 for Human cytomegalovirus T3215 expressing UL97 kinase A478V mutant gene infected in human foreskin fibroblast to EC50 for Human cytomegalovirus T2211 expressing UL97 kinase H587Y mutant gene infected in human foreskin fibroblast,Other,20385869.0,
2096,518645,1,3,,103504490,3454,Unspecified,,,,,Ratio of EC50 for Human cytomegalovirus T3240 expressing UL97 kinase N510S mutant gene infected in human foreskin fibroblast to EC50 for Human cytomegalovirus T2211 expressing UL97 kinase H587Y mutant gene infected in human foreskin fibroblast,Other,20385869.0,
2097,518646,4,2,,103504490,3454,Active,,,1.13,EC50,Antiviral activity against Human cytomegalovirus T3264 expressing UL97 kinase G623S mutant gene infected in human foreskin fibroblast measured 6 days post infection by SEAP reporter gene assay,Confirmatory,20385869.0,
2098,518647,4,2,,103504490,3454,Active,,,7.81,EC50,Antiviral activity against Human cytomegalovirus T3329 expressing UL97 kinase C603W mutant gene infected in human foreskin fibroblast measured 6 days post infection by SEAP reporter gene assay,Confirmatory,20385869.0,
2099,518825,4,2,,103504490,3454,Active,,,1.85,EC50,Antiviral activity against Human cytomegalovirus T3327 expressing UL97 kinase C603S mutant gene infected in human foreskin fibroblast measured 6 days post infection by SEAP reporter gene assay,Confirmatory,20385869.0,
2100,518826,4,2,,103504490,3454,Active,,,8.18,EC50,Antiviral activity against Human cytomegalovirus T3331 expressing UL97 kinase C603R mutant gene infected in human foreskin fibroblast measured 6 days post infection by SEAP reporter gene assay,Confirmatory,20385869.0,
2101,518827,4,2,,103504490,3454,Active,,,1.5,EC50,Antiviral activity against Human cytomegalovirus T3041 expressing UL97 kinase L600I mutant gene infected in human foreskin fibroblast measured 6 days post infection by SEAP reporter gene assay,Confirmatory,20385869.0,
2102,518828,4,2,,103504490,3454,Active,,,0.94,EC50,Antiviral activity against Human cytomegalovirus T3146 expressing UL97 kinase K599R mutant gene infected in human foreskin fibroblast measured 6 days post infection by SEAP reporter gene assay,Confirmatory,20385869.0,
2103,518829,4,2,,103504490,3454,Active,,,1.23,EC50,Antiviral activity against Human cytomegalovirus T3253 expressing UL97 kinase K599R mutant gene infected in human foreskin fibroblast measured 6 days post infection by SEAP reporter gene assay,Confirmatory,20385869.0,
2104,518830,4,2,,103504490,3454,Active,,,8.48,EC50,Antiviral activity against Human cytomegalovirus T3252 expressing UL97 kinase A594V mutant gene infected in human foreskin fibroblast measured 6 days post infection by SEAP reporter gene assay,Confirmatory,20385869.0,
2105,518831,4,2,,103504490,3454,Active,,,9.24,EC50,Antiviral activity against Human cytomegalovirus T2255 expressing UL97 kinase A594V mutant gene infected in human foreskin fibroblast measured 6 days post infection by SEAP reporter gene assay,Confirmatory,20385869.0,
2106,518832,4,2,,103504490,3454,Active,,,2.98,EC50,Antiviral activity against Human cytomegalovirus T3258 expressing UL97 kinase A594E mutant gene infected in human foreskin fibroblast measured 6 days post infection by SEAP reporter gene assay,Confirmatory,20385869.0,
2107,518833,4,2,,103504490,3454,Active,,,3.31,EC50,Antiviral activity against Human cytomegalovirus T3217 expressing UL97 kinase A594E mutant gene infected in human foreskin fibroblast measured 6 days post infection by SEAP reporter gene assay,Confirmatory,20385869.0,
2108,518834,4,2,,103504490,3454,Active,,,3.0,EC50,Antiviral activity against Human cytomegalovirus T3259 expressing UL97 kinase C592G mutant gene infected in human foreskin fibroblast measured 6 days post infection by SEAP reporter gene assay,Confirmatory,20385869.0,
2109,518835,4,2,,103504490,3454,Active,,,3.36,EC50,Antiviral activity against Human cytomegalovirus T2258 expressing UL97 kinase C592G mutant gene infected in human foreskin fibroblast measured 6 days post infection by SEAP reporter gene assay,Confirmatory,20385869.0,
2110,518836,4,2,,103504490,3454,Active,,,0.99,EC50,Antiviral activity against Human cytomegalovirus T3244 expressing UL97 kinase A588V mutant gene infected in human foreskin fibroblast measured 6 days post infection by SEAP reporter gene assay,Confirmatory,20385869.0,
2111,518837,4,2,,103504490,3454,Active,,,1.23,EC50,Antiviral activity against Human cytomegalovirus T3216 expressing UL97 kinase A588V mutant gene infected in human foreskin fibroblast measured 6 days post infection by SEAP reporter gene assay,Confirmatory,20385869.0,
2112,518838,4,2,,103504490,3454,Active,,,1.14,EC50,Antiviral activity against Human cytomegalovirus T3240 expressing UL97 kinase N510S mutant gene infected in human foreskin fibroblast measured 6 days post infection by SEAP reporter gene assay,Confirmatory,20385869.0,
2113,518839,4,2,,103504490,3454,Active,,,0.95,EC50,Antiviral activity against Human cytomegalovirus T3215 expressing UL97 kinase A478V mutant gene infected in human foreskin fibroblast measured 6 days post infection by SEAP reporter gene assay,Confirmatory,20385869.0,
2114,518840,4,2,,103504490,3454,Active,,,0.77,EC50,Antiviral activity against Human cytomegalovirus T3242 expressing UL97 kinase A478V mutant gene infected in human foreskin fibroblast measured 6 days post infection by SEAP reporter gene assay,Confirmatory,20385869.0,
2115,518841,4,2,,103504490,3454,Active,,,1.05,EC50,Antiviral activity against Human cytomegalovirus T3136 expressing UL97 kinase H469Y mutant gene infected in human foreskin fibroblast measured 6 days post infection by SEAP reporter gene assay,Confirmatory,20385869.0,
2116,518842,4,2,,103504490,3454,Active,,,1.33,EC50,Antiviral activity against Human cytomegalovirus T2924 expressing UL97 kinase H469Y mutant gene infected in human foreskin fibroblast measured 6 days post infection by SEAP reporter gene assay,Confirmatory,20385869.0,
2117,518843,4,2,,103504490,3454,Active,,,1.24,EC50,Antiviral activity against Human cytomegalovirus T3257 expressing UL97 kinase V466M mutant gene infected in human foreskin fibroblast measured 6 days post infection by SEAP reporter gene assay,Confirmatory,20385869.0,
2118,518844,4,2,,103504490,3454,Active,,,8.52,EC50,Antiviral activity against Human cytomegalovirus T2259 expressing UL97 kinase M460V mutant gene infected in human foreskin fibroblast measured 6 days post infection by SEAP reporter gene assay,Confirmatory,20385869.0,
2119,518845,4,2,,103504490,3454,Active,,,9.24,EC50,Antiviral activity against Human cytomegalovirus T3346 expressing UL97 kinase M460T mutant gene infected in human foreskin fibroblast measured 6 days post infection by SEAP reporter gene assay,Confirmatory,20385869.0,
2120,518846,4,2,,103504490,3454,Active,,,2.76,EC50,Antiviral activity against Human cytomegalovirus T3184 expressing UL97 kinase L405P mutant gene infected in human foreskin fibroblast measured 6 days post infection by SEAP reporter gene assay,Confirmatory,20385869.0,
2121,518847,4,2,,103504490,3454,Active,,,3.02,EC50,Antiviral activity against Human cytomegalovirus T2789 expressing UL97 kinase L405P mutant gene infected in human foreskin fibroblast measured 6 days post infection by SEAP reporter gene assay,Confirmatory,20385869.0,
2122,518848,4,2,,103504490,3454,Active,,,1.09,EC50,Antiviral activity against Human cytomegalovirus T3326 harboring Frt motif upstream of UL97 kinase N68D L126Q I244V mutant gene infected in human foreskin fibroblast measured 6 days post infection by SEAP reporter gene assay,Confirmatory,20385869.0,
2123,518849,4,2,,103504490,3454,Active,,,0.99,EC50,Antiviral activity against Human cytomegalovirus T3261 harboring Frt motif upstream of UL97 kinase infected in human foreskin fibroblast measured 6 days post infection by SEAP reporter gene assay,Confirmatory,20385869.0,
2124,518850,4,2,,103504490,3454,Active,,,0.96,EC50,Antiviral activity against Human cytomegalovirus T3185 harboring Frt motif upstream of UL97 gene and expressing UL97 kinase H587Y mutant gene infected in human foreskin fibroblast measured 6 days post infection by SEAP reporter gene assay,Confirmatory,20385869.0,
2125,518851,4,2,,103504490,3454,Active,,,1.0,EC50,Antiviral activity against Human cytomegalovirus T3135 expressing UL97 kinase H587Y mutant gene infected in human foreskin fibroblast measured 6 days post infection by SEAP reporter gene assay,Confirmatory,20385869.0,
2126,518852,4,2,,103504490,3454,Active,,,1.02,EC50,Antiviral activity against Human cytomegalovirus T3099 expressing UL97 kinase H587Y mutant gene infected in human foreskin fibroblast measured 6 days post infection by SEAP reporter gene assay,Confirmatory,20385869.0,
2127,518853,4,2,,103504490,3454,Active,,,1.11,EC50,Antiviral activity against Human cytomegalovirus T2233 expressing UL97 kinase H587Y mutant gene infected in human foreskin fibroblast measured 6 days post infection by SEAP reporter gene assay,Confirmatory,20385869.0,
2128,518854,4,2,,103504490,3454,Active,,,1.1,EC50,Antiviral activity against Human cytomegalovirus T2211 expressing UL97 kinase H587Y mutant gene infected in human foreskin fibroblast measured 6 days post infection by SEAP reporter gene assay,Confirmatory,20385869.0,
2129,518855,1,3,,103504490,3454,Unspecified,,,,,Ratio of EC50 for Human cytomegalovirus T3216 expressing UL97 kinase A588V mutant gene infected in human foreskin fibroblast to EC50 for Human cytomegalovirus T2211 expressing UL97 kinase H587Y mutant gene infected in human foreskin fibroblast,Other,20385869.0,
2130,518856,1,3,,103504490,3454,Unspecified,,,,,Ratio of EC50 for Human cytomegalovirus T3244 expressing UL97 kinase A588V mutant gene infected in human foreskin fibroblast to EC50 for Human cytomegalovirus T2211 expressing UL97 kinase H587Y mutant gene infected in human foreskin fibroblast,Other,20385869.0,
2131,518857,1,3,,103504490,3454,Unspecified,,,,,Ratio of EC50 for Human cytomegalovirus T2258 expressing UL97 kinase C592G mutant gene infected in human foreskin fibroblast to EC50 for Human cytomegalovirus T2211 expressing UL97 kinase H587Y mutant gene infected in human foreskin fibroblast,Other,20385869.0,
2132,518858,1,3,,103504490,3454,Unspecified,,,,,Ratio of EC50 for Human cytomegalovirus T3259 expressing UL97 kinase C592G mutant gene infected in human foreskin fibroblast to EC50 for Human cytomegalovirus T2211 expressing UL97 kinase H587Y mutant gene infected in human foreskin fibroblast,Other,20385869.0,
2133,518859,1,3,,103504490,3454,Unspecified,,,,,Ratio of EC50 for Human cytomegalovirus T3217 expressing UL97 kinase A594E mutant gene infected in human foreskin fibroblast to EC50 for Human cytomegalovirus T2211 expressing UL97 kinase H587Y mutant gene infected in human foreskin fibroblast,Other,20385869.0,
2134,518860,1,3,,103504490,3454,Unspecified,,,,,Ratio of EC50 for Human cytomegalovirus T3258 expressing UL97 kinase A594E mutant gene infected in human foreskin fibroblast to EC50 for Human cytomegalovirus T2211 expressing UL97 kinase H587Y mutant gene infected in human foreskin fibroblast,Other,20385869.0,
2135,518861,1,3,,103504490,3454,Unspecified,,,,,Ratio of EC50 for Human cytomegalovirus T2255 expressing UL97 kinase A594V mutant gene infected in human foreskin fibroblast to EC50 for Human cytomegalovirus T2211 expressing UL97 kinase H587Y mutant gene infected in human foreskin fibroblast,Other,20385869.0,
2136,518862,1,3,,103504490,3454,Unspecified,,,,,Ratio of EC50 for Human cytomegalovirus T3252 expressing UL97 kinase A594V mutant gene infected in human foreskin fibroblast to EC50 for Human cytomegalovirus T2211 expressing UL97 kinase H587Y mutant gene infected in human foreskin fibroblast,Other,20385869.0,
2137,518863,1,3,,103504490,3454,Unspecified,,,,,Ratio of EC50 for Human cytomegalovirus T3253 expressing UL97 kinase K599R mutant gene infected in human foreskin fibroblast to EC50 for Human cytomegalovirus T2211 expressing UL97 kinase H587Y mutant gene infected in human foreskin fibroblast,Other,20385869.0,
2138,518864,1,3,,103504490,3454,Unspecified,,,,,Ratio of EC50 for Human cytomegalovirus T3146 expressing UL97 kinase K599R mutant gene infected in human foreskin fibroblast to EC50 for Human cytomegalovirus T2211 expressing UL97 kinase H587Y mutant gene infected in human foreskin fibroblast,Other,20385869.0,
2139,518865,1,3,,103504490,3454,Unspecified,,,,,Ratio of EC50 for Human cytomegalovirus T3041 expressing UL97 kinase L600I mutant gene infected in human foreskin fibroblast to EC50 for Human cytomegalovirus T2211 expressing UL97 kinase H587Y mutant gene infected in human foreskin fibroblast,Other,20385869.0,
2140,518866,1,3,,103504490,3454,Unspecified,,,,,Ratio of EC50 for Human cytomegalovirus T3331 expressing UL97 kinase C603R mutant gene infected in human foreskin fibroblast to EC50 for Human cytomegalovirus T2211 expressing UL97 kinase H587Y mutant gene infected in human foreskin fibroblast,Other,20385869.0,
2141,518867,1,3,,103504490,3454,Unspecified,,,,,Ratio of EC50 for Human cytomegalovirus T3327 expressing UL97 kinase C603S mutant gene infected in human foreskin fibroblast to EC50 for Human cytomegalovirus T2211 expressing UL97 kinase H587Y mutant gene infected in human foreskin fibroblast,Other,20385869.0,
2142,518868,1,3,,103504490,3454,Unspecified,,,,,Ratio of EC50 for Human cytomegalovirus T3329 expressing UL97 kinase C603W mutant gene infected in human foreskin fibroblast to EC50 for Human cytomegalovirus T2211 expressing UL97 kinase H587Y mutant gene infected in human foreskin fibroblast,Other,20385869.0,
2143,518869,1,3,,103504490,3454,Unspecified,,,,,Ratio of EC50 for Human cytomegalovirus T3264 expressing UL97 kinase G623S mutant gene infected in human foreskin fibroblast to EC50 for Human cytomegalovirus T2211 expressing UL97 kinase H587Y mutant gene infected in human foreskin fibroblast,Other,20385869.0,
2144,518870,1,3,,103504490,3454,Unspecified,,,,,Ratio of EC50 for Human cytomegalovirus T3243 expressing UL97 kinase T659I mutant gene infected in human foreskin fibroblast to EC50 for Human cytomegalovirus T2211 expressing UL97 kinase H587Y mutant gene infected in human foreskin fibroblast,Other,20385869.0,
2145,518871,1,3,,103504490,3454,Unspecified,,,,,Ratio of EC50 for Human cytomegalovirus T3239 expressing UL97 kinase V665I mutant gene infected in human foreskin fibroblast to EC50 for Human cytomegalovirus T2211 expressing UL97 kinase H587Y mutant gene infected in human foreskin fibroblast,Other,20385869.0,
2146,521220,3,3,,103504490,3454,Active,,,,,Inhibition of neurosphere proliferation of mouse neural precursor cells by MTT assay,Other,17417631.0,
2147,523519,1,3,,103504490,3454,Inactive,,,,,Antiviral activity against 0.1 MOI human cytomegalovirus AD169 infected in human HFF assessed as inhibition of viral replication up to 72 hrs post infection,Other,20194695.0,
2148,523520,4,2,,103504490,3454,Active,,,1.9,EC50,Antiviral activity against human cytomegalovirus AD169 infected in human HFF assessed as inhibition of plaque formation by plaque reduction assay,Confirmatory,20194695.0,
2149,523521,4,2,,103504490,3454,Unspecified,,,550.0,CC50,Cytotoxicity against human HFF by MTT assay,Confirmatory,20194695.0,
2150,523522,1,4,,103504490,3454,Unspecified,,,,,"Selectivity index, ratio of CC50 for human HFF to EC50 for human cytomegalovirus AD169",Other,20194695.0,
2151,523525,1,3,,103504490,3454,Unspecified,,,,,Antiviral activity against human cytomegalovirus AD169 infected in human HFF assessed as inhibition of DNA synthesis after 72 hrs by qPCR,Other,20194695.0,
2152,523527,4,2,,103504490,3454,Active,,,0.8,EC50,Antiviral activity against 1 MOI human cytomegalovirus AD169 infected in human HFF assessed as virus yield reduction by yield reduction assay,Confirmatory,20194695.0,
2153,523528,4,2,,103504490,3454,Active,,,1.0,EC50,Antiviral activity against 0.1 MOI human cytomegalovirus AD169 infected in human HFF assessed as virus yield reduction by yield reduction assay,Confirmatory,20194695.0,
2154,523529,4,2,,103504490,3454,Active,,,1.0,EC50,Antiviral activity against 0.01 MOI human cytomegalovirus AD169 infected in human HFF assessed as virus yield reduction by yield reduction assay,Confirmatory,20194695.0,
2155,533773,4,2,,103504490,3454,Active,,,4.1,EC50,Antiviral activity against Human cytomegalovirus,Confirmatory,20547817.0,
2156,539914,3,1,,103504490,3454,Unspecified,,,,,Cytotoxicity against human HEL cells assessed as minimum concentration required to cause microscopically detectable alteration after 2 days,Other,20724039.0,
2157,539915,5,4,,103504490,3454,Unspecified,,,,,Antiviral activity against Herpes simplex virus-1 KOS infected in human HEL cells assessed as protection against virus-induced cytopathogenicity after 2 days,Other,20724039.0,
2158,539916,5,4,,103504490,3454,Unspecified,,,,,Antiviral activity against Herpes simplex virus-2 G infected in human HEL cells assessed as protection against virus-induced cytopathogenicity after 2 days,Other,20724039.0,
2159,539917,4,2,,103504490,3454,Unspecified,,,,,Antiviral activity against Vaccinia virus infected in human HEL cells assessed as protection against virus-induced cytopathogenicity after 2 days,Other,20724039.0,
2160,539918,4,2,,103504490,3454,Unspecified,,,,,Antiviral activity against Vesicular stomatitis virus infected in human HEL cells assessed as protection against virus-induced cytopathogenicity after 2 days,Other,20724039.0,
2161,539919,5,4,,103504490,3454,Unspecified,,,,,Antiviral activity against acyclovir-resistant TK deficient Herpes simplex virus-1 KOS infected in human HEL cells assessed as protection against virus-induced cytopathogenicity after 2 days,Other,20724039.0,
2162,539926,5,3,,103504490,3454,Unspecified,,,,,Cytotoxicity against cat CRFK cells by MTS assay,Other,20724039.0,
2163,539927,5,2,,103504490,3454,Unspecified,,,,,Antiviral activity against Feline coronavirus FIPV infected in cat CRFK cells assessed as protection against virus-induced cytopathogenicity after 2 days by MTS assay,Other,20724039.0,
2164,539928,4,2,,103504490,3454,Unspecified,,,,,Antiviral activity against Feline herpes virus infected in cat CRFK cells assessed as protection against virus-induced cytopathogenicity after 2 days by MTS assay,Other,20724039.0,
2165,540209,4,3,,103504490,3454,Unspecified,,,,,Volume of distribution at steady state in human after iv administration,Other,18426954.0,
2166,540210,4,3,,103504490,3454,Unspecified,,,,,Clearance in human after iv administration,Other,18426954.0,
2167,540211,2,5,,103504490,3454,Unspecified,,,,,Fraction unbound in human after iv administration,Other,18426954.0,
2168,540212,4,3,,103504490,3454,Unspecified,,,,,Mean residence time in human after iv administration,Other,18426954.0,
2169,540213,4,3,,103504490,3454,Unspecified,,,,,Half life in human after iv administration,Other,18426954.0,
2170,540253,1,1,,56424026,3454,Inactive,5031833.0,10073.0,,Potency,qHTS Assay for Inhibitors of RanGTP induced Rango (Ran-regulated importin-beta cargo) - Importin beta complex dissociation,Confirmatory,,
2171,540253,1,1,,56424026,3454,Inactive,5453555.0,5901.0,,Potency,qHTS Assay for Inhibitors of RanGTP induced Rango (Ran-regulated importin-beta cargo) - Importin beta complex dissociation,Confirmatory,,
2172,540253,1,1,,56424026,3454,Inactive,19923142.0,3837.0,,Potency,qHTS Assay for Inhibitors of RanGTP induced Rango (Ran-regulated importin-beta cargo) - Importin beta complex dissociation,Confirmatory,,
2173,540256,1,2,,8139883,3454,Inactive,,,,Potency,qHTS for Inhibitors of binding or entry into cells for Lassa Virus,Confirmatory,,
2174,540256,1,2,,50106328,3454,Inactive,,,,Potency,qHTS for Inhibitors of binding or entry into cells for Lassa Virus,Confirmatory,,
2175,540256,1,2,,90341439,3454,Inactive,,,,Potency,qHTS for Inhibitors of binding or entry into cells for Lassa Virus,Confirmatory,,
2176,540263,1,1,,56424026,3454,Inactive,5031833.0,10073.0,,Potency,qHTS Assay for Inhibitors of Rango (Ran-regulated importin-beta cargo) - Importin beta complex formation,Confirmatory,,
2177,540263,1,1,,56424026,3454,Inactive,19923142.0,3837.0,,Potency,qHTS Assay for Inhibitors of Rango (Ran-regulated importin-beta cargo) - Importin beta complex formation,Confirmatory,,
2178,540267,1,1,,50113251,3454,Inactive,,,,,Small Molecules that selectively kill Giardia lamblia: qHTS,Screening,,
2179,540267,1,1,,56424026,3454,Inactive,,,,,Small Molecules that selectively kill Giardia lamblia: qHTS,Screening,,
2180,540275,1,1,,8139883,3454,Inactive,74315350.0,7442.0,,,HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1,Screening,,
2181,540276,1,2,,8139883,3454,Inactive,420597.0,,,Potency,qHTS for inhibitors of binding or entry into cells for Marburg Virus,Confirmatory,,
2182,540276,1,2,,11111224,3454,Inactive,420597.0,,,Potency,qHTS for inhibitors of binding or entry into cells for Marburg Virus,Confirmatory,,
2183,540276,1,2,,11111225,3454,Inactive,420597.0,,,Potency,qHTS for inhibitors of binding or entry into cells for Marburg Virus,Confirmatory,,
2184,540276,1,2,,50106328,3454,Inconclusive,420597.0,,0.1259,Potency,qHTS for inhibitors of binding or entry into cells for Marburg Virus,Confirmatory,,
2185,540276,1,2,,50106329,3454,Inactive,420597.0,,,Potency,qHTS for inhibitors of binding or entry into cells for Marburg Virus,Confirmatory,,
2186,540276,1,2,,50113251,3454,Inactive,420597.0,,,Potency,qHTS for inhibitors of binding or entry into cells for Marburg Virus,Confirmatory,,
2187,540276,1,2,,85231063,3454,Inactive,420597.0,,,Potency,qHTS for inhibitors of binding or entry into cells for Marburg Virus,Confirmatory,,
2188,540276,1,2,,90341439,3454,Inactive,420597.0,,,Potency,qHTS for inhibitors of binding or entry into cells for Marburg Virus,Confirmatory,,
2189,540277,1,1,,8139883,3454,Inactive,74315350.0,7442.0,,,HTS Assay for Compounds that Act as Potentiators of the Vanilloid Receptor 1,Screening,,
2190,540295,1,1,,56424026,3454,Inactive,119508433.0,4160.0,,,TRFRET-based cell-based primary high throughput screening assay to identify biased ligands of the melanocortin 4 receptor (MC4R): antagonists of MC4R,Screening,,
2191,540299,1,2,,92125763,3454,Inactive,15607688.0,887529.0,,,A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis,Other,20850304.0,
2192,540303,1,1,,56424026,3454,Inactive,6679377.0,18792.0,,Potency,qHTS for Inhibitors of Cell Surface uPA Generation,Confirmatory,,
2193,540303,1,1,,56424026,3454,Inactive,7242179.0,18793.0,,Potency,qHTS for Inhibitors of Cell Surface uPA Generation,Confirmatory,,
2194,540303,1,1,,56424026,3454,Inactive,257471003.0,18815.0,,Potency,qHTS for Inhibitors of Cell Surface uPA Generation,Confirmatory,,
2195,540308,1,1,,56424026,3454,Inactive,119508433.0,4160.0,,,Luminescence-based cell-based primary high throughput screening assay to identify biased ligands of the melanocortin 4 receptor (MC4R): agonists of MC4R,Screening,,
2196,540317,1,1,,50113251,3454,Inactive,187960037.0,10951.0,,Potency,HTS for Inhibitors of HP1-beta Chromodomain Interactions with Methylated Histone Tails,Confirmatory,,
2197,540317,1,1,,56424026,3454,Inactive,187960037.0,10951.0,,Potency,HTS for Inhibitors of HP1-beta Chromodomain Interactions with Methylated Histone Tails,Confirmatory,,
2198,540336,1,1,,56424026,3454,Inactive,68474550.0,3639678.0,,,Rtt109/Vps75 Measured in Biochemical System Using Plate Reader - 2106-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
2199,540336,1,1,,56424026,3454,Inactive,68488893.0,3646682.0,,,Rtt109/Vps75 Measured in Biochemical System Using Plate Reader - 2106-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
2200,540364,1,2,,56424026,3454,Inactive,,2395.0,,,Luminescence-based cell-based primary high throughput screening assay to identify activators of the GAA850 frataxin (FXN) promoter,Screening,,
2201,544707,4,2,,103504490,3454,Active,,,1.9,EC50,Antiviral activity against Human cytomegalovirus AD169 infected in human foreskin fibroblast assessed as inhibition of viral replication after 10 days by plaque reduction assay,Confirmatory,19015358.0,
2202,544708,4,2,,103504490,3454,Unspecified,,,550.0,CC50,Cytotoxicity against human foreskin fibroblast after 5 days by MTT assay,Confirmatory,19015358.0,
2203,544709,1,3,,103504490,3454,Unspecified,,,,,"Selectivity index, ratio of CC50 for Human foreskin fibroblast to EC50 for Human cytomegalovirus AD169",Other,19015358.0,
2204,548420,5,4,,103504490,3454,Unspecified,,,,,Cytotoxicity against cat CRFK cells assessed as cell viability by MTS assay,Other,20971531.0,
2205,548421,4,3,,103504490,3454,Unspecified,,,,,Antiviral activity against Feline herpesvirus 1 infected in cat CRFK cells assessed as inhibition of virus induced cytopathicity after 2 to 4 days by MTS assay,Other,20971531.0,
2206,548422,4,3,,103504490,3454,Unspecified,,,,,Antiviral activity against Feline coronavirus infected in cat CRFK cells assessed as inhibition of virus induced cytopathicity after 2 to 4 days by MTS assay,Other,20971531.0,
2207,548423,4,3,,103504490,3454,Unspecified,,,,,Cytotoxicity against human HEL cells assessed as altered cell morphology,Other,20971531.0,
2208,548424,5,4,,103504490,3454,Unspecified,,,,,Antiviral activity against Herpes simplex virus 1 KOS infected in HEL cells assessed as inhibition of virus induced cytopathicity after 2 to 4 days by MTS assay,Other,20971531.0,
2209,548425,5,4,,103504490,3454,Unspecified,,,,,Antiviral activity against Herpes simplex virus 2 G infected in HEL cells assessed as inhibition of virus induced cytopathicity after 2 to 4 days by MTS assay,Other,20971531.0,
2210,548426,4,3,,103504490,3454,Unspecified,,,,,Antiviral activity against Vaccinia virus infected in HEL cells assessed as inhibition of virus induced cytopathicity after 2 to 4 days by MTS assay,Other,20971531.0,
2211,548427,4,3,,103504490,3454,Unspecified,,,,,Antiviral activity against Vesicular stomatitis virus infected in HEL cells assessed as inhibition of virus induced cytopathicity after 2 to 4 days by MTS assay,Other,20971531.0,
2212,548428,5,4,,103504490,3454,Unspecified,,,,,Antiviral activity against thymidine kinase deficient acyclovir-resistant Herpes simplex virus 1 KOS infected in HEL cells assessed as inhibition of virus induced cytopathicity after 2 to 4 days by MTS assay,Other,20971531.0,
2213,553336,5,3,,103504490,3454,Unspecified,,,,CC50,Cytotoxicity against human HEL cells after 3 days,Confirmatory,21128666.0,
2214,553337,4,4,,103504490,3454,Active,,,0.08,EC50,Antiviral activity against HSV1 KOS infected in human HEL cells assessed as reduction of virus-induced cytopathogenicity after 7 days,Confirmatory,21128666.0,
2215,553338,4,4,,103504490,3454,Active,,,0.05,EC50,Antiviral activity against HSV2 G infected in human HEL cells assessed as reduction of virus-induced cytopathogenicity after 7 days,Confirmatory,21128666.0,
2216,553339,4,4,,103504490,3454,Active,,,3.0,EC50,Antiviral activity against acyclovir-resistant thymidine kinase deficient HSV1 KOS infected in human HEL cells assessed as reduction of virus-induced cytopathogenicity after 7 days,Confirmatory,21128666.0,
2217,553340,4,2,,103504490,3454,Unspecified,,,100.0,EC50,Antiviral activity against Vaccinia virus infected in human HEL cells assessed as reduction of virus-induced cytopathogenicity after 7 days,Confirmatory,21128666.0,
2218,553341,4,2,,103504490,3454,Active,,,5.2,EC50,Antiviral activity against HCMV AD169/Davis infected in human HEL cells assessed as reduction of virus-induced cytopathogenicity after 7 days,Confirmatory,21128666.0,
2219,563747,4,2,,103504490,3454,Active,,,3.3,EC50,Antiviral activity against human cytomegalovirus AD169 infected in HFF after 8 to 10 days by plaque reduction assay,Confirmatory,19770274.0,
2220,563776,4,2,,103504490,3454,Active,,,44.0,EC50,Antiviral activity against human cytomegalovirus RC314 harboring UL97 K355M mutant gene infected in HFF after 8 to 10 days by plaque reduction assay,Confirmatory,19770274.0,
2221,563777,4,2,,103504490,3454,Unspecified,,,53.0,EC50,"Antiviral activity against human cytomegalovirus C8914-6 harboring UL97 I244V, L595F and UL54 L501F mutant gene infected in HFF after 8 to 10 days by plaque reduction assay",Confirmatory,19770274.0,
2222,563778,4,2,,103504490,3454,Unspecified,,,230.0,EC50,Antiviral activity against human cytomegalovirus 759D100 harboring deletion mutation in UL97 gene and UL54 A987G mutant gene infected in HFF after 8 to 10 days by plaque reduction assay,Confirmatory,19770274.0,
2223,563779,4,2,,103504490,3454,Active,,,15.0,EC50,Antiviral activity against human cytomegalovirus 1117 harboring UL54 K513N mutant gene infected in HFF after 8 to 10 days by plaque reduction assay,Confirmatory,19770274.0,
2224,563780,4,2,,103504490,3454,Active,,,7.2,EC50,Antiviral activity against human cytomegalovirus VR4955 harboring UL54 T700A mutant gene infected in HFF after 8 to 10 days by plaque reduction assay,Confirmatory,19770274.0,
2225,563781,4,2,,103504490,3454,Active,,,9.8,EC50,Antiviral activity against human cytomegalovirus PFAB300 harboring UL54 L724V mutant gene infected in HFF after 8 to 10 days by plaque reduction assay,Confirmatory,19770274.0,
2226,567091,2,6,,103504490,3454,Unspecified,,,,,Drug absorption in human assessed as human intestinal absorption rate,Other,21112128.0,
2227,569231,4,4,,103504490,3454,Active,,,0.01,EC50,Antiviral activity against HSV1 KOS infected in HEL cells assessed as inhibition of virus-induced cytopathic effect,Confirmatory,21232828.0,
2228,569232,4,4,,103504490,3454,Active,,,0.1,EC50,Antiviral activity against thymidine kinase deficient acyclovir-resistant HSV1 KOS infected in HEL cells assessed as inhibition of virus-induced cytopathic effect,Confirmatory,21232828.0,
2229,569233,4,4,,103504490,3454,Active,,,0.04,EC50,Antiviral activity against HSV2 G infected in HEL cells assessed as inhibition of virus-induced cytopathic effect,Confirmatory,21232828.0,
2230,569238,4,2,,103504490,3454,Unspecified,,,100.0,EC50,Antiviral activity against Vaccinia virus infected in HEL cells assessed as inhibition of virus-induced cytopathic effect,Confirmatory,21232828.0,
2231,569239,5,3,,103504490,3454,Unspecified,,,,CC50,Cytotoxicity against HEL cells after 3 days by coulter counter analysis,Confirmatory,21232828.0,
2232,570657,1,3,,103504490,3454,Unspecified,,,,,"Bioavailability in solid organ transplant patient exhibiting 57 L/hr creatinine clearance infected with cytomegalovirus at 5 mg/kg, iv bid for 5 days followed by 900 mg of oral valganciclovir dosed twice daily for 16 days dose adjustment for renal function by final population pharmacokinetic model",Other,19738014.0,
2233,570658,4,1,,103504490,3454,Unspecified,,,,,"Clearance in solid organ transplant patient exhibiting 57 L/hr creatinine clearance infected with cytomegalovirus at 5 mg/kg, iv bid for 5 days followed by 900 mg of oral valganciclovir dosed twice daily for 16 days dose adjustment for renal function by basal population pharmacokinetic model",Other,19738014.0,
2234,570659,2,2,,103504490,3454,Unspecified,,,,,"Central volume of distribution in solid organ transplant patient exhibiting 57 L/hr creatinine clearance infected with cytomegalovirus at 5 mg/kg, iv bid for 5 days followed by 900 mg of oral valganciclovir dosed twice daily for 16 days dose adjustment for renal function by basal population pharmacokinetic model",Other,19738014.0,
2235,570660,4,1,,103504490,3454,Unspecified,,,,,"Intercompartmental clearance between central and peripheral compartments in solid organ transplant patient exhibiting 57 L/hr creatinine clearance infected with cytomegalovirus at 5 mg/kg, iv bid for 5 days followed by 900 mg of oral valganciclovir dosed twice daily for 16 days dose adjustment for renal function by basal population pharmacokinetic model",Other,19738014.0,
2236,570661,2,2,,103504490,3454,Unspecified,,,,,"Peripheral volume of distribution in solid organ transplant patient exhibiting 57 L/hr creatinine clearance infected with cytomegalovirus at 5 mg/kg, iv bid for 5 days followed by 900 mg of oral valganciclovir dosed twice daily for 16 days dose adjustment for renal function by basal population pharmacokinetic model",Other,19738014.0,
2237,570662,5,1,,103504490,3454,Unspecified,,,,,"Drug absorption in solid organ transplant patient exhibiting 57 L/hr creatinine clearance infected with cytomegalovirus assessed as first-order absorption rate constant at 5 mg/kg, iv bid for 5 days followed by 900 mg of oral valganciclovir dosed twice daily for 16 days dose adjustment for renal function by basal population pharmacokinetic model",Other,19738014.0,
2238,570663,1,3,,103504490,3454,Unspecified,,,,,"Bioavailability in solid organ transplant patient exhibiting 57 L/hr creatinine clearance infected with cytomegalovirus at 5 mg/kg, iv bid for 5 days followed by 900 mg of oral valganciclovir dosed twice daily for 16 days dose adjustment for renal function by basal population pharmacokinetic model",Other,19738014.0,
2239,572819,4,4,,103504490,3454,Active,,,3.0,EC50,Antiviral activity against Human cytomegalovirus Towne infected in human hhTERT-BJ1 cells assessed as inhibition of virus mediated DNA synthesis after 2 days,Confirmatory,18458124.0,
2240,572820,4,4,,103504490,3454,Active,,,25.9,EC50,Antiviral activity against Guinea pig cytomegalovirus (strain 22122; ATCC VR-682) infected in guinea pig lung fibroblast after 6 to 7 days by plaque reduction assay,Confirmatory,18458124.0,
2241,572821,4,4,,103504490,3454,Active,,,1.4,EC50,Antiviral activity against Human cytomegalovirus Towne infected in human HFL after 10 to 12 days by plaque reduction assay,Confirmatory,18458124.0,
2242,572822,4,3,,103504490,3454,Active,,,5.7,EC50,Antiviral activity against Murine cytomegalovirus strain Smith infected in mouse NIH 3T3 cells after 4 to 5 days by plaque reduction assay,Confirmatory,18458124.0,
2243,574179,4,1,,103504490,3454,Unspecified,,,,,"Intercompartmental clearance between central and peripheral compartments in solid organ transplant patient exhibiting 57 L/hr creatinine clearance infected with cytomegalovirus at 5 mg/kg, iv bid for 5 days followed by 900 mg of oral valganciclovir dosed twice daily for 16 days dose adjustment for renal function by final population pharmacokinetic model",Other,19738014.0,
2244,574180,2,2,,103504490,3454,Unspecified,,,,,"Central volume of distribution in solid organ transplant patient exhibiting 57 L/hr creatinine clearance infected with cytomegalovirus at 5 mg/kg, iv bid for 5 days followed by 900 mg of oral valganciclovir dosed twice daily for 16 days dose adjustment for renal function by final population pharmacokinetic model",Other,19738014.0,
2245,574181,4,1,,103504490,3454,Unspecified,,,,,"Clearance in solid organ transplant patient exhibiting 57 L/hr creatinine clearance infected with cytomegalovirus at 5 mg/kg, iv bid for 5 days followed by 900 mg of oral valganciclovir dosed twice daily for 16 days dose adjustment for renal function by final population pharmacokinetic model",Other,19738014.0,
2246,574182,2,2,,103504490,3454,Unspecified,,,,,"Peripheral volume of distribution in solid organ transplant patient exhibiting 57 L/hr creatinine clearance infected with cytomegalovirus at 5 mg/kg, iv bid for 5 days followed by 900 mg of oral valganciclovir dosed twice daily for 16 days dose adjustment for renal function by final population pharmacokinetic model",Other,19738014.0,
2247,574183,5,1,,103504490,3454,Unspecified,,,,,"Drug absorption in solid organ transplant patient exhibiting 57 L/hr creatinine clearance infected with cytomegalovirus assessed as first-order absorption rate constant at 5 mg/kg, iv bid for 5 days followed by 900 mg of oral valganciclovir dosed twice daily for 16 days dose adjustment for renal function",Other,19738014.0,
2248,574383,4,2,,103504490,3454,Active,,,7.0,EC50,Antiviral activity against human cytomegalovirus infected in HELF assessed as decrease in plaque formation after 7 days by microscopy,Confirmatory,21256035.0,
2249,574384,5,3,,103504490,3454,Unspecified,,,580.0,CC50,Cytotoxicity against HELF cells assessed as after 3 days by Coulter counting analysis,Confirmatory,21256035.0,
2250,584546,4,4,,103504490,3454,Inactive,,,,IC50,Inhibition of inosine/L-alanine-induced Bacillus anthracis Sterne 34F2 spore germination pretreated for 15 mins before inosine/L-alanine challenge,Confirmatory,20921305.0,
2251,584547,4,4,,103504490,3454,Inactive,,,,IC50,Antibacterial activity against Bacillus anthracis Sterne 34F2 infected in mouse J774A.1 cells assessed as protection against bacteria-induced cytotoxicity using propidium iodide staining after 3 hrs measured every hours for up to 7 hrs,Confirmatory,20921305.0,
2252,584550,1,4,,103504490,3454,Unspecified,,,,,Cytotoxicity against mouse J774A1 cells,Other,20921305.0,
2253,588211,2,3,,103504490,3454,Unspecified,,,,,"Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in humans",Other,20014752.0,
2254,588212,2,3,,103504490,3454,Unspecified,,,,,"Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in rodents",Other,20014752.0,
2255,588213,2,3,,103504490,3454,Unspecified,,,,,"Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in non-rodents",Other,20014752.0,
2256,588214,2,3,,103504490,3454,Unspecified,,,,,"FDA HLAED, liver enzyme composite activity",Other,16472241.0,
2257,588215,2,3,,103504490,3454,Active,,,,,"FDA HLAED, alkaline phosphatase increase",Other,16472241.0,
2258,588216,2,3,,103504490,3454,Unspecified,,,,,"FDA HLAED, serum glutamic oxaloacetic transaminase (SGOT) increase",Other,16472241.0,
2259,588217,2,3,,103504490,3454,Unspecified,,,,,"FDA HLAED, serum glutamic pyruvic transaminase (SGPT) increase",Other,16472241.0,
2260,588218,2,3,,103504490,3454,Unspecified,,,,,"FDA HLAED, lactate dehydrogenase (LDH) increase",Other,16472241.0,
2261,588219,2,3,,103504490,3454,Unspecified,,,,,"FDA HLAED, gamma-glutamyl transferase (GGT) increase",Other,16472241.0,
2262,588334,1,1,,56424026,3454,Inactive,,,,,MITF Measured in Cell-Based System Using Plate Reader - 2084-01_Activator_SinglePoint_HTS_Activity,Screening,,
2263,588335,1,1,,56424026,3454,Inactive,,,,,Counterscreen for inhibitors of the fructose-bisphosphate aldolase (FBA) of M. tuberculosis: Absorbance-based biochemical high throughput Glycerophosphate Dehydrogenase-Triosephosphate Isomerase (GDH-TPI) full deck assay to identify assay artifacts,Screening,,
2264,588342,1,1,,8139883,3454,Inactive,160794.0,,,Potency,qHTS profiling assay for firefly luciferase inhibitor/activator using purifed enzyme and Km concentrations of substrates (counterscreen for miR-21 project),Confirmatory,,
2265,588349,1,1,,90341439,3454,Inactive,,,,Potency,qHTS for Inhibitors of ATXN expression: Validation of Cytotoxic Assay,Confirmatory,,
2266,588352,1,2,,56424026,3454,Inactive,32307126.0,8202.0,,,Luminescence-based cell-based primary high throughput screening assay to identify inhibitors of the Steroid Receptor Coactivator 3 (SRC3; NCOA3),Screening,,
2267,588354,1,1,,56424026,3454,Inactive,22538455.0,8648.0,,,Luminescence-based cell-based primary high throughput screening assay to identify inhibitors of the Steroid Receptor Coactivator 1 (SRC1; NCOA1),Screening,,
2268,588358,1,2,,56424026,3454,Inactive,,,,,HTS to Find Inhibitors of Pathogenic Pemphigus Antibodies,Screening,,
2269,588368,1,2,,8139883,3454,Inactive,,,,,HTS to Find Inhibitors of Pathogenic Pemphigus Antibodies from validation set,Screening,,
2270,588378,1,1,,90341439,3454,Inactive,171543895.0,6311.0,,Potency,qHTS for Inhibitors of ATXN expression: Validation,Confirmatory,,
2271,588391,1,1,,56424026,3454,Inactive,14790033.0,5034.0,,,Turbidometric Biochemical  Primary HTS  to identify inhibitors of Protein Disulfide Isomerase Measured in Biochemical System Using Plate Reader - 2137-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
2272,588405,1,1,,56424026,3454,Inactive,78486550.0,171071.0,,,HTS Assay for Peg3 Promoter Inhibitors,Screening,,
2273,588413,1,2,,56424026,3454,Inactive,6009644.0,14632.0,,,uHTS identification of Gli-Sufu Antagonists in a luminescence reporter assay,Screening,,
2274,588436,1,1,,56424026,3454,Inactive,,,,,"Cholera Quorum: HTS for inducers of light production in the absence ofautoinducers using BH1578 (luxS deficient, cqsA deficient) Measured in Microorganism System Using Plate Reader - 2132-01_Agonist_SinglePoint_HTS_Activity",Screening,,
2275,588453,1,1,,50113251,3454,Inactive,8659577.0,58819.0,,Potency,qHTS Assay for Inhibitors of Mammalian Selenoprotein Thioredoxin Reductase 1 (TrxR1): qHTS,Confirmatory,,
2276,588453,1,1,,56424026,3454,Inactive,8659577.0,58819.0,,Potency,qHTS Assay for Inhibitors of Mammalian Selenoprotein Thioredoxin Reductase 1 (TrxR1): qHTS,Confirmatory,,
2277,588453,1,1,,85231063,3454,Inactive,8659577.0,58819.0,,Potency,qHTS Assay for Inhibitors of Mammalian Selenoprotein Thioredoxin Reductase 1 (TrxR1): qHTS,Confirmatory,,
2278,588453,1,1,,90341439,3454,Inactive,8659577.0,58819.0,7.0795,Potency,qHTS Assay for Inhibitors of Mammalian Selenoprotein Thioredoxin Reductase 1 (TrxR1): qHTS,Confirmatory,,
2279,588456,1,1,,50113251,3454,Inactive,8659577.0,58819.0,,Potency,qHTS Assay for Substrates of Mammalian Selenoprotein Thioredoxin Reductase 1 (TrxR1): qHTS,Confirmatory,,
2280,588456,1,1,,56424026,3454,Inactive,8659577.0,58819.0,,Potency,qHTS Assay for Substrates of Mammalian Selenoprotein Thioredoxin Reductase 1 (TrxR1): qHTS,Confirmatory,,
2281,588456,1,1,,90341439,3454,Inactive,8659577.0,58819.0,,Potency,qHTS Assay for Substrates of Mammalian Selenoprotein Thioredoxin Reductase 1 (TrxR1): qHTS,Confirmatory,,
2282,588458,1,1,,56424026,3454,Inactive,4503351.0,1786.0,,,uHTS identification of DNMT1 inhibitors in a Fluorescent Molecular Beacon assay,Screening,,
2283,588459,1,2,,8139883,3454,Inactive,168184763.0,,,,"High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, Validation compound set",Screening,16604538.0,
2284,588459,1,2,,8139883,3454,Inactive,168184763.0,,,,"High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, Validation compound set",Screening,20035615.0,
2285,588459,1,2,,8139883,3454,Inactive,168184763.0,,,,"High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, Validation compound set",Screening,20938917.0,
2286,588460,1,2,,8139883,3454,Inactive,,5185061.0,,,"High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, Validation Compound Set",Screening,16604538.0,
2287,588460,1,2,,8139883,3454,Inactive,,5185061.0,,,"High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, Validation Compound Set",Screening,20035615.0,
2288,588460,1,2,,8139883,3454,Inactive,,5185061.0,,,"High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, Validation Compound Set",Screening,20938917.0,
2289,588461,1,2,,8139883,3454,Inactive,21392848.0,,,,"High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, Validation compound set",Screening,16604538.0,
2290,588461,1,2,,8139883,3454,Inactive,21392848.0,,,,"High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, Validation compound set",Screening,20035615.0,
2291,588461,1,2,,8139883,3454,Inactive,21392848.0,,,,"High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, Validation compound set",Screening,20938917.0,
2292,588473,1,1,,56424026,3454,Inactive,30219.0,1393.0,,,uHTS identification of agonists of the CRF-binding protein and CRF-R2 receptor complex,Screening,,
2293,588473,1,1,,56424026,3454,Inactive,38349113.0,1395.0,,,uHTS identification of agonists of the CRF-binding protein and CRF-R2 receptor complex,Screening,,
2294,588475,1,2,,56424026,3454,Inactive,30219.0,1393.0,,,uHTS identification of antagonists of the CRF-binding protein and CRF-R2 receptor complex,Screening,,
2295,588475,1,2,,56424026,3454,Inactive,38349113.0,1395.0,,,uHTS identification of antagonists of the CRF-binding protein and CRF-R2 receptor complex,Screening,,
2296,588478,1,2,,124801107,3454,Inactive,4877999.0,51377.0,,,"A screen for small molecule inhibitors of the human deubiquitinating enzyme, UCH37",Other,,
2297,588489,1,1,,56424026,3454,Inactive,46367787.0,26986.0,,,uHTS identification of microRNA-mediated mRNA deadenylation inhibitors by fluoresence polarization assay,Screening,,
2298,588492,1,1,,56424026,3454,Inactive,,,,,uHTS identification of small molecule modulators of myocardial damage,Screening,,
2299,588493,1,2,,56424026,3454,Inactive,16306916.0,10213.0,,,uHTS identification of inhibitors of Rpn11 in a Fluorescent Polarization assay,Screening,,
2300,588497,1,2,,56424026,3454,Inactive,168184763.0,,,,"High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set",Screening,16604538.0,
2301,588497,1,2,,56424026,3454,Inactive,168184763.0,,,,"High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set",Screening,20035615.0,
2302,588497,1,2,,56424026,3454,Inactive,168184763.0,,,,"High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set",Screening,20938917.0,
2303,588499,1,3,,56424026,3454,Inactive,148378801.0,5185061.0,,,"High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set",Screening,16604538.0,
2304,588499,1,3,,56424026,3454,Inactive,148378801.0,5185061.0,,,"High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set",Screening,20035615.0,
2305,588499,1,3,,56424026,3454,Inactive,148378801.0,5185061.0,,,"High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set",Screening,20938917.0,
2306,588501,1,2,,56424026,3454,Inactive,21392848.0,,,,"High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set",Screening,16604538.0,
2307,588501,1,2,,56424026,3454,Inactive,21392848.0,,,,"High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set",Screening,20035615.0,
2308,588501,1,2,,56424026,3454,Inactive,21392848.0,,,,"High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set",Screening,20938917.0,
2309,588506,1,2,,8139883,3454,Inactive,,,,,Phenotypic HTS multiplex for antifungal efflux pump inhibitors with Validation compound Set,Screening,,
2310,588511,1,2,,56424026,3454,Inactive,334278898.0,101772.0,,,Primary cell-based high-throughput screening for identification of compounds that inhibit/block calcium-activated chloride channels (TMEM16A),Screening,,
2311,588519,1,2,,92125763,3454,Inactive,52695378.0,,,,A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities,Other,21722674.0,
2312,588549,1,1,,56424026,3454,Inactive,1781172.0,,,,Fluorescence polarization to screen for inhibitor that competite the binding of FadD28 to bisubstrate Measured in Biochemical System Using Plate Reader - 2147-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
2313,588550,1,1,,8139883,3454,Inactive,9955963.0,10058.0,,,Flow Cytometric HTS Screen for inhibitors of the ABC transporter ABCB6 for Validation Compound Set,Screening,,
2314,588579,1,1,,11111225,3454,Inactive,7705344.0,51426.0,,Potency,qHTS for Inhibitors of Polymerase Kappa,Confirmatory,,
2315,588579,1,1,,50113251,3454,Inactive,7705344.0,51426.0,,Potency,qHTS for Inhibitors of Polymerase Kappa,Confirmatory,,
2316,588579,1,1,,56424026,3454,Inactive,7705344.0,51426.0,,Potency,qHTS for Inhibitors of Polymerase Kappa,Confirmatory,,
2317,588579,1,1,,90341439,3454,Inactive,7705344.0,51426.0,,Potency,qHTS for Inhibitors of Polymerase Kappa,Confirmatory,,
2318,588590,1,1,,50106328,3454,Inactive,154350220.0,11201.0,,Potency,qHTS for Inhibitors of Polymerase Iota,Confirmatory,,
2319,588590,1,1,,50113251,3454,Inactive,154350220.0,11201.0,,Potency,qHTS for Inhibitors of Polymerase Iota,Confirmatory,,
2320,588590,1,1,,56424026,3454,Inconclusive,154350220.0,11201.0,39.8107,Potency,qHTS for Inhibitors of Polymerase Iota,Confirmatory,,
2321,588591,1,1,,50106328,3454,Inactive,5729982.0,5429.0,,Potency,qHTS for Inhibitors of Polymerase Eta,Confirmatory,,
2322,588591,1,1,,56424026,3454,Inactive,5729982.0,5429.0,,Potency,qHTS for Inhibitors of Polymerase Eta,Confirmatory,,
2323,588621,1,1,,56424026,3454,Inactive,90652859.0,84867.0,,,uHTS identification of small molecule inhibitors of Striatal-Enriched Phosphatase via a fluorescence intensity assay,Screening,,
2324,588627,1,1,,56424026,3454,Inactive,195969650.0,259249.0,,,Primary cell-based high-throughput screening for identification of compounds that activate MrgX1 receptor signaling,Screening,,
2325,588664,1,2,,56424026,3454,Inactive,62362414.0,25.0,,,"TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)",Screening,,
2326,588664,1,2,,56424026,3454,Inactive,68989256.0,9610.0,,,"TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)",Screening,,
2327,588674,1,2,,56424026,3454,Inactive,,,,,Schnurri-3 Inhibitors: specific inducers of adult bone formation Measured in Cell-Based System Using Plate Reader - 2134-01_Inhibitor_SinglePoint_HTS_Activity_Set2,Screening,,
2328,588675,1,1,,56424026,3454,Inactive,195969650.0,259249.0,,,Primary cell-based high-throughput screening for identification of compounds that allosterically activate MrgX1 receptor signaling,Screening,,
2329,588676,1,1,,56424026,3454,Inactive,195969650.0,259249.0,,,Primary cell-based high-throughput screening for identification of compounds that antagonize MrgX1 receptor signaling,Screening,,
2330,588685,1,1,,8139883,3454,Inactive,,3205.0,,,HTS to identify compounds that promote myeloid differentiation with Validation compound set,Screening,,
2331,588689,1,1,,56424026,3454,Inactive,219689243.0,,,IC50,Primary and Confirmatory Screening for Flavivirus Genomic Capping Enzyme Inhibition,Confirmatory,,
2332,588692,2,1,,56424026,3454,Inactive,,,,,Luciferase Reporter Cell Based HTS to identify inhibitors of N-linked Glycosylation Measured in Cell-Based System Using Plate Reader - 2146-01_Inhibitor_SinglePoint_HTS_Activity_Set2,Screening,,
2333,588726,1,2,,56424026,3454,Inactive,15607504.0,886474.0,,,Fluorescence-based biochemical primary high throughput screening assay to identify inhibitors of the fructose-bisphosphate aldolase (FBA) of M. tuberculosis,Screening,,
2334,588727,1,1,,56424026,3454,Inactive,,,,IC50,"A Cell-Based Confirmatory Screen for Compounds that Inhibit VEEV, TC-83",Confirmatory,,
2335,588795,1,1,,50113251,3454,Inactive,4758356.0,2237.0,,Potency,qHTS Assay for the Inhibitors of Human Flap endonuclease 1 (FEN1).,Confirmatory,,
2336,588795,1,1,,56424026,3454,Inactive,4758356.0,2237.0,,Potency,qHTS Assay for the Inhibitors of Human Flap endonuclease 1 (FEN1).,Confirmatory,,
2337,588795,1,1,,90341439,3454,Inactive,4758356.0,2237.0,,Potency,qHTS Assay for the Inhibitors of Human Flap endonuclease 1 (FEN1).,Confirmatory,,
2338,588814,1,3,,56424026,3454,Inactive,37622910.0,1128.0,,,"Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)",Screening,,
2339,588819,1,4,,56424026,3454,Inactive,37622910.0,1128.0,,,Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).,Screening,,
2340,588834,2,1,,50106328,3454,Inactive,325651834.0,3757.0,,Potency,qHTS Assay for Small Molecule Inhibitors of the Human hERG Channel Activity,Confirmatory,,
2341,588834,2,1,,144203711,3454,Inactive,325651834.0,3757.0,,Potency,qHTS Assay for Small Molecule Inhibitors of the Human hERG Channel Activity,Confirmatory,,
2342,588849,1,1,,8139883,3454,Inactive,73858575.0,9986.0,,AC50_uM,Human Ras-Converting Enzyme Inhibition Assay Measured in Biochemical System Using Plate Reader - 2034-04_Inhibitor_Dose_CherryPick_Activity,Confirmatory,,
2343,588850,1,1,,56424026,3454,Inactive,90421313.0,1080.0,,,uHTS identification of cystic fibrosis induced NFkb Inhibitors in a fluoresence assay,Screening,,
2344,588852,1,3,,56424026,3454,Inactive,37622910.0,1128.0,,,Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1),Screening,,
2345,588855,1,1,,50113251,3454,Inactive,18418623.0,4088.0,,Potency,qHTS for Inhibitors of TGF-b,Confirmatory,,
2346,588855,1,1,,56424026,3454,Inactive,18418623.0,4088.0,,Potency,qHTS for Inhibitors of TGF-b,Confirmatory,,
2347,588856,1,1,,50113251,3454,Inactive,,,,Potency,qHTS for Inhibitors of TGF-b: Cytotox Counterscreen,Confirmatory,,
2348,588856,1,1,,56424026,3454,Inactive,,,,Potency,qHTS for Inhibitors of TGF-b: Cytotox Counterscreen,Confirmatory,,
2349,592681,1,4,,103504490,3454,Unspecified,,,,,Apparent permeability across human Caco2 cell membrane after 2 hrs by LC-MS/MS analysis,Other,21458999.0,
2350,595576,3,2,,103504490,3454,Inconclusive,,,,EC50,Antiviral activity against Varicella-zoster virus Ellen infected in 1 hr pretreated human HFF cells assessed as reduction in viral-induced cytopathic effect by neutral red uptake assay,Confirmatory,21376429.0,
2351,595577,3,2,,103504490,3454,Active,,,0.04,EC50,Antiviral activity against Human cytomegalovirus (strain AD169) infected in 1 hr pretreated human HFF cells assessed as reduction in viral-induced cytopathic effect by neutral red uptake assay,Confirmatory,21376429.0,
2352,595578,3,2,,103504490,3454,Inconclusive,,,,CC50,Cytotoxicity against human HFF cells infected with Varicella-zoster virus Ellen assessed as viable cells by neutral red uptake assay,Confirmatory,21376429.0,
2353,595579,3,2,,103504490,3454,Unspecified,,,100.0,CC50,Cytotoxicity against human HFF cells infected with Human cytomegalovirus AD169 assessed as viable cells by neutral red uptake assay,Confirmatory,21376429.0,
2354,595580,1,4,,103504490,3454,Inconclusive,,,,,"Selectivity index, ratio of CC50 for human HFF cells infected with Hepatitis C virus to EC50 for Varicella-zoster virus Ellen",Other,21376429.0,
2355,595581,1,4,,103504490,3454,Unspecified,,,,,"Selectivity index, ratio of CC50 for human HFF cells infected with Hepatitis C virus to EC50 for Human cytomegalovirus AD169",Other,21376429.0,
2356,595588,3,2,,103504490,3454,Inconclusive,,,,EC50,Antiviral activity against Cowpox virus (Brighton Red) infected in human HFF cells assessed as reduction in viral-induced cytopathic effect by neutral red uptake assay,Confirmatory,21376429.0,
2357,595589,3,2,,103504490,3454,Inactive,,,,EC50,Antiviral activity against Vaccinia virus Copenhagen infected in human HFF cells assessed as reduction in viral-induced cytopathic effect by neutral red uptake assay,Confirmatory,21376429.0,
2358,595590,3,2,,103504490,3454,Inconclusive,,,,CC50,Cytotoxicity against human HFF cells infected with Cowpox virus (Brighton Red) assessed as viable cells by neutral red uptake assay,Confirmatory,21376429.0,
2359,595592,1,4,,103504490,3454,Inconclusive,,,,,"Selectivity index, ratio of CC50 for human HFF cells infected with Cowpox virus (Brighton Red) to EC50 for Cowpox virus (Brighton Red)",Other,21376429.0,
2360,602123,1,1,,56424026,3454,Inactive,16128424.0,945085.0,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of Escherichia coli DNA-binding ATP-dependent protease La (eLon),Screening,,
2361,602141,1,1,,56424026,3454,Inactive,,,,,uHTS determination of small molecule cytotoxicity in a fluorescence assay to identify cystic fibrosis induced NFkb Inhibitors,Screening,,
2362,602162,1,1,,56424026,3454,Inactive,9955963.0,10058.0,,,Flow Cytometric HTS Screen for inhibitors of the ABC transporter ABCB6 for MLPCN Compound Set,Screening,,
2363,602163,1,1,,56424026,3454,Inactive,73586699.0,281312.0,,,Absorbance-based biochemical primary high throughput screening assay to identify activators of Methionine sulfoxide reductase A (MsrA),Screening,,
2364,602179,1,2,,56424026,3454,Inactive,89573979.0,3417.0,,Potency,qHTS for Inhibitors of mutant isocitrate dehydrogenase 1 (IDH1): qHTS,Confirmatory,,
2365,602229,1,1,,56424026,3454,Inactive,216409728.0,10002.0,,,"Luminescence-based cell-based high throughput primary screening assay to identify agonists of nuclear receptor subfamily 2, group E, member 3 (NR2E3)",Screening,,
2366,602233,1,1,,56424026,3454,Inactive,115503961.0,4357161.0,,Potency,qHTS Assay to Find Inhibitors of Phosphoglycerate Kinase,Confirmatory,,
2367,602244,1,2,,56424026,3454,Inactive,5730106.0,10663.0,,,uHTS identification of CXCR6 Inhibitors in a B-arrestin luminescence assay,Screening,,
2368,602247,1,2,,56424026,3454,Inactive,,,,,Full deck counterscreen for positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1): Fluorescence-based cell-based high throughput screening assay to identify nonselective activators and assay artifacts using the parental CHOK1 cell line,Screening,,
2369,602248,1,2,,56424026,3454,Inactive,,,,,Full deck counterscreen for agonists of the human M1 muscarinic receptor (CHRM1): Fluorescence-based cell-based high throughput screening assay to identify nonselective activators and assay artifacts using the parental CHOK1 cell line,Screening,,
2370,602250,1,2,,56424026,3454,Inactive,,,,,Full deck counterscreen for antagonists of the human M1 muscarinic receptor (CHRM1): Fluorescence-based cell-based high throughput screening assay to identify nonselective inhibitors and assay artifacts using the parental CHOK1 cell line,Screening,,
2371,602252,1,1,,56424026,3454,Inactive,62868213.0,57120.0,,,Fluorescence Polarization with CAL-PDZ Measured in Biochemical System Using Plate Reader - 2109-02_Inhibitor_SinglePoint_HTS_Activity,Screening,,
2372,602252,1,1,,56424026,3454,Inactive,90421313.0,1080.0,,,Fluorescence Polarization with CAL-PDZ Measured in Biochemical System Using Plate Reader - 2109-02_Inhibitor_SinglePoint_HTS_Activity,Screening,,
2373,602261,1,1,,56424026,3454,Inactive,41872631.0,2194.0,,,uHTS identification of small molecule inhibitors of  the thioesterase domain of fatty acid synthase via a fluorescence intensity assay,Screening,,
2374,602274,1,2,,56424026,3454,Inactive,,,,,uHTS luminescent assay for identification of compounds that enhance the survival of human induced pluripotent stem cells when cultured as single cells,Screening,,
2375,602281,1,1,,56424026,3454,Inactive,31542303.0,51099.0,,,"Luminescence-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the lipase co-activator protein, abhydrolase domain containing 5 (ABHD5) with perilipin-5 (MLDP; PLIN5)",Screening,,
2376,602281,1,1,,56424026,3454,Inactive,116292172.0,440503.0,,,"Luminescence-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the lipase co-activator protein, abhydrolase domain containing 5 (ABHD5) with perilipin-5 (MLDP; PLIN5)",Screening,,
2377,602310,1,2,,50113251,3454,Inactive,13399304.0,60489.0,,Potency,qHTS for Inhibitors of Vif-A3G Interactions: qHTS,Confirmatory,,
2378,602310,1,2,,56424026,3454,Inactive,13399304.0,60489.0,,Potency,qHTS for Inhibitors of Vif-A3G Interactions: qHTS,Confirmatory,,
2379,602313,1,1,,56424026,3454,Inactive,22907044.0,200316.0,,Potency,qHTS for Inhibitors of Vif-A3F Interactions: qHTS,Confirmatory,,
2380,602314,1,2,,92125763,3454,Inactive,151220867.0,,,,A screen for compounds that modulate the activity of the Staphylococcus aureus MgrA protein,Other,,
2381,602329,1,1,,56424026,3454,Inactive,216548193.0,8438.0,,,Identification of inhibitors of RAD54 Measured in Biochemical System Using Plate Reader - 2159-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
2382,602332,1,1,,11111225,3454,Inactive,168984549.0,,,Potency,qHTS for Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in Human Glioma: qHTS,Confirmatory,,
2383,602332,1,1,,50113251,3454,Inactive,168984549.0,,,Potency,qHTS for Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in Human Glioma: qHTS,Confirmatory,,
2384,602332,1,1,,56424026,3454,Inactive,168984549.0,,,Potency,qHTS for Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in Human Glioma: qHTS,Confirmatory,,
2385,602332,1,1,,90341439,3454,Inactive,168984549.0,,,Potency,qHTS for Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in Human Glioma: qHTS,Confirmatory,,
2386,602340,1,2,,56424026,3454,Inactive,,,,,HTS for suppressors of simvastatin-induced mytoxicity in differentiated C2C12 cells Measured in Cell-Based System Using Plate Reader - 2112-01_Suppressor_SinglePoint_HTS_Activity,Screening,,
2387,602342,2,1,,56424026,3454,Inactive,,,,,Small molecule inhibitors of miR122  Measured in Cell-Based System Using Plate Reader - 2144-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
2388,602346,1,1,,56424026,3454,Inactive,9629361.0,155459.0,,,Identification of VIF Inhibitors Measured in Cell-Based System Using Imaging - 2108-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
2389,602363,1,1,,56424026,3454,Inactive,,,,,Whole cell Yeast HTS to identify compounds modulating the fidelity of the start codon recognition in eukaryotes. Measured in Whole Organism System Using Plate Reader - 2155-01_Other_SinglePoint_HTS_Activity,Screening,,
2390,602393,1,1,,56424026,3454,Inactive,291463269.0,20586.0,,,Screen for inhibitors of the SWI/SNF chromatin remodeling complex (esBAF) in mouse embryonic stem cells with Luciferase reporter assay Measured in Cell-Based System Using Plate Reader - 2141-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
2391,602396,1,2,,56424026,3454,Inactive,4504343.0,2494.0,,,Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of the liver receptor homolog-1 (LRH-1; NR5A2),Screening,,
2392,602399,1,2,,56424026,3454,Inactive,15927174.0,,,,uHTS identification of inhibitors of NadD in a Colorimetric assay,Screening,,
2393,602405,1,1,,56424026,3454,Inactive,75495260.0,,,,PgID: DNTB colorimetric HTS to detect inhibitor of PgID Measured in Biochemical System Using Plate Reader - 2164-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
2394,602410,1,1,,56424026,3454,Inactive,11093520.0,3777.0,,,Primary cell-based screen for identification of compounds that inhibit the two-pore domain potassium channel KCNK3,Screening,,
2395,602429,1,1,,56424026,3454,Inactive,1762973.0,7341.0,,,uHTS identification of SUMO1-mediated protein-protein interactions,Screening,,
2396,602438,1,1,,56424026,3454,Inactive,160877737.0,,,,uHTS identification of modulators of interaction between CendR and NRP-1 using Fluorescence Polarization assay,Screening,,
2397,602440,1,1,,56424026,3454,Inactive,262118306.0,123228.0,,,uHTS Fluorescent Assay Using Nedd8 Protein Substrate for Identification of Inhibitors of Sentrin-Specific Protease 8 (SENP8),Screening,,
2398,602449,1,2,,56424026,3454,Inactive,,,,,uHTS identification of small molecule inhibitors of the mitochondrial permeability transition pore via an absorbance assay,Screening,,
2399,602481,1,1,,56424026,3454,Inactive,378544807.0,,,,Mycobacterium tuberculosis BioA enzyme inhibitor Measured in Biochemical System Using Plate Reader - 2163-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
2400,606842,3,4,,103504490,3454,Active,,,3.0,IC50,Antiviral activity against Human cytomegalovirus Towne infected in HFF cells assessed as reduction in plaque formation after 10 days,Confirmatory,21641218.0,
2401,607906,3,4,,103504490,3454,Active,,,0.03,EC50,Antiviral activity against Herpes simplex virus 1 KOS infected in human HEL cells assessed as inhibition of virus-induced cytopathic effect after 4 days by microscopic analysis,Confirmatory,21696963.0,
2402,607907,3,4,,103504490,3454,Active,,,0.8,EC50,Antiviral activity against acyclovir-resistant TK-deficient Herpes simplex virus-1 KOS infected in human HEL cells assessed as inhibition of virus-induced cytopathic effect after 4 days by microscopic analysis,Confirmatory,21696963.0,
2403,607909,3,4,,103504490,3454,Active,,,0.03,EC50,Antiviral activity against Herpes simplex virus-2 G infected in human HEL cells assessed as inhibition of virus-induced cytopathic effect after 4 days by microscopic analysis,Confirmatory,21696963.0,
2404,607910,3,2,,103504490,3454,Unspecified,,,100.0,EC50,Antiviral activity against Vaccinia virus infected in human HEL cells assessed as inhibition of virus-induced cytopathic effect after 4 days by microscopic analysis,Confirmatory,21696963.0,
2405,607911,3,3,,103504490,3454,Unspecified,,,,,Cytotoxicity against human HEL cells assessed as alteration of normal cell morphology by microscopic analysis,Other,21696963.0,
2406,609512,3,2,,103504490,3454,Inconclusive,,,,EC50,Antiviral activity against Varicella-zoster virus YS expressing thymidine kinase assessed as reduction of virus induced cytopathicity by cell based assay,Confirmatory,21745746.0,
2407,609571,3,3,,103504490,3454,Inconclusive,,,,EC50,Antiviral activity against Varicella-zoster virus strain OKA expressing thymidine kinase assessed as reduction of virus induced cytopathicity by cell based assay,Confirmatory,21745746.0,
2408,609572,3,2,,103504490,3454,Inconclusive,,,,EC50,Antiviral activity against thymidine kinase-deficient Varicella-zoster virus 07/1 assessed as reduction of virus induced cytopathicity by cell based assay,Confirmatory,21745746.0,
2409,609573,3,2,,103504490,3454,Inconclusive,,,,EC50,Antiviral activity against thymidine kinase-deficient Varicella-zoster virus YS/R assessed as reduction of virus induced cytopathicity by cell based assay,Confirmatory,21745746.0,
2410,609574,3,5,,103504490,3454,Active,,,0.017,EC50,Antiviral activity against Herpes simplex virus 1 strain KOS assessed as reduction of virus induced cytopathicity by cell based assay,Confirmatory,21745746.0,
2411,609575,3,5,,103504490,3454,Active,,,0.023,EC50,Antiviral activity against Herpes simplex virus 2 strain G assessed as reduction of virus induced cytopathicity by cell based assay,Confirmatory,21745746.0,
2412,609576,3,5,,103504490,3454,Active,,,0.12,EC50,Antiviral activity against thymidine kinase-deficient acyclovir-resistant Herpes simplex virus 1 strain KOS assessed as reduction of virus induced cytopathicity by cell based assay,Confirmatory,21745746.0,
2413,609577,3,2,,103504490,3454,Active,,,5.9,EC50,Antiviral activity against Human cytomegalovirus strain AD169 assessed as reduction of virus induced cytopathicity by cell based assay,Confirmatory,21745746.0,
2414,609578,3,2,,103504490,3454,Active,,,5.1,EC50,Antiviral activity against Human cytomegalovirus Davis assessed as reduction of virus induced cytopathicity by cell based assay,Confirmatory,21745746.0,
2415,609579,3,2,,103504490,3454,Unspecified,,,100.0,EC50,Antiviral activity against Vaccinia virus Lederle assessed as reduction of virus induced cytopathicity by cell based assay,Confirmatory,21745746.0,
2416,609580,3,3,,103504490,3454,Unspecified,,,,,Cytotoxicity against human HEL cells assessed as alteration of cell morphology after 3 days by microscopic analysis,Other,21745746.0,
2417,609581,3,3,,103504490,3454,Unspecified,,,543.0,CC50,Cytotoxicity against human HEL cells after 3 days by coulter counter,Confirmatory,21745746.0,
2418,611615,3,4,,103504490,3454,Active,,,0.03,EC50,Antiviral activity against Human herpesvirus 1 KOS infected in HEL cells assessed as protection against virus-induced cytopathicity,Confirmatory,21565516.0,
2419,611616,3,4,,103504490,3454,Active,,,15.7,EC50,Antiviral activity against acyclovir-resistant Human herpesvirus 1 KOS infected in HEL cells assessed as protection against virus-induced cytopathicity,Confirmatory,21565516.0,
2420,611617,3,4,,103504490,3454,Active,,,0.027000000000000003,EC50,Antiviral activity against Human herpesvirus 2 G infected in HEL cells assessed as protection against virus-induced cytopathicity,Confirmatory,21565516.0,
2421,611618,3,2,,103504490,3454,Inconclusive,,,,EC50,Antiviral activity against VZV OKA infected in HEL cells assessed as protection against virus-induced cytopathicity,Confirmatory,21565516.0,
2422,611619,3,2,,103504490,3454,Inconclusive,,,,EC50,Antiviral activity against VZV 07/1 infected in HEL cells assessed as protection against virus-induced cytopathicity,Confirmatory,21565516.0,
2423,611620,3,2,,103504490,3454,Active,,,6.0,EC50,Antiviral activity against Human cytomegalovirus AD169 infected in HEL cells assessed as protection against virus-induced cytopathicity,Confirmatory,21565516.0,
2424,611621,3,2,,103504490,3454,Active,,,6.54,EC50,Antiviral activity against Human cytomegalovirus Davis infected in HEL cells assessed as protection against virus-induced cytopathicity,Confirmatory,21565516.0,
2425,611622,3,2,,103504490,3454,Active,,,8.1,EC50,Antiviral activity against Feline herpesvirus infected in CRFK cells assessed as protection against virus-induced cytopathicity,Confirmatory,21565516.0,
2426,611623,3,2,,103504490,3454,Unspecified,,,250.0,EC50,Antiviral activity against Vaccinia virus infected in HEL cells assessed as protection against virus-induced cytopathicity,Confirmatory,21565516.0,
2427,611624,3,3,,103504490,3454,Unspecified,,,,,Cytotoxicity against human HEL cells assessed as alteration of cell morphology after 3 days by microscopy,Other,21565516.0,
2428,611625,3,3,,103504490,3454,Unspecified,,,435.0,CC50,Cytotoxicity against human HEL cells assessed as growth inhibition after 3 days by coulter counter,Confirmatory,21565516.0,
2429,611626,3,3,,103504490,3454,Unspecified,,,394.0,CC50,Cytotoxicity against cat CRFK cells assessed as growth inhibition after 3 days by coulter counter,Confirmatory,21565516.0,
2430,623870,1,1,,56424026,3454,Inactive,2702319.0,405.0,,,ARNT-TAC3: AlphaScreen HTS to detect disruption of ARNT/TAC3 interactions Measured in Biochemical System Using Plate Reader - 2158-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
2431,623870,1,1,,56424026,3454,Inactive,5454102.0,10460.0,,,ARNT-TAC3: AlphaScreen HTS to detect disruption of ARNT/TAC3 interactions Measured in Biochemical System Using Plate Reader - 2158-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
2432,623877,1,1,,56424026,3454,Inactive,334278898.0,101772.0,,,Primary cell-based high-throughput screening for identification of compounds that activate/potentiate calcium-activated chloride channels (TMEM16A),Screening,,
2433,623901,1,1,,56424026,3454,Inactive,,,,,Small molecule inhibitors of miR122  Measured in Cell-Based System Using Plate Reader - 2144-01_Activator_SinglePoint_HTS_Activity,Screening,,
2434,624030,1,2,,11111225,3454,Inactive,160794.0,,,Potency,Biochemical firefly luciferase enzyme assay for NPC,Confirmatory,,
2435,624031,1,2,,11111225,3454,Inactive,,,,Potency,S16 Schwann cell viability assay (CellTiter-Glo assay),Confirmatory,,
2436,624032,1,2,,11111225,3454,Inactive,8393992.0,24660.0,,Potency,S16 Schwann cell PMP22 intronic element firefly luciferase assay,Confirmatory,,
2437,624037,1,3,,56424026,3454,Inactive,7108336.0,1133.0,,,"Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 5 (CHRM5)",Screening,,
2438,624038,1,3,,56424026,3454,Inactive,7108336.0,1133.0,,,"Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human cholinergic receptor, muscarinic 5 (CHRM5)",Screening,,
2439,624040,1,3,,56424026,3454,Inactive,7108336.0,1133.0,,,"Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human cholinergic receptor, muscarinic 5 (CHRM5)",Screening,,
2440,624044,1,2,,11111225,3454,Inactive,8393992.0,24660.0,,Potency,S16 Schwann cell PMP22 intronic element beta-lactamase assay,Confirmatory,,
2441,624125,1,4,,56424026,3454,Inactive,52426748.0,1132.0,,,"Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human cholinergic receptor, muscarinic 4 (CHRM4)",Screening,,
2442,624126,1,3,,56424026,3454,Inactive,52426748.0,1132.0,,,"Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human cholinergic receptor, muscarinic 4 (CHRM4)",Screening,,
2443,624127,1,2,,56424026,3454,Inactive,52426748.0,1132.0,,,"Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 4 (CHRM4)",Screening,,
2444,624146,1,1,,90341439,3454,Inactive,71051501.0,2744.0,6.3096,Potency,qHTS for Inhibitors of Glutaminase (GLS): LOPAC Validation,Confirmatory,,
2445,624147,1,1,,90341439,3454,Inactive,62359610.0,,,Potency,qHTS of Trypanosoma Brucei Inhibitors: LOPAC Validation,Confirmatory,,
2446,624148,1,2,,90341439,3454,Inactive,1724069.0,2740.0,,Potency,qHTS of GLP-1 Receptor Agonists: LOPAC Validation,Confirmatory,,
2447,624149,1,1,,90341439,3454,Inactive,693842.0,4780.0,,Potency,qHTS of Nrf2 Activators: LOPAC Validation,Confirmatory,,
2448,624168,1,1,,56424026,3454,Inactive,47678551.0,9215.0,,,uHTS identification of small molecule activators of alpha dystroglycan glycosylation,Screening,,
2449,624169,1,1,,56424026,3454,Inactive,27753985.0,15558.0,,,Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A),Screening,,
2450,624170,1,1,,11111225,3454,Inactive,71051501.0,2744.0,,Potency,qHTS for Inhibitors of Glutaminase (GLS),Confirmatory,,
2451,624170,1,1,,56424026,3454,Inactive,71051501.0,2744.0,,Potency,qHTS for Inhibitors of Glutaminase (GLS),Confirmatory,,
2452,624171,1,1,,56424026,3454,Inactive,693842.0,4780.0,,Potency,qHTS of Nrf2 Activators,Confirmatory,,
2453,624172,1,1,,11111225,3454,Inactive,1724069.0,2740.0,,Potency,qHTS of GLP-1 Receptor Agonists,Confirmatory,,
2454,624172,1,1,,56424026,3454,Inactive,1724069.0,2740.0,,Potency,qHTS of GLP-1 Receptor Agonists,Confirmatory,,
2455,624173,1,3,,11111225,3454,Inactive,62359610.0,,,Potency,qHTS of Trypanosoma Brucei Inhibitors,Confirmatory,,
2456,624173,1,3,,56424026,3454,Inactive,62359610.0,,,Potency,qHTS of Trypanosoma Brucei Inhibitors,Confirmatory,,
2457,624178,1,1,,50113251,3454,Unspecified,179095.0,6609.0,,Potency,qHTS for Inhibitors of Human Acid Sphingomyelinase Assay: Native Substrate,Confirmatory,,
2458,624178,1,1,,56424026,3454,Unspecified,179095.0,6609.0,,Potency,qHTS for Inhibitors of Human Acid Sphingomyelinase Assay: Native Substrate,Confirmatory,,
2459,624202,1,1,,50113251,3454,Inactive,1698399.0,672.0,,Potency,qHTS Assay to Identify Small Molecule Activators of BRCA1 Expression,Confirmatory,,
2460,624202,1,1,,56424026,3454,Inactive,1698399.0,672.0,,Potency,qHTS Assay to Identify Small Molecule Activators of BRCA1 Expression,Confirmatory,,
2461,624204,1,2,,56424026,3454,Inactive,7657550.0,,,,"uHTS identification of small molecule inhibitors of the catalytic domain of the SUMO protease, SENP1 in a FRET assay",Screening,,
2462,624246,1,1,,56424026,3454,Inactive,343478176.0,2078.0,,Potency,qHTS for Small Molecule Inhibitors of the ERG Ets/DNA interaction,Confirmatory,,
2463,624256,1,2,,56424026,3454,Active,,3205.0,,,HTS to identify compounds that promote myeloid differentiation with MLPCN compound set,Screening,,
2464,624263,1,1,,50113251,3454,Inactive,3063388.0,5071.0,,Potency,A Quantitative High throughput Screen to Identify Chemical Modulators of PINK1 Expression,Confirmatory,,
2465,624263,1,1,,50113251,3454,Inactive,37183032.0,,,Potency,A Quantitative High throughput Screen to Identify Chemical Modulators of PINK1 Expression,Confirmatory,,
2466,624263,1,1,,56424026,3454,Inactive,3063388.0,5071.0,,Potency,A Quantitative High throughput Screen to Identify Chemical Modulators of PINK1 Expression,Confirmatory,,
2467,624263,1,1,,56424026,3454,Inactive,37183032.0,,,Potency,A Quantitative High throughput Screen to Identify Chemical Modulators of PINK1 Expression,Confirmatory,,
2468,624267,1,2,,56424026,3454,Inactive,4506537.0,8767.0,,,Fluorescence-based cell-based primary high throughput screening assay to identify inhibitors of the interaction of nucleotide-binding oligomerization domain containing 2 (NOD2) and the receptor-interacting serine-threonine kinase 2 (RIPK2),Screening,,
2469,624267,1,2,,56424026,3454,Inactive,119603173.0,64127.0,,,Fluorescence-based cell-based primary high throughput screening assay to identify inhibitors of the interaction of nucleotide-binding oligomerization domain containing 2 (NOD2) and the receptor-interacting serine-threonine kinase 2 (RIPK2),Screening,,
2470,624268,1,3,,56424026,3454,Inactive,71746704.0,3662741.0,,,Luminescence-based biochemical primary high throughput screening assay to identify inhibitors of Trypanosoma brucei methionyl tRNA synthetase (MetRS),Screening,,
2471,624288,1,1,,56424026,3454,Inactive,52000961.0,2778.0,,Potency,"qHTS for Antagonists of gsp, the Etiologic Mutation Responsible for Fibrous Dysplasia/McCune-Albright Syndrome: qHTS",Confirmatory,,
2472,624296,1,1,,8139883,3454,Inactive,7705682.0,51053.0,,Potency,A quantitative high throughput screen for small molecules that induce DNA re-replication in MCF 10a normal breast cells.,Confirmatory,,
2473,624296,1,1,,11111225,3454,Inactive,7705682.0,51053.0,,Potency,A quantitative high throughput screen for small molecules that induce DNA re-replication in MCF 10a normal breast cells.,Confirmatory,,
2474,624296,1,1,,56424026,3454,Inactive,7705682.0,51053.0,,Potency,A quantitative high throughput screen for small molecules that induce DNA re-replication in MCF 10a normal breast cells.,Confirmatory,,
2475,624297,1,1,,8139883,3454,Inactive,7705682.0,51053.0,,Potency,A quantitative high throughput screen for small molecules that induce DNA re-replication in SW480 colon adenocarcinoma cells.,Confirmatory,,
2476,624297,1,1,,11111225,3454,Inactive,7705682.0,51053.0,,Potency,A quantitative high throughput screen for small molecules that induce DNA re-replication in SW480 colon adenocarcinoma cells.,Confirmatory,,
2477,624297,1,1,,56424026,3454,Inconclusive,7705682.0,51053.0,3.2643,Potency,A quantitative high throughput screen for small molecules that induce DNA re-replication in SW480 colon adenocarcinoma cells.,Confirmatory,,
2478,624304,1,2,,56424026,3454,Inactive,25148072.0,177343.0,,,uHTS identification of SKN-1 Inhibitors in a fluoresence assay,Screening,,
2479,624330,1,2,,56424026,3454,Inactive,21361397.0,29127.0,,IC50,Discovery of small molecule inhibitors of the oncogenic and cytokinetic protein MgcRacGAP -  Primary and Confirmatory Screens,Confirmatory,,
2480,624349,1,2,,92309204,3454,Inactive,,,,,A screen for compounds that inhibit liver stage malaria,Other,,
2481,624349,1,2,,121362387,3454,Inactive,,,,,A screen for compounds that inhibit liver stage malaria,Other,,
2482,624349,1,2,,121363434,3454,Inactive,,,,,A screen for compounds that inhibit liver stage malaria,Other,,
2483,624352,1,1,,56424026,3454,Inactive,40254439.0,2034.0,,,uHTS identification of HIF-2a Inhibitors in a luminesence assay,Screening,,
2484,624354,1,1,,56424026,3454,Inactive,224494019.0,8795.0,,,uHTS identification of Caspase-8 TRAIL sensitizers in a luminesence assay,Screening,,
2485,624377,1,1,,8139883,3454,Inactive,351542238.0,50807.0,,,"Fluorescence polarization-based biochemical primary high throughput screening assay to identify inhibitors of ArfGAP with SH3 domain, ankyrin repeat and PH domain 1 (ASAP1)",Screening,,
2486,624414,1,1,,50113251,3454,Inactive,10092597.0,57192.0,,,qHTS for Agonists of the Human Mucolipin Transient Receptor Potential 1 (TRPML1),Screening,,
2487,624414,1,1,,56424026,3454,Inactive,10092597.0,57192.0,,,qHTS for Agonists of the Human Mucolipin Transient Receptor Potential 1 (TRPML1),Screening,,
2488,624415,1,2,,56424026,3454,Inactive,10092597.0,57192.0,,,qHTS for Inhibitors of the Human Mucolipin Transient Receptor Potential 1 (TRPML1),Screening,,
2489,624416,1,1,,8139883,3454,Inactive,9629363.0,155971.0,,,"TRFRET-based biochemical primary high throughput screening assay to identify small molecules that bind to the HIV-1-gp120 binding antibody, PG9",Screening,,
2490,624417,1,1,,56424026,3454,Inactive,1724069.0,2740.0,,Potency,qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode),Confirmatory,,
2491,624418,1,1,,56424026,3454,Inactive,,,,Potency,qHTS of GLP-1 Receptor Inverse Agonists: Cytotox Screen,Confirmatory,,
2492,624455,1,1,,90341439,3454,Inactive,299681.0,1812.0,,Potency,HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Hit Validation in HTRF,Confirmatory,,
2493,624463,1,1,,56424026,3454,Inactive,4503385.0,1813.0,,,Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists,Other,,
2494,624464,1,1,,56424026,3454,Inactive,4503385.0,1813.0,,,Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators,Other,,
2495,624465,1,1,,56424026,3454,Inactive,4503385.0,1813.0,,,Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists,Other,,
2496,624466,1,3,,8139883,3454,Inactive,21264324.0,134864.0,,,Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human trace amine associated receptor 1 (TAAR1),Screening,,
2497,624467,1,1,,8139883,3454,Inactive,21264324.0,134864.0,,,Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human trace amine associated receptor 1 (TAAR1),Screening,,
2498,624483,1,1,,56424026,3454,Inactive,,,,,Counterscreen of compound fluorescence effects on High-throughput multiplex microsphere screening for inhibitors of toxin protease,Screening,,
2499,625144,5,5,,103504490,3454,Unspecified,239977155.0,,,IC50,DRUGMATRIX: Leukotriene LTC4 Synthase enzyme inhibition (substrate: LTA4),Confirmatory,,
2500,625145,4,7,,103504490,3454,Unspecified,20138087.0,10800.0,,IC50,DRUGMATRIX: Cysteinyl leukotriene receptor 1 radioligand binding (ligand: [3H]LTD4),Confirmatory,,
2501,625146,5,5,,103504490,3454,Unspecified,126397.0,100009114.0,,IC50,DRUGMATRIX: Lipoxygenase 15-LO enzyme inhibition (substrate: Linoleic acid),Confirmatory,,
2502,625147,4,7,,103504490,3454,Unspecified,395398606.0,4159.0,,IC50,DRUGMATRIX: Melanocortin MC3 radioligand binding (ligand: [125I] NDP-alpha-MSH),Confirmatory,,
2503,625148,4,7,,103504490,3454,Unspecified,60392672.0,4160.0,,IC50,DRUGMATRIX: Melanocortin MC4 radioligand binding (ligand: [125I] NDP-alpha-MSH),Confirmatory,,
2504,625149,4,7,,103504490,3454,Unspecified,729996.0,4161.0,,IC50,DRUGMATRIX: Melanocortin MC5 radioligand binding (ligand: [125I] NDP-alpha-MSH),Confirmatory,,
2505,625150,5,5,,103504490,3454,Unspecified,113978.0,4128.0,,IC50,DRUGMATRIX: Monoamine Oxidase MAO-A enzyme inhibition (substrate: Kynuramine),Confirmatory,,
2506,625151,4,7,,103504490,3454,Unspecified,113118.0,1128.0,,IC50,DRUGMATRIX: Muscarinic M1 radioligand binding (ligand: [3H] N-Methylscopolamine),Confirmatory,,
2507,625152,4,7,,103504490,3454,Unspecified,113122.0,1129.0,,IC50,DRUGMATRIX: Muscarinic M2 radioligand binding (ligand: [3H] N-Methylscopolamine),Confirmatory,,
2508,625153,4,7,,103504490,3454,Unspecified,113125.0,1131.0,,IC50,DRUGMATRIX: Muscarinic M3 radioligand binding (ligand: [3H] N-Methylscopolamine),Confirmatory,,
2509,625154,4,7,,103504490,3454,Unspecified,23503039.0,1132.0,,IC50,DRUGMATRIX: Muscarinic M4 radioligand binding (ligand: [3H] N-Methylscopolamine),Confirmatory,,
2510,625155,4,7,,103504490,3454,Unspecified,543761.0,1133.0,,IC50,DRUGMATRIX: Muscarinic M5 radioligand binding (ligand: [3H] N-Methylscopolamine),Confirmatory,,
2511,625156,1,9,,103504490,3454,Unspecified,128997.0,4886.0,,,DRUGMATRIX: Neuropeptide Y Y1 radioligand binding (ligand: [125I] Peptide YY),Other,,
2512,625157,6,2,,103504490,3454,Unspecified,1352610.0,4887.0,,IC50,DRUGMATRIX: Neuropeptide Y Y2 radioligand binding (ligand: [125I] Peptide YY),Confirmatory,,
2513,625158,3,4,,103504490,3454,Unspecified,,,,IC50,DRUGMATRIX: Nicotinic Acetylcholine radioligand binding (ligand: [125I] Epibatidine),Confirmatory,,
2514,625159,5,5,,103504490,3454,Unspecified,266646.0,24598.0,,IC50,"DRUGMATRIX: Nitric Oxide Synthase, Neuronal (nNOS) radioligand binding (ligand: [3H]L-Arginine)",Confirmatory,,
2515,625160,1,9,,103504490,3454,Unspecified,266649.0,18126.0,,,"DRUGMATRIX: Nitric Oxide Synthase, Inducible (iNOS) enzyme inhibition (substrate: L-Arginine)",Other,,
2516,625161,4,7,,103504490,3454,Unspecified,311033488.0,4985.0,,IC50,"DRUGMATRIX: Opiate delta1 (OP1, DOP) radioligand binding (ligand: [3H] Naltrindole)",Confirmatory,,
2517,625162,4,7,,103504490,3454,Unspecified,116242691.0,4986.0,,IC50,"DRUGMATRIX: Opiate kappa (OP2, KOP) radioligand binding (ligand: [3H] Diprenorphine)",Confirmatory,,
2518,625163,4,7,,103504490,3454,Unspecified,2851402.0,4988.0,,IC50,"DRUGMATRIX: Opiate mu (OP3, MOP) radioligand binding (ligand: [3H] Diprenorphine)",Confirmatory,,
2519,625164,1,6,,103504490,3454,Unspecified,,,,,DRUGMATRIX: Phorbol Ester radioligand binding (ligand: [3H] PDBu),Other,,
2520,625165,3,4,,103504490,3454,Unspecified,,,,IC50,DRUGMATRIX: Phosphodiesterase PDE3 enzyme inhibition (substrate: [3H]cAMP + cAMP),Confirmatory,,
2521,625166,3,4,,103504490,3454,Unspecified,,,,IC50,DRUGMATRIX: Phosphodiesterase PDE4 enzyme inhibition (substrate: [3H]cAMP + cAMP),Confirmatory,,
2522,625167,5,5,,103504490,3454,Unspecified,317373261.0,8654.0,,IC50,DRUGMATRIX: Phosphodiesterase PDE5 enzyme inhibition (substrate: [3H]cGMP + cGMP),Confirmatory,,
2523,625168,4,7,,103504490,3454,Unspecified,129557.0,5724.0,,IC50,DRUGMATRIX: Platelet Activating Factor (PAF) radioligand binding (ligand: [3H] PAF),Confirmatory,,
2524,625169,1,6,,103504490,3454,Unspecified,,,,,DRUGMATRIX: Platelet-Derived Growth Factor (PDGF) radioligand binding (ligand: [125I] PDGF),Other,,
2525,625170,3,4,,103504490,3454,Unspecified,,,,IC50,DRUGMATRIX: Potassium Channel [KATP] radioligand binding (ligand: [3H] Glyburide),Confirmatory,,
2526,625171,4,7,,103504490,3454,Unspecified,7531135.0,3757.0,,IC50,DRUGMATRIX: Potassium Channel HERG radioligand binding (ligand: [3H] Astemizole),Confirmatory,,
2527,625172,4,7,,103504490,3454,Unspecified,75071465.0,,,IC50,DRUGMATRIX: Progesterone radioligand binding (ligand: [3H] R-5020),Confirmatory,,
2528,625173,5,5,,103504490,3454,Unspecified,2822103.0,100009274.0,,IC50,"DRUGMATRIX: Peptidase, Angiotensin Converting Enzyme enzyme inhibition (substrate: FAPGG)",Confirmatory,,
2529,625174,5,5,,103504490,3454,Unspecified,266321.0,834.0,,IC50,"DRUGMATRIX: Protease, Caspase 1 enzyme inhibition (substrate: Ac-YVAD-AMC)",Confirmatory,,
2530,625175,5,5,,103504490,3454,Unspecified,115725.0,1511.0,,IC50,"DRUGMATRIX: Protease, Cathepsin G enzyme inhibition (substrate: Suc-Ala-Ala-Pro-Phe-AMC)",Confirmatory,,
2531,625176,1,9,,103504490,3454,Unspecified,119292.0,1991.0,,,"DRUGMATRIX: Peptidase, ELA2 (Neutrophil Elastase 2) enzyme inhibition (substrate: N-MeOSuc-Ala-Ala-Pro-Val-pNA)",Other,,
2532,625177,5,5,,103504490,3454,Unspecified,116852.0,4312.0,,IC50,"DRUGMATRIX: Peptidase, Matrix Metalloprotease-1 (MMP-1) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Confirmatory,,
2533,625178,5,5,,103504490,3454,Unspecified,269849668.0,4318.0,,IC50,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Confirmatory,,
2534,625179,1,9,,103504490,3454,Unspecified,317373571.0,5578.0,,,DRUGMATRIX: Protein Serine/Threonine Kinase PKCalpha enzyme inhibition (substrate: Histone),Other,,
2535,625180,5,5,,103504490,3454,Unspecified,232066.0,5595.0,,IC50,"DRUGMATRIX: Protein Serine/Threonine Kinase, ERK1 enzyme inhibition (substrate: Myelin Basic Protein)",Confirmatory,,
2536,625181,5,5,,103504490,3454,Unspecified,119554.0,5594.0,,IC50,"DRUGMATRIX: Protein Serine/Threonine Kinase, ERK2 enzyme inhibition (substrate: Myelin Basic Protein)",Confirmatory,,
2537,625182,5,5,,103504490,3454,Unspecified,2499600.0,1432.0,,IC50,"DRUGMATRIX: Protein Serine/Threonine Kinase, p38alpha enzyme inhibition (substrate: Myelin Basic Protein)",Confirmatory,,
2538,625183,5,5,,103504490,3454,Unspecified,1352673.0,5530.0,,IC50,"DRUGMATRIX: Protein Serine/Threonine Phosphatase, PPP3CA (Calcineurin, PP2B) enzyme inhibition (substrate: DiFMUP)",Confirmatory,,
2539,625184,5,5,,103504490,3454,Unspecified,2811086.0,1956.0,,IC50,"DRUGMATRIX: Protein Tyrosine Kinase, EGF Receptor enzyme inhibition (substrate: Poly(Glu:Tyr))",Confirmatory,,
2540,625185,5,5,,103504490,3454,Unspecified,125370.0,2534.0,,IC50,"DRUGMATRIX: Protein Tyrosine Kinase, Fyn enzyme inhibition (substrate: Poly(Glu:Tyr))",Confirmatory,,
2541,625186,5,5,,103504490,3454,Unspecified,119533.0,2064.0,,IC50,"DRUGMATRIX: Protein Tyrosine Kinase, ERBB2 (HER2) enzyme inhibition (substrate: Poly(Glu:Tyr))",Confirmatory,,
2542,625187,5,5,,103504490,3454,Unspecified,125474.0,3932.0,,IC50,"DRUGMATRIX: Protein Tyrosine Kinase, LCK enzyme inhibition (substrate: Poly(Glu:Tyr))",Confirmatory,,
2543,625188,1,9,,103504490,3454,Unspecified,33112650.0,5788.0,,,"DRUGMATRIX: Protein Tyrosine Phosphatase, PTPRC (CD45) enzyme inhibition (substrate: DiFMUP)",Other,,
2544,625189,1,7,,103504490,3454,Unspecified,,,,,"DRUGMATRIX: Purinergic P2X radioligand binding (ligand: [3H] alpha, beta-Methylene-ATP)",Other,,
2545,625190,4,5,,103504490,3454,Unspecified,,,,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT1A radioligand binding (ligand: [3H] 8-OH-DPAT),Confirmatory,,
2546,625191,4,7,,103504490,3454,Unspecified,112815.0,25075.0,,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT1B radioligand binding (ligand: [125I] Cyanopindolol),Confirmatory,,
2547,625192,4,7,,103504490,3454,Unspecified,543727.0,3356.0,,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Confirmatory,,
2548,625193,5,5,,103504490,3454,Unspecified,113037.0,43.0,,IC50,DRUGMATRIX: Acetylcholinesterase enzyme inhibition (substrate: acetylthiocholine),Confirmatory,,
2549,625194,4,7,,103504490,3454,Unspecified,231473.0,134.0,,IC50,DRUGMATRIX: Adenosine A1 radioligand binding (ligand: DPCPX),Confirmatory,,
2550,625195,4,7,,103504490,3454,Unspecified,543740.0,135.0,,IC50,DRUGMATRIX: Adenosine A2A radioligand binding (ligand: AB-MECA),Confirmatory,,
2551,625196,5,6,,103504490,3454,Unspecified,803374855.0,140.0,,IC50,DRUGMATRIX: Adenosine A3 radioligand binding (ligand: AB-MECA),Confirmatory,,
2552,625197,3,4,,103504490,3454,Unspecified,,,,IC50,DRUGMATRIX: Sodium/nucleoside co-transporter radioligand binding (ligand: nitrobenzylthioinosine),Confirmatory,,
2553,625198,4,7,,103504490,3454,Unspecified,1168247.0,29412.0,,IC50,DRUGMATRIX: Alpha-1A adrenergic receptor radioligand binding (ligand: prazosin),Confirmatory,,
2554,625199,4,7,,103504490,3454,Unspecified,543734.0,24173.0,,IC50,DRUGMATRIX: Alpha-1B adrenergic receptor radioligand binding (ligand: prazosin),Confirmatory,,
2555,625200,4,7,,103504490,3454,Unspecified,1168243.0,146.0,,IC50,DRUGMATRIX: Alpha-1D adrenergic receptor radioligand binding (ligand: prazosin),Confirmatory,,
2556,625201,4,7,,103504490,3454,Unspecified,1351829.0,150.0,,IC50,DRUGMATRIX: Alpha-2A adrenergic receptor radioligand binding (ligand: MK-912),Confirmatory,,
2557,625202,4,7,,103504490,3454,Unspecified,613504690.0,151.0,,IC50,DRUGMATRIX: Alpha-2B adrenergic receptor radioligand binding (ligand: Rauwolscine),Confirmatory,,
2558,625203,4,7,,103504490,3454,Unspecified,20141211.0,152.0,,IC50,DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912),Confirmatory,,
2559,625204,4,7,,103504490,3454,Unspecified,48429211.0,153.0,,IC50,DRUGMATRIX: Adrenergic beta1 radioligand binding (ligand: [125I] Cyanopindolol),Confirmatory,,
2560,625205,4,7,,103504490,3454,Unspecified,296439450.0,154.0,,IC50,DRUGMATRIX: Adrenergic beta2 radioligand binding (ligand: [3H] CGP-12177),Confirmatory,,
2561,625206,4,7,,103504490,3454,Unspecified,461604.0,155.0,,IC50,DRUGMATRIX: Adrenergic beta3 radioligand binding (ligand: [125I] Cyanopindolol),Confirmatory,,
2562,625207,4,7,,103504490,3454,Unspecified,128616.0,6530.0,,IC50,DRUGMATRIX: Norepinephrine Transporter radioligand binding (ligand: [125I] RTI-55),Confirmatory,,
2563,625208,5,5,,103504490,3454,Unspecified,1168407.0,24192.0,,IC50,DRUGMATRIX: Aldose Reductase enzyme inhibition (substrate: DL-Glyceraldehyde),Confirmatory,,
2564,625209,4,7,,103504490,3454,Unspecified,1703214.0,186.0,,IC50,DRUGMATRIX: Angiotensin AT2 radioligand binding (ligand: [125I] CGP-42112A),Confirmatory,,
2565,625210,3,4,,103504490,3454,Unspecified,,,,IC50,"DRUGMATRIX: ATPase, Na+/K+ enzyme inhibition (substrate: ATP)",Confirmatory,,
2566,625211,1,6,,103504490,3454,Unspecified,,,,,DRUGMATRIX: Atrial Natriuretic Factor (ANF) radioligand binding (ligand: [125I] ANF (rat)),Other,,
2567,625212,3,4,,103504490,3454,Unspecified,,,,IC50,DRUGMATRIX: beta-Lactamase enzyme inhibition (substrate: Nitrocefin),Confirmatory,,
2568,625213,4,7,,103504490,3454,Unspecified,2506481.0,624.0,,IC50,DRUGMATRIX: Bradykinin B2 radioligand binding (ligand: [3H] Bradykinin),Confirmatory,,
2569,625214,1,9,,103504490,3454,Unspecified,550544247.0,799.0,,,DRUGMATRIX: Calcitonin radioligand binding (ligand: [125I] Calcitonin (salmon)),Other,,
2570,625215,3,4,,103504490,3454,Unspecified,,,,IC50,"DRUGMATRIX: Calcium Channel Type L, Benzothiazepine radioligand binding (ligand: [3H] Diltiazem)",Confirmatory,,
2571,625216,3,4,,103504490,3454,Unspecified,,,,IC50,"DRUGMATRIX: Calcium Channel Type L, Dihydropyridine radioligand binding (ligand: [3H] Nitrendipine)",Confirmatory,,
2572,625217,4,7,,103504490,3454,Unspecified,1168220.0,3357.0,,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2B radioligand binding (ligand: [3H] Lysergic acid diethylamide),Confirmatory,,
2573,625218,4,7,,103504490,3454,Unspecified,112816.0,3358.0,,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2C radioligand binding (ligand: [3H] Mesulergine),Confirmatory,,
2574,625219,3,4,,103504490,3454,Unspecified,,,,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT3 radioligand binding (ligand: [3H] GR-65630),Confirmatory,,
2575,625220,4,7,,103504490,3454,Unspecified,6224984.0,100135548.0,,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT4 radioligand binding (ligand: [3H] GR-113808),Confirmatory,,
2576,625221,4,7,,103504490,3454,Unspecified,1703010.0,3362.0,,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT6 radioligand binding (ligand: [3H] Lysergic acid diethylamide),Confirmatory,,
2577,625222,4,7,,103504490,3454,Unspecified,400630.0,6532.0,,IC50,"DRUGMATRIX: Transporter, Serotonin (5-Hydroxytryptamine) (SERT) radioligand binding (ligand: [3H] Paroxetine)",Confirmatory,,
2578,625223,4,7,,103504490,3454,Unspecified,74752153.0,10280.0,,IC50,DRUGMATRIX: Sigma1 radioligand binding (ligand: [3H] Haloperidol),Confirmatory,,
2579,625224,3,4,,103504490,3454,Unspecified,,,,IC50,DRUGMATRIX: Sigma2 radioligand binding (ligand: [3H] Ifenprodil),Confirmatory,,
2580,625225,3,4,,103504490,3454,Unspecified,,,,IC50,"DRUGMATRIX: Sodium Channel, Site 2 radioligand binding (ligand: [3H] Batrachotoxin)",Confirmatory,,
2581,625226,4,7,,103504490,3454,Unspecified,128359.0,6869.0,,IC50,DRUGMATRIX: Tachykinin NK1 radioligand binding (ligand: [3H] Substance P),Confirmatory,,
2582,625227,4,7,,103504490,3454,Unspecified,229462950.0,6865.0,,IC50,DRUGMATRIX: Tachykinin NK2 radioligand binding (ligand: [3H] SR-48968),Confirmatory,,
2583,625228,4,7,,103504490,3454,Unspecified,113832.0,24208.0,,IC50,DRUGMATRIX: Androgen (Testosterone) AR radioligand binding (ligand: [3H] Mibolerone),Confirmatory,,
2584,625229,5,5,,103504490,3454,Unspecified,254763392.0,6916.0,,IC50,DRUGMATRIX: Thromboxane Synthetase enzyme inhibition (substrate: PGH2),Confirmatory,,
2585,625230,1,6,,103504490,3454,Unspecified,,,,,"DRUGMATRIX: Tumor Necrosis Factor (TNF), Non-Selective radioligand binding (ligand: [125I] TNF-alpha)",Other,,
2586,625231,4,7,,103504490,3454,Unspecified,143811474.0,2321.0,,IC50,DRUGMATRIX: Vascular Endothelial Growth Factor (VEGF) radioligand binding (ligand: [125I] VEGF),Confirmatory,,
2587,625232,1,9,,103504490,3454,Unspecified,418253.0,7433.0,,,DRUGMATRIX: Vasoactive Intestinal Peptide VIP1 radioligand binding (ligand: [125I] VIP),Other,,
2588,625233,4,7,,103504490,3454,Unspecified,586197.0,552.0,,IC50,DRUGMATRIX: Vasopressin V1A radioligand binding (ligand: [125I] PhenylacetylTyr(Me)PheGlnAsnArgProArgTyr),Confirmatory,,
2589,625234,3,4,,103504490,3454,Unspecified,,,,IC50,"DRUGMATRIX: Calcium Channel Type L, Phenylalkylamine radioligand binding (ligand: [3H] (-)-Desmethoxyverapamil (D-888))",Confirmatory,,
2590,625235,4,7,,103504490,3454,Unspecified,115562.0,1268.0,,IC50,DRUGMATRIX: Cannabinoid CB1 radioligand binding (ligand: [3H] SR141716A),Confirmatory,,
2591,625236,5,5,,103504490,3454,Unspecified,115456.0,760.0,,IC50,DRUGMATRIX: Carbonic Anhydrase II enzyme inhibition (substrate: 4-Nitrophenyl acetate (4-NPA)),Confirmatory,,
2592,625237,4,7,,103504490,3454,Unspecified,1168965.0,729230.0,,IC50,DRUGMATRIX: Chemokine CCR2B radioligand binding (ligand: [125I] MCP-1),Confirmatory,,
2593,625238,4,7,,103504490,3454,Unspecified,1705894.0,1233.0,,IC50,DRUGMATRIX: Chemokine CCR4 radioligand binding (ligand: [125I] TARC),Confirmatory,,
2594,625239,4,7,,103504490,3454,Unspecified,1705896.0,1234.0,,IC50,DRUGMATRIX: Chemokine CCR5 radioligand binding (ligand: [125I] MIP-1alpha),Confirmatory,,
2595,625240,1,9,,103504490,3454,Unspecified,108936015.0,3577.0,,,DRUGMATRIX: Chemokine CXCR1 (IL-8A),Other,,
2596,625241,4,7,,103504490,3454,Unspecified,1352454.0,3579.0,,IC50,DRUGMATRIX: Chemokine CXCR2 (IL-8B) radioligand binding (ligand: [125I] IL-8),Confirmatory,,
2597,625242,4,7,,103504490,3454,Unspecified,416772.0,886.0,,IC50,"DRUGMATRIX: Cholecystokinin CCKA radioligand binding (ligand: [3H] L-364,718)",Confirmatory,,
2598,625243,5,5,,103504490,3454,Unspecified,317373262.0,5742.0,,IC50,DRUGMATRIX: Cyclooxygenase COX-1 enzyme inhibition (substrate: Arachidonic acid),Confirmatory,,
2599,625244,5,5,,103504490,3454,Unspecified,3915797.0,5743.0,,IC50,DRUGMATRIX: Cyclooxygenase COX-2 enzyme inhibition (substrate: Arachidonic acid),Confirmatory,,
2600,625245,5,5,,103504490,3454,Unspecified,117144.0,1544.0,,IC50,"DRUGMATRIX: CYP450, 1A2 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)",Confirmatory,,
2601,625246,1,9,,103504490,3454,Unspecified,308153612.0,1548.0,,,"DRUGMATRIX: CYP450, 2A6 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)",Other,,
2602,625247,5,5,,103504490,3454,Unspecified,60416369.0,1557.0,,IC50,"DRUGMATRIX: CYP450, 2C19 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)",Confirmatory,,
2603,625248,5,5,,103504490,3454,Unspecified,6686268.0,1559.0,,IC50,"DRUGMATRIX: CYP450, 2C9 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)",Confirmatory,,
2604,625249,5,5,,103504490,3454,Unspecified,84028191.0,1565.0,,IC50,"DRUGMATRIX: CYP450, 2D6 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)",Confirmatory,,
2605,625250,5,5,,103504490,3454,Unspecified,117250.0,1571.0,,IC50,"DRUGMATRIX: CYP450, 2E1 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)",Confirmatory,,
2606,625251,5,5,,103504490,3454,Unspecified,116241312.0,1576.0,,IC50,"DRUGMATRIX: CYP450, 3A4 enzyme inhibition (substrate: 7-Benzyloxy-4-(trifluoromethyl)-coumarin)",Confirmatory,,
2607,625252,4,7,,103504490,3454,Unspecified,118228.0,1812.0,,IC50,DRUGMATRIX: Dopamine D1 radioligand binding (ligand: [3H] SCH-23390),Confirmatory,,
2608,625253,4,7,,103504490,3454,Unspecified,118206.0,1813.0,,IC50,DRUGMATRIX: Dopamine D2L radioligand binding (ligand: [3H] Spiperone),Confirmatory,,
2609,625254,4,7,,103504490,3454,Unspecified,1169206.0,1814.0,,IC50,DRUGMATRIX: Dopamine D3 radioligand binding (ligand: [3H] Spiperone),Confirmatory,,
2610,625255,4,7,,103504490,3454,Unspecified,1345939.0,1815.0,,IC50,DRUGMATRIX: Dopamine D4.2 radioligand binding (ligand: [3H] Spiperone),Confirmatory,,
2611,625256,4,7,,103504490,3454,Unspecified,266667.0,6531.0,,IC50,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),Confirmatory,,
2612,625257,4,7,,103504490,3454,Unspecified,119606.0,1909.0,,IC50,DRUGMATRIX: Endothelin ETA radioligand binding (ligand: [125I] Endothelin-1),Confirmatory,,
2613,625258,4,7,,103504490,3454,Unspecified,544257.0,2099.0,,IC50,DRUGMATRIX: Estrogen ERalpha radioligand binding (ligand: [3H] Estradiol),Confirmatory,,
2614,625259,4,7,,103504490,3454,Unspecified,6166154.0,2100.0,,IC50,DRUGMATRIX: Estrogen ERbeta radioligand binding (ligand: [3H] Estradiol),Confirmatory,,
2615,625260,3,4,,103504490,3454,Unspecified,,,,IC50,"DRUGMATRIX: GABAA, Muscimol, Central radioligand binding (ligand: [3H] Muscimol)",Confirmatory,,
2616,625261,3,4,,103504490,3454,Unspecified,,,,IC50,"DRUGMATRIX: GABAA, Flunitrazepam, Central radioligand binding (ligand: [3H] Flunitrazepam)",Confirmatory,,
2617,625262,3,4,,103504490,3454,Unspecified,,,,IC50,"DRUGMATRIX: GABAA, Chloride Channel, TBOB radioligand binding (ligand: [3H] TBOB)",Confirmatory,,
2618,625263,4,7,,103504490,3454,Unspecified,121069.0,2908.0,,IC50,DRUGMATRIX: Glucocorticoid radioligand binding (ligand: [3H] Dexamethasone),Confirmatory,,
2619,625264,3,4,,103504490,3454,Unspecified,,,,IC50,"DRUGMATRIX: Glutamate, AMPA radioligand binding (ligand: [3H] AMPA)",Confirmatory,,
2620,625265,1,6,,103504490,3454,Unspecified,,,,,"DRUGMATRIX: Glutamate, Kainate radioligand binding (ligand: [3H] Kainic acid)",Other,,
2621,625266,3,4,,103504490,3454,Unspecified,,,,IC50,"DRUGMATRIX: Glutamate, NMDA, Agonism radioligand binding (ligand: [3H] CGP-39653)",Confirmatory,,
2622,625267,3,4,,103504490,3454,Unspecified,,,,IC50,"DRUGMATRIX: Glutamate, NMDA, Phencyclidine radioligand binding (ligand: [3H] TCP)",Confirmatory,,
2623,625268,4,2,,103504490,3454,Unspecified,121579.0,24397.0,,IC50,"DRUGMATRIX: Glycine, Strychnine-Sensitive radioligand binding (ligand: [3H] Strychnine)",Confirmatory,,
2624,625268,4,2,,103504490,3454,Unspecified,121580.0,114516.0,,IC50,"DRUGMATRIX: Glycine, Strychnine-Sensitive radioligand binding (ligand: [3H] Strychnine)",Confirmatory,,
2625,625268,4,2,,103504490,3454,Unspecified,121604.0,25456.0,,IC50,"DRUGMATRIX: Glycine, Strychnine-Sensitive radioligand binding (ligand: [3H] Strychnine)",Confirmatory,,
2626,625268,4,2,,103504490,3454,Unspecified,12230887.0,25674.0,,IC50,"DRUGMATRIX: Glycine, Strychnine-Sensitive radioligand binding (ligand: [3H] Strychnine)",Confirmatory,,
2627,625269,4,7,,103504490,3454,Unspecified,547645.0,3269.0,,IC50,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",Confirmatory,,
2628,625270,4,7,,103504490,3454,Unspecified,123120.0,3274.0,,IC50,DRUGMATRIX: Histamine H2 radioligand binding (ligand: [125I] Aminopotentidine),Confirmatory,,
2629,625271,5,5,,103504490,3454,Unspecified,123343.0,3156.0,,IC50,DRUGMATRIX: HMG-CoA Reductase enzyme inhibition (substrate: [14C]HMG-CoA),Confirmatory,,
2630,625272,3,4,,103504490,3454,Unspecified,,,,IC50,"DRUGMATRIX: Imidazoline I2, Central radioligand binding (ligand: [3H] Idazoxan)",Confirmatory,,
2631,625273,4,6,,103504490,3454,Unspecified,124531.0,24954.0,,IC50,DRUGMATRIX: Insulin radioligand binding (ligand: [125I] Insulin),Confirmatory,,
2632,625274,1,6,,103504490,3454,Unspecified,,,,,DRUGMATRIX: Interleukin IL-1 radioligand binding (ligand: [125I] interleukin 1beta),Other,,
2633,625275,3,4,,103504490,3454,Unspecified,,,,IC50,"DRUGMATRIX: Leukotriene, BLT (LTB4) radioligand binding (ligand: [3H]LTB4)",Confirmatory,,
2634,625277,1,3,,103504490,3454,Unspecified,,,,,FDA Liver Toxicity Knowledge Base Benchmark Dataset (LTKB-BD) drugs of less concern for DILI,Other,21624500.0,
2635,625279,1,3,,103504490,3454,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for bilirubinemia,Other,22194678.0,
2636,625280,1,3,,103504490,3454,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholecystitis,Other,22194678.0,
2637,625281,1,3,,103504490,3454,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholelithiasis,Other,22194678.0,
2638,625282,1,3,,103504490,3454,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cirrhosis,Other,22194678.0,
2639,625283,1,3,,103504490,3454,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for elevated liver function tests,Other,22194678.0,
2640,625284,1,3,,103504490,3454,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic failure,Other,22194678.0,
2641,625285,1,3,,103504490,3454,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic necrosis,Other,22194678.0,
2642,625286,1,3,,103504490,3454,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatitis,Other,22194678.0,
2643,625287,1,3,,103504490,3454,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatomegaly,Other,22194678.0,
2644,625288,1,3,,103504490,3454,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for jaundice,Other,22194678.0,
2645,625289,1,3,,103504490,3454,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver disease,Other,22194678.0,
2646,625290,1,3,,103504490,3454,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver fatty,Other,22194678.0,
2647,625291,1,3,,103504490,3454,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver function tests abnormal,Other,22194678.0,
2648,625292,1,3,,103504490,3454,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) combined score,Other,22194678.0,
2649,634746,1,6,,103504490,3454,Inactive,,,,,Antiviral activity against Herpes simplex virus 1 KOS infected in human HEL cells assessed as inhibition of viral plaque formation at 250 uM,Other,22137458.0,
2650,634747,1,6,,103504490,3454,Inactive,,,,,Antiviral activity against Herpes simplex virus 2 G infected in human HEL cells assessed as inhibition of viral plaque formation at 250 uM,Other,22137458.0,
2651,634748,1,6,,103504490,3454,Inactive,,,,,Antiviral activity against thymidine kinase-deficient acv-resistant Herpes simplex virus 1 KOS infected in human HEL cells assessed as inhibition of viral plaque formation at 250 uM,Other,22137458.0,
2652,634749,1,4,,103504490,3454,Inactive,,,,,Antiviral activity against Vaccinia virus infected in human HEL cells assessed as inhibition of viral plaque formation at 250 uM,Other,22137458.0,
2653,634750,1,4,,103504490,3454,Inactive,,,,,Antiviral activity against Vesicular stomatitis virus infected in human HEL cells assessed as inhibition of viral plaque formation at 250 uM,Other,22137458.0,
2654,634751,1,4,,103504490,3454,Inactive,,,,,Antiviral activity against Human cytomegalovirus AD169 infected in human HEL cells assessed as inhibition of viral plaque formation at 250 uM,Other,22137458.0,
2655,634752,1,4,,103504490,3454,Inactive,,,,,Antiviral activity against Human cytomegalovirus Davis infected in human HEL cells assessed as inhibition of viral plaque formation at 250 uM,Other,22137458.0,
2656,634753,1,4,,103504490,3454,Inactive,,,,,Antiviral activity against thymidine kinase-positive Varicella Zoster virus Oka infected in human HEL cells assessed as inhibition of viral plaque formation at 250 uM,Other,22137458.0,
2657,634754,1,4,,103504490,3454,Inactive,,,,,Antiviral activity against thymidine kinase-deficient Varicella Zoster virus 07/1 infected in human HEL cells assessed as inhibition of viral plaque formation at 250 uM,Other,22137458.0,
2658,634755,1,4,,103504490,3454,Inactive,,,,,Antiviral activity against Parainfluenza-3 virus infected in african green monkey Vero cells assessed as inhibition of viral plaque formation at 250 uM,Other,22137458.0,
2659,634756,1,4,,103504490,3454,Inactive,,,,,Antiviral activity against Reovirus-1 infected in african green monkey Vero cells assessed as inhibition of viral plaque formation at 250 uM,Other,22137458.0,
2660,634757,1,4,,103504490,3454,Inactive,,,,,Antiviral activity against Sindbis virus infected in african green monkey Vero cells assessed as inhibition of viral plaque formation at 250 uM,Other,22137458.0,
2661,634758,1,4,,103504490,3454,Inactive,,,,,Antiviral activity against Coxsackievirus B4 infected in african green monkey Vero cells assessed as inhibition of viral plaque formation at 250 uM,Other,22137458.0,
2662,634759,1,4,,103504490,3454,Inactive,,,,,Antiviral activity against Punta Toro virus infected in african green monkey Vero cells assessed as inhibition of viral plaque formation at 250 uM,Other,22137458.0,
2663,634760,1,4,,103504490,3454,Inactive,,,,,Antiviral activity against Vesicular stomatitis virus infected in human Hela cells assessed as inhibition of viral plaque formation at 250 uM,Other,22137458.0,
2664,634761,1,4,,103504490,3454,Inactive,,,,,Antiviral activity against Coxsackievirus B4 infected in human HeLa cells assessed as inhibition of viral plaque formation at 250 uM,Other,22137458.0,
2665,634831,1,4,,103504490,3454,Inactive,,,,,Antiviral activity against Respiratory syncytial virus infected in human HeLa cells assessed as inhibition of viral plaque formation at 250 uM,Other,22137458.0,
2666,634832,1,5,,103504490,3454,Inactive,,,,,Antiviral activity against Influenza A virus H1N1 infected in MDCK cells assessed as inhibition of viral plaque formation at 250 uM,Other,22137458.0,
2667,634833,1,5,,103504490,3454,Inactive,,,,,Antiviral activity against Influenza A virus H3N2 infected in MDCK cells assessed as inhibition of viral plaque formation at 250 uM,Other,22137458.0,
2668,634834,1,5,,103504490,3454,Inactive,,,,,Antiviral activity against Influenza B virus infected in MDCK cells assessed as inhibition of viral plaque formation at 250 uM,Other,22137458.0,
2669,634835,1,4,,103504490,3454,Inactive,,,,,Antiviral activity against Felid herpesvirus 1 infected in CrFK cells assessed as inhibition of viral plaque formation at 250 uM,Other,22137458.0,
2670,634836,1,4,,103504490,3454,Inactive,,,,,Antiviral activity against Feline coronavirus infected in CrFK cells assessed as inhibition of viral plaque formation at 250 uM,Other,22137458.0,
2671,634837,1,4,,103504490,3454,Inactive,,,,,Antiviral activity against Human immunodeficiency virus 2 infected in human CEM cells assessed as inhibition of virus-induced giant cell formation after 4 days by microscopic analysis,Other,22137458.0,
2672,634838,1,4,,103504490,3454,Inactive,,,,,Antiviral activity against Human immunodeficiency virus 1 infected in human CEM cells assessed as inhibition of virus-induced giant cell formation after 4 days by microscopic analysis,Other,22137458.0,
2673,636695,3,2,,103504490,3454,Inconclusive,,,,IC50,Antiviral activity against Cowpox virus Brighton infected in HFF cells incubated for 3 days by plaque reduction assay,Confirmatory,21812420.0,
2674,636696,3,2,,103504490,3454,Inconclusive,,,,IC50,Antiviral activity against Vaccinia virus Copenhagen infected in HFF cells incubated for 3 days by plaque reduction assay,Confirmatory,21812420.0,
2675,636697,3,4,,103504490,3454,Inconclusive,,,,IC50,Antiviral activity against HSV1 KOS infected in HFF cells incubated for 3 days by plaque reduction assay,Confirmatory,21812420.0,
2676,636698,3,4,,103504490,3454,Active,,,0.14,IC50,Antiviral activity against HCMV Towne infected in HFF cells incubated for 10 days by plaque reduction assay,Confirmatory,21812420.0,
2677,636699,3,2,,103504490,3454,Inconclusive,,,,IC50,Cytotoxicity against human KB cells after 48 hrs by crystal violet staining based spectrophotometric analysis,Confirmatory,21812420.0,
2678,636700,3,2,,103504490,3454,Unspecified,,,100.0,IC50,Cytotoxicity against HFF cells after 48 hrs by visual cytotoxicity observation assay,Confirmatory,21812420.0,
2679,651550,1,1,,56424026,3454,Inactive,60391226.0,207.0,,,HTS Assay for Inhibitors of Akt Phophorylation: Primary Screen,Screening,,
2680,651560,1,1,,56424026,3454,Inactive,1709543.0,52.0,,,"uHTS identification of small molecule inhibitors of Low Molecular Weight Protein Tyrosine Phosphatase, LMPTP, via a fluorescence intensity assay",Screening,,
2681,651572,1,2,,8139883,3454,Inactive,21489979.0,246310.0,,,Fluorescence polarization-based biochemical primary high throughput screening assay to identify inhibitors of ADP-ribosylation factor GTPase activating protein 1 (ARFGAP1),Screening,,
2682,651582,1,1,,56424026,3454,Inactive,,,,,uHTS identification of small molecule Triacylglycerol inhbitors in a fluoresence assay,Screening,,
2683,651602,1,1,,8139883,3454,Inactive,16130723.0,947287.0,,,Absorbance-based primary bacterial cell-based high throughput screening assay to identify inhibitors of RecBCD (with phage),Screening,,
2684,651602,1,1,,8139883,3454,Inactive,16130724.0,947286.0,,,Absorbance-based primary bacterial cell-based high throughput screening assay to identify inhibitors of RecBCD (with phage),Screening,,
2685,651602,1,1,,8139883,3454,Inactive,16130726.0,947294.0,,,Absorbance-based primary bacterial cell-based high throughput screening assay to identify inhibitors of RecBCD (with phage),Screening,,
2686,651610,2,1,,8139883,3454,Inactive,,,,,HIV entry: Env-mediated Cell Fusion Measured in Cell-Based System Using Plate Reader - 7013-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
2687,651631,4,1,,144203711,3454,Inactive,269849759.0,7157.0,,Potency-Replicate_1,qHTS assay for small molecule agonists of the p53 signaling pathway,Confirmatory,,
2688,651632,4,1,,144203711,3454,Inactive,296439460.0,79915.0,,Potency-Replicate_1,qHTS assay for small molecules that induce genotoxicity in human embryonic kidney cells expressing luciferase-tagged ATAD5,Confirmatory,,
2689,651633,4,1,,144203711,3454,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecule agonists of the p53 signaling pathway - cell viability,Confirmatory,,
2690,651634,4,1,,144203711,3454,Inactive,,,16.0447,Potency-Replicate_1,qHTS assay for small molecules that induce genotoxicity in human embryonic kidney cells expressing luciferase-tagged ATAD5 - cell viability,Confirmatory,,
2691,651635,1,3,,56424026,3454,Inactive,171543895.0,6311.0,,Potency,qHTS for Inhibitors of ATXN expression,Confirmatory,,
2692,651635,1,3,,90341439,3454,Inactive,171543895.0,6311.0,,Potency,qHTS for Inhibitors of ATXN expression,Confirmatory,,
2693,651636,1,1,,56424026,3454,Inactive,4826706.0,1880.0,,,uHTS identification of small molecule antagonists of the EBI2 receptor via a luminescent beta-arrestin assay,Screening,,
2694,651640,1,1,,8139883,3454,Inactive,,,,,DENV2 CPE-Based HTS Measured in Cell-Based and Microorganism Combination System Using Plate Reader - 2149-01_Other_SinglePoint_HTS_Activity,Screening,,
2695,651644,1,1,,56424026,3454,Inactive,28872817.0,155807.0,,Potency,qHTS Assay for Inhibitors of the HIV-1 protein Vpr,Confirmatory,,
2696,651647,1,1,,56424026,3454,Inactive,4826834.0,4323.0,,,uHTS identification of inhibitors of MT1-MMP activation in a fluoresence assay,Screening,,
2697,651654,1,1,,56424026,3454,Inactive,,,,,HTS for the detection of C. neoformans cell lysis via adenylate kinase (AK) release Measured in Microorganism System Using Plate Reader - 2162-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
2698,651658,1,1,,8139883,3454,Inactive,10190672.0,27006.0,,,Small Molecule Inhibitors of FGF22-Mediated Excitatory Synaptogenesis & Epilepsy Measured in Biochemical System Using RT-PCR - 7012-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
2699,651660,1,1,,56424026,3454,Inactive,109637798.0,5893.0,,,FRET-based HTS for detection of RAD52 Inhibitors             Measured in Biochemical System Using Plate Reader - 7018-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
2700,651661,2,1,,8139883,3454,Inactive,,,,,Luminescence Cell-Based Primary HTS to identify inhibitors of the oncoprotein EWS/Fli transcriptional activity Measured in Cell-Based System Using Plate Reader - 7014-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
2701,651687,1,1,,56424026,3454,Inactive,,,,,MLPCN PGC1a Modulators Measured in Cell-Based System Using Plate Reader - 2139-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
2702,651699,1,1,,56424026,3454,Inactive,4502169.0,8883.0,,,uHTS identification of inhibitors of cullin neddylation in a TR-FRET assay,Screening,,
2703,651699,1,1,,56424026,3454,Inactive,4507791.0,9040.0,,,uHTS identification of inhibitors of cullin neddylation in a TR-FRET assay,Screening,,
2704,651702,1,2,,56424026,3454,Inactive,,,,,Flow Cytometric HTS Screening for Inhibitors of Lytic Granule Exocytosis with MLPCN Compound Library,Screening,,
2705,651704,2,1,,8139883,3454,Inactive,156104889.0,4300.0,,,Inhibition of the MLL-AF4-AF9 Interaction in Pediatric Leukemia Measured in Biochemical System Using Plate Reader - 2160-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
2706,651704,2,1,,56424026,3454,Inactive,156104889.0,4300.0,,,Inhibition of the MLL-AF4-AF9 Interaction in Pediatric Leukemia Measured in Biochemical System Using Plate Reader - 2160-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
2707,651710,1,1,,8139883,3454,Inactive,109637798.0,5893.0,,,FRET-based HTS for detection of RAD52 Inhibitors Measured in Biochemical System Using Plate Reader - 7018-01_Inhibitor_SinglePoint_HTS_Activity_Set2,Screening,,
2708,651711,2,1,,8139883,3454,Inactive,2501205.0,10130.0,,,Turbidometric Biochemical  Primary HTS  to identify inhibitors of ERp5 Measured in Biochemical System Using Plate Reader - 7002-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
2709,651718,1,2,,8139883,3454,Inactive,73586699.0,281312.0,,,Absorbance-based biochemical primary high throughput screening assay to identify inhibitors of Methionine sulfoxide reductase A (MsrA),Screening,,
2710,651719,1,2,,8139883,3454,Inactive,4503907.0,8484.0,,,Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the Galanin Receptor 3 (GalR3),Screening,,
2711,651723,1,1,,56424026,3454,Inactive,,,,,MLPCN PGC1a Modulators Measured in Cell-Based System Using Plate Reader - 2139-01_Activator_SinglePoint_HTS_Activity,Screening,,
2712,651724,1,1,,56424026,3454,Inactive,1730321.0,5932.0,,,qHTS Assay for Inhibitors of the CtBP/E1A Interaction,Screening,,
2713,651725,1,1,,56424026,3454,Inactive,1246761.0,6495.0,,,qHTS Assay for Inhibitors of the Six1/Eya2 Interaction,Screening,,
2714,651768,1,2,,56424026,3454,Inactive,3719421.0,7486.0,,Potency,qHTS for Inhibitors of WRN Helicase,Confirmatory,,
2715,651800,1,1,,8139883,3454,Inactive,2358024.0,6955.0,,,Fluorescence-based biochemical primary high throughput assay to identify inhibitors of T-cell receptor (TCR)-CD3 interaction using a TAMRA-labeled TCR probe,Screening,,
2716,651819,1,1,,56424026,3454,Inactive,83758679.0,153562.0,,,High-Throughput Screening for Modulators of Cytosolic Chaperonin Activity,Screening,,
2717,651820,1,1,,8139883,3454,Inactive,,,,Potency,qHTS Assay for Inhibitors of Hepatitis C Virus (HCV),Confirmatory,,
2718,651820,1,1,,56424026,3454,Inactive,,,,Potency,qHTS Assay for Inhibitors of Hepatitis C Virus (HCV),Confirmatory,,
2719,651821,2,4,,8139883,3454,Inactive,,,,,Fluorescence-based biochemical primary high throughput screening assay to identify molecules that bind r(CAG) RNA repeats,Screening,,
2720,651828,1,2,,92309204,3454,Inactive,127925.0,,,,A screen for compounds that inhibit nucleocapsid/RNA interactions in Rift Valley Fever Virus,Other,,
2721,651828,1,2,,121361363,3454,Inactive,127925.0,,,,A screen for compounds that inhibit nucleocapsid/RNA interactions in Rift Valley Fever Virus,Other,,
2722,651828,1,2,,121362387,3454,Inactive,127925.0,,,,A screen for compounds that inhibit nucleocapsid/RNA interactions in Rift Valley Fever Virus,Other,,
2723,651957,1,1,,8139883,3454,Inactive,5729858.0,10499.0,,,Luminescence-based cell-based primary high throughput screening assay to identify inhibitors of the Steroid Receptor Coactivator 2 (SRC2; NCOA2),Screening,,
2724,651958,1,1,,8139883,3454,Inactive,76364066.0,2943075.0,,,Fluorescence-based biochemical high throughput screening primary assay to identify inhibitors of Crimean-Congo Hemorrhagic Fever (CCHF) viral ovarian tumor domain protease (vOTU): Pep-AMC substrate,Screening,,
2725,651965,1,1,,50113251,3454,Inconclusive,2668494.0,,0.7079,Potency,qHTS Assay for Activators of ClpP,Confirmatory,,
2726,651965,1,1,,56424026,3454,Inactive,2668494.0,,,Potency,qHTS Assay for Activators of ClpP,Confirmatory,,
2727,651999,1,1,,56424026,3454,Inactive,38027923.0,10987.0,,,"uHTS identification of small molecule inhibitors of Csn-mediated Deneddylation of Cullin-Ring Ligases, vis a fluorescence polarization assay",Screening,,
2728,652010,1,1,,8139883,3454,Inactive,5016090.0,190.0,,,"Luminescence-based cell-based primary high throughput screening assay for inhibitors of the orphan nuclear receptor subfamily 0, group B, member 1 (DAX1; NR0B1): repression of SF-1 (NR5A1) activated StAR promoter by full-length DAX-1",Screening,,
2729,652017,1,1,,8139883,3454,Inactive,119579215.0,6595.0,,,"Luminescence-based cell-based primary high throughput screening assay to identify activators of the function of SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily a, member 2 (SMARCA2, BRM)",Screening,,
2730,652025,1,1,,56424026,3454,Inactive,7110653.0,16183.0,,Potency,qHTS of IL-2 Activators,Confirmatory,,
2731,652039,1,1,,8139883,3454,Inactive,21327705.0,5650.0,,,Fluorescence Intensity-based biochemical primary high throughput screening assay to identify activators of kallikrein-7 (K7) zymogen,Screening,,
2732,652048,1,2,,56424026,3454,Inactive,89191863.0,1814.0,,,qHTS of D3 Dopamine Receptor Agonist: qHTS,Screening,,
2733,652048,1,2,,144203711,3454,Inactive,89191863.0,1814.0,,,qHTS of D3 Dopamine Receptor Agonist: qHTS,Screening,,
2734,652051,1,1,,56424026,3454,Inactive,89191863.0,1814.0,,,qHTS of D3 Dopamine Receptor Potentiators: qHTS,Screening,,
2735,652051,1,1,,144203711,3454,Inactive,89191863.0,1814.0,,,qHTS of D3 Dopamine Receptor Potentiators: qHTS,Screening,,
2736,652054,1,1,,56424026,3454,Inactive,89191863.0,1814.0,,,qHTS of D3 Dopamine Receptor Antagonist: qHTS,Screening,,
2737,652067,1,4,,8139883,3454,Inactive,71987181.0,181263.0,,,Luminescence-based cell-based primary high throughput screening assay to identify activators of the DAF-12 from the parasite H. contortus (hcDAF-12),Screening,,
2738,652104,1,1,,56424026,3454,Inactive,20140568.0,23435.0,,Potency,qHTS of TDP-43 Inhibitors,Confirmatory,,
2739,652105,1,1,,56424026,3454,Inactive,18266879.0,5305.0,,Potency,qHTS for Inhibitors of phosphatidylinositol 5-phosphate 4-kinase (PI5P4K),Confirmatory,,
2740,652106,1,1,,50113251,3454,Inactive,586067.0,6622.0,,Potency,qHTS of alpha-syn Inhibitors,Confirmatory,,
2741,652106,1,1,,56424026,3454,Inactive,586067.0,6622.0,,Potency,qHTS of alpha-syn Inhibitors,Confirmatory,,
2742,652106,1,1,,90341439,3454,Inactive,586067.0,6622.0,,Potency,qHTS of alpha-syn Inhibitors,Confirmatory,,
2743,652115,1,1,,8139883,3454,Inactive,38258652.0,23408.0,,,MLPCN SirT-5 Measured in Biochemical System Using Imaging - 7044-01_Inhibitor_SinglePoint_HTS_Activity_Set5,Screening,,
2744,652126,1,3,,8139883,3454,Inactive,71987181.0,181263.0,,,Luminescence-based cell-based primary high throughput screening assay to identify activators of the DAF-12 from the parasite S. stercoralis (ssDAF-12),Screening,,
2745,652154,1,1,,8139883,3454,Inactive,998701.0,7849.0,,,HTS for PAX8 inhibitors using PAX8 luciferase reporter gene assay in RMG-I cells Measured in Cell-Based System Using Plate Reader - 7054-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
2746,652162,2,1,,8139883,3454,Inactive,126698238.0,4914074.0,,,C. difficile toxins: HTS for inhibitors of TcdB glycohydrolase activity Measured in Biochemical System Using Plate Reader - 7074-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
2747,652163,1,1,,8139883,3454,Inactive,47496637.0,6275.0,,,S100A4: HTS Measured in Biochemical System Using Plate Reader - 7045-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
2748,652163,1,1,,56424026,3454,Inactive,47496637.0,6275.0,,,S100A4: HTS Measured in Biochemical System Using Plate Reader - 7045-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
2749,652197,1,1,,8139883,3454,Inactive,21315078.0,51752.0,,,MLPCN ERAP1 Measured in Biochemical System Using Plate Reader - 7016-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
2750,652257,1,1,,8139883,3454,Inactive,32425330.0,3276.0,,,Primary biochemical fluorescence polarization-based high throughput screening assay to identify inhibitors of protein arginine methyltransferase 1 (PRMT1),Screening,,
2751,654288,1,2,,103504490,3454,Unspecified,,,,,"Antiviral activity against MCMV infected in BALB/c mouse assessed as decrease in virus-induced mortality at 50 mg/kg, po qd for 5 days administered 24 hrs after viral infection (Rvb = 67%)",Other,22417649.0,
2752,654289,1,2,,103504490,3454,Unspecified,,,,,"Antiviral activity against MCMV infected in BALB/c mouse assessed as decrease in virus-induced mortality at 16.7 mg/kg, po qd for 5 days administered 24 hrs after viral infection (Rvb = 67%)",Other,22417649.0,
2753,654290,1,2,,103504490,3454,Unspecified,,,,,"Antiviral activity against MCMV infected in BALB/c mouse assessed as decrease in virus-induced mortality at 5.6 mg/kg, po qd for 5 days administered 24 hrs after viral infection (Rvb = 67%)",Other,22417649.0,
2754,654291,1,2,,103504490,3454,Unspecified,,,,,"Antiviral activity against MCMV infected in BALB/c mouse assessed as decrease in virus-induced mortality at 50 mg/kg, po qd for 5 days administered 48 hrs after viral infection (Rvb = 100%)",Other,22417649.0,
2755,654292,1,2,,103504490,3454,Unspecified,,,,,"Antiviral activity against MCMV infected in BALB/c mouse assessed as decrease in virus-induced mortality at 16.7 mg/kg, po qd for 5 days administered 48 hrs after viral infection (Rvb = 100%)",Other,22417649.0,
2756,654293,1,2,,103504490,3454,Unspecified,,,,,"Antiviral activity against MCMV infected in BALB/c mouse assessed as decrease in virus-induced mortality at 5.6 mg/kg, po qd for 5 days administered 48 hrs after viral infection (Rvb = 100%)",Other,22417649.0,
2757,654294,1,2,,103504490,3454,Unspecified,,,,,"Antiviral activity against MCMV infected in BALB/c mouse assessed as decrease in virus-induced mean day of death at 50 mg/kg, po qd for 5 days administered 24 hrs after viral infection (Rvb = 4.9 +/- 0.7 days)",Other,22417649.0,
2758,654295,1,2,,103504490,3454,Unspecified,,,,,"Antiviral activity against MCMV infected in BALB/c mouse assessed as decrease in virus-induced mean day of death at 16.7 mg/kg, po qd for 5 days administered 24 hrs after viral infection (Rvb = 4.9 +/- 0.7 days)",Other,22417649.0,
2759,654296,1,2,,103504490,3454,Unspecified,,,,,"Antiviral activity against MCMV infected in BALB/c mouse assessed as decrease in virus-induced mean day of death at 5.6 mg/kg, po qd for 5 days administered 24 hrs after viral infection (Rvb = 4.9 +/- 0.7 days)",Other,22417649.0,
2760,654297,1,2,,103504490,3454,Unspecified,,,,,"Antiviral activity against MCMV infected in BALB/c mouse assessed as decrease in virus-induced mean day of death at 50 mg/kg, po qd for 5 days administered 48 hrs after viral infection (Rvb = 5.1 +/- 0.9 days)",Other,22417649.0,
2761,654298,1,2,,103504490,3454,Unspecified,,,,,"Antiviral activity against MCMV infected in BALB/c mouse assessed as decrease in virus-induced mean day of death at 16.7 mg/kg, po qd for 5 days administered 48 hrs after viral infection (Rvb = 5.1 +/- 0.9 days)",Other,22417649.0,
2762,654450,1,2,,103504490,3454,Unspecified,,,,,"Antiviral activity against MCMV infected in BALB/c mouse assessed as decrease in virus-induced mean day of death at 5.6 mg/kg, po qd for 5 days administered 48 hrs after viral infection (Rvb = 5.1 +/- 0.9 days)",Other,22417649.0,
2763,655431,2,5,,103504490,3454,Active,,,0.01,EC50,Antiviral activity against HSV-1 KOS infected in HEL cells assessed as inhibition of viral-induced cytopathogenicity,Confirmatory,23795238.0,
2764,655432,2,5,,103504490,3454,Active,,,0.01,EC50,Antiviral activity against HSV-2 G infected in HEL cells assessed as inhibition of viral-induced cytopathogenicity,Confirmatory,23795238.0,
2765,655433,2,3,,103504490,3454,Unspecified,,,100.0,EC50,Antiviral activity against Vaccinia virus Lederle infected in HEL cells assessed as inhibition of viral-induced cytopathogenicity,Confirmatory,23795238.0,
2766,655434,2,5,,103504490,3454,Active,,,1.0,EC50,Antiviral activity against ACV-resistant TK-deficient HSV-1 KOS infected in HEL cells assessed as inhibition of viral-induced cytopathogenicity,Confirmatory,23795238.0,
2767,655435,2,4,,103504490,3454,Unspecified,,,,,Cytotoxicity against human HEL cells assessed as changes in cell morphology by microscopy,Other,23795238.0,
2768,655438,1,3,,103504490,3454,Unspecified,,,,,Ratio of EC50 for ACV-resistant TK-deficient HSV-1 KOS to EC50 for wild type HIV-1,Other,23795238.0,
2769,658617,2,4,,103504490,3454,Active,,,0.02,EC50,Antiviral activity against HSV1 KOS infected in HEL cells assessed as inhibition of virus-induced cytopathogenicity after 4 days,Confirmatory,22459876.0,
2770,658618,2,4,,103504490,3454,Active,,,0.03,EC50,Antiviral activity against HSV2 G infected in HEL cells assessed as inhibition of virus-induced cytopathogenicity after 4 days,Confirmatory,22459876.0,
2771,658619,2,2,,103504490,3454,Unspecified,,,100.0,EC50,Antiviral activity against Vaccinia virus infected in HEL cells assessed as inhibition of virus-induced cytopathogenicity after 4 days,Confirmatory,22459876.0,
2772,658739,2,2,,103504490,3454,Unspecified,,,100.0,EC50,Antiviral activity against Vesicular stomatitis virus infected in HEL cells assessed as inhibition of virus-induced cytopathogenicity after 4 days,Confirmatory,22459876.0,
2773,658740,2,4,,103504490,3454,Unspecified,,,100.0,EC50,Antiviral activity against thymidine kinase-deficient acyclovir-resistant HSV1 KOS infected in HEL cells assessed as inhibition of virus-induced cytopathogenicity after 4 days,Confirmatory,22459876.0,
2774,658741,2,3,,103504490,3454,Unspecified,,,,,Cytotoxicity against human HEL cells assessed as minimum compound concentration required to causes microscopically detectable alteration of normal cell morphology,Other,22459876.0,
2775,658752,2,2,,103504490,3454,Active,,,1.65,EC50,Antiviral activity against Cytomegalovirus AD-169 infected in HEL cells assessed as inhibition of virus plaque formation after 4 days,Confirmatory,22459876.0,
2776,658753,2,2,,103504490,3454,Active,,,1.65,EC50,Antiviral activity against Human cytomegalovirus Davis infected in HEL cells assessed as inhibition of virus plaque formation after 4 days,Confirmatory,22459876.0,
2777,658754,2,2,,103504490,3454,Unspecified,,,221.8,CC50,Cytotoxicity against human HeLa cells assessed as cell viability by colorimetric formazan-based MTS assay,Confirmatory,22459876.0,
2778,658757,4,1,,103504490,3454,Unspecified,,,100.0,CC50,Cytotoxicity against cat CRFK cells assessed as cell viability by colorimetric formazan-based MTS assay,Confirmatory,22459876.0,
2779,658758,4,1,,103504490,3454,Unspecified,,,100.0,EC50,Antiviral activity against FIPV infected in cat CRFK cells assessed as inhibition of virus-induced cytopathic effect after 4 days by colorimetric formazan-based MTS assay,Confirmatory,22459876.0,
2780,658759,4,1,,103504490,3454,Active,,,4.1,EC50,Antiviral activity against Feline herpesvirus infected in cat CRFK cells assessed as inhibition of virus-induced cytopathic effect after 4 days by colorimetric formazan-based MTS assay,Confirmatory,22459876.0,
2781,665386,2,2,,103504490,3454,Active,,,7.5,EC50,Antiviral activity against Human cytomegalovirus AD169 infected in HEL cells assessed as reduction in virus-induced cytopathicity,Confirmatory,22578783.0,
2782,665387,2,2,,103504490,3454,Active,,,7.1,EC50,Antiviral activity against Human cytomegalovirus Davis infected in HEL cells assessed as reduction in virus-induced cytopathicity,Confirmatory,22578783.0,
2783,665388,2,3,,103504490,3454,Unspecified,,,,,Cytotoxicity against human HEL cells assessed as change in cell morphology by microscopic analysis,Other,22578783.0,
2784,665389,2,3,,103504490,3454,Unspecified,,,130.0,CC50,Cytostatic against human HEL cells assessed as reduction in cell growth after 3 days by coulter counter,Confirmatory,22578783.0,
2785,665761,2,2,,103504490,3454,Active,,,2.1,IC50,Antiviral activity against HCMV infected in human HFF cells assessed as reduction in cytopathic effect after 8 days by plaque reduction assay,Confirmatory,22607883.0,
2786,665762,2,2,,103504490,3454,Unspecified,,,300.0,CC50,Cytotoxicity against human HFF cells after 3 to 8 days by crystal voilet staining,Confirmatory,22607883.0,
2787,675210,2,2,,103504490,3454,Inconclusive,,,,EC50,Antiviral activity against thymidine kinase positive VZV YS infected in HEL cells by plaque formation assay,Confirmatory,22858222.0,
2788,675211,2,2,,103504490,3454,Inconclusive,,,,EC50,Antiviral activity against thymidine kinase positive VZV OKa infected in HEL cells by plaque formation assay,Confirmatory,22858222.0,
2789,675212,2,2,,103504490,3454,Inconclusive,,,,EC50,Antiviral activity against thymidine kinase negative VZV 07/01 infected in HEL cells by plaque formation assay,Confirmatory,22858222.0,
2790,675213,2,2,,103504490,3454,Inconclusive,,,,EC50,Antiviral activity against thymidine kinase negative VZV YS/R infected in HEL cells by plaque formation assay,Confirmatory,22858222.0,
2791,675214,2,2,,103504490,3454,Active,,,0.027000000000000003,EC50,Antiviral activity against HSV1 KOS infected in HEL cells by viral CPE assay,Confirmatory,22858222.0,
2792,675215,2,4,,103504490,3454,Active,,,0.028999999999999998,EC50,Antiviral activity against HSV2 G infected in HEL cells by viral CPE assay,Confirmatory,22858222.0,
2793,675216,2,2,,103504490,3454,Active,,,14.7,EC50,Antiviral activity against thymidine kinase negative and ACV resistant HSV1 KOS infected in HEL cells by viral CPE assay,Confirmatory,22858222.0,
2794,675217,2,2,,103504490,3454,Active,,,9.1,EC50,Antiviral activity against HCMV AD169 infected in HEL cells by viral CPE assay,Confirmatory,22858222.0,
2795,675218,2,2,,103504490,3454,Active,,,5.9,EC50,Antiviral activity against HCMV Davis infected in HEL cells by viral CPE assay,Confirmatory,22858222.0,
2796,675219,2,2,,103504490,3454,Active,,,1.15,EC50,Antiviral activity against Feline herpesvirus infected in CRFK cells by viral CPE assay,Confirmatory,22858222.0,
2797,675220,2,2,,103504490,3454,Unspecified,,,93.0,EC50,Antiviral activity against Vaccinia virus Lederie infected in HEL cells by viral CPE assay,Confirmatory,22858222.0,
2798,675221,2,3,,103504490,3454,Unspecified,,,,,Cytotoxicity against HEL cells assessed as effect on cell morphology incubated for 3 days by microscopy,Other,22858222.0,
2799,675222,2,3,,103504490,3454,Unspecified,,,231.0,CC50,Cytotoxicity against HEL cells assessed as effect on cell growth incubated for 3 days by Coulter counter assay,Confirmatory,22858222.0,
2800,679320,2,7,,103504490,3454,Unspecified,74762955.0,9356.0,895.5,Km,TP_TRANSPORTER: uptake in OAT1-expressing S2 cells,Confirmatory,11861798.0,
2801,680360,2,7,,103504490,3454,Unspecified,313104181.0,6580.0,516.2,Km,TP_TRANSPORTER: uptake in OCT1-expressing S2 cells,Confirmatory,11861798.0,
2802,680950,1,8,,103504490,3454,Unspecified,74753520.0,10864.0,,,"TP_TRANSPORTER: inhibition of PGF2alpha uptake (PGF2alpha: 0.005 uM, GCV: 1000 uM) in OAT2-expressing S2 cells",Other,11861798.0,
2803,681056,1,7,,103504490,3454,Unspecified,74730587.0,9376.0,,,"TP_TRANSPORTER: inhibition of E1S uptake (E1S: 0.05 uM, GCV: 1000 uM) in OAT3-expressing S2 cells",Other,11861798.0,
2804,681942,1,7,,103504490,3454,Unspecified,313104181.0,6580.0,,,"TP_TRANSPORTER: inhibition of TEA uptake (TEA: 5 uM, GCV: 1000 uM) in OCT1-expressing S2 cells",Other,11861798.0,
2805,682055,1,8,,103504490,3454,Unspecified,74762955.0,9356.0,,,"TP_TRANSPORTER: inhibition of PAH uptake (PAH: 5 uM, GCV: 1000 uM) in OAT1-expressing S2 cells",Other,11861798.0,
2806,686940,1,1,,8139883,3454,Inactive,14149746.0,7026.0,,,Luminescence-based cell-based primary high throughput screening assay to identify inhibitors of COUP-TFII (NR2F2),Screening,,
2807,686964,1,1,,8139883,3454,Inactive,21595776.0,8932.0,,,TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of 5-meCpG-binding domain protein 2 (MBD2)-DBD binding to methylated oligonucleotide,Screening,,
2808,686970,1,2,,56424026,3454,Inactive,49168486.0,3417.0,,Potency,qHTS for induction of synthetic lethality in tumor cells producing 2HG: qHTS for the HT-1080-NT fibrosarcoma cell line,Confirmatory,,
2809,686971,1,2,,56424026,3454,Inactive,,,,Potency,qHTS for induction of synthetic lethality in tumor cells producing 2HG: qHTS for the HT-1080-IDH1KD cell line,Confirmatory,,
2810,686977,2,1,,49698657,3454,Inactive,9657203.0,2615631.0,,IC50,Vibrio cholerae assay for pro-quorum sensing small molecules,Confirmatory,,
2811,686978,1,1,,50113251,3454,Inconclusive,79154014.0,55775.0,5.0119,Potency,qHTS for Inhibitors of human tyrosyl-DNA phosphodiesterase 1 (TDP1): qHTS in cells in absence of CPT,Confirmatory,,
2812,686978,1,1,,56424026,3454,Active,79154014.0,55775.0,2.5929,Potency,qHTS for Inhibitors of human tyrosyl-DNA phosphodiesterase 1 (TDP1): qHTS in cells in absence of CPT,Confirmatory,,
2813,686978,1,1,,144203711,3454,Active,79154014.0,55775.0,1.0137,Potency,qHTS for Inhibitors of human tyrosyl-DNA phosphodiesterase 1 (TDP1): qHTS in cells in absence of CPT,Confirmatory,,
2814,686979,1,1,,50113251,3454,Inconclusive,79154014.0,55775.0,3.5481,Potency,qHTS for Inhibitors of human tyrosyl-DNA phosphodiesterase 1 (TDP1): qHTS in cells in presence of CPT,Confirmatory,,
2815,686979,1,1,,56424026,3454,Active,79154014.0,55775.0,1.2995,Potency,qHTS for Inhibitors of human tyrosyl-DNA phosphodiesterase 1 (TDP1): qHTS in cells in presence of CPT,Confirmatory,,
2816,686979,1,1,,144203711,3454,Active,79154014.0,55775.0,1.6067,Potency,qHTS for Inhibitors of human tyrosyl-DNA phosphodiesterase 1 (TDP1): qHTS in cells in presence of CPT,Confirmatory,,
2817,686992,2,1,,8139883,3454,Inactive,187960042.0,6401.0,,,Identification of agents that induce E-selectin on human endothelial cells Measured in Cell-Based System Using Imaging - 2152-01_Activator_SinglePoint_HTS_Activity,Screening,,
2818,686996,1,1,,8139883,3454,Inactive,13325293.0,839.0,,,VEID(2) R110 Enzymatic Primary HTS to identify Inhibitors of Caspase 6 Measured in Biochemical System Using Plate Reader - 7052-01_Inhibitor_SinglePoint_HTS_Activity_Set2,Screening,,
2819,687014,1,1,,8139883,3454,Inactive,71987181.0,181263.0,,,Luminescence-based cell-based primary high throughput screening assay to identify agonists of the DAF-12 from the parasite H. glycines (hgDAF-12).,Screening,,
2820,687016,1,1,,8139883,3454,Inactive,115430235.0,29128.0,,,Counterscreen for inhibitors of 5-meCpG-binding domain protein 2 (MBD2): TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of binding of ubiquitin-like with PHD and ring finger domains 1 (UHRF1) to methylated oligonucleotide,Screening,,
2821,687035,1,1,,163564493,3454,Inactive,125541954.0,,,,Fluorescence polarization based primary biochemical high throughput screening assay of LOPAC1280 to identify inhibitors of hepatitis C non-structural protein 3 helicase,Screening,,
2822,687037,1,3,,163564493,3454,Inactive,,,,,Fluorescence-based counterscreen assay of HCV NS3 helicase-DNA binding inhibitors in LOPAC1280: biochemical high-throughput screening assay to identify compounds that enhance or quench fluorescence of a Cy5-DNA-NS3h complex,Screening,,
2823,687668,2,2,,103504490,3454,Active,,,1.2,EC50,Antiviral activity against Feline herpesvirus infected in CRFK cells assessed as inhibition of virus-induced cytopathicity after 3 days,Confirmatory,23047229.0,
2824,687669,2,3,,103504490,3454,Unspecified,,,100.0,CC50,Cytotoxicity against CRFK cells after 3 days,Confirmatory,23047229.0,
2825,718733,2,3,,103504490,3454,Unspecified,,,,,Toxicity in HEL cells assessed as induction of cell morphology changes,Other,23099097.0,
2826,718734,2,4,,103504490,3454,Active,,,4.0,EC50,Antiviral activity against thymidine kinase deficient and acyclovir-resistant HSV1 KOS infected in HEL cells assessed as inhibition of virus-induced cytopathic effect,Confirmatory,23099097.0,
2827,718735,2,2,,103504490,3454,Unspecified,,,100.0,EC50,Antiviral activity against Vesicular stomatitis virus infected in HEL cells assessed as inhibition of virus-induced cytopathic effect,Confirmatory,23099097.0,
2828,718736,2,2,,103504490,3454,Unspecified,,,100.0,EC50,Antiviral activity against Vaccinia virus infected in HEL cells assessed as inhibition of virus-induced cytopathic effect,Confirmatory,23099097.0,
2829,718737,2,4,,103504490,3454,Active,,,0.013000000000000001,EC50,Antiviral activity against HSV2 G infected in HEL cells assessed as inhibition of virus-induced cytopathic effect,Confirmatory,23099097.0,
2830,718738,2,4,,103504490,3454,Active,,,0.015,EC50,Antiviral activity against HSV1 KOS infected in HEL cells assessed as inhibition of virus-induced cytopathic effect,Confirmatory,23099097.0,
2831,720504,1,1,,56424026,3454,Inactive,21359873.0,5347.0,,Potency,qHTS for Inhibitors of PLK1-PDB (polo-like kinase 1 - polo-box domain): Primary Screen,Confirmatory,,
2832,720508,1,1,,8139883,3454,Inactive,28373962.0,,,,Fluorescence polarization-based biochemical primary high throughput screening assay to identify inhibitors that disrupt the binding of a cyclic peptide (Tn7) to the fibrin proteolytic product D-Dimer and fragment E complex [DD(E )],Screening,,
2833,720509,1,1,,8139883,3454,Inactive,28373962.0,,,,Fluorescence polarization-based biochemical primary high throughput screening assay to identify inhibitors that disrupt the binding of a cyclic peptide (Tn6) to the fibrin proteolytic product D-Dimer and fragment E complex [DD(E )],Screening,,
2834,720511,1,1,,8139883,3454,Inactive,89348172.0,1080.0,,,Identification of Small Molecule Correctors of the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Delta508 Mutation Function in Human Bronchial Epithelial Cells. Measured in Cell-Based System Using Plate Reader - 7017-01_Other_SinglePoint_HTS_Activity,Screening,,
2835,720516,2,1,,144203711,3454,Inactive,296439460.0,79915.0,,ATAD5 Potency (uM),qHTS assay for small molecules that induce genotoxicity in human embryonic kidney cells expressing luciferase-tagged ATAD5: Summary,Summary,,
2836,720532,1,1,,144203711,3454,Inactive,420597.0,,,Potency,qHTS for Inhibitors of binding or entry into cells for Marburg Virus,Confirmatory,,
2837,720533,1,1,,144203711,3454,Inactive,,,,Potency,qHTS for Inhibitors of binding or entry into cells for Lassa Virus,Confirmatory,,
2838,720538,1,2,,90341439,3454,Inactive,220983390.0,410.0,0.0301,Potency,qHTS screen for enhancers of Arylsulfatase A (ASA1): LOPAC Validation Assay,Confirmatory,,
2839,720542,1,2,,56424026,3454,Inactive,23496270.0,810891.0,,Potency,qHTS for Inhibitors of AMA1-RON; Towards Development of Antimalarial Drug Lead: Primary Screen,Confirmatory,,
2840,720543,1,1,,8139883,3454,Inactive,326937491.0,105501.0,,,Fluorescence polarization-based biochemical high throughput primary assay to identify inhibitors of alpha/beta hydrolase domain containing 4 (ABHD4).,Screening,,
2841,720551,1,2,,56424026,3454,Inactive,342840031.0,3757.0,,Potency,qHTS for Inhibitors of KCHN2 3.1: Wildtype qHTS,Confirmatory,,
2842,720552,2,1,,144203711,3454,Inactive,269849759.0,7157.0,,Ratio Potency (uM),qHTS assay for small molecule agonists of the p53 signaling pathway: Summary,Summary,,
2843,720553,1,2,,56424026,3454,Inactive,342840031.0,3757.0,,Potency,qHTS for Inhibitors of KCHN2 3.1: Mutant qHTS,Confirmatory,,
2844,720554,1,3,,121362387,3454,Inactive,52423132.0,3087402.0,,,Inhibition of the Burkholderia mallei acyl-homoserine lactone synthase BmaI1,Other,,
2845,720559,1,2,,90341439,3454,Inactive,112927.0,351.0,,Potency,qHTS for compounds that reverse cellular toxicity of Amyloid beta (A-beta) peptide in yeast: LOPAC Validation Assay,Confirmatory,,
2846,720572,1,2,,90341439,3454,Inactive,3063388.0,5071.0,,Potency,qHTS for Activators of Parkin Expression:  LOPAC Validation Assay (NLuc Reporter),Confirmatory,,
2847,720573,1,2,,90341439,3454,Inactive,3063388.0,5071.0,,Potency,qHTS for Activators of Parkin Expression:  LOPAC Validation Assay (FLuc Reporter),Confirmatory,,
2848,720579,2,1,,50113251,3454,Inactive,222762.0,3707576.0,,Potency,qHTS for Stage-Specific Inhibitors of Vaccinia Orthopoxvirus: mCherry Reporter Primary qHTS,Confirmatory,,
2849,720579,2,1,,56424026,3454,Inactive,222762.0,3707576.0,,Potency,qHTS for Stage-Specific Inhibitors of Vaccinia Orthopoxvirus: mCherry Reporter Primary qHTS,Confirmatory,,
2850,720580,1,1,,50113251,3454,Inactive,222762.0,3707576.0,,Potency,qHTS for Stage-Specific Inhibitors of Vaccinia Orthopoxvirus: Venus Reporter Primary qHTS,Confirmatory,,
2851,720580,1,1,,56424026,3454,Inactive,222762.0,3707576.0,,Potency,qHTS for Stage-Specific Inhibitors of Vaccinia Orthopoxvirus: Venus Reporter Primary qHTS,Confirmatory,,
2852,720582,1,1,,8139883,3454,Inactive,2393947.0,102.0,,,QFRET-based biochemical primary high throughput screening assay to identify exosite inhibitors of ADAM10.,Screening,,
2853,720596,1,1,,8139883,3454,Inactive,4506113.0,5621.0,,,TRFRET-based cell-based primary high throughput screening assay to identify inhibitors of cell surface Prion Protein (PRPC),Screening,,
2854,720634,2,1,,144203711,3454,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecule disruptors of the mitochondrial membrane potential - cell viability,Confirmatory,,
2855,720635,2,1,,144203711,3454,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecule disruptors of the mitochondrial membrane potential,Confirmatory,,
2856,720637,2,1,,144203711,3454,Inactive,,,,Ratio Potency (uM),qHTS assay for small molecule disruptors of the mitochondrial membrane potential: Summary,Summary,,
2857,720641,1,2,,92309204,3454,Inactive,15923709.0,,,,A screen for compounds that inhibit the activity of LtaS in Staphylococcus aureus,Other,,
2858,720647,1,2,,8139883,3454,Inactive,,,,,Bursicon-induced LGR2 mediated cAMP production in LGR-2/CRE6x-Luciferase co-transfected HEK293 cells Inhibition,Screening,,
2859,720648,1,1,,8139883,3454,Inactive,73747889.0,6868.0,,,QFRET-based biochemical primary high throughput screening assay to identify exosite inhibitors of ADAM17.,Screening,,
2860,720674,2,2,,144203711,3454,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 590 nm (red) in HepG2 cells,Confirmatory,,
2861,720675,2,2,,144203711,3454,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 535 nm (green) in HepG2 cells,Confirmatory,,
2862,720678,2,1,,144203711,3454,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 460 nm (blue) in HEK293 cells,Confirmatory,,
2863,720679,2,1,,144203711,3454,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 590 nm (red) in HEK293 cells,Confirmatory,,
2864,720680,2,1,,144203711,3454,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 535 nm (green) in HEK293 cells,Confirmatory,,
2865,720681,2,1,,144203711,3454,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 460 nm (blue) in HEK293 cell free culture,Confirmatory,,
2866,720682,2,1,,144203711,3454,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 535 nm (green) in HEK293 cell free culture,Confirmatory,,
2867,720683,2,1,,144203711,3454,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 590 nm (red) in HEK293 cell free culture,Confirmatory,,
2868,720684,2,1,,144203711,3454,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 590 nm (red) in HepG2 cell free culture,Confirmatory,,
2869,720685,2,1,,144203711,3454,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 460 nm (blue) in HepG2 cell free culture,Confirmatory,,
2870,720686,2,1,,144203711,3454,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 535 nm (green) in HepG2 cell free culture,Confirmatory,,
2871,720687,2,2,,144203711,3454,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 460 nm (blue) in HepG2 cells,Confirmatory,,
2872,720691,4,1,,144203711,3454,Inactive,311348376.0,2908.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the glucocorticoid receptor (GR) signaling pathway,Confirmatory,,
2873,720692,3,1,,144203711,3454,Inconclusive,311348376.0,2908.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the glucocorticoid receptor (GR) signaling pathway,Confirmatory,,
2874,720693,3,1,,144203711,3454,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the glucocorticoid receptor (GR) signaling pathway - cell viability counter screen,Confirmatory,,
2875,720700,1,4,,8139883,3454,Inactive,223459640.0,5335.0,,,Fluorescence-based biochemical high throughput primary assay to identify inhibitors of phospholipase C isozymes (PLC-gamma1).,Screening,,
2876,720702,1,1,,8139883,3454,Inactive,23510348.0,51567.0,,,Epi Absorbance-based biochemical primary high throughput screening assay to identify inhibitors of human tyrosyl-DNA phosphodiesterase 2 (TDP2),Screening,,
2877,720704,1,4,,8139883,3454,Inactive,148745659.0,5331.0,,,Fluorescence-based biochemical high throughput primary assay to identify inhibitors of phospholipase C isozymes (PLC-beta3).,Screening,,
2878,720707,1,2,,56424026,3454,Inactive,317373593.0,10411.0,,Potency,qHTS for Agonist of cAMP-regulated guanine nucleotide exchange factor 3 (EPAC1): primary screen,Confirmatory,,
2879,720708,1,2,,56424026,3454,Inactive,32171491.0,11069.0,,Potency,qHTS for Antagonist of cAMP-regulated guanine nucleotide exchange factor 2 (EPAC2): primary screen,Confirmatory,,
2880,720709,1,2,,56424026,3454,Inactive,317373593.0,10411.0,,Potency,qHTS for Antagonist of cAMP-regulated guanine nucleotide exchange factor 3 (EPAC1): primary screen,Confirmatory,,
2881,720711,1,2,,56424026,3454,Inactive,32171491.0,11069.0,,Potency,qHTS for Agonist of cAMP-regulated guanine nucleotide exchange factor 4 (EPAC2): primary screen,Confirmatory,,
2882,720717,1,3,,92125763,3454,Inactive,1718329.0,,,,Chemical Probes of Kaposi's Sarcoma Herpes Virus Latent Infection,Other,,
2883,720717,1,3,,92309204,3454,Inactive,1718329.0,,,,Chemical Probes of Kaposi's Sarcoma Herpes Virus Latent Infection,Other,,
2884,720719,2,1,,144203711,3454,Inactive,311348376.0,2908.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the glucocorticoid receptor (GR) signaling pathway: Summary,Summary,,
2885,720725,2,1,,144203711,3454,Inactive,311348376.0,2908.0,,,qHTS assay to identify small molecule antagonists of the glucocorticoid receptor (GR) signaling pathway: Summary,Summary,,
2886,736036,1,2,,103504490,3454,Active,,,5.7,IC50,Antiviral activity against HCMV Davis,Confirmatory,23357038.0,
2887,736037,1,2,,103504490,3454,Active,,,6.3,IC50,Antiviral activity against HCMV AD169,Confirmatory,23357038.0,
2888,742601,2,2,,103504490,3454,Active,118878.0,,,,Human herpesvirus 1 DNA polymerase inhibitor,Other,,
2889,743012,3,1,,144203711,3454,Active,,,2.8532,Potency-Replicate_1,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against isogenic chicken DT40 cell lines with known DNA damage response pathways - wild type cell line,Confirmatory,,
2890,743014,3,1,,144203711,3454,Inconclusive,,,12.7448,Potency-Replicate_1,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against isogenic chicken DT40 cell lines with known DNA damage response pathways - Rev3 mutant cell line,Confirmatory,,
2891,743015,3,1,,144203711,3454,Active,,,8.0414,Potency-Replicate_1,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against isogenic chicken DT40 cell lines with known DNA damage response pathways - Rad54/Ku70 mutant cell line,Confirmatory,,
2892,743033,3,1,,144203711,3454,Inconclusive,,,11.4554,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen  receptor (AR) signaling pathway - cell viability counter screen,Confirmatory,,
2893,743035,2,1,,144203711,3454,Inactive,124375976.0,367.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway,Confirmatory,,
2894,743036,2,1,,144203711,3454,Inactive,124375976.0,367.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway,Confirmatory,,
2895,743040,3,1,,144203711,3454,Inactive,124375976.0,367.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the androgen  receptor (AR) signaling pathway using the MDA cell line,Confirmatory,,
2896,743041,3,1,,144203711,3454,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen  receptor (AR) signaling pathway using the MDA cell line - cell viability counter screen,Confirmatory,,
2897,743042,3,1,,144203711,3454,Inactive,124375976.0,367.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen  receptor (AR) signaling pathway using the MDA cell line,Confirmatory,,
2898,743053,2,1,,144203711,3454,Inactive,124375976.0,367.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway: Summary,Summary,,
2899,743054,2,1,,144203711,3454,Inconclusive,124375976.0,367.0,,AR Potency (uM),qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway using the MDA cell line: Summary,Summary,,
2900,743063,2,1,,144203711,3454,Inactive,124375976.0,367.0,,Ratio Potency (uM),qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway: Summary,Summary,,
2901,743064,3,1,,144203711,3454,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the thyroid receptor (TR) signaling pathway - cell viability counter screen,Confirmatory,,
2902,743065,3,1,,144203711,3454,Inactive,399498506.0,24831.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the thyroid receptor (TR) signaling pathway,Confirmatory,,
2903,743066,3,1,,144203711,3454,Inactive,399498506.0,24831.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the thyroid receptor (TR) signaling pathway,Confirmatory,,
2904,743067,2,1,,144203711,3454,Inactive,399498506.0,24831.0,,TR Potency (uM),qHTS assay to identify small molecule antagonists of the thyroid receptor (TR) signaling pathway: Summary,Summary,,
2905,743069,2,1,,144203711,3454,Inactive,348019627.0,2099.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway,Confirmatory,,
2906,743074,2,1,,144203711,3454,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway - cell viability counter screen,Confirmatory,,
2907,743075,2,1,,144203711,3454,Inactive,348019627.0,2099.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway,Confirmatory,,
2908,743077,2,1,,144203711,3454,Inactive,348019627.0,2099.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway: Summary,Summary,,
2909,743078,2,1,,144203711,3454,Inactive,348019627.0,2099.0,,Ratio Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway: Summary,Summary,,
2910,743079,3,1,,144203711,3454,Inactive,348019627.0,2099.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line,Confirmatory,,
2911,743080,3,1,,144203711,3454,Inconclusive,348019627.0,2099.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line,Confirmatory,,
2912,743081,3,1,,144203711,3454,Inconclusive,,,0.2543,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line - cell viability counter screen,Confirmatory,,
2913,743083,3,1,,144203711,3454,Inactive,119597822.0,1588.0,,Potency-Replicate_1,qHTS assay to identify aromatase inhibitors,Confirmatory,,
2914,743084,3,1,,144203711,3454,Inactive,,,,Potency-Replicate_1,qHTS assay to identify aromatase inhibitors - cell viability counter screen,Confirmatory,,
2915,743085,3,1,,144203711,3454,Inactive,51095037.0,196.0,,Potency-Replicate_1,qHTS assay to identify small molecule that activate the aryl hydrocarbon receptor (AhR) signaling pathway,Confirmatory,,
2916,743086,3,1,,144203711,3454,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule that activate the aryl hydrocarbon receptor (AhR) signaling pathway - cell viability counter screen,Confirmatory,,
2917,743091,2,1,,144203711,3454,Inconclusive,348019627.0,2099.0,,ER Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line: Summary,Summary,,
2918,743094,3,1,,144203711,3454,Inactive,216409692.0,5468.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway,Confirmatory,,
2919,743122,2,1,,144203711,3454,Inactive,51095037.0,196.0,,AhR Potency (uM),qHTS assay to identify small molecule that activate the aryl hydrocarbon receptor (AhR) signaling pathway: Summary,Summary,,
2920,743126,1,1,,8139883,3454,Inactive,119580345.0,50487.0,,,QFRET-based biochemical high throughput primary assay to identify inhibitors of human group III secreted phospholipase A2 enzyme (HGIII-sPLA2),Screening,,
2921,743139,2,1,,144203711,3454,Inactive,119597822.0,1588.0,,,qHTS assay to identify aromatase inhibitors: Summary,Summary,,
2922,743140,2,1,,144203711,3454,Inactive,216409692.0,5468.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway: Summary,Summary,,
2923,743191,3,1,,170464961,3454,Inactive,216409692.0,5468.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway,Confirmatory,,
2924,743194,3,1,,170464961,3454,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway - cell viability counter screen,Confirmatory,,
2925,743199,2,1,,170464961,3454,Inactive,216409692.0,5468.0,,,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway: Summary,Summary,,
2926,743202,4,1,,170464961,3454,Inactive,20149576.0,4780.0,,Potency-Replicate_1,qHTS assay for small molecule agonists of the antioxidant response element (ARE) signaling pathway,Confirmatory,,
2927,743203,3,1,,170464961,3454,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecule agonists of the antioxidant response element (ARE) signaling pathway - cell viability counter screen,Confirmatory,,
2928,743205,1,1,,90341439,3454,Inactive,4503951.0,2645.0,,Potency,qHTS assay for inhibitors of recombinant human GCK-GKRP interaction: Diaphorase-coupled assay,Confirmatory,,
2929,743205,1,1,,90341439,3454,Inactive,221625433.0,2646.0,,Potency,qHTS assay for inhibitors of recombinant human GCK-GKRP interaction: Diaphorase-coupled assay,Confirmatory,,
2930,743206,1,1,,90341439,3454,Inactive,4503951.0,2645.0,,Potency,qHTS assay for inhibitors of recombinant human GCK-GKRP interaction: ADP-Glo assay,Confirmatory,,
2931,743206,1,1,,90341439,3454,Inactive,221625433.0,2646.0,,Potency,qHTS assay for inhibitors of recombinant human GCK-GKRP interaction: ADP-Glo assay,Confirmatory,,
2932,743207,1,1,,90341439,3454,Inactive,4503951.0,2645.0,,Potency,qHTS assay for inhibitors of recombinant human GCK-GKRP interaction: HTRF assay,Confirmatory,,
2933,743207,1,1,,90341439,3454,Inactive,221625433.0,2646.0,,Potency,qHTS assay for inhibitors of recombinant human GCK-GKRP interaction: HTRF assay,Confirmatory,,
2934,743209,3,1,,170464961,3454,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecule activators of the heat shock response signaling pathway - cell viability counter screen,Confirmatory,,
2935,743210,4,1,,170464961,3454,Inactive,4504517.0,3315.0,,Potency-Replicate_1,qHTS assay for small molecule activators of the heat shock response signaling pathway,Confirmatory,,
2936,743211,3,1,,170464961,3454,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway - cell viability counter screen,Confirmatory,,
2937,743212,3,1,,170464961,3454,Inactive,216409690.0,5467.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway,Confirmatory,,
2938,743213,3,1,,170464961,3454,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway - cell viability counter screen,Confirmatory,,
2939,743215,3,1,,170464961,3454,Inactive,216409690.0,5467.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway,Confirmatory,,
2940,743217,3,1,,170464961,3454,Inactive,325495553.0,9971.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the farnesoid-X-receptor (FXR) signaling pathway,Confirmatory,,
2941,743218,3,1,,170464961,3454,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the farnesoid-X-receptor (FXR) signaling pathway - cell viability counter screen,Confirmatory,,
2942,743219,3,1,,170464961,3454,Inactive,20149576.0,4780.0,,Ratio Potency (uM),qHTS assay for small molecule agonists of the antioxidant response element (ARE) signaling pathway: Summary,Summary,,
2943,743220,3,1,,170464961,3454,Inactive,325495553.0,9971.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the farnesoid-X-receptor (FXR) signaling pathway,Confirmatory,,
2944,743221,3,1,,170464961,3454,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the farnesoid-X-receptor (FXR) signaling pathway - cell viability counter screen,Confirmatory,,
2945,743222,3,1,,170464961,3454,Inactive,216409708.0,7421.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the vitamin D receptor (VDR) signaling pathway,Confirmatory,,
2946,743223,3,1,,170464961,3454,Inactive,216409708.0,7421.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the vitamin D receptor (VDR) signaling pathway,Confirmatory,,
2947,743224,3,1,,170464961,3454,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the vitamin D receptor (VDR) signaling pathway - cell viability counter screen,Confirmatory,,
2948,743225,3,1,,170464961,3454,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the vitamin D receptor (VDR) signaling pathway - cell viability counter screen,Confirmatory,,
2949,743226,2,1,,170464961,3454,Inactive,216409690.0,5467.0,,,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway: Summary,Summary,,
2950,743227,2,1,,170464961,3454,Inactive,216409690.0,5467.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway: Summary,Summary,,
2951,743228,3,1,,170464961,3454,Inactive,4504517.0,3315.0,,Ratio Potency (uM),qHTS assay for small molecule activators of the heat shock response signaling pathway: Summary,Summary,,
2952,743238,1,1,,8139883,3454,Inactive,,,,,High Content Cell-Based Imaging Primary HTS to Identify Small Molecules Involved in X-Chromosome Reactivation and Reprogramming Measured in Cell-Based System Using Imaging - 7015-01_Activator_SinglePoint_HTS_Activity_Set2,Screening,,
2953,743239,2,1,,170464961,3454,Inactive,325495553.0,9971.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the farnesoid-X-receptor (FXR) signaling pathway: Summary,Summary,,
2954,743240,2,1,,170464961,3454,Inactive,325495553.0,9971.0,,,qHTS assay to identify small molecule antagonists of the farnesoid-X-receptor (FXR) signaling pathway: Summary,Summary,,
2955,743241,2,1,,170464961,3454,Inactive,216409708.0,7421.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the vitamin D receptor (VDR) signaling pathway: Summary,Summary,,
2956,743242,2,1,,170464961,3454,Inactive,216409708.0,7421.0,,,qHTS assay to identify small molecule antagonists of the vitamin D receptor (VDR) signaling pathway: Summary,Summary,,
2957,743244,1,1,,90341439,3454,Inactive,,,,Potency,qHTS Assay for Identifying Gametocytocidal Compounds,Confirmatory,,
2958,743244,1,1,,144203711,3454,Inactive,,,,Potency,qHTS Assay for Identifying Gametocytocidal Compounds,Confirmatory,,
2959,743247,1,2,,8139883,3454,Inactive,,,,,Inhibition of Alexa 488-Fibronectin deposition #on AH1F cell monolayers Measured in Cell-Based System Using Plate Reader - 7059-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
2960,743247,1,2,,56424026,3454,Inactive,,,,,Inhibition of Alexa 488-Fibronectin deposition #on AH1F cell monolayers Measured in Cell-Based System Using Plate Reader - 7059-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
2961,743255,1,1,,56424026,3454,Inactive,118600387.0,7398.0,,Potency,Inhibitors of USP1/UAF1: Primary Screen,Confirmatory,,
2962,743266,1,2,,56424026,3454,Inactive,296080761.0,5745.0,,Potency,qHTS of PTHR Inhibitors: Primary Screen,Confirmatory,,
2963,743268,1,1,,172080770,3454,Inactive,,,,,Fluorescence-based counterscreen assay for HCV NS3 helicase inhibitors of the NIH Clinical Collection: biochemical high-throughput screening assay to identify compounds that enhance or quench fluorescence of a Cy5-labeled substrate oligonucliotide bound to E. coli SSB,Screening,,
2964,743269,1,1,,8139883,3454,Inactive,2853980.0,,,,TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of HIV-1 LEDGF/p75 DNA Integration,Screening,,
2965,743269,1,1,,8139883,3454,Inactive,6708281.0,11168.0,,,TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of HIV-1 LEDGF/p75 DNA Integration,Screening,,
2966,743270,1,1,,172080770,3454,Inactive,125541954.0,,,,Fluorescence polarization based primary biochemical high throughput screening  assay of the NIH Clinical Collections to identify inhibitors of hepatitis C non-structural protein 3 helicase,Screening,,
2967,743271,1,1,,172080770,3454,Inactive,,,,,Biochemical high throughput counterscreening assay of the NIH Clinical Collection for inhibitors of the Hepatitis C Virus non-structural protein 3 helicase (NS3): fluorescence polarization based assay to identify compounds that can displace E. coli single stranded binding protein,Screening,,
2968,743272,1,1,,172080770,3454,Inactive,,,,,Fluorescence-based counterscreen assay for HCV NS3 helicase inhibitors of the NIH Clinical Collection: a biochemical high-throughput screening assay to identify compounds that cause fluorescent interference,Screening,,
2969,743279,1,2,,56424026,3454,Inactive,10835145.0,3553.0,,,qHTS for Inhibitors of Inflammasome Signaling:  IL-1-beta AlphaLISA Primary Screen,Screening,,
2970,743344,1,1,,90341439,3454,Inactive,,,0.0007,Potency,qHTS profiling of the MIPE4 collection as inhibitors of Plasmodium falciparum (3D7) proliferation,Confirmatory,,
2971,743345,1,1,,90341439,3454,Inactive,,,0.5952,Potency,qHTS profiling of the MIPE4 collection as inhibitors of Plasmodium falciparum (DD2) proliferation,Confirmatory,,
2972,743346,1,1,,90341439,3454,Inactive,,,0.0038,Potency,qHTS profiling of the MIPE4 collection as inhibitors of Plasmodium falciparum (DD2) proliferation (Rep 2),Confirmatory,,
2973,743347,1,1,,90341439,3454,Inactive,,,0.0038,Potency,qHTS profiling of the MIPE4 collection as inhibitors of Plasmodium falciparum (HB3) proliferation,Confirmatory,,
2974,743397,1,1,,8139883,3454,Inactive,,,,,HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
2975,743398,1,1,,8139883,3454,Inactive,,,,,Wnt/Beta-catenin HTS Measured in Cell-Based System Using Plate Reader - 2161-01_Activator_SinglePoint_HTS_Activity,Screening,,
2976,743398,1,1,,56424026,3454,Inactive,,,,,Wnt/Beta-catenin HTS Measured in Cell-Based System Using Plate Reader - 2161-01_Activator_SinglePoint_HTS_Activity,Screening,,
2977,753935,1,1,,103504490,3454,Active,,,2.7,EC50,Antiviral activity against Cytomegalovirus infected in HFF after 72 hrs by luciferase reporter gene assay,Confirmatory,23673218.0,
2978,756520,1,2,,103504490,3454,Unspecified,,,200.0,CC50,Cytotoxicity against HEL,Confirmatory,23743443.0,
2979,756521,1,2,,103504490,3454,Active,,,8.3,EC50,Antiviral actiivty against Human herpesvirus 5 Davis infected in HEL assessed as reduction of virus-induced plaque formation,Confirmatory,23743443.0,
2980,756522,1,2,,103504490,3454,Active,,,7.0,EC50,Antiviral actiivty against Human herpesvirus 5 AD169 infected in HEL assessed as reduction of virus-induced plaque formation,Confirmatory,23743443.0,
2981,756523,1,2,,103504490,3454,Unspecified,,,,,Cytotoxicity against HEL assessed as minimum cytotoxic concentration required to cause microscopically detectable alteration in cell morphology,Other,23743443.0,
2982,766676,1,2,,103504490,3454,Unspecified,,,350.0,CC50,Cytotoxicity against human HEL cells after 3 days by Coulter counting method,Confirmatory,23911854.0,
2983,766677,1,1,,103504490,3454,Active,,,8.2,EC50,Antiviral activity against human Cytomegalovirus AD169 infected in HEL cells assessed as inhibition of virus-induced cytopathicity after,Confirmatory,23911854.0,
2984,766699,1,3,,103504490,3454,Active,,,0.9,EC50,Antiviral activity against Herpes simplex virus-2 G infected in human HEL cells assessed as reduction in virus-induced cytopathogenicity,Confirmatory,23911856.0,
2985,766700,1,3,,103504490,3454,Unspecified,,,100.0,EC50,Antiviral activity against Herpes simplex virus-1 KOS infected in human HEL cells assessed as reduction in virus-induced cytopathogenicity,Confirmatory,23911856.0,
2986,766701,1,1,,103504490,3454,Active,,,0.9,EC50,Antiviral activity against Feline Herpes virus infected in cat CRFK cells assessed as inhibition of virus-induced cytopathic effect by MTS assay,Confirmatory,23911856.0,
2987,766702,1,1,,103504490,3454,Unspecified,,,100.0,EC50,Antiviral activity against Feline coronavirus infected in cat CRFK cells assessed as inhibition of virus-induced cytopathic effect by MTS assay,Confirmatory,23911856.0,
2988,766705,1,1,,103504490,3454,Active,,,0.38,EC50,Antiviral activity against Cytomegalovirus Davis infected in human HEL cells assessed as reduction in virus plaque formation,Confirmatory,23911856.0,
2989,766708,1,1,,103504490,3454,Unspecified,,,,,Cytotoxicity against human HeLa cells assessed as morphological changes,Other,23911856.0,
2990,766709,1,2,,103504490,3454,Unspecified,,,,,Cytotoxicity against cat CRFK cells assessed as cell viability by MTS assay,Other,23911856.0,
2991,766710,1,1,,103504490,3454,Active,,,3.1,EC50,Antiviral activity against Cytomegalovirus AD-169 infected in human HEL cells assessed as reduction in virus plaque formation,Confirmatory,23911856.0,
2992,766711,1,2,,103504490,3454,Unspecified,,,,,Cytotoxicity against human HEL cells assessed as morphological changes,Other,23911856.0,
2993,768185,1,1,,103504490,3454,Active,,,4.1,EC50,Antiviral activity against feline herpesvirus infected in cat CRFK cells assessed as reduction of virus-induced cytopathogenicity by MTS assay,Confirmatory,23811093.0,
2994,768186,1,1,,103504490,3454,Unspecified,,,100.0,EC50,Antiviral activity against Feline coronavirus infected in cat CRFK cells assessed as reduction of virus-induced cytopathogenicity by MTS assay,Confirmatory,23811093.0,
2995,768200,1,3,,103504490,3454,Active,,,4.0,EC50,Antiviral activity against TK-negative Herpes simplex virus 1 KOS infected in human HEL cells assessed as reduction of virus-induced cytopathogenicity,Confirmatory,23811093.0,
2996,768201,1,1,,103504490,3454,Unspecified,,,100.0,EC50,Antiviral activity against Vesicular stomatitis virus infected in human HEL cells assessed as reduction of virus-induced cytopathogenicity,Confirmatory,23811093.0,
2997,768202,1,1,,103504490,3454,Unspecified,,,100.0,EC50,Antiviral activity against Vaccinia virus infected in human HEL cells assessed as reduction of virus-induced cytopathogenicity,Confirmatory,23811093.0,
2998,768203,1,3,,103504490,3454,Active,,,0.03,EC50,Antiviral activity against Herpes simplex virus-2 G infected in human HEL cells assessed as reduction of virus-induced cytopathogenicity,Confirmatory,23811093.0,
2999,768204,1,3,,103504490,3454,Active,,,0.03,EC50,Antiviral activity against Herpes simplex virus-1 KOS infected in human HEL cells assessed as reduction of virus-induced cytopathogenicity,Confirmatory,23811093.0,
3000,768207,1,2,,103504490,3454,Unspecified,,,,,Cytotoxicity against human HEL cells,Other,23811093.0,
3001,768208,1,1,,103504490,3454,Active,,,5.98,EC50,Antiviral activity against Cytomegalovirus Davis infected in human HEL cells assessed as reduction of plaque formation,Confirmatory,23811093.0,
3002,768209,1,1,,103504490,3454,Active,,,7.87,EC50,Antiviral activity against Cytomegalovirus AD-169 infected in human HEL cells assessed as reduction of plaque formation,Confirmatory,23811093.0,
3003,768210,1,2,,103504490,3454,Unspecified,,,100.0,CC50,Cytotoxicity against cat CRFK cells,Confirmatory,23811093.0,
3004,768857,1,3,,103504490,3454,Unspecified,,,,,Toxicity in Wistar albino rat,Other,,
3005,768865,1,4,,103504490,3454,Unspecified,,,,,Immunomodulatory activity in human neutrophils assessed as increase in intracellular killing activity at 1000 ug/mL after 20 mins by NBT dye reduction assay relative to control,Other,,
3006,768866,1,4,,103504490,3454,Unspecified,,,,,Immunomodulatory activity in human neutrophils assessed as increase in intracellular killing activity at 100 ug/mL after 20 mins by NBT dye reduction assay relative to control,Other,,
3007,768867,1,4,,103504490,3454,Unspecified,,,,,Immunomodulatory activity in human neutrophils assessed as increase in intracellular killing activity at 40 ug/mL after 20 mins by NBT dye reduction assay relative to control,Other,,
3008,768868,1,4,,103504490,3454,Unspecified,,,,,Immunomodulatory activity in human neutrophils assessed as increase in intracellular killing activity at 10 ug/mL after 20 mins by NBT dye reduction assay relative to control,Other,,
3009,768869,1,4,,103504490,3454,Unspecified,,,,,Immunomodulatory activity in human neutrophils assessed as increase in intracellular killing activity at 20 ug/mL after 20 mins by NBT dye reduction assay relative to control,Other,,
3010,1053175,2,1,,178126368,3454,Inactive,,,,,A screen for compounds that inhibit growth of Escherichia coli,Other,,
3011,1053188,2,1,,56424026,3454,Inactive,,,,,Primary Screen Inhibitors of CD40 Signaling in BL2 Cells Measured in Cell-Based System Using Plate Reader - 7124-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
3012,1053197,1,1,,8139883,3454,Inactive,74734243.0,54414.0,,,Fluorescence polarization-based biochemical high throughput primary assay to identify inhibitors of sialic acid acetylesterase (SIAE),Screening,,
3013,1079931,1,1,,103504490,3454,Unspecified,,,,,"Moderate liver toxicity, defined via clinical-chemistry results: ALT or AST serum activity 6 times the normal upper limit (N) or alkaline phosphatase serum activity of 1.7 N. Value is number of references indexed. [column 'BIOL' in source]",Other,15646539.0,
3014,1079932,1,1,,103504490,3454,Unspecified,,,,,"Highest frequency of moderate liver toxicity observed during clinical trials, expressed as a percentage. [column '% BIOL' in source]",Other,15646539.0,
3015,1079933,1,1,,103504490,3454,Unspecified,,,,,"Acute liver toxicity defined via clinical observations and clear clinical-chemistry results: serum ALT or AST activity > 6 N or serum alkaline phosphatases activity > 1.7 N. This category includes cytolytic, choleostatic and mixed liver toxicity. Value is number of references indexed. [column 'AIGUE' in source]",Other,15646539.0,
3016,1079934,1,1,,103504490,3454,Unspecified,,,,,"Highest frequency of acute liver toxicity observed during clinical trials, expressed as a percentage. [column '% AIGUE' in source]",Other,15646539.0,
3017,1079935,1,1,,103504490,3454,Unspecified,,,,,"Cytolytic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is > 5 (see ACUTE). Value is number of references indexed. [column 'CYTOL' in source]",Other,15646539.0,
3018,1079936,1,1,,103504490,3454,Unspecified,,,,,"Choleostatic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is < 2 (see ACUTE). Value is number of references indexed. [column 'CHOLE' in source]",Other,15646539.0,
3019,1079937,1,1,,103504490,3454,Unspecified,,,,,"Severe hepatitis, defined as possibly life-threatening liver failure or through clinical observations. Value is number of references indexed. [column 'MASS' in source]",Other,15646539.0,
3020,1079938,1,1,,103504490,3454,Unspecified,,,,,"Chronic liver disease either proven histopathologically, or through a chonic elevation of serum amino-transferase activity after 6 months. Value is number of references indexed. [column 'CHRON' in source]",Other,15646539.0,
3021,1079939,1,1,,103504490,3454,Unspecified,,,,,"Cirrhosis, proven histopathologically. Value is number of references indexed. [column 'CIRRH' in source]",Other,15646539.0,
3022,1079940,1,1,,103504490,3454,Unspecified,,,,,"Granulomatous liver disease, proven histopathologically. Value is number of references indexed. [column 'GRAN' in source]",Other,15646539.0,
3023,1079941,1,1,,103504490,3454,Unspecified,,,,,"Liver damage due to vascular disease: peliosis hepatitis, hepatic veno-occlusive disease, Budd-Chiari syndrome. Value is number of references indexed. [column 'VASC' in source]",Other,15646539.0,
3024,1079942,1,1,,103504490,3454,Unspecified,,,,,"Steatosis, proven histopathologically. Value is number of references indexed. [column 'STEAT' in source]",Other,15646539.0,
3025,1079943,1,1,,103504490,3454,Unspecified,,,,,"Malignant tumor, proven histopathologically. Value is number of references indexed. [column 'T.MAL' in source]",Other,15646539.0,
3026,1079944,1,1,,103504490,3454,Unspecified,,,,,"Benign tumor, proven histopathologically. Value is number of references indexed. [column 'T.BEN' in source]",Other,15646539.0,
3027,1079945,1,1,,103504490,3454,Unspecified,,,,,Animal toxicity known. [column 'TOXIC' in source],Other,15646539.0,
3028,1079946,1,1,,103504490,3454,Unspecified,,,,,Presence of at least one case with successful reintroduction. [column 'REINT' in source],Other,15646539.0,
3029,1079947,1,1,,103504490,3454,Unspecified,,,,,Comments (NB not yet translated). [column 'COMMENTAIRES' in source],Other,15646539.0,
3030,1079948,1,1,,103504490,3454,Unspecified,,,,,"Times to onset, minimal and maximal, observed in the indexed observations. [column 'DELAI' in source]",Other,15646539.0,
3031,1079949,1,1,,103504490,3454,Unspecified,,,,,Proposed mechanism(s) of liver damage. [column 'MEC' in source],Other,15646539.0,
3032,1095321,3,1,,103504490,3454,Active,,,6.0,EC50,Antiviral activity against acyclovir-resistant TK-deficient Hepres simplex virus 1 KOS infected in HEL cells assessed as inhibition of virus-induced cytopathic effect after 3 days by MTT assay,Confirmatory,,
3033,1095322,3,1,,103504490,3454,Unspecified,,,100.0,EC50,Antiviral activity against Vesicular stomatitis virus infected HEL cells assessed as inhibition of virus-induced cytopathic effect after 3 days by MTT assay,Confirmatory,,
3034,1095323,3,1,,103504490,3454,Unspecified,,,100.0,EC50,Antiviral activity against Vaccinia virus infected in HEL cells assessed as inhibition of virus-induced cytopathic effect after 3 days by MTT assay,Confirmatory,,
3035,1095324,3,1,,103504490,3454,Active,,,0.08,EC50,Antiviral activity against Human herpesvirus 2 strain G infected HEL cells assessed as inhibition of virus-induced cytopathic effect after 3 days by MTT assay,Confirmatory,,
3036,1095325,3,1,,103504490,3454,Active,,,0.08,EC50,Antiviral activity against Human herpesvirus 1 strain KOS infected in HEL cells assessed as inhibition of virus-induced cytopathic effect after 3 days by MTT assay,Confirmatory,,
3037,1095326,3,1,,103504490,3454,Unspecified,,,,,Cytotoxicity against Homo sapiens (human) HEL cells after 3 days by microscopic analysis,Other,,
3038,1097055,1,2,,103504490,3454,Unspecified,,,,,Cytotoxicity against HEL assessed as minimum concentration required to cause morphological changes,Other,,
3039,1097056,1,2,,103504490,3454,Unspecified,,,,,Antiviral activity against Human herpesvirus 5 Davis infected human HEL cells assessed as reduction in the virus plaque formation,Other,,
3040,1097057,1,2,,103504490,3454,Unspecified,,,,,Antiviral activity against Human herpesvirus 5 strain AD169 infected human HEL cells assessed as reduction in the virus plaque formation,Other,,
3041,1097058,1,2,,103504490,3454,Unspecified,,,,,Cytotoxicity against HEL,Other,,
3042,1106656,1,2,,103504490,3454,Unspecified,,,,,"Antiviral activity against thymidine kinase-deficient, acylcovir-resistant Human herpesvirus 1 strain KOS infected in HEL cells",Other,,
3043,1106657,1,2,,103504490,3454,Unspecified,,,,,Antiviral activity against Vesicular stomatitis virus infected HEL cells,Other,,
3044,1106658,1,2,,103504490,3454,Unspecified,,,,,Antiviral activity against Vaccinia virus infected HEL cells,Other,,
3045,1106659,1,2,,103504490,3454,Unspecified,,,,,Antiviral activity against Human herpesvirus 2 strain G infected HEL cells,Other,,
3046,1106660,1,2,,103504490,3454,Unspecified,,,,,Antiviral activity against Human herpesvirus 1 strain KOS infected in HEL cells,Other,,
3047,1106662,1,2,,103504490,3454,Unspecified,,,,,Cytotoxicity against Homo sapiens (human) HEL cells,Other,,
3048,1113466,1,2,,103504490,3454,Unspecified,,,20.0,EC50,Antiviral activity against acyclovir-resistant thymidine kinase negative Human herpesvirus 1 strain KOS infected human HEL cells assessed as reduction of virus-induced cytopathic effect after 3 days by colorimetric formazan-based MTS assay,Confirmatory,,
3049,1113467,1,2,,103504490,3454,Unspecified,,,100.0,EC50,Antiviral activity against Vesicular stomatitis virus infected human HEL cells assessed as reduction of virus-induced cytopathic effect after 3 days by colorimetric formazan-based MTS assay,Confirmatory,,
3050,1113468,1,2,,103504490,3454,Unspecified,,,100.0,EC50,Antiviral activity against Vaccinia virus infected human HEL cells assessed as reduction of virus-induced cytopathic effect after 3 days by colorimetric formazan-based MTS assay,Confirmatory,,
3051,1113469,1,2,,103504490,3454,Active,,,0.07,EC50,Antiviral activity against Human herpesvirus 2 strain G infected human HEL cells assessed as reduction of virus-induced cytopathic effect after 3 days by colorimetric formazan-based MTS assay,Confirmatory,,
3052,1113470,1,2,,103504490,3454,Unspecified,,,,,Cytotoxicity against Homo sapiens (human) HEL cells assessed as change in cellular morphology,Other,,
3053,1113471,1,2,,103504490,3454,Active,,,0.09,EC50,Antiviral activity against Human herpesvirus 1 strain KOS infected human HEL cells assessed as reduction of virus-induced cytopathic effect after 3 days by colorimetric formazan-based MTS assay,Confirmatory,,
3054,1113472,1,2,,103504490,3454,Active,,,7.3,EC50,Antiviral activity against Felid herpesvirus 1 infected cat CRFK cells assessed as reduction of virus-induced cytopathic effect after 3 days by colorimetric formazan-based MTS assay,Confirmatory,,
3055,1113473,1,2,,103504490,3454,Unspecified,,,100.0,EC50,Antiviral activity against Feline Infectious peritonitis virus infected cat CRFK cells assessed as reduction of virus-induced cytopathic effect after 3 days by colorimetric formazan-based MTS assay,Confirmatory,,
3056,1113474,1,3,,103504490,3454,Unspecified,,,100.0,CC50,Cytotoxicity against Felis catus (cat) CRFK cells assessed as change in cellular morphology,Confirmatory,,
3057,1117298,1,2,,170464961,3454,Inactive,,,0.7079,AC50 (uM),"qHTS Assay for Identifying Compounds that block Entry of Ebola Virus, Screen 2 green channel",Confirmatory,,
3058,1117301,1,2,,170464961,3454,Inactive,,,10.0,AC50 (uM),"qHTS Assay for Identifying Compounds that block Entry of Ebola Virus, Screen 1 blue channel",Confirmatory,,
3059,1117302,1,2,,170464961,3454,Inactive,,,10.0,AC50 (uM),"qHTS Assay for Identifying Compounds that block Entry of Ebola Virus, Screen1 green channel",Confirmatory,,
3060,1117303,1,2,,170464961,3454,Inactive,,,0.29,AC50 (uM),"qHTS Assay for Identifying Compounds that block Entry of Ebola Virus, Screen 1 ratio channel",Confirmatory,,
3061,1117304,1,2,,170464961,3454,Inactive,,,19.9526,AC50 (uM),"qHTS Assay for Identifying Compounds that block Entry of Ebola Virus, Screen 2 blue channel",Confirmatory,,
3062,1117305,1,2,,170464961,3454,Unspecified,,,,AC50 (uM),"qHTS Assay for Identifying Compounds that block Entry of Ebola Virus, Screen 2 ratio channel",Confirmatory,,
3063,1117310,1,1,,170464961,3454,Inactive,,,0.707946,Ac50,"qHTS Assay for Identifying Compounds that block Entry of Ebola Virus: Screen 2, green channel",Confirmatory,,
3064,1117311,1,1,,170464961,3454,Inactive,,,10.0,Ac50,"qHTS Assay for Identifying Compounds that block Entry of Ebola Virus: Screen1, blue channel",Confirmatory,,
3065,1117312,1,1,,170464961,3454,Inactive,,,,Ac50,"qHTS Assay for Identifying Compounds that block Entry of Ebola Virus: Screen2, ratio channel",Confirmatory,,
3066,1117314,1,1,,170464961,3454,Inactive,,,19.9526,Ac50,"qHTS Assay for Identifying Compounds that block Entry of Ebola Virus: Screen 2, blue channel",Confirmatory,,
3067,1117315,1,1,,170464961,3454,Inactive,,,10.0,Ac50,"qHTS Assay for Identifying Compounds that block Entry of Ebola Virus: Screen1, green channel",Confirmatory,,
3068,1117318,1,1,,170464961,3454,Inactive,,,0.28183800000000003,Ac50,"qHTS Assay for Identifying Compounds that block Entry of Ebola Virus: Screen1, ratio channel",Confirmatory,,
3069,1117319,1,2,,8139883,3454,Inactive,9629361.0,155459.0,,Average IC50,High Throughput Screen to Identify Inhibitors Targeting HIV-1 Vif-dependent Degradation of Human APOBEC3G:#A time-resolved fluorescence resonance energy transfer (TR-FRET) assay for HIV-1 Vif-APOBEC3G interaction,Confirmatory,,
3070,1117319,1,2,,8139883,3454,Inactive,13399304.0,60489.0,,Average IC50,High Throughput Screen to Identify Inhibitors Targeting HIV-1 Vif-dependent Degradation of Human APOBEC3G:#A time-resolved fluorescence resonance energy transfer (TR-FRET) assay for HIV-1 Vif-APOBEC3G interaction,Confirmatory,,
3071,1117326,1,1,,170464961,3454,Inactive,,,,,nuclear beta catenin stimulation in WNT3A conditioned C2C12 cells-screen,Screening,,
3072,1117329,1,1,,170464961,3454,Inactive,,,,,insulin secretion from INS-1E cells in the presence of 5 mM glucose-screen,Screening,,
3073,1117336,1,1,,170464961,3454,Inactive,,,,,GSK3B-pretreated HCT116 viability from Cell TiterGlo-screen,Screening,,
3074,1117340,1,1,,170464961,3454,Inactive,,,,,VEGF stimulated ADSC/ECFC co-culture CD31-stained tube area decrease-screen,Screening,,
3075,1117341,1,1,,170464961,3454,Inactive,,,,,GLP1 secretion from NCI-H716 cells-screen,Screening,,
3076,1117342,1,1,,170464961,3454,Inactive,,,,,HCT116 viability from Cell TiterGlo-screen,Screening,,
3077,1117343,1,1,,170464961,3454,Inactive,,,,,SW480 viability from Cell TiterGlo-screen,Screening,,
3078,1117346,1,1,,170464961,3454,Inactive,,,,,DLD-1 viability from Cell TiterGlo-screen,Screening,,
3079,1159509,1,1,,170464961,3454,Inactive,119626539.0,4790.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the NFkB signaling pathway,Confirmatory,,
3080,1159515,1,1,,170464961,3454,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the NFkB signaling pathway - cell viability counter screen,Confirmatory,,
3081,1159516,1,1,,170464961,3454,Inactive,119611100.0,22926.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the endoplasmic reticulum stress response signaling pathway,Confirmatory,,
3082,1159517,1,1,,170464961,3454,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the endoplasmic reticulum stress response signaling pathway - cell viability counter screen,Confirmatory,,
3083,1159518,1,1,,170464961,3454,Inactive,119626539.0,4790.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the NFkB signaling pathway: Summary,Summary,,
3084,1159519,1,1,,170464961,3454,Inactive,119611100.0,22926.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the endoplasmic reticulum stress response signaling pathway: Summary,Summary,,
3085,1159520,1,1,,170464961,3454,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the retinoid-related orphan receptor gamma (ROR-gamma) signaling pathway - cell viability counter screen,Confirmatory,,
3086,1159521,1,1,,170464961,3454,Inactive,15928672.0,19885.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the retinoid-related orphan receptor gamma (ROR-gamma) signaling pathway,Confirmatory,,
3087,1159523,1,1,,170464961,3454,Inactive,15928672.0,19885.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the retinoid-related orphan receptor gamma (ROR-gamma) signaling pathway: Summary,Summary,,
3088,1159524,1,1,,56424026,3454,Inactive,,,,Potency,High Throughput Screening for Foot and Mouth Disease Virus Antivirals,Confirmatory,,
3089,1159525,1,1,,170464961,3454,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the AP-1 signaling pathway - cell viability counter screen,Confirmatory,,
3090,1159526,1,1,,170464961,3454,Inactive,119627033.0,3725.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the AP-1 signaling pathway,Confirmatory,,
3091,1159527,1,1,,170464961,3454,Inactive,325495497.0,6256.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the RXR signaling pathway,Confirmatory,,
3092,1159528,1,1,,170464961,3454,Inactive,119627033.0,3725.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the AP-1 signaling pathway: Summary,Summary,,
3093,1159529,1,1,,170464961,3454,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the RXR signaling pathway - cell viability counter screen,Confirmatory,,
3094,1159531,1,1,,170464961,3454,Inactive,325495497.0,6256.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the RXR signaling pathway: Summary,Summary,,
3095,1159551,1,1,,170464961,3454,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the retinoid acid receptor (RAR) signaling pathway - cell viability counter screen,Confirmatory,,
3096,1159552,1,1,,170464961,3454,Inactive,325495463.0,5914.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the retinoic acid receptor (RAR) signaling pathway,Confirmatory,,
3097,1159553,2,1,,170464961,3454,Inactive,325495463.0,5914.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the retinoic acid receptor (RAR) signaling pathway,Confirmatory,,
3098,1159555,1,1,,170464961,3454,Inactive,325495463.0,5914.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the retinoic acid receptor (RAR) signaling pathway: Summary,Summary,,
3099,1159580,2,1,,268738154,3454,Inactive,,,,,"The chemical genetic matrix (CGM) dataset as reported in Wildenhain et al. (2015) Prediction of Synergism from Chemical-Genetic Interactions by Machine Learning. Cell Systems Volume 1, Issue 6, p383-395",Summary,,
3100,1159583,2,1,,178126368,3454,Inactive,,,,,High throughput screen for small molecule inhibitors of a hypoxia-regulated fluorescent biosensor in Mycobacterium tuberculosis,Other,,
3101,1159606,1,1,,56424026,3454,Inactive,,,,,"uHTS identification of small molecule inhibitors of TWEAK-Fn14 interactions, using a cell-based reporter assay",Other,,
3102,1159607,2,1,,312309862,3454,Inactive,,,,,Screen for inhibitors of RMI FANCM (MM2) intereaction,Other,26962873.0,
3103,1159614,1,2,,170464961,3454,Inactive,22328079.0,2581.0,,Potency,A Novel Cell-Based Assay to Identify Small Molecules for B -Galactocerebrosidase,Confirmatory,,
3104,1159620,1,1,,103504490,3454,Active,,,,,Summary of drug indications.,Other,,
3105,1189129,1,1,,103504490,3454,Unspecified,,,240.17,IC50,"DNDI: Chagas in Vitro, 96 hour",Confirmatory,,
3106,1189130,1,1,,103504490,3454,Unspecified,,,179.44,IC50,"DNDI: Cytotoxicity in Vitro, 72 hour, in rat skeletal myoblast cells",Confirmatory,,
3107,1189131,1,1,,103504490,3454,Unspecified,,,117.54,IC50,"DNDI: Cytotoxicity in Vitro, 96 hour, in mouse macrophages (infected-amastigotes)",Confirmatory,,
3108,1189133,1,1,,103504490,3454,Unspecified,,,251.53,IC50,"DNDI: HAT in Vitro, 72 hour",Confirmatory,,
3109,1189134,1,1,,103504490,3454,Unspecified,,,391.8,IC50,"DNDI: Leish (axenic) in Vitro, 72 hour",Confirmatory,,
3110,1189135,1,1,,103504490,3454,Unspecified,,,117.54,IC50,"DNDI: Leish (macro) in Vitro, 96 hour",Confirmatory,,
3111,1189136,1,1,,103504490,3454,Unspecified,,,195.9,IC50,"DNDI: Malaria in Vitro, 72 hour",Confirmatory,,
3112,1209333,1,2,,103504490,3454,Unspecified,,,,,"Ratio of drug level in brain to plasma in Sprague-Dawley rat at 3 mg/kg, sc by LC-MS/MS analysis",Other,22899853.0,
3113,1209341,1,2,,103504490,3454,Unspecified,,,,,"Ratio of drug level in cerebrospinal fluid to unbound plasma concentration in Sprague-Dawley rat at 3 mg/kg, sc by LC-MS/MS analysis",Other,22899853.0,
3114,1209349,1,1,,103504490,3454,Unspecified,,,,,"Ratio of unbound brain concentration to drug level in cerebrospinal fluid in Sprague-Dawley rat at 3 mg/kg, sc by LC-MS/MS analysis",Other,22899853.0,
3115,1209357,1,1,,103504490,3454,Unspecified,,,,,"Ratio of unbound drug level in brain to plasma in Sprague-Dawley rat at 3 mg/kg, sc by LC-MS/MS analysis",Other,22899853.0,
3116,1209379,1,2,,103504490,3454,Unspecified,,,,,"AUC(0 to 7 hrs) in Sprague-Dawley rat plasma at 3 mg/kg, sc by LC-MS/MS analysis",Other,22899853.0,
3117,1209385,1,2,,103504490,3454,Unspecified,,,,,"AUC(0 to infinity) in Sprague-Dawley rat plasma at 3 mg/kg, sc by LC-MS/MS analysis",Other,22899853.0,
3118,1209393,1,2,,103504490,3454,Unspecified,,,,,"AUC(0 to 7 hrs) in Sprague-Dawley rat cerebrospinal fluid at 3 mg/kg, sc by LC-MS/MS analysis",Other,22899853.0,
3119,1209401,1,2,,103504490,3454,Unspecified,,,,,"AUC(0 to infinity) in Sprague-Dawley rat cerebrospinal fluid at 3 mg/kg, sc by LC-MS/MS analysis",Other,22899853.0,
3120,1209409,1,2,,103504490,3454,Unspecified,,,,,"AUC(0 to 7 hrs) in Sprague-Dawley rat brain at 3 mg/kg, sc by LC-MS/MS analysis",Other,22899853.0,
3121,1209417,1,2,,103504490,3454,Unspecified,,,,,"AUC(0 to infinity) in Sprague-Dawley rat brain at 3 mg/kg, sc by LC-MS/MS analysis",Other,22899853.0,
3122,1219930,1,2,,103504490,3454,Unspecified,74753520.0,10864.0,,,Drug transport in human OAT2 expressed in HEK Flp-In cells at 0.19 uM for 10 mins relative to control,Other,22190696.0,
3123,1219934,1,2,,103504490,3454,Inactive,74762955.0,9356.0,,,Drug transport in human OAT1 expressed in HEK Flp-In cells at 0.19 uM for 10 mins relative to control,Other,22190696.0,
3124,1219935,1,2,,103504490,3454,Inactive,74730587.0,9376.0,,,Drug transport in human OAT3 expressed in HEK Flp-In cells at 0.19 uM for 10 mins relative to control,Other,22190696.0,
3125,1219936,1,2,,103504490,3454,Inactive,123402.0,5452.0,,,Drug transport in human OCT2 expressed in HEK Flp-In cells at 0.19 uM for 10 mins relative to control,Other,22190696.0,
3126,1219941,1,1,,103504490,3454,Inactive,,,,,Drug transport in human ENT in HEK cells in presence of 100 uM ENT inhibitor benzythioinosine,Other,22190696.0,
3127,1219942,1,2,,103504490,3454,Unspecified,123402.0,5452.0,,,Drug transport in human OAT2 expressed in HEK Flp-In cells assessed as maximal rate of transport measured per mg of protein,Other,22190696.0,
3128,1219943,1,2,,103504490,3454,Unspecified,123402.0,5452.0,264.0,Km,Drug transport in human OAT2 expressed in HEK Flp-In cells,Confirmatory,22190696.0,
3129,1219944,1,2,,103504490,3454,Unspecified,123402.0,5452.0,,,"Transport efficiency, ratio of maximal rate of transport to Km for drug transport in human OAT2 expressed in HEK Flp-In cells measured per mg of protein",Other,22190696.0,
3130,1224818,1,1,,312344664,3454,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen related receptor (ERR) signaling pathway - cell viability counter screen,Confirmatory,,
3131,1224819,1,1,,312344664,3454,Inactive,325495545.0,2101.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen related receptor (ERR) signaling pathway,Confirmatory,,
3132,1224820,1,1,,312344664,3454,Inactive,325495545.0,2101.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen related receptor (ERR) signaling pathway,Confirmatory,,
3133,1224821,1,1,,312344664,3454,Inactive,325495545.0,2101.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC),Confirmatory,,
3134,1224822,1,1,,312344664,3454,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) ### cell viability counter screen,Confirmatory,,
3135,1224823,1,1,,312344664,3454,Inactive,325495545.0,2101.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC),Confirmatory,,
3136,1224824,1,1,,90341439,3454,Inactive,,,,Potency,High-throughput drug toxicity screening in the BPDCN cell line Gen2.2,Confirmatory,,
3137,1224825,1,1,,90341439,3454,Inactive,,,,Potency,High-throughput drug toxicity screening in the BPDCN cell line Cal-1,Confirmatory,,
3138,1224834,3,1,,170464961,3454,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library - cell viability counter screen,Confirmatory,,
3139,1224835,1,1,,170464961,3454,Inactive,160794.0,,,Potency-Replicate_1,qHTS assay to identify small molecule inhibitors of firefly luciferase,Confirmatory,,
3140,1224836,1,1,,170464961,3454,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the constitutive androstane receptor (CAR) signaling pathway - cell viability counter screen,Confirmatory,,
3141,1224837,1,1,,170464961,3454,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the constitutive androstane receptor (CAR) signaling pathway - cell viability counter screen,Confirmatory,,
3142,1224838,1,1,,170464961,3454,Inactive,66775687.0,9970.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the constitutive androstane receptor (CAR) signaling pathway,Confirmatory,,
3143,1224839,1,1,,170464961,3454,Inactive,66775687.0,9970.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the constitutive androstane receptor (CAR) signaling pathway,Confirmatory,,
3144,1224840,3,1,,170464961,3454,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library - cell viability counter screen,Confirmatory,,
3145,1224841,3,1,,170464961,3454,Inactive,325495545.0,2101.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library,Confirmatory,,
3146,1224842,3,1,,170464961,3454,Inactive,325495545.0,2101.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library,Confirmatory,,
3147,1224843,1,1,,170464961,3454,Inactive,119601739.0,7253.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway,Confirmatory,,
3148,1224844,1,1,,170464961,3454,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the hypoxia (HIF-1) signaling pathway - cell viability counter screen,Confirmatory,,
3149,1224845,1,1,,170464961,3454,Inactive,344243002.0,100757539.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of H2AX,Confirmatory,,
3150,1224846,1,1,,170464961,3454,Inactive,11995455.0,3091.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the hypoxia (HIF-1) signaling pathway,Confirmatory,,
3151,1224847,1,1,,170464961,3454,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of H2AX - cell viability counter screen,Confirmatory,,
3152,1224848,3,1,,170464961,3454,Inactive,325495545.0,2101.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library,Confirmatory,,
3153,1224849,3,1,,170464961,3454,Inactive,325495545.0,2101.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library,Confirmatory,,
3154,1224857,2,1,,90341439,3454,Inactive,,,18.6548,Potency,qHTS assay for measurement of the activity of small molecule inhibitors on Zika virus induced Caspase-3 activity in human iPSC derived neural progenitor cells (hNPCs),Confirmatory,,
3155,1224857,2,1,,170464961,3454,Inactive,,,,Potency,qHTS assay for measurement of the activity of small molecule inhibitors on Zika virus induced Caspase-3 activity in human iPSC derived neural progenitor cells (hNPCs),Confirmatory,,
3156,1224857,2,1,,312344664,3454,Inactive,,,,Potency,qHTS assay for measurement of the activity of small molecule inhibitors on Zika virus induced Caspase-3 activity in human iPSC derived neural progenitor cells (hNPCs),Confirmatory,,
3157,1224859,2,1,,90341439,3454,Inactive,,,,Potency,qHTS assay for measurement of the activity of small molecule inhibitors on Zika virus induced Caspase-3 activity in human astrocytoma cells,Confirmatory,,
3158,1224859,2,1,,170464961,3454,Inactive,,,,Potency,qHTS assay for measurement of the activity of small molecule inhibitors on Zika virus induced Caspase-3 activity in human astrocytoma cells,Confirmatory,,
3159,1224863,1,1,,176484374,3454,Inactive,90421313.0,1080.0,,IC50,Phenotypic Assay to Identify Small Molecules that Upregulate Production of hCFTR in HeLa Cells,Confirmatory,,
3160,1224863,1,1,,316920170,3454,Inactive,90421313.0,1080.0,,IC50,Phenotypic Assay to Identify Small Molecules that Upregulate Production of hCFTR in HeLa Cells,Confirmatory,,
3161,1224864,1,2,,316933827,3454,Inactive,,,,,HCS microscopy assay (F508del-CFTR),Screening,27732613.0,
3162,1224865,1,2,,56424026,3454,Inactive,578162.0,,,,Identify inhibitors of HNF4 alpha protein binding to DNA,Screening,,
3163,1224867,1,1,,170464961,3454,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 24 hour,Confirmatory,,
3164,1224868,1,1,,170464961,3454,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 32 hour,Confirmatory,,
3165,1224869,1,1,,170464961,3454,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 0 hour,Confirmatory,,
3166,1224870,1,1,,170464961,3454,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 40 hour,Confirmatory,,
3167,1224871,1,1,,170464961,3454,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 40 hour,Confirmatory,,
3168,1224872,1,1,,170464961,3454,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 16 hour,Confirmatory,,
3169,1224873,1,1,,170464961,3454,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 8 hour,Confirmatory,,
3170,1224874,1,1,,170464961,3454,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 40 hour,Confirmatory,,
3171,1224875,1,1,,170464961,3454,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 24 hour,Confirmatory,,
3172,1224876,1,1,,170464961,3454,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 16 hour,Confirmatory,,
3173,1224877,1,1,,170464961,3454,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 32 hour,Confirmatory,,
3174,1224878,1,1,,170464961,3454,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 24 hour,Confirmatory,,
3175,1224879,1,1,,170464961,3454,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 40 hour,Confirmatory,,
3176,1224880,1,1,,170464961,3454,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 0 hour,Confirmatory,,
3177,1224881,1,1,,170464961,3454,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 32 hour,Confirmatory,,
3178,1224882,1,1,,170464961,3454,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 0 hour,Confirmatory,,
3179,1224883,1,1,,170464961,3454,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 32 hour,Confirmatory,,
3180,1224884,1,1,,170464961,3454,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 8 hour,Confirmatory,,
3181,1224885,1,1,,170464961,3454,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 16 hour,Confirmatory,,
3182,1224886,1,1,,170464961,3454,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 24 hour,Confirmatory,,
3183,1224887,1,1,,170464961,3454,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 8 hour,Confirmatory,,
3184,1224888,1,1,,170464961,3454,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 16 hour,Confirmatory,,
3185,1224889,1,1,,170464961,3454,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 0 hour,Confirmatory,,
3186,1224890,1,1,,170464961,3454,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 8 hour,Confirmatory,,
3187,1224892,1,1,,170464961,3454,Inactive,66775687.0,9970.0,,,qHTS assay to identify small molecule agonists of the constitutive androstane receptor (CAR) signaling pathway: Summary,Summary,,
3188,1224893,1,1,,170464961,3454,Inactive,66775687.0,9970.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the constitutive androstane receptor (CAR) signaling pathway: Summary,Summary,,
3189,1224894,1,1,,170464961,3454,Inactive,11995455.0,3091.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the hypoxia (HIF-1) signaling pathway: Summary,Summary,,
3190,1224895,1,1,,170464961,3454,Inactive,119601739.0,7253.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway: Summary,Summary,,
3191,1224896,1,1,,170464961,3454,Inactive,344243002.0,100757539.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of H2AX: Summary,Summary,,
3192,1224905,2,1,,92309204,3454,Inactive,120997.0,25643.0,,,High-throughput screen for inhibitors of the GIV GBA-motif interaction with Galpha-i G protein subunits,Screening,,
3193,1224905,2,1,,92309204,3454,Inactive,74356043.0,55704.0,,,High-throughput screen for inhibitors of the GIV GBA-motif interaction with Galpha-i G protein subunits,Screening,,
3194,1224905,2,1,,121361363,3454,Inactive,120997.0,25643.0,,,High-throughput screen for inhibitors of the GIV GBA-motif interaction with Galpha-i G protein subunits,Screening,,
3195,1224905,2,1,,121361363,3454,Inactive,74356043.0,55704.0,,,High-throughput screen for inhibitors of the GIV GBA-motif interaction with Galpha-i G protein subunits,Screening,,
3196,1230097,1,1,,103504490,3454,Active,,,6.3,EC50,Antiviral activity against Cytomegalovirus AD-169 infected in HEL cells assessed as reduction of virus-induced cytopathogenicity,Confirmatory,26001344.0,
3197,1230098,1,1,,103504490,3454,Active,,,7.1,EC50,Antiviral activity against Cytomegalovirus Davis infected in HEL cells assessed as reduction of virus-induced cytopathogenicity,Confirmatory,26001344.0,
3198,1230099,1,1,,103504490,3454,Unspecified,,,,,Cytotoxicity against HEL cells assessed as alternation of cell morphology by microscopic analysis,Other,26001344.0,
3199,1230102,1,1,,103504490,3454,Active,,,0.02,EC50,Antiviral activity against Herpes simplex virus 1 KOS infected in HEL cells assessed as reduction of virus-induced cytopathogenicity,Confirmatory,26001344.0,
3200,1230103,1,1,,103504490,3454,Active,,,0.5,EC50,Antiviral activity against thymidine kinase-deficient acyclovir-resistant Herpes simplex virus 1 KOS infected in HEL cells assessed as reduction of virus-induced cytopathogenicity,Confirmatory,26001344.0,
3201,1230104,1,1,,103504490,3454,Active,,,0.03,EC50,Antiviral activity against Herpes simplex virus 2 G infected in HEL cells assessed as reduction of virus-induced cytopathogenicity,Confirmatory,26001344.0,
3202,1230105,1,1,,103504490,3454,Unspecified,,,100.0,EC50,Antiviral activity against Vaccinia virus infected in HEL cells assessed as reduction of virus-induced cytopathogenicity,Confirmatory,26001344.0,
3203,1239481,1,1,,103504490,3454,Active,,,2.6,IC50,Antiviral activity against Human cytomegalovirus AD169 expressing GFP infected in HFF assessed as inhibition of viral replication after 7 days,Confirmatory,26260339.0,
3204,1241022,1,1,,103504490,3454,Active,,,3.6,IC50,Antiviral activity against HCMV infected in HFF after 3 days by neutral red dye-based plaque reduction assay,Confirmatory,26260336.0,
3205,1241031,1,1,,103504490,3454,Unspecified,,,100.0,CC50,Cytotoxicity against HFF,Confirmatory,26260336.0,
3206,1251989,1,1,,103504490,3454,Active,,,13.9,EC50,Antiviral activity against human cytomegalovirus AD169 infected in HEL cells assessed as reduction in viral plaque formation,Confirmatory,26443550.0,
3207,1251990,1,1,,103504490,3454,Active,,,7.8,EC50,Antiviral activity against human cytomegalovirus Davis infected in HEL cells assessed as reduction in viral plaque formation,Confirmatory,26443550.0,
3208,1251991,1,1,,103504490,3454,Unspecified,,,,,Cytotoxicity against human cytomegalovirus infected HEL cells assessed as alteration of cell morphology incubated for 3 days by microscopy,Other,26443550.0,
3209,1251992,1,1,,103504490,3454,Unspecified,,,319.0,CC50,Cytotoxicity against human cytomegalovirus infected HEL cells assessed as cell growth inhibition incubated for 3 days by coulter counter method,Confirmatory,26443550.0,
3210,1252396,1,1,,103504490,3454,Unspecified,,,,,Cytotoxicity against human HEL cells assessed as alteration in cell morphology incubated for 3 days by microscopy,Other,26291038.0,
3211,1252397,1,1,,103504490,3454,Unspecified,,,328.5,CC50,Cytotoxicity against human HEL cells assessed as cell growth reduction incubated for 3 days,Confirmatory,26291038.0,
3212,1252398,1,1,,103504490,3454,Active,,,6.12,EC50,Antiviral activity against Human cytomegalovirus AD169 expressed in HEL cells assessed as reduction in plaque formation incubated for 7 days by Giemsa stain based microscopy,Confirmatory,26291038.0,
3213,1252399,1,1,,103504490,3454,Active,,,4.72,EC50,Antiviral activity against Human cytomegalovirus Davis expressed in HEL cells assessed as reduction in plaque formation incubated for 7 days by Giemsa stain based microscopy,Confirmatory,26291038.0,
3214,1256243,1,1,,103504490,3454,Active,,,0.9,EC50,Antiviral activity against Herpes simplex virus 1 strain F VR-733 infected in African green monkey Vero cells after 3 days by MTT assay,Confirmatory,26460883.0,
3215,1256244,1,1,,103504490,3454,Active,,,1.4,EC50,Antiviral activity against Herpes simplex virus 2 strain MS VR-540 infected in African green monkey Vero cells after 3 days by MTT assay,Confirmatory,26460883.0,
3216,1256245,1,1,,103504490,3454,Active,,,11.1,EC50,Antiviral activity against Varicella-zoster virus Ellen VR-1367 infected in African green monkey Vero cells after 3 days by MTT assay,Confirmatory,26460883.0,
3217,1256246,1,1,,103504490,3454,Active,,,2.14,EC50,Antiviral activity against Human cytomegalovirus Davis VR-807 infected in African green monkey Vero cells after 3 days by MTT assay,Confirmatory,26460883.0,
3218,1256247,1,1,,103504490,3454,Unspecified,,,100.0,CC50,Cytotoxicity against human HEL299 cells after 3 days by MTT assay,Confirmatory,26460883.0,
3219,1256248,1,1,,103504490,3454,Unspecified,,,,,Solubility of compound in double-deionized water after 3 days by LC-MS/MS analysis,Other,26460883.0,
3220,1259241,1,1,,170464961,3454,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line in the presence of 0.1 nM 17-beta-estradiol - cell viability counter screen,Confirmatory,,
3221,1259242,1,1,,170464961,3454,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway using the MDA cell line in the presence of 0.5 nM R1881 - cell viability counter screen,Confirmatory,,
3222,1259243,1,1,,170464961,3454,Inactive,124375976.0,367.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway using the MDA cell line in the presence of 0.5 nM R1881,Confirmatory,,
3223,1259244,1,1,,170464961,3454,Inactive,348019627.0,2099.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line in the presence of 0.1 nM 17-beta-estradiol,Confirmatory,,
3224,1259247,1,1,,170464961,3454,Inactive,124375976.0,367.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway using the MDA cell line in the presence of 0.5 nM R1881: Summary,Summary,,
3225,1259248,1,1,,170464961,3454,Inactive,348019627.0,2099.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line in the presence of 0.1 nM 17-beta-estradiol: Summary,Summary,,
3226,1259252,1,1,,90341439,3454,Active,169655958.0,,26.3506,Potency,qHTS Screen of the MIPE 4.0 Collection Against Ewings Sarcoma (RDES),Confirmatory,,
3227,1259253,1,1,,90341439,3454,Active,169655958.0,,23.485,Potency,qHTS Screen of the MIPE 4.0 Collection Against Ewings Sarcoma (TC71),Confirmatory,,
3228,1259255,1,1,,90341439,3454,Inconclusive,169655958.0,,29.5659,Potency,qHTS Screen of the MIPE 4.0 Collection Against Ewings Sarcoma (EW8),Confirmatory,,
3229,1259256,1,1,,90341439,3454,Inactive,169655958.0,,0.0053,Potency,qHTS Screen of the MIPE 4.0 Collection Against Ewings Sarcoma (TC32),Confirmatory,,
3230,1259309,1,1,,178126368,3454,Inactive,,,,,A screen for compounds that are lethal to S. aureus RN4220 with the processive glycosyltransferase UgtP deleted,Other,,
3231,1259310,1,1,,104170145,3454,Inactive,,,,,AlphaScreen-based biochemical high throughput primary assay to identify activators of the E3 ligase (FBW7).,Screening,,
3232,1259310,1,1,,321942736,3454,Inactive,,,,,AlphaScreen-based biochemical high throughput primary assay to identify activators of the E3 ligase (FBW7).,Screening,,
3233,1259310,1,1,,332950846,3454,Inactive,,,,,AlphaScreen-based biochemical high throughput primary assay to identify activators of the E3 ligase (FBW7).,Screening,,
3234,1259310,1,1,,333473332,3454,Inactive,,,,,AlphaScreen-based biochemical high throughput primary assay to identify activators of the E3 ligase (FBW7).,Screening,,
3235,1259311,1,1,,178126368,3454,Inactive,,,,,A screen for compounds that are lethal to S. aureus RN4220,Other,,
3236,1259313,1,1,,56424026,3454,Inactive,,,,,uHTS identification of small molecule modulators of NR3A,Screening,,
3237,1259318,1,1,,8139883,3454,Inactive,,,,,uHTS identification of small molecule modulators of Rev-erb Alpha.,Screening,,
3238,1259325,1,2,,336954502,3454,Inactive,4504843.0,3763.0,,,Discovering small molecule activators of G protein-gated inwardly-rectifying potassium subunit 2 (GIRK2) containing channels utilizing methyl-2 4-pentanediol (MPD) for partial channel activation during screening,Screening,,
3239,1259344,1,1,,144203711,3454,Inactive,,,,Potency,qHTS assay to identify small molecule phospholipidosis (PLD) inducers,Confirmatory,,
3240,1259354,1,1,,348429905,3454,Inactive,534286618.0,,,,Small-molecule inhibitors of ST2 (IL1RL1),Screening,,
3241,1259355,1,1,,144203711,3454,Inactive,,,,Potency,qHTS assay to identify small molecule inhibitors of chordoma cells - UCH-1,Confirmatory,,
3242,1259356,1,1,,144203711,3454,Inactive,,,,Potency,qHTS assay to identify small molecule inhibitors of chordoma cells - UCH-2,Confirmatory,,
3243,1259364,1,1,,170464961,3454,Inactive,1013403374.0,9734.0,,Potency-Replicate_1,qHTS assay to identify small molecule HDAC inhibitors,Confirmatory,,
3244,1259365,1,1,,170464961,3454,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule HDAC inhibitors - cell viability counter screen,Confirmatory,,
3245,1259366,1,1,,170464961,3454,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the sonic hedgehog signaling (Shh) pathway - cell viability counter screen,Confirmatory,,
3246,1259367,1,1,,170464961,3454,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the sonic hedgehog signaling (Shh) pathway - cell viability counter screen,Confirmatory,,
3247,1259368,1,1,,170464961,3454,Inactive,109731339.0,2737.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the sonic hedgehog signaling (Shh) pathway,Confirmatory,,
3248,1259369,1,1,,170464961,3454,Inactive,109731339.0,2737.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the sonic hedgehog signaling (Shh) pathway,Confirmatory,,
3249,1259370,2,2,,124749793,3454,Inactive,312803.0,1017.0,,,Inhibitors of CDC25B-CDK2/CyclinA interaction,Other,,
3250,1259370,2,2,,124749793,3454,Inactive,510604.0,890.0,,,Inhibitors of CDC25B-CDK2/CyclinA interaction,Other,,
3251,1259370,2,2,,124749793,3454,Inactive,14602917.0,994.0,,,Inhibitors of CDC25B-CDK2/CyclinA interaction,Other,,
3252,1259377,1,1,,170464961,3454,Inactive,54288833.0,2100.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor beta (ER-beta) signaling pathway,Confirmatory,,
3253,1259378,1,1,,170464961,3454,Inactive,54288833.0,2100.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor beta (ER-beta) signaling pathway,Confirmatory,,
3254,1259379,1,1,,170464961,3454,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway in the presence of an antagonist - cell viability counter screen,Confirmatory,,
3255,1259380,1,1,,170464961,3454,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor beta (ER-beta) signaling pathway - cell viability counter screen,Confirmatory,,
3256,1259381,1,1,,170464961,3454,Inactive,124375976.0,367.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway in the presence of an antagonist,Confirmatory,,
3257,1259382,1,1,,170464961,3454,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor beta (ER-beta) signaling pathway - cell viability counter screen,Confirmatory,,
3258,1259383,1,1,,170464961,3454,Inactive,348019627.0,2099.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway in the presence of an antagonist,Confirmatory,,
3259,1259384,1,1,,170464961,3454,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists or antagonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway - wild type cell line counter screen,Confirmatory,,
3260,1259385,1,1,,170464961,3454,Inactive,119601739.0,7253.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway,Confirmatory,,
3261,1259386,1,1,,170464961,3454,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway in the presence of an antagonist - cell viability counter screen,Confirmatory,,
3262,1259387,1,1,,170464961,3454,Inactive,124375976.0,367.0,,,qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway in the presence of an antagonist: Summary,Summary,,
3263,1259388,1,1,,170464961,3454,Inactive,1013403374.0,9734.0,,Antagonist Potency (uM),qHTS assay to identify small molecule HDAC inhibitors: Summary,Summary,,
3264,1259390,1,1,,170464961,3454,Inactive,109731339.0,2737.0,,,qHTS assay to identify small molecule agonists of the sonic hedgehog signaling (Shh) pathway: Summary,Summary,,
3265,1259391,1,1,,170464961,3454,Inactive,348019627.0,2099.0,,,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway in the presence of an antagonist: Summary,Summary,,
3266,1259392,1,1,,170464961,3454,Inactive,109731339.0,2737.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the sonic hedgehog signaling (Shh) pathway: Summary,Summary,,
3267,1259393,1,1,,170464961,3454,Inactive,119601739.0,7253.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists or antagonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway - wild type cell line counter screen: Summary,Summary,,
3268,1259394,1,1,,170464961,3454,Inactive,54288833.0,2100.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the estrogen receptor beta (ER-beta) signaling pathway: Summary,Summary,,
3269,1259395,1,1,,170464961,3454,Inactive,119601739.0,7253.0,,Ratio Potency (uM),qHTS assay to identify small molecule antagonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway: Summary,Summary,,
3270,1259396,1,1,,170464961,3454,Inactive,54288833.0,2100.0,,,qHTS assay to identify small molecule antagonists of the estrogen receptor beta (ER-beta) signaling pathway: Summary,Summary,,
3271,1259400,1,1,,170464961,3454,Inactive,166209887.0,59350.0,,,qHTS Assay for Antagonists of the Relaxin Receptor RXFP1,Screening,,
3272,1259401,1,1,,170464961,3454,Inactive,325495545.0,2101.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library: Summary,Summary,,
3273,1259402,1,1,,170464961,3454,Inactive,325495545.0,2101.0,,,qHTS assay to identify small molecule agonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library: Summary,Summary,,
3274,1259403,1,1,,170464961,3454,Inactive,325495545.0,2101.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library: Summary,Summary,,
3275,1259404,1,1,,170464961,3454,Inactive,325495545.0,2101.0,,,qHTS assay to identify small molecule agonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library: Summary,Summary,,
3276,1259406,1,1,,363920219,3454,Unspecified,,,,,BK Channel Variant Modulator Selectivity Assay,Screening,,
3277,1259406,1,1,1.0,363920219,3454,Inactive,26638650.0,3778.0,-0.00258303,LogChange(F380Y),BK Channel Variant Modulator Selectivity Assay,Screening,,
3278,1259406,1,1,2.0,363920219,3454,Inactive,4758626.0,3779.0,0.0387552,LogChange(F380Y/beta1),BK Channel Variant Modulator Selectivity Assay,Screening,,
3279,1259406,1,1,3.0,363920219,3454,Inactive,5031823.0,10242.0,0.046143800000000006,LogChange(F380Y/beta2Delta),BK Channel Variant Modulator Selectivity Assay,Screening,,
3280,1259406,1,1,4.0,363920219,3454,Inactive,26051275.0,27345.0,0.0376774,LogChange(F380Y/beta4),BK Channel Variant Modulator Selectivity Assay,Screening,,
3281,1259406,1,1,5.0,363920219,3454,Inactive,160410009.0,389816.0,-0.00436875,LogChange(F380Y/Slo1WT/gamma1),BK Channel Variant Modulator Selectivity Assay,Screening,,
3282,1259406,1,1,6.0,363920219,3454,Inactive,26638650.0,3778.0,0.07081339999999998,LogChange(R275C),BK Channel Variant Modulator Selectivity Assay,Screening,,
3283,1259406,1,1,7.0,363920219,3454,Inactive,4758626.0,3779.0,-0.0192142,LogChange(R275C/beta1),BK Channel Variant Modulator Selectivity Assay,Screening,,
3284,1259406,1,1,8.0,363920219,3454,Inactive,5031823.0,10242.0,0.047239800000000005,LogChange(R275C/beta2Delta),BK Channel Variant Modulator Selectivity Assay,Screening,,
3285,1259406,1,1,9.0,363920219,3454,Inactive,26051275.0,27345.0,-0.0223514,LogChange(R275C/beta4),BK Channel Variant Modulator Selectivity Assay,Screening,,
3286,1259406,1,1,10.0,363920219,3454,Inactive,5031823.0,10242.0,-0.0030302,LogChange(R275C/Slo1WT/beta2),BK Channel Variant Modulator Selectivity Assay,Screening,,
3287,1259407,1,1,,363907159,3454,Active,,,,,CCRIS mutagenicity studies,Other,,
3288,1259413,1,2,,104170145,3454,Inactive,47605623.0,173990.0,,,Modulators of fzo-1,Other,,
3289,1259415,1,1,,8139883,3454,Active,,,,,qHTS Assay for inhibitors of the human cytomegalovirus (HCMV),Screening,,
3290,1259416,1,2,,8139883,3454,Inactive,56786138.0,3458.0,,,Toxoplasma gondii inhibition HTS in the presence of IFN-y,Screening,,
3291,1259416,1,2,,340079978,3454,Inactive,56786138.0,3458.0,,,Toxoplasma gondii inhibition HTS in the presence of IFN-y,Screening,,
3292,1259416,1,2,,340079979,3454,Inactive,56786138.0,3458.0,,,Toxoplasma gondii inhibition HTS in the presence of IFN-y,Screening,,
3293,1259421,1,1,,340079978,3454,Inactive,56786138.0,3458.0,,,Toxoplasma gondii HTS in the absence of IFN-y,Screening,,
3294,1259421,1,1,,340079979,3454,Inactive,56786138.0,3458.0,,,Toxoplasma gondii HTS in the absence of IFN-y,Screening,,
3295,1259423,1,2,,354804095,3454,Inactive,,,,,Primary cell-based high-throughput screening assay for identification of small molecule agonists of Aedes aegypti NPYLR7 [Small Molecule Inhibitors of Mosquito Biting Behavior],Screening,,
3296,1259423,1,2,,354844380,3454,Inactive,,,,,Primary cell-based high-throughput screening assay for identification of small molecule agonists of Aedes aegypti NPYLR7 [Small Molecule Inhibitors of Mosquito Biting Behavior],Screening,,
3297,1259423,1,2,,354936340,3454,Inactive,,,,,Primary cell-based high-throughput screening assay for identification of small molecule agonists of Aedes aegypti NPYLR7 [Small Molecule Inhibitors of Mosquito Biting Behavior],Screening,,
3298,1259423,1,2,,355018124,3454,Inactive,,,,,Primary cell-based high-throughput screening assay for identification of small molecule agonists of Aedes aegypti NPYLR7 [Small Molecule Inhibitors of Mosquito Biting Behavior],Screening,,
